<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003135.pub4" GROUP_ID="AIRWAYS" ID="545799112523484210" MERGED_FROM="" MODIFIED="2009-05-21 12:02:30 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;&lt;span modified=&quot;2008-07-10 10:51:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;July 10th. Hi Toby, Mammoth task. I cannot find Nielsen in the included studies so no link in ast&lt;/span&gt;&lt;span modified=&quot;2008-07-10 10:52:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;hma severity section?&lt;/span&gt;&lt;span modified=&quot;2008-07-10 10:55:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; I think we M&lt;/span&gt;&lt;span modified=&quot;2008-07-10 10:56:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;UST separate children from adults in reporting the results. The trend for FEV1&lt;/span&gt;&lt;span modified=&quot;2008-07-10 11:08:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; &amp;amp;&lt;/span&gt;&lt;span modified=&quot;2008-07-10 11:09:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; PEF&lt;/span&gt;&lt;span modified=&quot;2008-07-10 10:56:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; may just be due to more children on lower doses!!!!!&lt;/span&gt;&lt;span modified=&quot;2008-07-10 11:09:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; We could combine % predicted change but not values in litres please.&lt;/span&gt;&lt;span modified=&quot;2008-07-10 11:49:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-07-10 11:49:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;I have removed Jadad from the tables and text (w&lt;/span&gt;&lt;span modified=&quot;2008-07-10 11:50:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;here I can see it). Are we still ok to say that sensitivity analysis is not possible based on the new risks of bias??&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-07-10 11:50:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;Chris&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-07-10 10:51:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;=====================================&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Edit by CJC July 28&lt;br&gt;What is different about Katz, Peden, Nathan and Boonswat. Post hoc data dredging suggests that these studies show smaller differences in FEV1 than the others and this is going to confound the sub-group comparisons.?&lt;br&gt;Please amend the new GIV labels (usually outcomes 1 and 3 of comparisons) to Litres for FEV1 and Litres/min for PEF. Thanks.&lt;br&gt;I have altered the emphasis in the sub-group reporting and left this in red.&lt;br&gt;This is ready for submission then.&lt;br&gt;Well done for all this sorting out.&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;&lt;br&gt;======================================&lt;/p&gt;&lt;p&gt;75 studies (142 references)&lt;/p&gt;&lt;p&gt;PLEASE USE THIS VERSION AS i MADE A MISTAKE IN THE ABSTRACT OF THE LAST VERSION IN RELATION TO LACK OF EFFICACY FOR THE nnt OF 3 OR 4.&lt;br&gt;CJC relook 17 Feb 2005&lt;br&gt;Wonderful piece of work. Few minor changes made (eg NNT(H) for NNH ) and this is ready to submit.&lt;br&gt;THANKS!&lt;br&gt;Chris&lt;br&gt;---------------------------------&lt;br&gt;11th Feb 05&lt;/p&gt;&lt;p&gt;Liz has read and approved the search strategy&lt;br&gt;----------------------------------&lt;br&gt;Editing by CJC 3 feb 2005&lt;/p&gt;&lt;p&gt;Authors' Contribution: fine&lt;/p&gt;&lt;p&gt;What's new: Good.&lt;/p&gt;&lt;p&gt;Objectives: unchanged.&lt;/p&gt;&lt;p&gt;References: fine&lt;/p&gt;&lt;p&gt;Table of included studies: very thorough!&lt;/p&gt;&lt;p&gt;Metaview Labels: Need reversing for 1#2,3,6,11-16, 19,20,24; 5#8,9,11-13, 26-30, 44; 6#5,10; 8#12,20 (labels); 9#9, 16; 10#1,3; 11#1; 12#1,3; 13#5, 11,12-15; 24#2 (labels)&lt;br&gt;Also 4#1, 7#4, 13#3,4; 14#2,5, 6; 15#2,3,6; 16#2,3,6; 25#3,4,5, 8-12; 26#3,4,5, 8-12 needs reversing and stripping out of negative signs in old studies please.&lt;br&gt;10#9, 11#9, 12#7, 14#11, 15#11, 16#11, need reverse and change from percentages please!&lt;br&gt;14#19,20 change from RD to Peto for default stats.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Methods; NNT calculation. &amp;quot;Numbers needed to treat (NNT) were calculated from the pooled OR and its 95% CI applied to the risk in the placebo group using an online calculator (Visual Rx at www.nntonline.net). This calculator converts a specified risk (over a stated time period) in the placebo group to the corresponding odds, applies the OR to estimate the odds in the tiotropium group, converts that odds to the corresponding risk and calculates the risk difference, the inverse of which is the NNT.&amp;quot;&lt;/p&gt;&lt;p&gt;Next action; Back to Toby to sort out Metaview and then back to me. Also could Liz check search and references at the same time.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;---------------------------------------------------------------------------------------------&lt;br&gt;Remember to put the Okamoto study FP 31, with the Noonan study 26&lt;/p&gt;&lt;p&gt;---------------------------------------------------------------------------------------------------------&lt;br&gt;20th December 2004&lt;br&gt;TJL - entered data extracted by BG; entered unpublished data provided by GSK.&lt;/p&gt;&lt;p&gt;Need to enter all data for remaining studies with only placebo control arms.&lt;br&gt;-----------------------------------------------------------------------------------------------------------&lt;br&gt;Old title: #Inhaled fluticasone versus placebo for chronic asthma UPDATE&lt;br&gt;Old title: #Inhaled fluticasone versus placebo for chronic asthma in adults and children UPDATE&lt;/p&gt;" NOTES_MODIFIED="2009-05-21 11:00:55 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="IFL3-AST" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2009-05-21 12:02:30 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Fluticasone versus placebo for chronic asthma in adults and children</TITLE>
<CONTACT MODIFIED="2009-05-21 12:02:30 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="12372" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nick</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Adams</LAST_NAME><POSITION>Consultant Physician</POSITION><EMAIL_1>Nick.Adams@wash.nhs.uk</EMAIL_1><EMAIL_2>nadams2002@btinternet.com</EMAIL_2><ADDRESS><DEPARTMENT>Respiratory Medicine</DEPARTMENT><ORGANISATION>Worthing &amp; Southlands NHS Trust</ORGANISATION><CITY>Worthing</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01903 205111</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-21 12:02:30 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="12372" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nick</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Adams</LAST_NAME><POSITION>Consultant Physician</POSITION><EMAIL_1>Nick.Adams@wash.nhs.uk</EMAIL_1><EMAIL_2>nadams2002@btinternet.com</EMAIL_2><ADDRESS><DEPARTMENT>Respiratory Medicine</DEPARTMENT><ORGANISATION>Worthing &amp; Southlands NHS Trust</ORGANISATION><CITY>Worthing</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01903 205111</PHONE_1></ADDRESS></PERSON><PERSON ID="8553" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Janine</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Bestall</LAST_NAME><POSITION>Research Assistant</POSITION><ADDRESS><DEPARTMENT>Division of Physiological Medicine</DEPARTMENT><ORGANISATION>St George's Hospital Medical School</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 ORE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 020 8725 5383</PHONE_1><FAX_1>+44 020 8725 5955</FAX_1></ADDRESS></PERSON><PERSON ID="8583" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Toby</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Lasserson</LAST_NAME><POSITION>Managing Editor, Cochrane Airways Group</POSITION><EMAIL_1>tlassers@sgul.ac.uk</EMAIL_1><URL>www.airways.cochrane.org</URL><ADDRESS><DEPARTMENT>Community Health Sciences</DEPARTMENT><ORGANISATION>St George's, University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><ADDRESS_2>Tooting</ADDRESS_2><CITY>London</CITY><ZIP>SW17 ORE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+20 8725 2790</PHONE_1><FAX_1>+20 8725 3584</FAX_1></ADDRESS></PERSON><PERSON ID="7702" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Paul</FIRST_NAME><LAST_NAME>Jones</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>pjones@sgul.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cardiovascular Medicine</DEPARTMENT><ORGANISATION>St George's Hospital Medical School</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 8725 5371</PHONE_1><FAX_1>+44 20 8725 5955</FAX_1></ADDRESS></PERSON><PERSON ID="7270" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christopher</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Cates</LAST_NAME><SUFFIX>MA FRCGP</SUFFIX><POSITION>Senior Research Fellow</POSITION><EMAIL_1>ccates@sgul.ac.uk</EMAIL_1><URL>www.nntonline.net</URL><ADDRESS><DEPARTMENT>Community Health Sciences</DEPARTMENT><ORGANISATION>St George's, University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 208 725 5412</PHONE_1><FAX_1>+44 208 725 3584</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-05-21 09:17:13 +0100" MODIFIED_BY="Toby J Lasserson">
<UP_TO_DATE>
<DATE DAY="4" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="1" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2009-05-21 11:00:55 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-21 11:00:55 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Reference added to Derom 2001 (now Derom 2005); minor amendments to data from Pinnas 2005. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-05-21 10:47:50 +0100" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-05-21 10:47:50 +0100" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="4" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment. New studies (12): <LINK REF="STD-Caffey-2005" TYPE="STUDY">Caffey 2005</LINK>; <LINK REF="STD-Pinnas-2005" TYPE="STUDY">Pinnas 2005</LINK>; <LINK REF="STD-FLIC15" TYPE="STUDY">FLIC15</LINK>; <LINK REF="STD-FLTA4030" TYPE="STUDY">FLTA4030</LINK>; <LINK REF="STD-FLTA3014" TYPE="STUDY">FLTA3014</LINK>; <LINK REF="STD-FLTA2007" TYPE="STUDY">FLTA2007</LINK>; <LINK REF="STD-FLTA3020" TYPE="STUDY">FLTA3020</LINK>; <LINK REF="STD-FLTA3022" TYPE="STUDY">FLTA3022</LINK>; Philips 2004; <LINK REF="STD-Bernstein-2004" TYPE="STUDY">Bernstein 2004</LINK>; Subbarao 2005; Oaquandah 2006<BR/>
<BR/>Unpublished data for previously published studies: <LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK>; Pearlman 2002; <LINK REF="STD-Pearlman-2004" TYPE="STUDY">Pearlman 2004</LINK>; <LINK REF="STD-Kemp-2004" TYPE="STUDY">Kemp 2004</LINK>; Wolfe 2000 BD; <LINK REF="STD-Wolfe-2000-ICS" TYPE="STUDY">Wolfe 2000 ICS</LINK>; Rooklin 2001; <LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK>; <LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK>; <LINK REF="STD-Busse-2001" TYPE="STUDY">Busse 2001</LINK>; <LINK REF="STD-Katz-1998" TYPE="STUDY">Katz 1998</LINK>; <LINK REF="STD-MacKenzie-1993" TYPE="STUDY">MacKenzie 1993</LINK>
<BR/>
<BR/>The data from these studies do not alter the conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 15:54:13 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-12 15:54:13 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Search re-run in January 2008</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Nederlands Astma Fonds</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-21 10:57:43 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-07-04 09:52:44 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-04 09:52:44 +0100" MODIFIED_BY="Toby J Lasserson">Fluticasone versus placebo for chronic asthma in adults and children</TITLE>
<SUMMARY_BODY>
<P>Fluticasone is a well-established inhaled steroid for use a preventative agent in controlling asthma symptoms. This review found that it is highly effective even in low doses. The effect does appear to increase with higher doses, but these improvements are small. This drug is associated with symptoms such a thrush, sore throat and hoarseness and these get worse with higher doses. In people with severe asthma who need oral steroid tablets to control their asthma, it can reduce the dose of oral steroids they need and improve their asthma at the same time. However, high or very high doses are needed for this effect. The drug appears to work in children and adults.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-23 16:13:23 +0100" MODIFIED_BY="Christopher J Cates">
<ABS_BACKGROUND>
<P>Inhaled fluticasone propionate (FP) is a relatively new inhaled corticosteroid for the treatment of asthma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess efficacy and safety outcomes in studies that compared FP to placebo for treatment of chronic asthma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-04 11:40:29 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We searched the Cochrane Airways Group Specialised Register (January 2008), reference lists of articles, contacted trialists and searched abstracts of major respiratory society meetings (1997-2006).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-07-04 09:52:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Randomised trials in children and adults comparing FP to placebo in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and risk of bias.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-07-07 15:21:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Two review authors extracted data. Quantitative analyses were undertaken using Review Manager software.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-23 16:13:23 +0100" MODIFIED_BY="Christopher J Cates">
<P>Eighty-six studies met the inclusion criteria, recruiting 16,160 participants. In non-oral steroid treated asthmatics with mild and moderate disease FP resulted in improvements from baseline compared with placebo across all dose ranges (100 to 1000 mcg/d) in FEV1 (between 0.1 to 0.43 litres); morning PEF (between 23 and 46 L/min); symptom scores (based on a standardised scale, between 0.44 and 0.7); reduction in rescue beta-2 agonist use (between 1 and 1.4 puffs/day). High dose FP increased the number of patients who could withdraw from prednisolone: FP 1000-1500 mcg/day Peto Odds Ratio 14.07 (95% CI 7.17 to 27.57). FP at all doses led to a greater likelihood of sore throat, hoarseness and oral Candidiasis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Doses of FP in the range 100-1000 mcg/day are effective. In most patients with mild-moderate asthma improvements with low dose FP are only a little less than those associated with high doses<B> </B>when compared with placebo. High dose FP appears to have worthwhile oral-corticosteroid reducing properties. FP use is accompanied by an increased likelihood of oropharyngeal side effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-21 10:57:43 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND MODIFIED="2008-07-10 12:17:39 +0100" MODIFIED_BY="Toby J Lasserson">
<P>There is now wide recognition that asthma is a chronic inflammatory disease characterised by inflammatory cell infiltration, inflammatory mediator release, and epithelial damage within the airways (<LINK REF="REF-Barnes-1998" TYPE="REFERENCE">Barnes 1998</LINK>). Current management guidelines reflect this awareness in a recommendation that inhaled corticosteroids are considered in all patients except those with the mildest disease and intermittent symptoms (<LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>; <LINK REF="REF-GINA-1995" TYPE="REFERENCE">GINA 1995</LINK>; <LINK REF="REF-NHBLI-1997" TYPE="REFERENCE">NHBLI 1997</LINK>). Fluticasone propionate (FP) is a newer synthetic corticosteroid widely used for the treatment chronic asthma in the UK, Europe and United States. Many controlled studies have been undertaken to assess its efficacy and safety and a number of narrative reviews have summarised these studies in qualitative fashion (<LINK REF="REF-Barnes-1998" TYPE="REFERENCE">Barnes 1998</LINK>; <LINK REF="REF-Pedersen-1997" TYPE="REFERENCE">Pedersen 1997</LINK>).</P>
<P> This systematic review has been carried out to determine how the efficacy of FP varies with dose and explore the potential influence of asthma severity, age, and delivery device and treatment duration on clinically relevant outcomes. This review has been conducted with the aim of trying to provide answers to these questions by assessing those trials that have compared FP to placebo.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-07-07 15:19:56 +0100" MODIFIED_BY="Toby J Lasserson">
<P> To assess efficacy and safety outcomes in studies that compared inhaled fluticasone propionate to placebo in the treatment of chronic asthma.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-21 10:46:43 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-07-10 12:17:39 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES MODIFIED="2008-07-10 12:17:39 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Only prospective, randomised controlled trials (RCTs) were considered. Double, single and unblinded studies were eligible for inclusion. Both parallel group design and crossover studies were considered, although only data from parallel studies were combined for analysis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies including children and/or adults with a clinical diagnosis of chronic asthma were reviewed. The patients needed to be at least two years of age or older. A diagnosis of chronic asthma; diagnosis based on the physician opinion alone was acceptable, as well as asthma diagnosed using objective criteria related to asthma symptoms airway reversibility, and all bronchial hyper-responsiveness. Treatment in the setting of primary care, hospital outpatient clinic, or institutional care was considered.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Fluticasone propionate versus placebo. Treatment periods had to be for at least one week. Delivery by metered dose inhalers (MDI), with or without a spacer/chamber, or dry powder (DPI) was acceptable. Studies using nebulisers were specifically excluded. The nominal daily dose of fluticasone had to be stated. Any concurrent therapy was acceptable, including the use of oral corticosteroids (OCS).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-10 10:22:35 +0100" MODIFIED_BY="Christopher J Cates">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-08 08:41:46 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Our primary outcome was forced expiratory volume in one second (FEV1).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-07-10 10:22:35 +0100" MODIFIED_BY="Christopher J Cates">
<P>We identified a number of key secondary outcomes which were of interest to people with asthma and clinicians:</P>
<OL>
<LI>Diary card and clinic PEFR, diurnal PEFR variability.</LI>
<LI>Symptoms.</LI>
<LI>Rescue bronchodilator use</LI>
<LI>Health status/health related quality of life (HRQOL)</LI>
<LI>Rates of asthma exacerbation leading to primary care physician visits, emergency room visits, hospital admission and days loss from work or school</LI>
<LI>Safety assessment: hypothalamo-pituitary-adrenal (HPA) function, as assessed by plasma and urinary cortisol measures</LI>
<LI>Oropharyngeal side-effects and skin bruising</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as 'asthma' were searched using the following terms:</P>
<P>steroid* OR glucocorticoid* OR corticosteroid* OR fluticasone OR Flixotide OR Flovent</P>
<P>The most recent search was conducted in January 2008. See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for the full search history of this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-07 15:23:48 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>Reference lists of all included studies and relevant narrative reviews were searched for additional RCTs.</LI>
<LI>The UK headquarters of GSK (manufacturers of Becotide, Becloforte and Flixotide) and the Swedish headquarters of Astra Zeneca (manufacturers of Pulmicort) were asked if they were aware of further missed trials.</LI>
<LI>We handsearched the <A HREF="http://www.ctr.gsk.co.uk">GSK trials register</A> for unpublished data</LI>
<LI>Authors of studies were asked if they were aware of further missed trials.</LI>
<LI>The British Journal of Clinical Research and the European Journal of Clinical Research (journals not electronically indexed on MEDLINE or EMBASE) were hand-searched.</LI>
<LI>Proceedings of the British Thoracic Society (1997 to 2003), European Respiratory Society (1997 to 2003) and the American Thoracic Society (1997 to 2003) were searched for relevant trials. </LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-21 10:46:43 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-07-04 09:54:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The decision to exclude studies prior to full paper retrieval was made independently by two reviewers (NPA and JB). In cases of disagreement, the full text article was retrieved. Papers retrieved in full text were assessed by two reviewers independently (NPA and JB), any disagreement regarding eligibility was resolved by consensus. Two reviewers (NPA and JB) who were blinded to the author's names, institution and funding sources, independently assessed included studies for methodological quality</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-10 12:17:40 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Two authors (NPA and TL) extracted data for each outcome from the published results of included trials. In the case of continuous outcomes (such as FEV1), only data from the last evaluable time point was used. Where data had to be extracted from graphical plots, an attempt was made to verify the data by contacting authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-04 10:11:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We assessed the risk of bias for each included study according to recommendations described in the <LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>. We have assessed the risk of bias for the generation and concealment of allocation schedules for the eligible studies. Our previous approach is described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-07-04 09:55:53 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For continuous outcomes, a weighted mean difference (WMD) or standardised mean difference (SMD) was calculated, as appropriate. For binary/dichotomous outcomes odds ratios (OR) were calculated.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2009-05-21 10:46:43 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Authors were written to (by mail, fax and/or electronic mail) in an attempt to clarify details of methods, and to request missing or incomplete outcome data. Attempts were made to send requests to correct current addresses by searching MEDLINE, EMBASE and hospital web sites for up to date contact details. Glaxo Wellcome (UK) was also approached for data concerning trials in which contact authors did not initially reply, or when authors suggested doing so. Data that were not available for inclusion in the meta-analysis have been listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>In previous versions of this review we imputed a number of missing standard deviations for a number of studies. </P>
<P>We have maintained an approach consistent with the recommendations regarding imputation in the <LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>, whereby these studies represent a small proportion of the studies included in a given outcome. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-07-10 12:17:42 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Heterogeneity in effect size, across studies pooled was calculated with P &lt; 0.05 used as the cut-off level for significance.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-14 11:08:30 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A weighted treatment effect across trials was calculated using the Cochrane statistical package RevMan 5.1. Pooled treatment effects are expressed with their 95% confidence intervals (95% CI).</P>
<P>A number of conditions were established a priori regarding the comparisons to be made. Firstly, parallel and crossover trials were not pooled. Secondly, studies were categorised based on the presence or absence of regular oral corticosteroid use (OCS) at enrolment. It was expected that most trials in patients on regular oral steroids would use a 'steroid-sparing' design in which daily dose of OCS was progressively reduced. In such studies the principal outcome variable is the dose of oral steroid needed to maintain asthma control unchanged. Conversely, studies in which patients were not treated with regular OCS would be more likely to have designs aimed at detecting improvements in asthma control. It would be inappropriate to combine trials with such different designs and aims.</P>
<P>All comparisons concern fluticasone versus placebo. Because many studies assessed more than one dose of fluticasone within the same trial but only had a single placebo group, it was not appropriate to pool different doses of fluticasone in the meta-analysis. Comparisons are therefore made according to daily dose i.e. 100 mcg/day or less, 200 mcg/day, 500 mcg/day or 1000 mcg/day.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-14 11:08:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For each reported outcome, subgroup analyses have been undertaken. These are based on patient age (children or adults); treatment duration (one to four weeks, one to five months, six months or longer); delivery device (MDI or DPI); asthma severity (mild, mild-to-moderate, moderate). These analyses have been used to explore variations in treatment response according to these factors. In particular, for outcomes where heterogeneity exists between studies, subgroup analyses have been used to try to identify factors that may account for heterogeneity. These are discussed as appropriate in the following section.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-21 10:57:43 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for a description of the search histories for this review. This update includes an additional 12 trials; a total of 86 studies represented by 196 references, recruiting 16,160 participants are included in the review. See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> for text of archived 'What's New' sections.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A detailed description of the studies is provided in the included studies table.</P>
<P>
<B>
<U>Populations</U> </B>The majority of studies were large multicentre trials conducted in the USA. The remaining studies largely recruited patients from Europe (Belgium, Finland, Italy, The Netherlands, UK). Two multicentre studies (<LINK REF="STD-Katz-1998" TYPE="STUDY">Katz 1998</LINK>; <LINK REF="STD-MacKenzie-1993" TYPE="STUDY">MacKenzie 1993</LINK>) also recruited patients from Asia and South Africa respectively. All studies were undertaken in a secondary care/hospital outpatient clinic setting. No studies were conducted in primary care. Eight studies (<LINK REF="STD-Arets-2002" TYPE="STUDY">Arets 2002</LINK>; <LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK>; <LINK REF="STD-Caffey-2005" TYPE="STUDY">Caffey 2005</LINK>; <LINK REF="STD-Hoekstra-1996" TYPE="STUDY">Hoekstra 1996</LINK>; <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>; <LINK REF="STD-Katz-1998" TYPE="STUDY">Katz 1998</LINK>; <LINK REF="STD-Laforce-2000" TYPE="STUDY">Laforce 2000</LINK>; <LINK REF="STD-MacKenzie-1993" TYPE="STUDY">MacKenzie 1993</LINK>; <LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK>) were conducted in children. All remaining studies were in adults and adolescents.</P>
<P>
<B>
<U>Study design</U> </B>Seventy-five studies had a parallel group design. Twelve studies had a crossover design (<LINK REF="STD-Agertoft-1997" TYPE="STUDY">Agertoft 1997</LINK>; <LINK REF="STD-Caffey-2005" TYPE="STUDY">Caffey 2005</LINK>; <LINK REF="STD-O_x0027_Shaughnessy-1993" TYPE="STUDY">O'Shaughnessy 1993</LINK>; <LINK REF="STD-van-Schoor-2002" TYPE="STUDY">van Schoor 2002</LINK>; <LINK REF="STD-Derom-2005" TYPE="STUDY">Derom 2005</LINK>; <LINK REF="STD-Parameswaren-2000" TYPE="STUDY">Parameswaren 2000</LINK>; <LINK REF="STD-Langley-2002" TYPE="STUDY">Langley 2002</LINK>; <LINK REF="STD-Lanz-2001" TYPE="STUDY">Lanz 2001</LINK>; <LINK REF="STD-Derom-1999" TYPE="STUDY">Derom 1999</LINK>; <LINK REF="STD-Jeffery-2002" TYPE="STUDY">Jeffery 2002</LINK>; <LINK REF="STD-Pauwels-2002" TYPE="STUDY">Pauwels 2002</LINK>). The majority of parallel group studies had a treatment period of 12 weeks. Twenty-one studies had treatment periods of between four and eight weeks, six studies had a treatment period of between 16 and 24 weeks. Four studies (<LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK>; <LINK REF="STD-Li-1999b" TYPE="STUDY">Li 1999b</LINK>; <LINK REF="STD-Ward-2001" TYPE="STUDY">Ward 2001</LINK>; <LINK REF="STD-Chuchalin-2008" TYPE="STUDY">Chuchalin 2008</LINK>) had longer treatment periods of between 12 and 24 months.</P>
<P>
<B>
<U>Interventions</U> </B>The studies compared a range of nominal daily doses of FP to placebo, and several studies had multiple treatment arms. Twenty-one studies assessed FP 50-100 mcg/day; 42 studies assessed FP 200 mcg/day; 26 studies assessed FP 500 mcg/day; 18 studies assessed FP 1000 mcg/day. In one study the dosage was unclear (<LINK REF="STD-Jayaram-2005" TYPE="STUDY">Jayaram 2005</LINK>). Seven studies (<LINK REF="STD-Faul-1998" TYPE="STUDY">Faul 1998</LINK>; <LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>; <LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>; <LINK REF="STD-Convery-2000" TYPE="STUDY">Convery 2000</LINK>; <LINK REF="STD-Corsico-2000" TYPE="STUDY">Corsico 2000</LINK>; <LINK REF="STD-van-Rensen-1999" TYPE="STUDY">van Rensen 1999</LINK>; <LINK REF="STD-Ward-2001" TYPE="STUDY">Ward 2001</LINK>) assessed FP 1500-2000 mcg/day versus placebo. Thirteen studies (<LINK REF="STD-SAS30023" TYPE="STUDY">SAS30023</LINK>; <LINK REF="STD-Caffey-2005" TYPE="STUDY">Caffey 2005</LINK>; <LINK REF="STD-Kavuru-2000" TYPE="STUDY">Kavuru 2000</LINK>; <LINK REF="STD-Lipworth-2005" TYPE="STUDY">Lipworth 2005</LINK>; <LINK REF="STD-SAS30021" TYPE="STUDY">SAS30021</LINK>; <LINK REF="STD-Chuchalin-2008" TYPE="STUDY">Chuchalin 2008</LINK>; <LINK REF="STD-SAS30022" TYPE="STUDY">SAS30022</LINK>; <LINK REF="STD-Condemi-1997" TYPE="STUDY">Condemi 1997</LINK>; <LINK REF="STD-Busse-2001" TYPE="STUDY">Busse 2001</LINK>; <LINK REF="STD-Shapiro-2000" TYPE="STUDY">Shapiro 2000</LINK>; <LINK REF="STD-Sorkness-1999a" TYPE="STUDY">Sorkness 1999a</LINK>; <LINK REF="STD-Sorkness-1999b" TYPE="STUDY">Sorkness 1999b</LINK>) incorporated treatment arms with agents other than fluticasone or placebo including triamcinolone, salmeterol and zafirlukast. These interventions were not considered in this review.<BR/>
<B>
<BR/>
<U>Delivery device</U> </B>Thirty-seven<B> </B>studies used a dry powder delivery device. Twenty-four studies used a metered dose inhaler; six studies used a MDI/spacer combination. In one crossover study, both devices were assessed (<LINK REF="STD-Langley-2002" TYPE="STUDY">Langley 2002</LINK>). In the case of ten studies, the delivery device used was not stated.</P>
<P>
<B>
<U>Prior treatment with corticosteroids</U> </B>Three studies (<LINK REF="STD-Allen-2000" TYPE="STUDY">Allen 2000</LINK>; <LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>; <LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>) recruited oral corticosteroid dependent asthmatics. This was a specific inclusion criterion for these studies. In the remaining trials, oral corticosteroid use was either a specific exclusion criterion, or it was clear from a description of the baseline characteristics of patients enrolled than none were receiving oral corticosteroids at the time of randomisation. In 27 studies patients were not receiving inhaled corticosteroid at the time of enrolment. In 17 studies prior treatment with an inhaled corticosteroid was an inclusion criterion. In five studies (<LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK>; <LINK REF="STD-Galant-1999" TYPE="STUDY">Galant 1999</LINK>; <LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>; <LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>; <LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK>) a proportion of patients were receiving inhaled corticosteroids at the time of enrolment but this was not an inclusion criterion for the study. <LINK REF="STD-Laforce-2000" TYPE="STUDY">Laforce 2000</LINK> recruited participants if they required unspecified pharmacotherapy for three months previously. In 15 studies it was unclear if patients had received regular steroid therapy prior to enrolment.</P>
<P>
<B>
<U>Asthma severity</U> </B>Patients with a range of asthma severity were studied. <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> provides a breakdown of included studies according to baseline FEV 1 (% predicted), symptom frequency reported at baseline, and the stated opinion of investigators as to degree of asthma severity. To obtain an index of the severity of asthma at baseline and in the absence of any other standardised approach to the classification of asthma severity, we applied <LINK REF="REF-NHBLI-1997" TYPE="REFERENCE">NHBLI 1997</LINK>/<LINK REF="REF-GINA-1995" TYPE="REFERENCE">GINA 1995</LINK> criteria to each study, recognising these criteria were developed for the assessment of untreated patients. Twenty-four studies recruited patients with mild asthma, 19 studies mild to moderate asthma, 23 studies moderate asthma and three studies (<LINK REF="STD-Allen-2000" TYPE="STUDY">Allen 2000</LINK>; <LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>; <LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>) severe asthma. In the case of eight studies asthma severity could not be estimated (<LINK REF="STD-Derom-2005" TYPE="STUDY">Derom 2005</LINK>; <LINK REF="STD-Faul-1998" TYPE="STUDY">Faul 1998</LINK>; <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>; <LINK REF="STD-Jayaram-2005" TYPE="STUDY">Jayaram 2005</LINK>; <LINK REF="STD-Micheletto-2000" TYPE="STUDY">Micheletto 2000</LINK>; Nielsen 2002; <LINK REF="STD-Pauwels-2002" TYPE="STUDY">Pauwels 2002</LINK>).</P>
<P>
<B>
<U>Outcomes assessed</U> </B>An extensive range of outcomes was reported, and almost all have been considered in this review. Those measures that have not been considered include height assessment in children, bone densitometry, and biochemical markers of bone turnover. These were excluded because of the complexity of the issues lay outside the scope of this review. Markers of inflammation were also not reviewed, because this review was concerned with clinical efficacy, rather than basic mechanisms. Studies of FP on such markers include: bronchial biopsy inflammatory cell counts and/or broncho-alveolar lavage fluid cell counts (<LINK REF="STD-Faul-1998" TYPE="STUDY">Faul 1998</LINK>; <LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>), exhaled nitric oxide levels (<LINK REF="STD-Ekroos-1999" TYPE="STUDY">Ekroos 1999</LINK>), serum and urine eosinophil derived neurotoxin levels (<LINK REF="STD-Hoekstra-1996" TYPE="STUDY">Hoekstra 1996</LINK>), detailed characteristics of the methacholine dose response curve (<LINK REF="STD-Overbeek-1996" TYPE="STUDY">Overbeek 1996</LINK>), spirometry and histamine BHR following inhaled allergen challenge (<LINK REF="STD-O_x0027_Shaughnessy-1993" TYPE="STUDY">O'Shaughnessy 1993</LINK>), neurokinin-A BHR (<LINK REF="STD-van-Schoor-2002" TYPE="STUDY">van Schoor 2002</LINK>) and urinary leukotriene levels (<LINK REF="STD-O_x0027_Shaughnessy-1993" TYPE="STUDY">O'Shaughnessy 1993</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-10 12:17:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The overall risk of bias as determined by the processes of allocation and blinding in the studies we included was low. In only nine cases was there insufficient information available to us to make any judgment regarding trial design (<LINK REF="STD-Caffey-2005" TYPE="STUDY">Caffey 2005</LINK>; <LINK REF="STD-Casale-2001" TYPE="STUDY">Casale 2001</LINK>; <LINK REF="STD-Convery-2000" TYPE="STUDY">Convery 2000</LINK>; <LINK REF="STD-Corsico-2000" TYPE="STUDY">Corsico 2000</LINK>; <LINK REF="STD-Ekroos-1999" TYPE="STUDY">Ekroos 1999</LINK>; <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>; <LINK REF="STD-Jayaram-2005" TYPE="STUDY">Jayaram 2005</LINK>; <LINK REF="STD-Sovij_x00e4_rvi-2003" TYPE="STUDY">Sovijärvi 2003</LINK>; <LINK REF="STD-van-Rensen-1999" TYPE="STUDY">van Rensen 1999</LINK>). These studies were generally small and constitute a small amount of the available evidence. Our judgments for the two domains of bias we have assessed for this review are represented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. All studies were described as randomised, and all were double blind. Following correspondence with GSK from a related review of inhaled therapy we were able to ascertain the process by which GSK-sponsored studies are randomised (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). On this basis we have assigned a low risk of bias to the studies we have identified as GSK-sponsored. Identical inhaler devices were used for the majority of the trials we have included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-21 10:57:43 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome: FEV1</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Change in FEV1 compared to baseline</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Children</HEADING>
<P>In children at daily doses of between 100 and 200mcg, FP led to improvements in FEV1 of between 0.1 and 0.18 L compared with placebo. We could not find any placebo-controlled studies that assessed the effects of FP above a daily dose of 200mcg on FEV1 in children:</P>
<TABLE COLS="6" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Daily dose of FP</P>
</TH>
<TH ALIGN="CENTER">
<P>Point estimate (L)</P>
</TH>
<TH ALIGN="CENTER">
<P>95% confidence intervals</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of studies</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of participants</P>
</TH>
<TH ALIGN="CENTER">
<P>Figure</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>100mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>0.1</P>
</TD>
<TD ALIGN="CENTER">
<P>0.36 to 0.15</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>719</P>
</TD>
<TD>
<P>
<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>200mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>0.18</P>
</TD>
<TD ALIGN="CENTER">
<P>0.13 to 0.23</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>670</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>*</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>500mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1000-1500mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adults</HEADING>
<P>In adults at daily doses of between 100 and 1500 mcg, FP led to improvements in FEV1 of between 0.26 to 0.43 L</P>
<TABLE COLS="6" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Daily dose of FP</P>
</TH>
<TH ALIGN="CENTER">
<P>Point estimate (L)</P>
</TH>
<TH ALIGN="CENTER">
<P>95% confidence intervals</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of studies</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of participants</P>
</TH>
<TH ALIGN="CENTER">
<P>Figure</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>100mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>0.26</P>
</TD>
<TD ALIGN="CENTER">
<P>0.21 to 0.31</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>1352</P>
</TD>
<TD>
<P>
<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>200mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>0.25</P>
</TD>
<TD ALIGN="CENTER">
<P>0.23 to 0.27</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER">
<P>5414</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>*</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>500mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>0.39</P>
</TD>
<TD ALIGN="CENTER">
<P>0.34 to 0.43</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>1724</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>*</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1000-1500mcg</P>
</TD>
<TD ALIGN="CENTER">
<P>0.43</P>
</TD>
<TD ALIGN="CENTER">
<P>0.37 to 0.5</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>816</P>
</TD>
<TD ALIGN="CENTER">
<P>Analysis 7.3*</P>
</TD>
</TR>
</TABLE>
<P>*Significant heterogeneity apparent when studies were pooled for the lower three FP doses (100 mcg/day, 200 mcg/day, 500 mcg/day). The I square tests all exceeded 60% for these outcomes, but random-effects modelling did not alter the significance of the findings in all three cases.</P>
<P>The subgroup analyses based on delivery device, length of treatment and severity did not adequately explain heterogeneity to non-significant levels. Statistically significant differences between subgroup estimates disappeared with a random effects model, and the degree of variation within subgroups suggested that our definitions may be confounded. It should be noted that in the majority of individual studies FP led to significant improvements in FEV1 compared to baseline, when compared with placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">FEV1: other measurements</HEADING>
<P>Change and absolute data in litres and percent predicted FEV1 were also recorded in several studies. There were significant differences in favour of FP for both measurements in the 200 mcg/day dose range: Change in FEV1: WMD 13% (95%CI 8 to 18%; two studies, 280 participants); change in predicted FEV1: WMD 10% (95% CI 8 to 12%; five studies, 674 participants).</P>
<P>The findings were also significant when data were presented as absolute scores for FEV1 % predicted:</P>
<P>FP 200 mcg/day WMD 4% (95% CI 1 to 8%; four trials, 157 participants)<BR/>FP 500 mcg/day WMD 25% (95% CI 16 to 33%; two trials, 50 participants)</P>
<P>When data were presented as litres for two studies in the 200 mcg/d dose range, this was only marginally significant: WMD 0.06 litres (95% CI 0 to 0.13 litres; two trials, 86 participants). This may reflect the relatively low statistical power of the studies in this outcome.</P>
<P>Absolute FEV1 was also recorded in three studies in the 1000 mcg/day dose range. There was no significant difference between FP and placebo: WMD 0.13 litres (95% CI -0.2 to 0.5 litres; 3 studies, 73 participants). As with the FEV1 outcome presented above, low statistical power in this analysis may explain the discrepancy between these findings and the change from baseline data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in FVC and FEF 25-75 compared to baseline</HEADING>
<P>One study (<LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK>) in adult patients conducted over an eight week treatment period assessed the effects of FP 100 mcg/day, 200 mcg/day and 1000 mcg/day versus placebo. A second study (<LINK REF="STD-Chuchalin-2008" TYPE="STUDY">Chuchalin 2008</LINK>) measured change in FEF 25-75 for FP given at 200mcg/day. Compared to placebo, there was a significantly greater improvement in FVC compared to baseline at each dose of FP: FP 100 mcg/day WMD 0.29 litres (95% CI 0.09 to 0.49 litres); FP 200 mcg/day WMD 0.39 litres (95% CI 0.2 to 0.58 litres); FP 1000 mcg/day WMD 0.52 (95% CI 0.35 to 0.69 litres).<BR/>
<BR/>
<LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK> also reported change in FEF 25-75 compared to baseline at doses of 100, and 1000mcg/day. Again, for each daily doses FP there were significant improvements in the active treatment group when compared to placebo: FP 100 mcg/day WMD 0.38 litres per second (95% CI 0.15 to 0.61 litres per second) and FP 1000 mcg/day WMD 0.56 litres per second (95% CI 0.34 to 0.78 litres per second). At a dose of 200mcg/day, there was a significant change from baseline in favour of FP when data from the studies were polled (WMD: 0.25 litres per second (95% CI 0.16 to 0.34 litres per second). Although there was a high level of heterogeneity, the pooled effect remained significant with random-effects modelling.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Peak flow</HEADING>
<P>The majority of studies that reported diary card peak flow measures expressed the outcome as a change compared to baseline. For all daily doses of FP, there were significantly greater improvements in both morning and evening PEFR compared to baseline, when compared with placebo:</P>
<SUBSECTION>
<HEADING LEVEL="5">Change in morning PEFR compared to baseline</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Children</HEADING>
<P>FP significantly improved the change in am PEF in children by 26 L/min (100mcg, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) and 21 L/min (200mcg, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). One study assessed the effect of 500mcg of FP in children and reported a significant change in am PEF favouring FP of 16L/min.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adults</HEADING>
<P>FP significantly improved the change in am PEF in adults by 22 L/min (100mcg, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>*), 28 L/min (200mcg, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>*), 40 L/min (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>*) and 46L/min (1000-1500 mcg, Analysis 7.7*).</P>
<P>*In spite of high levels of heterogeneity observed in these outcomes, random-effects modelling did not alter the significance or the direction of the effects which remained in favour of FP. This suggests that whilst there may be some variation between the response to therapy exhibited by the study populations, there does remain a significant underlying effect in favour of FP.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in evening peak flow compared to baseline</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Children</HEADING>
<P>FP significantly improved the change in pm PEF in children by 7L/min (100mcg, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) and 21 L/min (200mcg, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>). We could not identify studies which assessed the effects of FP on evening PEF.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adults</HEADING>
<P>FP significantly improved the change in pm PEF in adults by 17L/min (100mcg, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>*), 23 L/min (200mcg, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>*), 31 L/min (500mcg, <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>*), 41 L/min (1000-1500mcg, <LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK>*).</P>
<P>*There were moderate to high levels of statistical heterogeneity observed in all of the above outcomes. Random-effects modelling did not alter the significance or the direction of the effect, which remained in favour of FP.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in clinic PEFR compared to baseline</HEADING>
<P>A single study (<LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK>) reported change in clinic recorded PEFR compared to baseline. The effects of FP 100 mcg/day, 200 mcg/day or placebo were assessed in 437 children with moderately severe asthma over a 12 week treatment period. Both daily doses of FP led to significantly greater improvements compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Absolute clinic PEFR</HEADING>
<P>Two small trials assessed FP given at 200 mcg/day (<LINK REF="STD-Giannini-2003" TYPE="STUDY">Giannini 2003</LINK>; <LINK REF="STD-Li-1999a" TYPE="STUDY">Li 1999a</LINK>). There was a significant difference in favour of FP of WMD 69 L/min (95% CI 8 to 128 L/min; two trials, 50 participants). There was a high level of statistical heterogeneity observed. When a random-effects model was applied, this resulted in a non-significant difference. Both trials contributed small sample sizes undermining the statistical power of the pooled effect estimate for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Diary card PEFR: other measures</HEADING>
<P>Only two trials reported diary card peak flow as an absolute measure (L/min). In the 100 mcg/d dose range <LINK REF="STD-MacKenzie-1993" TYPE="STUDY">MacKenzie 1993</LINK> assessed FP in 258 children with moderately severe asthma over a four week treatment period. Active treatment resulted in a significantly greater morning PEFR (19 L/min, 95% CI 10 to 27 L/min) and evening PEFR (18 L/min, 95% CI 10 to 26 L/min) compared to placebo. <LINK REF="STD-Hoekstra-1996" TYPE="STUDY">Hoekstra 1996</LINK> assessed FP 200 mcg/day versus placebo in 34 children with moderately severe asthma over a 12 week treatment period. This study was also of fair methodological quality (Jadad score 3). Active treatment led to significant improvements in morning peak PEFR (41 L/min, 95% CI 19 to 62 L/min) and evening PEFR are (33 L/min, 95% CI 13 to 52 L/min).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Asthma symptoms</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Change in daily asthma symptom score compared to baseline</HEADING>
<P>FP at all daily doses led to significantly greater improvement in daily asthma symptom score from baseline when compared to placebo:</P>
<P>FP 100 mcg/day or less: SMD -0.57 (95% CI -0.69 to -0.46; eight trials, 1238 participants, <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>)*<BR/>FP 200 mcg/day: SMD -0.44 (95% CI -0.50 to -0.38; 26 trials, 5093 participants, <LINK REF="CMP-003.17" TYPE="ANALYSIS">Analysis 3.17</LINK>)*<BR/>FP 500 mcg/day: SMD -0.69 (95% CI -0.8. to -0.58; eight trials, 1371 participants, <LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>)*<BR/>FP 1000 mcg/day: SMD -0.67 (95% CI -0.84 to -0.51; four trials, 611 participants, <LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK>)</P>
<P>*Although we observed a significant degree of variation between the trials in the lower dose ranges, Random-effects modelling did not alter the significance of the summary estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in number of night-time awakenings per week</HEADING>
<P>FP at all daily doses led to significant reductions in the number of night-time awakenings per week compared to placebo:</P>
<P>FP 100 mcg/day or less: WMD -0.11 awakenings/wk (95% CI -0.17 to -0.05 awakening/wk)<BR/>FP 200 mcg/day: WMD -0.17 awakenings/wk (95% CI -0.23 to-0.12 awakening/wk) *<BR/>FP 1000 mcg/day: WMD -0.18 awakenings/wk (95% CI -0.11 to -0.25 awakenings/wk)<BR/>
<BR/>* Significant heterogeneity<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in number of night-time awakenings per night</HEADING>
<P>Treatment with FP significantly reduced the number of awakenings per night:</P>
<P>FP 200: WMD -0.12 awakenings/nt (95% CI -0.17 to -0.08; five trials, 1359 participants)</P>
<P>One study in the 500 mcg/day range reported data on the change in the number of night time awakenings per night (<LINK REF="STD-ZuWallack-2000" TYPE="STUDY">ZuWallack 2000</LINK>). FP significantly reduced the frequency of nocturnal awakenings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in nighttime awakenings (unspecified timeframe)</HEADING>
<P>There was a significant reduction in nocturnal awakenings in the 200 mcg/day dose range: WMD -0.07 awakenings (95% CI -0.11 to -0.02; two trials, 280 participants).</P>
<P>One study in the 500 mcg/day reported a significant difference in favour of FP in terms of the percentage change of nocturnal awakenings compared with baseline (<LINK REF="STD-Shapiro-2000" TYPE="STUDY">Shapiro 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in night-time awakenings score compared to baseline</HEADING>
<P>Two trials (<LINK REF="STD-Condemi-1997" TYPE="STUDY">Condemi 1997</LINK>; <LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK>) reported night-time awakenings but did not specify the time scale over which awakenings were calculated (i.e. per night or per week). The scores from these trials have been combined with those from trials that reported the number of night-time awakenings per week. The pooled treatment effect for each dose has been expressed as a standardised mean difference (SMD). Incorporating the results of the trials led to the following results for change in night-time awakenings score compared to baseline. Again, FP resulted in significantly greater reductions in night-time awakening compared to baseline when compared to placebo:</P>
<P>FP 100 mcg/day or less: SMD 0.25 (95% CI 0.1 to 0.38)<BR/>FP 200 mcg/day: SMD 0.45 (95% CI 0.3 to 0.59) *<BR/>FP 500 mcg/day: SMD 0.74 (95% CI 0.5 to 0.96)</P>
<P>* Significant heterogeneity<BR/>
</P>
<P>
<B>Asthma symptoms: other measures</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in symptom free days</HEADING>
<P>There was a significant difference in favour of FP:<BR/>
<U>
<BR/>
</U>200 mcg/day: WMD 7.03 (95% CI 3.3 to 11%; three trials, 971 participants)*<BR/>500 mcg/day: WMD 21.32 (95% CI 13.54 to 29.09%; two trials, 361 participants)</P>
<P>*Significant heterogeneity</P>
<P>Although there was a modest level of statistical heterogeneity between the trials in the 200 mcg/day dose range (I square 35.7%), Random-effects modelling did not alter the significance of the summary estimate.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rescue Beta-2 agonist use</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Change in daily use of beta 2 agonist compared with baseline</HEADING>
<P>When beta-2 agonist use was reported, this was usually as a change in daily use compared to baseline. FP resulted in significantly greater reductions in beta-2 agonist use from baseline, when compared with placebo:</P>
<P>FP 100 mcg/day or less: WMD -0.94 puffs/day (95% CI -1.14 to -0.74 puffs/d; 10 trials, 2000 participants, <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>)*<BR/>FP 200 mcg/day: WMD -1.13 puffs/day (95% CI -1.25 to -1.01 puffs/d; 28 trials, 6373 participants, <LINK REF="CMP-003.26" TYPE="ANALYSIS">Analysis 3.26</LINK>)*<BR/>FP 500 mcg/day: WMD -1.73 puffs/day (95% CI -1.98 to -1.49 puffs/d; eight trials, 1367 participants, <LINK REF="CMP-005.16" TYPE="ANALYSIS">Analysis 5.16</LINK>)*<B>
<BR/>
</B>FP 1000 mcg/day: WMD -1.36 puffs/day (95% CI -1.64 to -1.08 puffs/d; five trials, 810 participants, <LINK REF="CMP-007.09" TYPE="ANALYSIS">Analysis 7.9</LINK>)*</P>
<P>* Significant heterogeneity. It should be noted however that all individual trials found significant reductions in rescue beta-2 agonist use favouring FP over placebo, and that in all instances, random-effects modelling yielded statistically significant summary estimates.</P>
<P>
<B>Rescue beta-2 agonist use: other measures</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in percentage of rescue beta-2 agonist free days compared with baseline.</HEADING>
<P>There was a significant difference in favour of FP 200 mcg/day (WMD 10.49% (95% CI 5.48 to 15.51; two trials, 809 participants).<B> </B>A single study in the 500 mcg/day dose range reported a significantly greater improvement in the percentage of rescue beta-2 agonist free days (<LINK REF="STD-Condemi-1997" TYPE="STUDY">Condemi 1997</LINK>; WMD 25% (95% CI 14 to 36%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subjective assessment of treatment efficacy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Physician rated efficacy</HEADING>
<P>A number of trials reported the investigator assessment of global treatment efficacy when patients attended clinic during the trial. All doses of FP led to significantly greater numbers of patients deemed to have effective or very effective treatment compared to placebo:<BR/>
<B>
<BR/>
</B>FP 100 mcg/day or less: Peto OR 5.12 (95% CI 3.76 to 6.98; four trials, 664 participants)*<BR/>FP 200 mcg/day: Peto OR 5.83 (95% CI 4.16 to 8.16; three trials, 568 participants)*<BR/>FP 500 mcg/day: Peto OR 5.86 (95% CI 4.09 to 8.39; three trials, 480 participants)*<BR/>FP 1000 mcg/day: Peto OR 9.62 (95% CI 6.18 to 14.99; two trials, 311 participants)*</P>
<P>* Significant heterogeneity</P>
<P>There were significant levels of heterogeneity when we pooled data across the dose ranges for this outcome. In all the trials assembled for this outcome, significant differences were reported individually by each study.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health Status</HEADING>
<P>
<LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK> studied 344 children with mild to moderate asthma who received treatment over 12 months with either FP 100 mcg/day, FP 200 mcg/day or placebo. The heath status of children was assessed using two instruments completed by parents: the Functional Status IIR (FSII) and the Sleep Scale-Children Questionnaire (SLP-C). Significantly better FSII and SLP-C scores were apparent for both FP groups when compared to placebo. The health status of parents was also evaluated using the Quality of Life of Parents of Asthmatic Children Questionnaire (QOL-PAC). Significantly better (i.e. lower) scores were found for parents of children receiving either daily dose of FP when compared to placebo for the Burden dimension of this instrument. FP 200 mcg/day also led to significantly better scores compared to placebo for the Social dimension of the QOL-PAC questionnaire, however no difference between FP 100 mcg/day and placebo was demonstrated. No difference between FP and placebo was apparent for the Subjective Norms dimension of the QOL-PAC for either daily dose of FP.</P>
<P>Data for the AQLQ in adults were available, indicating that in the 200mcg dose range, FP led to statistically significant differences in quality of life compared with placebo (<LINK REF="CMP-003.29" TYPE="ANALYSIS">Analysis 3.29</LINK>)</P>
<P>A single study in adult asthmatics (<LINK REF="STD-Pearlman-1997" TYPE="STUDY">Pearlman 1997</LINK>) assessed health status. This 12 week study in 342 subjects with moderately severe asthma assessed FP 100 mcg/day, 200 mcg/day, 500 mcg/day and placebo. All doses of FP led to significantly better (i.e. higher) scores for a number of dimensions of the Medical Outcomes Study Short Form 36 (SF-36), a general health status questionnaire. Similarly, all doses of FP led to significantly better (i.e. lower) scores compared to placebo for the Living With Asthma Questionnaire (LWA-20), an asthma-specific health status instrument.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bronchial hyper-responsiveness (BHR)</HEADING>
<P>Bronchial hyper responsiveness to methacholine and histamine was reported in a number of trials, however data was rarely reported in a form suitable for inclusion in the meta-analysis. In one study (<LINK REF="STD-Olivieri-1997" TYPE="STUDY">Olivieri 1997</LINK>) methacholine BHR was assessed, however randomised treatment groups were not compared directly (results expressed as a change compared to baseline for each group only). Only two other trials (<LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK>; <LINK REF="STD-Overbeek-1996" TYPE="STUDY">Overbeek 1996</LINK>) reported methacholine BHR. Both were conducted in adult patients, and had treatment periods of between 8 and 12 weeks . A range of daily doses of FP were compared to placebo. Methacholine BHR was expressed as either the provocative dose (PD) or the provocative concentration (PC) required producing a 20% fall in FEV1. In both trials, data were log transformed prior to analysis. FP at doses of 100 mcg/day and 200 mcg/day led to significantly greater improvements in methacholine BHR compared to baseline (<LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK>), the reader is referred to the original paper for further details as change scores are reported in graphical format only. FP 1000 mcg/day (<LINK REF="STD-Overbeek-1996" TYPE="STUDY">Overbeek 1996</LINK>) resulted in a significantly greater absolute methacholine BHR when compared to placebo: WMD 3.51 log base 2 PC20 FEV1 (95% CI 1.84 to 5.18 log base 2 PC20 FEV1). Histamine BHR was assessed in two trials. One study (<LINK REF="STD-Ekroos-1999" TYPE="STUDY">Ekroos 1999</LINK>) was only available in abstract form and provided no comparative results for FP and placebo treated groups. <LINK REF="STD-Hoekstra-1996" TYPE="STUDY">Hoekstra 1996</LINK> was a small study (34 subjects) of fair quality (Jadad score 3) conducted in children. FP 200 mcg/day led to a significantly higher histamine BHR compared to placebo after 12 weeks of treatment: WMD 1.23 log base 2 PC20 FEV1 (95% CI 0.30 to 1.23 log base 2 PC20 FEV1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawal due to worsening asthma</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Withdrawal due to lack of treatment efficacy</HEADING>
<P>A number of trials used criteria for patient withdrawal due to lack of efficacy that were defined a priori. Patients were withdrawn if they experienced reductions in clinic measured FEV1 (15-20%), PEFR in the week prior to clinic visit (&gt; 20% on 3 to 4 or more days), night time awakening due to symptoms (on two to three or more nights in seven days prior to visit) or a need for excessive rescue beta-2 agonist use (12 or more puffs or two to three or more days in seven days prior to clinic visit). The precise criteria for withdrawal due to lack of treatment efficacy is provided in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; these were all very similar. FP at all daily doses resulted in a significantly lower likelihood of withdrawal due to lack of treatment efficacy compared to placebo:</P>
<P>FP 100 mcg/day: Peto OR 0.27 (95% CI 0.22 to 0.34; 10 trials, 1908 participants, <LINK REF="CMP-001.29" TYPE="ANALYSIS">Analysis 1.29</LINK>)*<BR/>FP 200 mcg/day: Peto OR 0.22 (95% CI 0.19 to 0.25; 23 trials, 5204 participants, <LINK REF="CMP-003.38" TYPE="ANALYSIS">Analysis 3.38</LINK>)*<BR/>FP 500 mcg/day: Peto OR 0.15 (95% CI 0.12 to 0.17; nine trials, 1538 participants, <LINK REF="CMP-005.22" TYPE="ANALYSIS">Analysis 5.22</LINK>) <B>
<BR/>
</B>FP 1000 mcg/day: Peto OR 0.11 (95% CI 0.07 to 0.15; seven trials, 1077 participants, <LINK REF="CMP-007.17" TYPE="ANALYSIS">Analysis 7.17</LINK>)</P>
<P>* Significant heterogeneity. All individual trials demonstrated a lower likelihood of withdrawal due to lack of treatment efficacy for FP treated patients compared to placebo. Heterogeneity was present when trials were pooled for the lower three doses. It is possible that the variations in response are a consequence of the minor differences in the criteria used to define lack of treatment efficacy, although this conclusion can only be speculative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Withdrawal due to clinical asthma exacerbation</HEADING>
<P>Withdrawal due to clinical asthma exacerbation was reported in only a few trials. <LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK> reported a significant difference in favour of FP 100 mcg/day in reducing the likelihood of study withdrawal due to an asthma exacerbation.</P>
<P>We pooled data for the following dose ranges:<BR/>FP 200 mcg/day: Peto OR 0.22 (95% CI 0.12 to 0.39; four trials, 702 participants, <LINK REF="CMP-003.37" TYPE="ANALYSIS">Analysis 3.37</LINK>)<BR/>FP 500 mcg/day: Peto OR 0.4 (95% CI 0.23 to 0.72; three studies, 394 participants, <LINK REF="CMP-005.21" TYPE="ANALYSIS">Analysis 5.21</LINK>)</P>
<P>Where definitions of withdrawal criteria were reported in the trials, these were similar (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>), and featured deteriorating lung function, frequent nocturnal symptoms and increased beta-agonist usage beyond threshold values.</P>
<P>A single study (<LINK REF="STD-Overbeek-1996" TYPE="STUDY">Overbeek 1996</LINK>) conducted in 33 adults with mild asthma assessed the effects of FP 1000 mcg/day versus placebo over a 12 week treatment period and did not demonstrate any difference between treatment groups in terms of the number of patients experiencing a 'pulmonary exacerbation', but no definition of an exacerbation was given.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety and tolerability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Withdrawal due to adverse events</HEADING>
<P>FP 100mcg/day or less: Peto OR 0.89 (95% CI 0.37 to 2.12; five trials, 1378 participants, <LINK REF="CMP-001.30" TYPE="ANALYSIS">Analysis 1.30</LINK>)</P>
<P>FP 200mcg/day: Peto OR 1.23 (95% CI 0.81 to 1.86; 22 trials, 5284 participants, <LINK REF="CMP-003.40" TYPE="ANALYSIS">Analysis 3.40</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oropharyngeal side-effects</HEADING>
<P>Sore throat/pharyngitis was more likely with FP than with placebo across the 200 to 1000mcg/day dose ranges: <I>
<BR/>
</I>
<BR/>FP 100 mcg/day or less: Peto OR 1.34 (95% CI 0.78 to 2.29; nine trials, 1928 participants, <LINK REF="CMP-001.33" TYPE="ANALYSIS">Analysis 1.33</LINK>)<BR/>FP 200 mcg/day: Peto OR 1.78 (95% CI 1.34 to 2.35; 23 trials, 4778 participants, <LINK REF="CMP-003.43" TYPE="ANALYSIS">Analysis 3.43</LINK>)<BR/>FP 500 mcg/day: Peto OR 2.2 (95% CI 1.17 to 4.13; seven trials, 1158 participants, <LINK REF="CMP-005.25" TYPE="ANALYSIS">Analysis 5.25</LINK>)<BR/>FP 1000 mcg/day: Peto OR 4.95 (95% CI 1.83 to 13.43; four trials, 524 participants, <LINK REF="CMP-007.18" TYPE="ANALYSIS">Analysis 7.18</LINK>)<BR/>
<BR/>No heterogeneity was apparent when trials were pooled for any daily dose of FP.</P>
<P>At all daily doses FP, there was a significantly greater likelihood of patient reporting hoarseness/dysphonia compared to placebo:</P>
<P>FP 100 mcg/day or less: Peto OR 5.00 (95% CI 1.53 to 16.37; seven trials, 1215 participants, <LINK REF="CMP-001.34" TYPE="ANALYSIS">Analysis 1.34</LINK>)<BR/>FP 200 mcg/day: Peto OR 4.13 (95% CI 2.21 to 7.72; 14 trials, 2321 participants, <LINK REF="CMP-003.45" TYPE="ANALYSIS">Analysis 3.45</LINK>) <B>
<BR/>
</B>FP 500 mcg/day: Peto OR 5.56 (95% CI 2.6 to 11.9; eight trials, 1361 participants, <LINK REF="CMP-005.26" TYPE="ANALYSIS">Analysis 5.26</LINK>)<BR/>FP 1000 mcg/day: Peto OR 6.42 (95% CI 3.37 to 12.26; eight trials, 1175 participants, <LINK REF="CMP-007.19" TYPE="ANALYSIS">Analysis 7.19</LINK>)</P>
<P>There was no significant heterogeneity in effect size at any dose of FP. The trials using the higher two daily doses of FP were 6 to 24 weeks in duration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oral candidiasis</HEADING>
<P>All daily doses of FP led to a significantly greater likelihood of oral candidiasis compared to placebo:</P>
<P>FP 100 mcg/day or less: Peto OR 3.45 (95% CI 1.29 to 9.26; 12 trials, 1298 participants, <LINK REF="CMP-001.35" TYPE="ANALYSIS">Analysis 1.35</LINK>)<BR/>FP 200 mcg/day: Peto OR 2.9 (95% CI 1.78 to 4.72; 17 trials, 2841 participants, <LINK REF="CMP-003.42" TYPE="ANALYSIS">Analysis 3.42</LINK>)<BR/>FP 500 mcg/day: Peto OR 5.17 (95% CI 2.5 to 10.67; seven trials, 1254 participants, <LINK REF="CMP-005.27" TYPE="ANALYSIS">Analysis 5.27</LINK>) <B>
<BR/>
</B>FP 1000 mcg/day: Peto OR 4.57 (95% CI 2.48 to 8.43; eight trials, 1175 participants, <LINK REF="CMP-007.20" TYPE="ANALYSIS">Analysis 7.20</LINK>)</P>
<P>It is important to note that diagnosis of oral Candidiasis was made, based upon a variety of assessments. Mouth swab cultures were used to confirm the diagnosis in only one study (<LINK REF="STD-Katz-1998" TYPE="STUDY">Katz 1998</LINK>). Diagnosis based on clinical examination alone was used in three trials (<LINK REF="STD-Allen-1998" TYPE="STUDY">Allen 1998</LINK>; <LINK REF="STD-Sheffer-1996" TYPE="STUDY">Sheffer 1996</LINK>; <LINK REF="STD-Wolfe-1996" TYPE="STUDY">Wolfe 1996</LINK>). In nine trials (<LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK>; <LINK REF="STD-Condemi-1997" TYPE="STUDY">Condemi 1997</LINK>; <LINK REF="STD-MacKenzie-1993" TYPE="STUDY">MacKenzie 1993</LINK>; <LINK REF="STD-Kavuru-2000" TYPE="STUDY">Kavuru 2000</LINK>; <LINK REF="STD-Laforce-2000" TYPE="STUDY">Laforce 2000</LINK>; <LINK REF="STD-Pearlman-1997" TYPE="STUDY">Pearlman 1997</LINK>; <LINK REF="STD-Shapiro-2000" TYPE="STUDY">Shapiro 2000</LINK>; <LINK REF="STD-Sorkness-1999b" TYPE="STUDY">Sorkness 1999b</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>) it was not clearly stated how the diagnosis was made, although it seems likely to have been by clinical examination alone. No significant heterogeneity in effect size was apparent when trials were pooled for any daily dose of FP versus placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hypothalamo-pituitary-adrenal (HPA) function</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Basal adrenocortical activity: plasma cortisol</HEADING>
<P>Absolute morning plasma cortisol levels were assessed in a number of trials, but complete numerical data (mean and standard deviation values) were rarely available in the study reports.<B> </B>Only a limited amount of data could be pooled in a formal meta-analysis. Three trials in children (<LINK REF="STD-Hoekstra-1996" TYPE="STUDY">Hoekstra 1996</LINK>; <LINK REF="STD-MacKenzie-1993" TYPE="STUDY">MacKenzie 1993</LINK>; <LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK>) assessed FP 100 mcg/day and 200 mcg/day. No significant differences between FP and placebo were apparent. Three trials in adults (<LINK REF="STD-Pearlman-1997" TYPE="STUDY">Pearlman 1997</LINK>; <LINK REF="STD-Wolfe-1996" TYPE="STUDY">Wolfe 1996</LINK>; <LINK REF="STD-Li-1999b" TYPE="STUDY">Li 1999b</LINK>) assessed FP 100-200 mcg/day, 500 mcg/day and 1000 mcg/day, whilst <LINK REF="STD-Galant-1999" TYPE="STUDY">Galant 1999</LINK> assessed FP 1000 mcg/day. Significant differences were not apparent between any daily dose of FP and placebo<B>. </B>A pooled analysis was possible for trials in the 100 mcg/day dose range; no significant difference was observed (WMD 0.27 mcg/dL (95% CI -1.05 to 1.59 mcg/dL; two trials, 197 participants).</P>
<P>Two trials reported change in plasma cortisol levels compared to baseline. <LINK REF="STD-Lawrence-1997" TYPE="STUDY">Lawrence 1997</LINK> assessed FP 100 mcg/day, 1000 mcg/day and placebo. This was a large study (261 adults). No significant difference between FP 100 mcg/day and placebo was apparent. However FP 1000 mcg/day led to a small but significantly greater fall in plasma cortisol level from baseline value when compared to placebo over the six week treatment period of the trial: mean difference 3.1 mcg/dL (95% CI 0.37 to 5.83 mcg/dL). <LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK> assessed FP 50 mcg/day, 100 mcg/day, 1000 mcg/day and placebo over an eight week treatment period in 331 adults. This study found no significant difference between any FP group and placebo for this measure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Basal adrenocortical activity: urinary cortisol</HEADING>
<P>Two trials reported urinary cortisol measures. <LINK REF="STD-Peden-1998" TYPE="STUDY">Peden 1998</LINK> assessed 24 hour urinary free cortisol excretion rates in children with moderately severe asthma receiving FP 100 mcg/day, 200 mcg/day or placebo over a 12 week treatment period. 24 hour urinary free cortisol was measured in a subgroup of patients (153 subjects). These data were pooled with that of <LINK REF="STD-Li-1999b" TYPE="STUDY">Li 1999b</LINK> in the 100 mcg/day dose range: WMD 0 mcg/dL (95% CI -1.33 to 1.33 mcg/dL; two trials, 194 participants). No difference between any daily dose of FP and placebo was demonstrated. <LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK> reported change in 24 hour urinary free cortisol compared to baseline for adults with mild to moderate asthma randomised to receive FP 100 mcg/day, 200 mcg/day, 1000 mcg/day or placebo over an eight week treatment period. No difference between any FP dose and placebo was apparent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dynamic tests of adrenocortical reserve</HEADING>
<P>Two trials in adults conducted over eight weeks (<LINK REF="STD-Chervinsky-1994" TYPE="STUDY">Chervinsky 1994</LINK>) and 12 weeks (<LINK REF="STD-Pearlman-1997" TYPE="STUDY">Pearlman 1997</LINK>) reported results of the standard short ACTH stimulation test, i.e. plasma cortisol measured 30-60 min post 250 mcg iv injection of cosyntropin. No difference in post ACTH cortisol levels between FP and placebo were demonstrated over a daily dose range of 50 to 1000 mcg/day. A single study (<LINK REF="STD-Li-1999b" TYPE="STUDY">Li 1999b</LINK>) reported the effects of treatment on sensitive measures of adrenocortical reserve. In this study adults with mild asthma received either FP 1000 mcg/day or placebo over a two year treatment period. During a six hour infusion of synthetic ACTH (cosyntropin), stimulated plasma cortisol measurements were made. 8 hour area under curve (AUC) plasma cortisol levels were significantly higher in placebo treated patients compared to FP: WMD 35.5 mcg hour/dL (95% CI 2.0 to 69.0 mcg hour/dL); as were peak plasma cortisol levels during infusion: WMD 5.7 mcg/dL (95% CI 0.3 to 11.1 mcg/dL).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral steroid-treated asthma</HEADING>
<P>Two parallel group trials were conducted in oral steroid-treated patients (<LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>; <LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>). Results from these trials were pooled. Both trials were large, Multicentre trials conducted in the USA in adult asthmatics. Both were conducted over 16 weeks. Patient treatment with, and dependence on, oral prednisolone for asthma control at the time of enrolment was an inclusion criterion for both trials. Two nominal daily doses of FP were compared to placebo in each trial; either FP 1000 mcg/day or 2000 mcg/day (<LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>) delivered via the Accuhaler DPI, and FP 1500 mcg/d or 2000 mcg/d delivered via MDI (<LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>). The mean daily baseline dose of oral prednisolone was 13.0-13.6 mg/d and 9.5-10.2 mg/day for the two trials, respectively. In both, a high proportion of patients (&gt;80%) were also receiving treatment with a regular ICS (beclomethasone, triamcinolone or flunisolide) at enrolment but this was not an inclusion criterion in either case. Reduction in daily dose of oral prednisolone was the primary outcome measure in both trials. A priori defined criteria for prednisolone dose reduction were established in both trials, and were based around maintenance of stable asthma control in relation to baseline. This was assessed using changes in FEV1, PEFR, rescue beta-2 agonist use and frequency of symptoms at clinic visits. Over a 16 week treatment period, significantly more patients treated were able to discontinue prednisolone completely when treated with FP compared to placebo.</P>
<SUBSECTION>
<HEADING LEVEL="5">Patients able to discontinue prednisolone completely:</HEADING>
<P>FP 1000-1500 mcg/day: Peto OR 0.07 (95% CI 0.04 to 0.14)<BR/>FP 2000 mcg/day: Peto OR 0.04 (95% CI 0.02 to 0.08)</P>
<P>Significantly greater reductions in the mean daily dose of prednisolone were achieved in FP treated patients compared to placebo:</P>
<P>FP 1000-1500 mcg/day: WMD 7.5 mg/day (95% CI 5.3 to 9.9 mg/day)<BR/>FP 2000 mcg/day: WMD 9.7 mg/day (95% CI 7.4 to 12.1 mg/day)</P>
<P>In these trials, treatment with FP led to significant improvements in FEV1 and PEFR, significant reductions in asthma symptom scores and rescue beta-2 agonist use and (or despite) a significantly greater reduction in oral corticosteroid dose compared to placebo.</P>
<P>In addition to these measures, health status was also assessed. An asthma specific instrument, the Asthma Quality of Life Questionnaire (AQLQ) was used by <LINK REF="STD-Nelson-1999" TYPE="STUDY">Nelson 1999</LINK>. Both daily doses of FP (1000 mcg/day, 2000 mcg/day) led to significant improvements in all domains of this questionnaire compared to placebo. A general health status questionnaire, i.e. the Medical Outcomes Study Short Form-36 (SF-36) was used by <LINK REF="STD-Noonan-1995" TYPE="STUDY">Noonan 1995</LINK>. FP 2000 mcg/day led to significant improvements in most dimensions of this instrument, FP 1500 mcg/day led to significant improvements in fewer dimensions</P>
<P>These benefits of FP were accompanied by an increased risk of oropharyngeal side effects:</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hoarseness or dysphonia</HEADING>
<P>FP 1000-1500 mcg/day: Peto OR 0.08 (95% CI 0.01 to 0.16)<BR/>FP 2000 mcg/day: Peto OR 0.17 (95% CI 0.07 to 0.27)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oral Candidiasis</HEADING>
<P>FP 1000-1500 mcg/day: Peto OR 0.09 (95% CI 0.01 to 0.17)<BR/>FP 2000 mcg/day: Peto OR 0.18 (95% CI 0.06 to 0.29)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Non-OCS-treated asthma: Crossover trials</HEADING>
<P>Although most trials reported non-significant differences across clinical parameters, the difficulties associated with conducting crossover trials with pharmacological interventions such as inadequate washout and more general issues such as the exclusion of data from first arm withdrawals in paired analyses preclude firm answers being drawn from these trials. Data from these trials can be accessed in comparisons 18-21 of the data screen.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>This review has compared the efficacy and safety of fluticasone compared to placebo in both non-oral steroid treated and oral steroid dependent asthma. Only randomised, prospective trials were assessed. Eighty-seven trials (14,208 participants) met the inclusion criteria. The risk of bias based on our assessment of the studies was low.</P>
<SUBSECTION>
<HEADING LEVEL="5">NON-ORAL CORTICOSTEROID TREATED ASTHMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Efficacy: overall effectiveness</HEADING>
<P>There is clear evidence that FP offers worthwhile treatment benefits compared with placebo in the treatment of non-oral steroid dependent asthma. This was evident for a number of outcomes. Withdrawal criteria based around clinically significant thresholds for deterioration in asthma control were defined in a number of trials (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Over a wide daily dose range (100-1000 mcg/day), FP led to a significantly lower likelihood of trial withdrawal compared to placebo. The numbers needed to treat (NNT) to prevent one withdrawal over a 6-24 week treatment period ranged between 2.9 (with FP 100 mcg/day or less) to 2.1 (with FP 1000 mcg/day). Such advantages are clearly worthwhile from a clinical perspective.</P>
<P>FP also led to improvements in FEV1. Trials reporting this outcome usually did so in the form of change compared to baseline. The observed changes in FP treated subjects when compared to placebo are clinically significant. A clinically significant change in spirometric values has not been established, but a change in FEV1 of 0.20 litre from baseline is commonly accepted as constituting the size of bronchodilator response needed for the purposes of asthma diagnosis (<LINK REF="REF-NHBLI-1997" TYPE="REFERENCE">NHBLI 1997</LINK>). The improvement in FEV1 across the dose ranges studied was either close to or in excess of this threshold value. FP treatment led to statistically significant reductions in rescue beta-2 agonist use compared to placebo. Mean baseline beta-2 agonist use in trials contributing to the analysis ranged between one and a half and five puffs per day. When set against the level of baseline use, the observed reductions compared with placebo of between one and two puffs per day, these differences also appear clinically worthwhile.</P>
<P>More frequent use of health status measurements in clinical trials has also confirmed the beneficial effect of fluticasone on quality of life of people with moderate asthma. A major research priority for future trials will be to ascertain the effects of this drug in terms of quality of life with validated instruments in children and in people of all ages with more severe disease. <B>
<BR/>
</B>
<BR/>The greater improvements in diary card morning PEFR and evening PEFR observed for FP are harder to assess in terms of their clinical significance. Over the dose range of 100 mcg/day to 1000 mcg/day changes favouring FP of between 23 L/min and 46 L/min for morning PEFR and between 12 L/min and 41 L/min for evening PEFR were seen.</P>
<P>The greater reductions in frequency of night-time awakening from 0.11/wk (FP 100 mcg/day) to 0.18 (FP 1000 mcg/day) compared to placebo seem small. However the magnitude of this effect should be set against the baseline frequency of awakenings. Only one study reported baseline levels of sleep disturbance, with a mean of 0.05 awakenings per week (<LINK REF="STD-Pearlman-1997" TYPE="STUDY">Pearlman 1997</LINK>). If this low level, equating to one awakening per 20 weeks, was representative of other trials in the pooled analysis then perhaps the change scores attain greater clinical significance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Efficacy: dose response effects</HEADING>
<P>The primary aim of this review is to test efficacy and not dose response, as all the comparisons we have analysed are between FP and placebo. Therefore any apparent response to increasing doses of FP are based upon indirect comparisons between summary estimates from across the dose ranges, and should be interpreted with caution. Many of the trials contributing data had a multiple arm design, in which comparisons of between two and four-fold increases, in addition to a placebo arm, were made. Whilst this lends a certain degree of authority to apparent dose response effects for the<B> </B>likelihood of trial withdrawal due to lack of efficacy, change in FEV1, morning PEFR, evening PEFR, night-time awakening score and physician rated efficacy, it does not supplant randomised comparisons between FP at different doses. For example, it is important to appreciate that a 'dose response' was only evident when improvements over placebo were compared for highest dose FP (1000 mcg/day) and lowest dose FP (100 mcg/day). The 95% confidence intervals for treatment effects overlapped heavily for these outcomes when any other doses were compared (e.g. FP 200 versus 100 mcg/day, FP 500 versus 200 mcg/day, FP 1000 versus 500 mcg/day).</P>
<P>Steroid dose may be a proxy for asthma severity, with more severe patients being recruited to trials assessing higher doses of FP. In such a scenario any differences in effect sizes between differing doses of FP and placebo would be unrepresentative of a dose response relationship in a homogenous patient population.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Efficacy: influence of patient age, delivery device, treatment duration and asthma severity</HEADING>
<P>The trials that could be included in this review encompassed: children and adults; mild to moderate-severe asthma and treatment periods ranging from less than a month to one year. Both MDI and DPI delivery devices were used. The studies were conducted in similar patient populations and settings, characterised by largely adult and adolescent participants with moderately severe asthma, receiving therapy for around three months. In this update, we have observed some significant subgroup differences on measurements of lung function, which would indicate that patients with lower baseline FEV1s show larger increases than those with higher FEV1 at outset. This conclusion should be tempered with the observation that the majority of trials were in moderately severe asthma, and the lesser effect in mild and mild to moderate subgroups were drawn from a relatively small number of trials. Furthermore the number of subgroup analyses in this review make this exercise one more of hypothesis generation rather than hypothesis testing. Nevertheless baseline severity is a clinically plausible explanation for these differences, in spite of high levels of heterogeneity within these subgroups.</P>
<P>Without access to individual patient data, the degree of methodological similarity between the trials did not allow us to explore adequately whether diverse characteristics of baseline populations or study duration affect treatment outcome.<B> </B>Although subgroups identified some potentially meaningful differences in patients more likely to respond, they did not help to explain heterogeneity between trials within subgroups. It could be that the <I>combination</I> of study duration, baseline FEV1, and whether patients were steroid naive at outset determines response to treatment. Further trials in children may only serve to tighten confidence intervals around an already clinically important effect. trials in distinctly mild and severe asthma would also assist in better exploring variability in response to therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Safety</HEADING>
<P>Improvements in asthma control with FP compared to placebo are accompanied by an increased likelihood of a number of oropharyngeal side effects. The incidence of hoarseness and oral Candidiasis were significantly greater in FP treated subjects at all daily doses and appeared higher with larger doses. Individual trials assessed absolute basal plasma cortisol levels, absolute urinary free cortisol levels and stimulated plasma cortisol levels following the short ACTH stimulation test over a range of daily doses in adults and children. Significant differences between FP and placebo treated subjects were not found. Only two trials found statistically significant differences between FP and placebo for measures of adrenal function; both assessed FP 1000 mcg/day in adults. These effects included a change in morning plasma cortisol following six weeks of treatment (<LINK REF="STD-Lawrence-1997" TYPE="STUDY">Lawrence 1997</LINK>), and post ACTH infusion plasma cortisol levels following two years of treatment (<LINK REF="STD-Li-1999b" TYPE="STUDY">Li 1999b</LINK>). </P>
<P>The short term randomised controlled design of most of the studies in our review is not a reliable way of confirming serious systemic effects of prolonged inhaled steroid exposure. Adrenal suppression has been documented as a serious side-effect of fluticasone (<LINK REF="REF-Tattersfield-2004" TYPE="REFERENCE">Tattersfield 2004</LINK>). The clinical implications of small perturbations observed in <LINK REF="STD-Li-1999b" TYPE="STUDY">Li 1999b</LINK> are hard to interpret. The long-term predictive value that changes in such measures have on the risk of developing an acute adrenal crisis are unknown (<LINK REF="REF-Sorkness-1998" TYPE="REFERENCE">Sorkness 1998</LINK>), although there is some evidence that fluticasone may have a greater effect on the adrenal glands than budesonide (<LINK REF="STD-Harrison-2001" TYPE="STUDY">Harrison 2001</LINK>). Information on these harms are more likely to emerge from case-controlled or cohort studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ORAL CORTICOSTEROID DEPENDENT ASTHMA</HEADING>
<P>A clear oral steroid sparing effect of FP was evident. The numbers needed to treat to allow one patient to stop oral prednisolone completely compared to placebo over a 16 week treatment period are extremely low: 1.6 for FP 1000-1500 mcg/day and 1.2 for FP 2000 mcg/day. There was a significantly greater risk of hoarseness and oral Candidiasis associated with active treatment.</P>
<SUBSECTION>
<HEADING LEVEL="6">Methodological Limitations</HEADING>
<P>1. A large volume of literature was searched for trials meeting the inclusion criteria. There is a possibility that further relevant trials were missed, however this possibility is offset by the fact that Glaxo Wellcome, world-wide manufacturers of FP were only able to identify two additional trials that were published following the date of the electronic search. This provides reassurance that the search strategy was comprehensive and effective. A number of unpublished trials, and documents containing unpublished data from full-text articles were identified from the online GSK trials registry; their inclusion in our analyses will have to some degree limited the influence of publication bias.</P>
<P>2. A proportion of incompletely reported outcome data from individual trials could not be included in the meta-analysis (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Authors were approached for this data but were unable or unwilling to provide it. This missing data will have diminished the power of the meta-analysis. We have attempted to overcome this with imputing or calculating estimates of variance. This will have gone some way to redressing the potential bias of under-reporting outcome data, but it does not replace raw data from the trials, and may itself be subject to unmet assumptions regarding the distribution of data within each study. Our methods are described in Table 1. Outcomes including both unimputed (i.e. completely available) and imputed standard deviations are presented in the review.</P>
<P>3. There was a notable absence of studies conducted in a primary care setting. Although it seems reasonable to extrapolate the conclusions regarding efficacy and safety to patients treated in primary care there is a possibility that such patients may differ in terms of their overall asthma severity (e.g. relatively milder disease/less impaired control at baseline). Although subjects with mild asthma were included in the studies reviewed there remains the possibility that inclusion of a greater proportion of such patients may have made a quantitative (if not qualitative) difference to the pooled treatment effects found. The direction of any such change cannot be predicted, however. Milder patients may show greater responsiveness to corticosteroids, but may have less capacity to show improvement.</P>
<P>4. The results for non-oral steroid treated chronic asthmatics apply to children and adults, treated for up 12 months with FP delivered via MDI , MDI+spacer/chamber or DPI. The results should not be extrapolated to infants under the age of two years, or for adults over the age of 65, nor for FP delivered via nebuliser.</P>
<P>5. We have combined data from trials where once and twice daily administrations of fluticasone were studied. <LINK REF="REF-Masoli-2005" TYPE="REFERENCE">Masoli 2005</LINK> has undertaken a meta-analysis which suggests that where head-to-head comparisons have been made between once and twice daily dosing schedules of the same dose of FP, the twice daily dosing schedule led to greater benefit in FEV1, peak flow and withdrawals due to poor asthma control. However, it is possible that evening administration may produce a more significant impact on airway calibre than morning administration. The placebo-controlled trials in this review have assessed once daily dosing schedules tended to be conducted in mild/mild to moderate asthma, and so apparent differences in response to therapy could also be explained by baseline asthma severity. <BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-10 12:17:58 +0100" MODIFIED_BY="Toby J Lasserson">
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-10 12:17:57 +0100" MODIFIED_BY="Toby J Lasserson">
<P>This review strongly supports the use of fluticasone in the treatment of patients with non-oral steroid treated chronic asthma. This applies to children aged over two years, adolescents and adults. Current guidelines recommend a dose titration approach for the use of inhaled corticosteroids in asthma (<LINK REF="REF-BTS-2003" TYPE="REFERENCE">BTS 2003</LINK>). The findings of this review are consistent with the rationale for this approach, since they indicate that most patients achieve improved asthma control on lower doses of FP. Based upon indirect comparisons with the effects of higher doses of FP, it would appear that FP in the lower dose ranges confers similar benefit when compared with placebo.<B> </B>This factor should reinforce the recommendation that, in clinical practice, patients receiving FP for asthma prophylaxis should have their daily dose requirements regularly assessed and down titrated as necessary.</P>
<P>All oral steroid treated asthmatics should be considered for a trial of fluticasone. Clinically worthwhile reductions in oral prednisolone use can be achieved when patients are treated with high dose FP 1000-2000 mcg/day.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-10 12:17:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>An important outstanding area of research is the need to compare differences in time course of response and ultimate outcome with different dosing regimes e.g.:</P>
<UL>
<LI>Low dose through out</LI>
<LI>High then low dose.</LI>
<LI>trials in children and in more severe asthma across all age ranges would add to the evidence base for FP.</LI>
</UL>
<P>
<BR/>Such studies should be carried out over time periods that are realistic for routine asthma care and should not be less than six months in duration and preferably longer. All serious adverse events should also be fully documented.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-21 10:47:30 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We would like to thank the support staff of the Cochrane Airways Group, Liz Arnold, Anna Bara and Jane Dennis for assistance in the electronic search and retrieval of papers, and Steve Milan for statistical support.</P>
<P>We would like to thank the following authors who were kind enough to extra details concerning their trials including Professor D.B. Allen, Dr Y Katz, Dr Nieto, Prof Anssi Sovijärvi and Dr A.L. Sheffer. We would like to thank Julia Earnshaw and Karen Richardson who co-ordinated efforts of behalf of GSK to search for additional trials and provided further information regarding a number of included trials that were sponsored by the company.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-07-08 10:32:28 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Nick Adams retrieved papers identified by electronic search, handsearched additional sources for relevant trials, assessed trials for methodological quality, contacted authors to clarify details of trial design and/or request missing data, extracted data from included trials and wrote text of review.</P>
<P>Janine Bestall retrieved papers identified by search, assessed trials for methodological quality, contacted authors for clarification or trial details and/or request missing data.</P>
<P>Toby Lasserson assessed trials for inclusion in the update of the review, contacted trialists, extracted and entered data and wrote-up the findings.</P>
<P>Paul Jones provided guidance for the overall review and editorial support .</P>
<P>Chris Cates provided direction for reporting of results and discussion.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-07-10 12:25:56 +0100" MODIFIED_BY="Toby J Lasserson">
<P>No primary outcome was specified in the protocol, so FEV1 has been chosen as the primary outcome for this update (post hoc). We have decided against pooling lung function data expressed as absolutes (i.e. L/sec and L/min) for adults and children, in view of their different lung volumes. This is likely to affect the size of the effect for these subgroups, without providing valuable clinical information on differences between them. We have decided to retain pooled estimates for data expressed as % predicted, since this allows for the different lung volumes in both adults and children. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-05-21 09:16:51 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES MODIFIED="2009-05-21 09:16:51 +0100" MODIFIED_BY="Toby J Lasserson">
<INCLUDED_STUDIES MODIFIED="2009-05-21 09:16:51 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="PUB" ID="STD-Agertoft-1997" MODIFIED="2008-07-04 14:56:46 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Agertoft 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agertoft L, Pedersen S</AU>
<TI>Bone, growth and collagen markers in children treated with fluticasone propionate and budesonide</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>23 Suppl</NO>
<PG>295s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Agertoft L, Pedersen S</AU>
<TI>Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>7</NO>
<PG>1507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-04 14:56:46 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>FLIS-02</AU>
<TI>A single-centre, placebo-controlled, randomised, double-blind, double-dummy, cross-over study to investigate longitudinal growth using knemometry in children with mild asthma during treatment with budesonide (200µg/ day and 400µg/ day) and fluticasone propionate (200µg/ day and 400µg/ day) as dry powders</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1998" MODIFIED="2008-07-09 11:17:16 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, Konig P</AU>
<TI>Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>132</VL>
<NO>3 Pt 1</NO>
<PG>472-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLD-220</AU>
<TI>A randomized, double-blind, parallel-group, comparative trial assessing the long-term safety of inhaled fluticasone propionate rotadisks via diskhaler 50mcg BID and 100mcg BID versus placebo in patients aged 4 to 11 years with mild to moderate chronic asthma</TI>
<SO>http://ctr.gsk.co.uk/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:17:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig P, Ford L, Galant S, Lawrence M, Lemanske R, Mendelson L, et al</AU>
<TI>A 1-year comparison of the effects of inhaled fluticasone propionate (FP) and placebo on growth in pre-pubescent children with asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>Suppl</NO>
<PG>S294</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahajan P, Pearlman D, Okamoto L</AU>
<TI>The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2000" NAME="Allen 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allen T, Wire P, Wolford J, Harding S</AU>
<TI>Fluticasone propionate (FP) via the diskus device maintained prednisone reduction beyond one year</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>3 Suppl</NO>
<PG>A185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Arets-2002" NAME="Arets 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arets HGM, Kamps AWA, Brackel HJL, Mulder PGH, Vermue NA, van der Ent CK</AU>
<TI>Children with mild asthma: do they benefit from inhaled corticosteroids</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1470-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arets HGM, Kamps AWA, Brackel HJL, Mulder PGH, Vermue NAV, van der Ent CK</AU>
<TI>Children with mild asthma:do they benefit from inhaled corticosteroids?</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A768</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2002-ICS" MODIFIED="2008-07-08 10:37:41 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Berger 2002 ICS" YEAR="2002">
<REFERENCE MODIFIED="2008-07-08 10:37:41 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger WE, Ford LB, Mahr T, Nathan RA, Crim C, Edwards L, et al</AU>
<TI>Efficacy and safety of fluticasone propionate 250ug administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>4</NO>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FPD40010</AU>
<TI>A randomized, double-blind, parallel group trial assessing the efficacy and safety of fluticasone propionate inhalation powder (250mcg QD) and placebo in subjects at least 12 years of age with chronic asthma currently treated with inhaled corticosteroids</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2002-SABA" MODIFIED="2008-07-08 10:37:36 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Berger 2002 SABA" YEAR="2002">
<REFERENCE MODIFIED="2008-07-08 10:37:36 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berger WE, Ford LB, Mahr T, Nathan RA, Crim C, Edwards L et al</AU>
<TI>Efficacy and safety of fluticasone propionate 250ug administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>4</NO>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FPD40009</AU>
<TI>A randomized, double-blind, parallel group trial assessing the efficacy and safety of fluticasone propionate inhalation powder (250mcg QD) and placebo in subjects at least 12 years of age with chronic asthma currently receiving short acting beta agonist alone</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-2004" MODIFIED="2009-05-21 09:16:24 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Bernstein 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bernstein D, Berger W, Welch M, Kundu S, Banerji D</AU>
<TI>Once-daily ciclesonide significantly improves pulmonary function in adults/adolescents with mild-moderate asthma</TI>
<SO>American Thoracic Society 2005 International Conference; May 20-25; San Diego, California</SO>
<YR>2005</YR>
<PG>B35; poster: G27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein D, Nathan R, Ledford D, Ledoux E, Pedinoff A, Crivera C, et al</AU>
<TI>Ciclesonide, a new inhaled corticosteroid, significantly improves asthma-related quality of life in patients with severe, persistent asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>2 Suppl</NO>
<PG>S210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[Abstract].&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein JA, Noonan MJ, Rim C, Fish J, Kundu S, Williams J, et al</AU>
<TI>Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>2 Suppl</NO>
<PG>S113</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-21 09:16:24 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busse W, Kaliner M, Bernstein D, Nayak A, Kundu S, Williams J, Fish J, Banerji D</AU>
<TI>The novel inhaled corticosteroid ciclesonide is efficacious and has a favourable safety profile in adults and adolescents with severe persistent asthma [Abstract]</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>Suppl 2</NO>
<PG>213s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weinstein S, Friedman B, Kundu S, Banerji D</AU>
<TI>Ciclesonide is effective and well tolerated in adults/adolescents with severe persistent asthma</TI>
<SO>American Thoracic Society 2005 International Conference; May 20-25 San Diego, California</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Busse-2001" MODIFIED="2008-07-09 11:19:19 +0100" MODIFIED_BY="[Empty name]" NAME="Busse 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-09 11:18:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowers BW, Johnson M, Edwards L, Srebro S, Rickard K</AU>
<TI>The impact of fluticasone propionate and zafirlukast on patient quality of life</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>A761</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:37:51 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Busse W, Wolfe J, Storms W, Srebro S, Edwards L, Johnson M, et al</AU>
<TI>Fluticasone propionate compared with zafirlukast in controlling persistent asthma; a randomized double-blind, placebo controlled trial</TI>
<SO>The Journal of Family Practice</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>7</NO>
<PG>595-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:18:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busse WW, Srebro SH, Edwards L, Johnson MC, Rickard K</AU>
<TI>Low-dose inhaled fluticasone propionate versus oral zafirlukast in asthma patients</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>A628</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;. .&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creticos P, Knobil K, Edwards L, Rickard KA, Dorinsky P</AU>
<TI>Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>4</NO>
<PG>401-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA4031</AU>
<TI>A randomized, double-blind, double-dummy, placebo-controlled, parallel-group, comparative study of inhaled fluticasone propionate (88mcg BID) versus zafirlukast (20mg BID) in subjects who are currently receiving beta-agonists alone</TI>
<SO>http://www.ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:19:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rickard K, Srebro SH, Edwards L, Johnson MC</AU>
<TI>Inhaled fluticasone versus oral zafirlukast in asthma patients</TI>
<SO>European Respiratory Society Annual Congress, Madrid, Spain</SO>
<YR>1999</YR>
<PG>122S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caffey-2005" NAME="Caffey 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caffey LF, Raissy HH, Marshik P, Kelly HW</AU>
<TI>A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma</TI>
<SO>Pediatric Asthma Allergy &amp; Immunology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casale-2001" NAME="Casale 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Casale T B, Nelson HS, Stricker WE, Raff H, Newman KB</AU>
<TI>Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>5</NO>
<PG>379-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casale TB, Nelson HS, Stricker W, Fourre JA, Newman KB</AU>
<TI>Dose response of the effect of inhale fluticasone and flunisolide on endogenous cortisol secretion</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>3 Suppl</NO>
<PG>A776</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chervinsky-1994" NAME="Chervinsky 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, Pleskow W</AU>
<TI>Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1994</YR>
<VL>94</VL>
<NO>4</NO>
<PG>676-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLI-201</AU>
<TI>A randomized, double-blind comparative trial of three dosage regimens of inhaled fluticasone propionate versus placebo in adult patients with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chuchalin-2008" MODIFIED="2008-07-04 10:26:15 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Chuchalin 2008" YEAR="2005">
<REFERENCE MODIFIED="2008-07-04 10:25:20 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chuchalin A, Jacques L, Frith L</AU>
<TI>Salmeterol/fluticasone propionate via Diskus[trademark] once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>3</NO>
<PG>169-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>SAS30024</AU>
<TI>A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOVENT) 100mcg twice daily and placebo twice daily, all via the DISKUS/ACCUHALER as initial maintenance therapy in mild asthmatic subject</TI>
<SO>www.ctr.gsk.co.uk</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Condemi-1997" MODIFIED="2008-07-09 11:20:01 +0100" MODIFIED_BY="[Empty name]" NAME="Condemi 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-09 11:20:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chervinsky P, Ginchansky E, Ayars G, LaForce C, Taylor J, Rogenes P, et al</AU>
<TI>Fluticasone propionate 500 mcg/day is superior to triamcinolone acetonide 800 mcg/day in controlling asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9 Suppl</VL>
<PG>2378S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:38:02 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Condemi JJ, Chervinsky P, Glodstein MF, Ford LB, Berger WE, Ayars GH, et al</AU>
<TI>Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1997</YR>
<VL>100</VL>
<NO>4</NO>
<PG>467-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox F, Goodwin B, Cohen R, Rogenes P, Wisniewski M</AU>
<TI>Improvement in general quality of life for asthmatics receiving inhaled fluticasone propionate (FP) 500 µg/day versus triamcinolone acetonide (TAA) 800 µg/day or placebo (PL)</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9 Suppl</VL>
<PG>2380S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Convery-2000" NAME="Convery 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Convery RP, Leitch DN, Bromly C, Ward RJ, Bartlett G, Hendrick DJ</AU>
<TI>Effect of inhaled fluticasone propionate on airway responsiveness in treatment-naïve individuals - a lesser benefit in females</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corsico-2000" NAME="Corsico 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corsico A, Pellegrino R, Zoia MC, Barbano L, Brusaco V, Cerveri I.</AU>
<TI>Effects of inhaled steroids on methacholine-induced bronchoconstriction and gas tapping in mild asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>4</NO>
<PG>687-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derom-1999" NAME="Derom 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;: . &lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Derom E, van Schoor J, Verhaege W, Vincken W, Pauwels R</AU>
<TI>Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma</TI>
<SO>American Journal of Respiratory Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derom-2005" MODIFIED="2009-05-21 09:15:13 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Derom 2005" YEAR="2001">
<REFERENCE MODIFIED="2009-05-21 09:15:07 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="Publication Type: Journal: Article" NOTES_MODIFIED="2009-05-21 09:15:07 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Derom E, Van De Velde V, Marissens S, Engelstatter R, Vincken W, Pauwels R</AU>
<TI>Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients</TI>
<SO>Pulmonary Pharmacology &amp; Therapeutics</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>5</NO>
<PG>328-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-21 09:15:13 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derom E, Van De Velde V, Marissens S, Vincken W, Pauwels RA</AU>
<TI>Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>147s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels RA, Derom E, Van De Velde V, Marissens S, Vincken W</AU>
<TI>Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC²° for adenosine in asthma patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A768</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekroos-1999" MODIFIED="2008-07-09 11:20:38 +0100" MODIFIED_BY="[Empty name]" NAME="Ekroos 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-07-09 11:20:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ekroos H, Lindqvist A, Saarinen T, Poussa T, Haahtela T, Laitinen LA, et al</AU>
<TI>Significant association with the decrease of bronchial hyperresponsiveness and the decrease of exhaled nitric oxide after starting inhaled fluticasone in mild asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>Suppl 30</NO>
<PG>171S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Ekroos HJ, Sovijarvi ARA, Lindqvist A, Saarinen A, Poussa T, Haahtela T, Laitinen LA</AU>
<TI>Short-term effect of fluticasone propionate on exhaled nitric oxide in mild asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>A628</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sovijarvi ARA, Ekroos H, Lindqvist A, Saarinen A, Poussa T, Haahtela T, Laitnen LA</AU>
<TI>Short-term effect of fluticasone propionate on bronchial hyperresponsiveness to histamine diphosphate in mild asthma; significant effect within three days</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>A629</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falcoz-2000" NAME="Falcoz 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Falcoz C, Horton J, Mackie A, Harding S, Daley-Yates PT</AU>
<TI>Pharmacokinetics of fluticasone propionate inhaled via the diskhaler and diskus powder devices in patients with mild-to-moderate asthma</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>Suppl 1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faul-1998" NAME="Faul 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Faul JL, Leonard CT, Burke CM, Tormey VJ, Poulter LW</AU>
<TI>Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time</TI>
<SO>Thorax</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>9</NO>
<PG>753-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faul JL, Leonard CT, Burke CM, Tormey VJ, Poulter LW</AU>
<TI>Fluticasone propionate-induced alterations to lung function and the immunopathology of asthma over time</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>Suppl 3</NO>
<PG>A870</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-FLIC15" NAME="FLIC15" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLIC15</AU>
<TI>A multicenter, randomised, double-blind, parallel group study of the efficacy of fluticasone propionate (FP) diskus 100mcg/bid or 500mcg/bid to induce variations of eosinophils and of Eosinophil Cationic Protein (ECP) in serum and in sputum and to induce variations of exhaling nitric oxide (NO) in subjects with mild to moderate asthma</TI>
<SO>www.clinicalstudyresults.org</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FLTA2007" NAME="FLTA2007" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>FLTA2007</AU>
<TI>A Stratified, Randomized, Double-Blind, Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate via the Multi-Dose Powder Inhaler 50mcg BID, 100mcg QD, and Placebo in Subjects Aged 4 to 11 Years With Chronic Asthma</TI>
<SO>www.clinicalstudyresults.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FLTA3014" NAME="FLTA3014" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>FLTA3014</AU>
<TI>A Randomized, Double-Blind, Comparative Trial of Inhaled Fluticasone Propionate 250mcg BID With and Without a Spacer Device to Inhaled Fluticasone Propionate 100mcg BID Without a Spacer Device and Placebo With and Without a Spacer Device in Adolescent and Adult Subjects with Asthma</TI>
<SO>www.clinicalstudyresults.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FLTA3020" MODIFIED="2008-07-08 10:26:17 +0100" MODIFIED_BY="Toby J Lasserson" NAME="FLTA3020" YEAR="1997">
<REFERENCE MODIFIED="2008-07-08 10:26:17 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>FLTA3020</AU>
<TI>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Comparative Trial of Inhaled Fluticasone Propionate 110mcg BID and 220mcg BID via Metered-Dose Inhaler Propelled by Propellants 11/12 or by GR106642X in Adolescent and Adult Subjects with Asthma</TI>
<SO>http:ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-FLTA3022" MODIFIED="2008-07-08 10:26:24 +0100" MODIFIED_BY="Toby J Lasserson" NAME="FLTA3022" YEAR="1997">
<REFERENCE MODIFIED="2008-07-08 10:26:24 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>FLTA3022</AU>
<TI>A Randomized, Double-Blind, Placebo-Controlled Comparative Trial of Fluticasone Propionate 440mcg BID or 880mcg BID versus Placebo Administered via Metered-Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid Dependent Asthmatics.</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-FLTA4030" NAME="FLTA4030" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>FLTA4030</AU>
<TI>A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Comparative Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Zafirlukast (20mg BID) in Subjects Who Are Currently Receiving Beta-Agonists Alone</TI>
<SO>www.clinicalstudyresults.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galant-1996" NAME="Galant 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ</AU>
<TI>Fluticasone propionate compared with theophylline for mild-to-moderate asthma</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>2</NO>
<PG>112-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galant-1999" MODIFIED="2008-07-09 11:21:44 +0100" MODIFIED_BY="[Empty name]" NAME="Galant 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2001</AU>
<TI>A randomized, double-blind, double-dummy, parallel-group, comparative trial of inhaled fluticasone propionate Rotadisk® via diskhaler 500mcg bid, multi-dose powder inhaler 500mcg bid, and placebo in adolescent and adult patients with mild to moderate asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Galant SP, van Bavel J, Finn A, Gross G, Pleskow W, Brown A, et al</AU>
<TI>Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>3</NO>
<PG>273-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:21:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampel F, Van Bavel J, Selner J, Gross G, Brown A, Hamedani A, et al</AU>
<TI>Inhaled fluticasone propionate administered via the Diskus or Diskhaler is safe and effective in adolescent and adult subjects with mild to moderate asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>A338</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:21:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahajan P, Okamoto L</AU>
<TI>Patient satisfaction with the Diskhaler (R) and the Diskus (R) inhaler, a new multidose powder delivery system for the treatment of asthma</TI>
<SO>Clinical Therapeutics</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>5</NO>
<PG>1126-34</PG>
<IDENTIFIERS MODIFIED="2008-07-09 11:21:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannini-2003" MODIFIED="2008-07-08 10:26:32 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Giannini 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-07-08 10:26:32 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;. .&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:26:32 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Giannini D, Di Franco A, Bacci E, Bartoli ML, Carnevali S, Cianchetti S, et al</AU>
<TI>Different doses of inhaled fluticasone propionate FP in the management of moderate asthmatic subjects</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Giannini D, Di Franco A, Tonelli M, Bartoli ML, Carnevali S, Cianchetti S</AU>
<TI>Fifty mg b.i.d. of inhaled fluticasone propionate (FP) are effective in stable asthmatics previously treated with a higher dose of FP</TI>
<SO>Respiratory Medicine</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>5</NO>
<PG>463-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gross-1998" MODIFIED="2008-07-09 11:22:00 +0100" MODIFIED_BY="[Empty name]" NAME="Gross 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin B, Cox F, Noonan M, Rogenes P, Wisniewski M</AU>
<TI>Inhaled fluticasone propionate (FP) 500 µg/day improves asthma-specific quality of life more than triamcinolone acetonide (TAA) 800 µg/day or placebo (PL)</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9 Suppl</VL>
<PG>2380S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:22:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin B, Cox F, Noonan M, Rogenes P, Wisniewski M</AU>
<TI>The Impact of Inhaled Fluticasone Propionate 500 µg/day Versus Triamcinolone Acetonide 800 µg/day or Placebo on General Quality of Life in Adult Asthmatics</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<PG>536</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gross GN, Wolfe JD, Noonan MJ, Pinnas JL, Pleskow WW, Nathan RA, Edwards L, Pepsin PJ, Rogenes PR</AU>
<TI>Differential effects of inhaled corticosteroids: Fluticasone propionate versus triamcinolone acetonide</TI>
<SO>American Journal of Managed Care</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>2</NO>
<PG>233-244</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe JD, Lawrence M, Livezey M, Pleskow W, Schrum D, Thomas B, Rogenes P, Schaberg A, Wisniewski M, Pepsin P J</AU>
<TI>Comparison of fluticasone propionate (FP) 500 mcg/day versus triamcinolone acetonide (TAA) 800 mcg/day in subjects with moderate asthma</TI>
<SO>European Respiratory Journal. Supplement</SO>
<YR>1996</YR>
<VL>9 Suppl</VL>
<PG>2378S-9S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hart-2000" NAME="Hart 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hart L, Lim S, Adcock I, Barnes PJ, Fan Chung K</AU>
<TI>Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kB in asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<PG>224-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoekstra-1996" NAME="Hoekstra 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoekstra MO, Grol MH, Bouman K, Stijnen T, Koeter GH, Kauffman HF, Gerritsen J</AU>
<TI>Fluticasone propionate in children with moderate asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1996</YR>
<VL>154</VL>
<NO>4 Pt 1</NO>
<PG>1039-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofstra-2000" MODIFIED="2008-07-09 11:22:19 +0100" MODIFIED_BY="[Empty name]" NAME="Hofstra 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, et al</AU>
<TI>Dose-responses over time to inhaled fluticasone propionate treatment of exercise and methacholine-induced bronchoconstriction in children with asthma</TI>
<SO>Paediatric Pulmonology</SO>
<YR>2000</YR>
<VL>29</VL>
<NO>6</NO>
<PG>415-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:22:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra WB, Sterk PJ, Neijens HJ, Kuethe MC, Mulder PGH, Duiverman EJ</AU>
<TI>The effect of 24 weeks treatment with 100 mcg or 250 mcg b.d. fluticasone propionate in reducing exercise-induced bronchoconstriction in childhood asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<NO>4 (pt 2)</NO>
<PG>A267</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jayaram-2005" MODIFIED="2008-07-07 13:24:01 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jayaram 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jayaram L, Pizzichini E, Lemiere C, Man SF, Cartier A, Hargreave FE, Pizzichini MM</AU>
<TI>Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>2</NO>
<PG>100-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-07 13:24:01 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>Jayaram L, Pizzichini MMM, Hussack P, Lemiere C, Cartier A, Man SFP, et al</AU>
<TI>First line anti-inflammatory treatment for asthma; inhaled steroid or leukotriene antagonist?</TI>
<SO>Respirology</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>A19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Jeffery-2002" NAME="Jeffery 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jeffery PK, Venge P, Gizycki MJ, Egerod I, Dahl R, Faurschou P</AU>
<TI>Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1378-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1998" MODIFIED="2008-07-07 13:23:43 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Katz 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-07-07 13:23:43 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>FLIT85</AU>
<TI>A multicenter, randomized, double-blind, placebo controlled study to compare the efficacy and safety of fluticasone propionate dry powder 200mcg daily via a Diskhaler inhaler and fluticasone propionate 100mcg daily via a Diskhaler inhaler in comparison with placebo dry powder via a Diskhaler inhaler in children with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katz Y, Lebas FX, Medley HV, Robson R</AU>
<TI>Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group</TI>
<SO>Clinical Therapeutics</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>3</NO>
<PG>424-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kavuru-2000" MODIFIED="2008-07-09 11:22:47 +0100" MODIFIED_BY="[Empty name]" NAME="Kavuru 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards T, Gross G, Mitchell D, Chervinsky P, Woodring A, Baitinger L, et al</AU>
<TI>The salmeterol xinafoate/fluticasone propionate dry powder combination product via diskus(r) inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate dry powder alone</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A414</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, et al</AU>
<TI>Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>6 (pt 1)</NO>
<PG>1108-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:22:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan R, Woodring A, Baitinger L, Prillaman B, Faris M, House K, Shah T</AU>
<TI>The salmeterol/fluticasone propionate Diskus combination decreases the incidence of exacerbations compared to treatment with salmeterol or fluticasone propionate alone</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>123S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>SFCA3002</AU>
<TI>A randomized, double-blind, parallel-group trial evaluating safety and efficacy of salmeterol 50mcg BID and fluticasone propionate 100mcg BID individually and in combination and placebo in subjects with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-2004" NAME="Kemp 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA3001</AU>
<TI>A Randomized, Double-Blind, Parallel-Group Trial to Assess the Long Term Safety of Fluticasone Propionate Inhalation Aerosol 100mcg BID and 500mcg BID Versus Placebo BID in Adult Subjects with Moderate Asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM, et al</AU>
<TI>Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>4</NO>
<PG>458-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osur S, Chervinsky P, Herie N, Harding S, Kellerman D</AU>
<TI>Long term effects of fluticasone propionate (FP) inhalation aerosol in subjects with asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>Suppl 3</NO>
<PG>A405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laforce-2000" NAME="Laforce 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laforce CF, Pearlman DS, Ruff ME, Silvers WS, Weinstein SW, Clements DS, et al</AU>
<TI>Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>5</NO>
<PG>407-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langley-2002" NAME="Langley 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Langley SJ, Holden J, Derham A, Hedgeland P, Sharma RK, Woodcock A</AU>
<TI>Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>3</NO>
<PG>806-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanz-2001" NAME="Lanz 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanz MJ, Eisenlohr C, Llabre MM, Toledo Y, Lanz MA</AU>
<TI>The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>4</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawrence-1997" NAME="Lawrence 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence M, Wolfe J, Webb DR, Chervinsky P, Kellerman D, Schaumberg JP, Shah T</AU>
<TI>Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1997</YR>
<VL>156</VL>
<NO>3 Pt 1</NO>
<PG>744-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen K, Okamoto L, Shah T</AU>
<TI>Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device</TI>
<SO>Journal of Asthma</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>3</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Levy-2006" MODIFIED="2008-07-04 11:37:08 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Levy 2006" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>FAP30010</AU>
<TI>A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 Years of Age With Asthma</TI>
<SO>www.clinicalstudyresults.org</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Given J, Kent E, Gossage D, Clements D, Scott C, Wu W, Crim C</AU>
<TI>Safety of fluticasone propionate HFA in treating children 4-11 years of age with asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>Suppl 2</NO>
<PG>112s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy A, Condemi J, Landwehr L, Clements D, Scott C, Wu W, Crim C</AU>
<TI>Fluticasone propionate HFA improves asthma control children aged 4 to 11 years with asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>Suppl 2</NO>
<PG>113s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-04 11:36:50 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy AL, Given JT, Weinstein SF, Kent Jr EF, Clements DS, Wu W, et al</AU>
<TI>Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in four- to eleven-year-old children with asthma: A randomized, double-blinded, placebo-controlled study</TI>
<SO>Pediatric Asthma Allergy &amp; Immunology</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>2</NO>
<PG>106-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1999" MODIFIED="2008-07-08 10:38:36 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Li 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-07-08 10:38:36 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;.&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:38:36 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li JTC, Goldstein MF, Gross GN, Noonan MJ, Weisberg S, Edwards L, et al</AU>
<TI>Effects of fluticasone propionate, triamcinolone acetonide, prednisolone, and placebo on the hypothalamic-pituatary axis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>4</NO>
<PG>622-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1999a" MODIFIED="2008-07-08 10:38:52 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Li 1999a" YEAR="1999">
<REFERENCE MODIFIED="2008-07-08 10:38:52 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, et al</AU>
<TI>An antiinflammatory effect of salmeterol, a long-acting ß2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma</TI>
<SO>American Journal of Respiratory and Crtitical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>1493-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid DW, Ward C, Wang N, Zheng L, Bish R, Orsida B, Walters EH</AU>
<TI>Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>994-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1999b" NAME="Li 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harding S, Herje N, Hamedani A, Chervinsky P, Ford L, Kemp J, Li J, Pimnas J, Weisberg S</AU>
<TI>Long term effects of inhaled fluticasone propionate in subjects with asthma [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>Suppl 25</NO>
<PG>173s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Gross G, Osur S, Noonan M, Goldstein M, Sorkness C, et al</AU>
<TI>A comparison of commonly-prescribed doses of inhaled fluticasone propionate (FP) and inhaled triamcinolone acetonide (TAA) on HPA axis function</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>Suppl 3</NO>
<PG>A407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li JT, Ford LB, Chervinsky P, Weisberg SC, Kellerman DJ, Faulkner KG, et al</AU>
<TI>Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>6</NO>
<PG>1062-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindqvist-2003" MODIFIED="2008-07-08 10:26:48 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Lindqvist 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindqvist A, Karjalainen LA, Kava T, Altraja A, Pulkinnen M, Hulme M, Laitinen A</AU>
<TI>Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate</TI>
<SO>Journal of Allergy and Clinicial Immunology</SO>
<YR>2003</YR>
<VL>112</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:26:48 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindqvist AE, Karjalainen EM, Laitinen LA, Kava T, Altraja A, Pulkkinen M, et al</AU>
<TI>Salmeterol sim, fluticasone propionate fp or disodium cromoglycate dscg in the treatment of newly diagnosed asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipworth-2005" MODIFIED="2009-05-21 09:16:42 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Lipworth 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-21 09:16:42 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaForce CF, Baker JW, Amin D, Rohatagi S, Mendes P, Williams J et al</AU>
<TI>Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary adrenal (HPA)-axis function in mild to moderate asthmatics</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>2</NO>
<PG>s218</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lipworth BJ, Kaliner MA, LaForce CF, Baker JW, Kaiser HB, Amin D, et al</AU>
<TI>Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma</TI>
<SO>Annals of Allergy, Asthma, &amp; Immunology</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>4</NO>
<PG>465-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lumry-2006" MODIFIED="2008-07-08 10:39:07 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Lumry 2006" YEAR="2002">
<REFERENCE MODIFIED="2008-07-08 10:26:55 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="OTHER">
<AU>FAP3007</AU>
<TI>A randomized, double-blind, parallel-group, placebo-controlled 12-week trial of inhaled fluticasone propionate 88mcg BID, 220mcg BID, and 440mcg BID versus placebo in propellant GR106642X in adolescent and adult subjects with asthma who are maintained on inhaled corticosteroid therapy</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lumry WR, Conway MM, LaForce CF, Pearlman DS, Scott CA, Herje NE, et al</AU>
<TI>Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids</TI>
<SO>Annals of allergy, asthma &amp; immunology</SO>
<YR>2006</YR>
<VL>96</VL>
<NO>1</NO>
<PG>51-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen K, Herje N, Wu W</AU>
<TI>Inhaled fluticasone propionate via metered -dose inhaler with alternate propellant improves asthma-related quality of life</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:39:07 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman D, Kerwin E, Kim K, Murray A, Fischer T, Wu W, et al</AU>
<TI>Fluticasone propionate HFA-134 A significantly improves asthma control in inhaled corticosteroid dependent asthmatics</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A770</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacKenzie-1993" NAME="MacKenzie 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLIP20</AU>
<TI>A double-blind, parallel-group study to investigate the clinical safety and efficacy of fluticasone propionate, 50µg bd (100µg/day), compared with placebo in the management of moderately severe chronic asthma in children, aged 6-12 years</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MacKenzie CA, Weinberg EG, Tabachnik E, Taylor M, Havnen J, Crescenzi K</AU>
<TI>A placebo controlled trial of fluticasone propionate in asthmatic children</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>152</VL>
<NO>10</NO>
<PG>856-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacKenzie CA</AU>
<TI>Fluticasone propionate in childhood asthma - efficacy, safety and growth [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>Suppl 10</NO>
<PG>251s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Micheletto-2000" NAME="Micheletto 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Micheletto C, Tognella S, Trevisan F, Pomari C, Dal Negro R</AU>
<TI>Reduction of exhaled nitric oxide (e-NO) in mild to moderate asthma after a 4-wk treatment with fluticasone 250mcg BID</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>340s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathan-2000" NAME="Nathan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2016</AU>
<TI>A stratified, randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate via the multi-dose powder inhaler 100mcg QD, 200mcg QD, 500mcg QD and placebo in adolescent and adult subjects with chronic asthma.</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nathan RA, Li JTC, Finn A, Jones R, Payne E, Wolford JP, et al</AU>
<TI>A dose ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>2</NO>
<PG>296-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nathan-2006" MODIFIED="2009-05-21 09:16:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Nathan 2006" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edin HM, Payne E, Herrle MR, Schoaf L, Mather DB, Scott CA, et al</AU>
<TI>Salmeterol/fluticasone propionate combination via HFA MDI improves quality of life</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>2</NO>
<PG>S246</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-21 09:16:51 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan RA, Mitchell D, Condemi J, Heller A, Schoaf L, Herrle M, et al</AU>
<TI>Cardiovascular and hypothalamic-pituitary-adrenal axis safety of fluticasone propionate/salmeterol HFA MDI in adolescent and adult patients with asthma</TI>
<SO>American Journal for Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>5</NO>
<PG>A863</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P</AU>
<TI>Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study</TI>
<SO>Clinical therapeutics</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>1</NO>
<PG>73-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:39:17 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Kent E, Lanz MJ, Peden D, Baitinger L, Herrle M, et al</AU>
<TI>Fluticasone propionate/salmeterol HFA MDI has a rapid onset of effect in asthmatics treated with short or long-acting beta-agonists (BA) or inhaled corticosteroids (ICS)</TI>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>5</NO>
<PG>A865</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rooklin A, Elkayam D, Weiler J, Windom H, Schoaf L, Scott C, et al</AU>
<TI>The fluticasone propionate/salmeterol HFA MDI is significantly more efficacious in treating asthma than placebo HFA MDI, fluticasone propionate CFC MDI or salmeterol CFC MDI</TI>
<SO>Journal of Allergy and Clinicial Immunology</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>2</NO>
<PG>100s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>SAS30004</AU>
<TI>A randomized, double-blind, placebo-controlled, parallel-group 12-week trial evaluating the safety and efficacy of the salmeterol/fluticasone propionate combination in GR106642X MDI, 50/250mcg BID, and salmeterol in propellant 11/12 MDI, 50mcg BID, fluticasone propionate in propellant 11/12 MDI, 250mcg BID, and placebo propellant GR106642X MDI in adult and adolescent subjects with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1999" NAME="Nelson 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2002</AU>
<TI>A randomized, double-blind, placebo-controlled trial of fluticasone propionate 500mcg BID or 1000mcg BID via multi-dose powder inhaler or placebo with optional open-label Fluticasone Propionate 1000mcg BID via multi-dose powder inhaler in subjects with chronic oral steroid-dependent asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, et al</AU>
<TI>Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>2 Pt 1</NO>
<PG>267-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nimmagadda SR, Spahn JD, Nelson HS, Jenkins J, Szefler SJ, Leung DY</AU>
<TI>Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noonan-1995" NAME="Noonan 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Noonan M, Chervinsky P, Busse WW, Weisberg SC, Pinnas J, de Boisblanc BP, et al</AU>
<TI>Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life</TI>
<SO>American Journal Respiratory &amp; Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>5 Pt 1</NO>
<PG>1467-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okamoto LJ, Noonan M, DeBoisblanc BP, Kellerman DJ</AU>
<TI>Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1996</YR>
<VL>76</VL>
<NO>5</NO>
<PG>455-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noonan-1998" NAME="Noonan 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noonan MJ, Chervinsky P, Wolfe J, Liddle R, Kellerman DJ, Crescenzi KL</AU>
<TI>Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study</TI>
<SO>Journal of Asthma</SO>
<YR>1998</YR>
<VL>35</VL>
<NO>2</NO>
<PG>153-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Shaughnessy-1993" NAME="O'Shaughnessy 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW</AU>
<TI>Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>147</VL>
<NO>6 Pt 1</NO>
<PG>1472-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olivieri-1997" NAME="Olivieri 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Donno M, Foresi A, Chetta A, Bertorelli G, Pesci A, Casalini A, et al</AU>
<TI>Effect of six week treatment with low dose of inhaled fluticasone propionate on airway inflammation in mild asthma [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>Suppl 19</NO>
<PG>302s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, et al</AU>
<TI>Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<NO>6</NO>
<PG>1864-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overbeek-1996" NAME="Overbeek 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overbeek SE, Rijnbeek PR, Vons C, Mulder PG, Hoogsteden HC, Bogaard JM</AU>
<TI>Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>11</NO>
<PG>2256-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parameswaren-2000" NAME="Parameswaren 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parameswaren K, Inman MD, Watson RM, Moris MM, Efthimiadis A, Ventresca PG, et al</AU>
<TI>Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>4</NO>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauwels-2002" NAME="Pauwels 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels RA, Derom E, Van De Velde V, Marissens S, Vincken W</AU>
<TI>Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC²° for adenosine in asthma patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A768</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-1997" NAME="Pearlman 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahajan P, Okamoto LJ, Schaberg A, Kellerman D, Schoenwetter WF</AU>
<TI>Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma</TI>
<SO>Journal of Asthma</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>3</NO>
<PG>227-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Noonan MJ, Tashkin DP, Goldstein MF, Hamedani AG, Kellerman DJ, Schaberg A</AU>
<TI>Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>4</NO>
<PG>356-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-1999" NAME="Pearlman 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA3015</AU>
<TI>A randomized, double-blind, placebo-controlled, parallel-group pilot trial evaluating safety and efficacy of salmeterol xinafoate and fluticasone propionate individually and in combination in subjects with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, et al</AU>
<TI>Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>3</NO>
<PG>257-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pearlman-2004" NAME="Pearlman 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, et al</AU>
<TI>Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma</TI>
<SO>Journal of Asthma</SO>
<YR>2004</YR>
<VL>41</VL>
<NO>8</NO>
<PG>797-806</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>SAS30003</AU>
<TI>A stratified, randomised, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the salmeterol/fluticasone propionate combination in HFA 134a MDI, 42/88mcg BID, and salmeterol in propellant 11/12 MDI, 42mcg BID, fluticasone propionate in propellant 11/12 MDI, 88mcg BID, and placebo propellant HFA 134a MDI in adult and adolescent subjects with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein SF, Pearlman DS, Condemi JJ, Herrle MR, Scott CA, Payne JE, et al</AU>
<TI>Superior efficacy of the fluticasone propionate/salmeterol 88/42mcg HFA-MDI combination product versus the individual components in asthmatics previously treated with either short- or long-acting beta2-agonists or inhaled corticosteroids.</TI>
<SO>Journal of Allergy &amp; Clinial Immunology</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>2</NO>
<PG>S102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peden-1998" MODIFIED="2008-07-09 11:25:00 +0100" MODIFIED_BY="[Empty name]" NAME="Peden 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2006</AU>
<TI>A randomized, double-blind, double-dummy, parallel-group trial assessing the efficacy and safety of fluticasone propionate 50 or 100mcg BID via the multi-dose powder inhaler, fluticasone propionate 50 or 100mcg BID via the diskhaler and placebo in subjects aged 4 to 11 years with chronic asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:25:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noonan M, Berger W, Thomas R, Pinnas A, Nayak A, Hendricks V, et al</AU>
<TI>Inhaled fluticasone propionate dry powder administered via Diskus or Diskhaler is safe and effective in pediatric patients with chronic asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>Suppl 25</NO>
<PG>221S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peden DB, Berger WE, Noonan MJ, Thomas MR, Hendricks VL, Hamedani AG, et al</AU>
<TI>Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>1</NO>
<PG>32-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-2004" NAME="Phillips 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Phillips K, Oborne J, Lewis S, Harrison TW, Tattersfield AE</AU>
<TI>Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>1</NO>
<PG>26-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pinnas-2005" NAME="Pinnas 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FAP3008</AU>
<TI>A randomized, double-blind, parallel-group, placebo-controlled 12-week trial of inhaled fluticasone propionate 88mcg BID, 220mcg BID, and 440mcg BID versus placebo in propellant GR106642X in adolescent and adult subjects with asthma who are maintained on bronchodilator therapy</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pinnas JL, Noonan MJ, Weinstein SF, Chervinsky P, Scott CA, Herje NE et al</AU>
<TI>Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma</TI>
<SO>Journal of Asthma</SO>
<YR>2005</YR>
<VL>42</VL>
<NO>10</NO>
<PG>865-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein S, Korenblat P, Raphael G</AU>
<TI>Fluticasone propionate HFA 134-a significantly improves asthma control in inhaled corticosteroid naïve asthmatics</TI>
<SO>American Journal of Respiratory Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8</NO>
<PG>A770</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qaquandah-2006" MODIFIED="2008-07-08 08:59:37 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Qaquandah 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-07-04 11:53:40 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qaqundah PY, Sugerman RW, Ceruti E, Maspero JF, Kleha JF, et al</AU>
<TI>Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: A randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Pediatrics</SO>
<YR>2006</YR>
<VL>149</VL>
<NO>5</NO>
<PG>663-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SAS30021" NAME="SAS30021" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>SAS30021</AU>
<TI>A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma</TI>
<SO>www.clinicalstudyresults.org</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SAS30022" NAME="SAS30022" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Dorinsky P, Kerwin E, Schoaf L, Ellsworth A, House KM</AU>
<TI>The effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma</TI>
<SO>www.clinicalstudyresults.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorinsky P, Schoaf L, House K, Ellsworth A</AU>
<TI>The efficacy and safety of FP/salmeterol 250/50mcg once daily compared with FP/salmeterol 100/50mcg twice daily</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2004</YR>
<VL>169</VL>
<NO>7</NO>
<PG>A149</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorinsky P, Schoaf L, House KM, VanderMeer A</AU>
<TI>The safety and effectiveness of once daily administration of fluticasone propionate/salmeterol 250/50mcg</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>2</NO>
<PG>Abstract No: 67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>SAS30022</AU>
<TI>A randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate/salmeterol DISKUS combination product 100/50mcg twice daily versus fluticasone propionate DISKUS 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta2-agonists alone</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SAS30023" MODIFIED="2008-07-04 10:22:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="SAS30023" YEAR="2004">
<REFERENCE MODIFIED="2008-07-04 10:22:28 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Boonsawat W, Goryachkina L, Millns H, Balsara S</AU>
<TI>The efficacy and safety of seretide/advair once daily (50/100 mcg) compared with fluticasone propionate (100mcg) once daily and placebo as initial maintenance therapy in mild asthma [Abstract]</TI>
<SO>American Thoracic Society 100th International Conference, Orlando, May 21-26</SO>
<YR>2004</YR>
<PG>A37 Poster J82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goryachkina L, Boonsawat W, Millns H, Balsara S</AU>
<TI>Seretide/Advair 50/100mcg once daily is effective in patients with mild asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2004</YR>
<VL>169</VL>
<NO>7</NO>
<PG>A86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>SAS30023</AU>
<TI>A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects</TI>
<SO>www.ctr.gsk.co.uk</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-2000" MODIFIED="2008-07-09 11:26:00 +0100" MODIFIED_BY="[Empty name]" NAME="Shapiro 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aggarwal SK, Frith LJ, Ho M, Weeks T, Ho SY</AU>
<TI>Fluticasone propionate/salmeterol delivered from a single inhaler demonstrates synergistic benefits in asthma</TI>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>2003</YR>
<VL>167</VL>
<NO>7</NO>
<PG>A890</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman ED, Frith L, Braunstein GL</AU>
<TI>Achieving guideline-based asthma control - does the patient benefit?</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>588-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman ED, Frith L, Ho M</AU>
<TI>Guideline-based asthma control reduces maximally the impact of upon patient-assessed quality of life</TI>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8</NO>
<PG>A44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook CK, Prillaman BA, House KW, Rickard KA, Shah TP</AU>
<TI>Concurrent use of salmeterol/fluticasone propionate Diskus powder combination product and fluticasone propionate aqueous nasal spray does not adversely affect HPA-axis function</TI>
<SO>Annals of Allergy, Asthma and Immunology</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>1</NO>
<PG>98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorinsky P, Yancey S, Kral K, Emmett A, House K, Prillaman B, et al</AU>
<TI>Asthma control with salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma</TI>
<SO>Journal Allergy &amp; Clinical Immunology</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>Suppl 1</NO>
<PG>A195</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edin H, Prillaman B, Baitinger LA, House KW, Shah TP</AU>
<TI>Improved ability to perform strenuous activities after treatment with fluticasone/salmeterol combination</TI>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8</NO>
<PG>A112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lumry W, Windhom H, Mendelson L, Pedinoff A, Prillaman B, Baitinger L, et al</AU>
<TI>The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma</TI>
<SO>Journal Allergy &amp; Clinical Immunology</SO>
<YR>1999</YR>
<VL>103</VL>
<NO>1 Pt 2</NO>
<PG>S132</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundback B, Pieters WR, Johansson G, Palmqvist M, Price MJ, Sondhi S, et al</AU>
<TI>Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma 1: Introduction and Overview</TI>
<SO>Pharmacoeconomics</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>Suppl 2</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markham A, Adkins JC</AU>
<TI>Inhaled salmeterol/fluticasone propionate combination: A pharmacoeconomic review of its use in the management of asthma</TI>
<SO>Pharmacoeconomics</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>6</NO>
<PG>591-608</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy TP, Edin H, House K, Vandermeer AK</AU>
<TI>Quality of life and asthma control assessment in patients previously treated with inhaled corticosteroids (ICS), treated with salmeterol/fluticasone combination (SFC) metered dose inhaler (MDI)</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>Suppl 3</NO>
<PG>64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy TP, Edin HM, House K, Vandermeer AK, Scott C</AU>
<TI>Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 38</NO>
<PG>47s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:26:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan R, Woodring A, Baitinger L, Prillaman B, Faris M, House K, Shah T</AU>
<TI>The salmeterol/fluticasone propionate Diskus combination decreases the incidence of exacerbations compared to treatment with salmeterol or fluticasone propionate alone</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>123S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan RA, Dorinsky P, Carranza Rosenzweig JR, Shah T, Edin H, Prillaman B</AU>
<TI>Improved ability to perform strenuous exercises after treatment with fluticasone/salmeterol combination in patients with persistent asthma</TI>
<SO>Journal of Asthma</SO>
<YR>2003</YR>
<VL>40</VL>
<NO>7</NO>
<PG>815-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmqvist M, Price MJ, Sondhi S, et al</AU>
<TI>Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250mcg vs fluticasone propionate 250mcg in adults and adolescents with asthma. 4: Results</TI>
<SO>Pharmacoeconomics</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>Suppl 2</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman D, Baitinger L , Woodring A, Prillaman B, House K, Shah T</AU>
<TI>Salmeterol 50mcg/fluticasone propionate 250mcg diskus combination product demonstrates improvements in lung function regardless of baseline corticosteroid therapy</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>Suppl 3</NO>
<PG>A196</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pieters WR, Lundback B, Johansson G, Palmqvist M, Price MJ, Sondhi S, et al</AU>
<TI>Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma 2: Study Methodlogies</TI>
<SO>Pharmacoeconomics</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>Suppl 2</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reese PR, Mahajan P, Woodring A</AU>
<TI>Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>Suppl 28</NO>
<PG>35s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:28:14 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>SFCA3003</AU>
<TI>A randomized, double-blind, parallel-group trial evaluating safety and efficacy of salmeterol 50mcg BID and fluticasone propionate 250mcg BID individually and in combination and placebo in subjects with asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro G, Lumry W, Wolfe J, Given J, White M, Woodring A, et al</AU>
<TI>Combined salmeterol 50mcg and fluticasone propionate 250mcg in the diskus device for the treatment of asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<PG>527-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stempel DA</AU>
<TI>Salmeterol/fluticasone combination product in asthma - An evaluation of its cost-effectiveness vs fluticasone - foreword</TI>
<SO>Pharmacoeconmics</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>Suppl 2</NO>
<PG>U6-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White MV, Shapiro G, Taylor J, Dunn A, Woodring L, Baitinger B, et al</AU>
<TI>The salmeterol xinofoate/fluticasone propionate dry powder combination product via diskus r inhaler improves asthma control compared to the individual products in patients previously treated with inhaled corticosteroids</TI>
<SO>American Journal of Respiratory and Critical Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>3</NO>
<PG>A635</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheffer-1996" NAME="Sheffer 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A</AU>
<TI>Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group</TI>
<SO>Journal of Family Practice</SO>
<YR>1996</YR>
<VL>42</VL>
<NO>4</NO>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorkness-1999a" MODIFIED="2008-07-08 10:39:58 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Sorkness 1999a" YEAR="1999">
<REFERENCE MODIFIED="2008-07-08 10:39:58 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR</AU>
<TI>Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisolone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>2</NO>
<PG>353-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorkness-1999b" MODIFIED="2008-07-08 10:40:05 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Sorkness 1999b" YEAR="1999">
<REFERENCE MODIFIED="2008-07-08 10:40:05 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR</AU>
<TI>Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisolone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>2</NO>
<PG>353-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sovij_x00e4_rvi-2003" NAME="Sovijärvi 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Authors responded with unpublished data as per request 170904&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sovijärvi AR, Haahtela T, Ekroos HJ, Lindqvist A, Saarinen A, Poussa T, Laitinen LA</AU>
<TI>Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment</TI>
<SO>Thorax</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>6</NO>
<PG>500-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sovijärvi ARA, Haahtela T, Ekroos HJ, Lindqvist A, Poussa T, Laitinen LA</AU>
<TI>Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 38</NO>
<PG>197s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subburao-2005" NAME="Subburao 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Subbarao P, Dorman SC, Rerecich T, Watson RM, Gauvreau GM, O'Byrne PM</AU>
<TI>Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>4</NO>
<PG>745-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Subbarao P, Watson RM, Rerecich T, O'Byrne PM</AU>
<TI>Protective effects of budesonide and fluticasone on allergen-induced airway hyperresponsiveness and inflammation 12 hours after discontinuation of therapy [abstract]</TI>
<SO>American Thoracic Society 99th International Conference</SO>
<YR>2003</YR>
<VL>D094 Poster 614</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Grunsven-2000" NAME="van Grunsven 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Grunsven PM, van Schayck CP, van Deuveren M, van Heerwarden CLA, Akkermans RP, van Weel C</AU>
<TI>Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): Results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) study</TI>
<SO>Journal of Asthma</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>3</NO>
<PG>225-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Rensen-1999" NAME="van Rensen 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Rensen E, Straathof KCM, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ</AU>
<TI>Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma</TI>
<SO>Thorax</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>403-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Schoor-2002" MODIFIED="2008-07-09 11:26:48 +0100" MODIFIED_BY="[Empty name]" NAME="van Schoor 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-07-09 11:26:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Schoor J, Joos GF, Pauwels RA</AU>
<TI>The effects of inhaled fluticasone propionate on methacholine and neurokinin induced bronchoconstriction in asthmatics</TI>
<SO>European Respiratory Journal</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>531S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Schoor J, Joos GF, Pauwels RA</AU>
<TI>Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>6</NO>
<PG>997-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-2001" MODIFIED="2008-07-08 10:40:12 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ward 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-08 10:40:12 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johns DP, Bish R, Reid DW, Ward C, Wilson JW, Ingram C, Walters EH</AU>
<TI>Twelve months treatment with fluticasone propionate (FP) decreases airway reactivity but does not affect airway distensibility (AD)</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>341s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward C, Johns DP, Bish R, Pais M, Reid DW, Ingrim C, et al</AU>
<TI>Reduced airway distensibility, fixed airflow limitation, and airway wall remodelling in asthma</TI>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>164</VL>
<PG>1718-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ward C, Pais M, Bish R, Feltis B, Johns D, Walters EH</AU>
<TI>Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>4</NO>
<PG>309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:28:36 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;. .&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:28:36 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wignarajah D, Zheng L, Pais M, Reid D, Harding R, Ward C, Walters EH</AU>
<TI>Inhaled corticosteroids decrease vessel numbers in the airway wall of asthmatics</TI>
<SO>Proceedings of the Thoracic Society of Australia &amp; New Zealand, Annual Scientific Meeting, Adelaide, 4-9 April</SO>
<YR>2003</YR>
<PG>P010</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasserman-1996" NAME="Wasserman 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Kral KM, Schaberg A, Kellerman DJ</AU>
<TI>A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma</TI>
<SO>Journal of Asthma</SO>
<YR>1996</YR>
<VL>33</VL>
<NO>4</NO>
<PG>265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfe-1996" NAME="Wolfe 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe JD, Selner JC, Mendelson LM, Hampel FJr, Schaberg A</AU>
<TI>Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study</TI>
<SO>Clinical Therapeutics</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>4</NO>
<PG>635-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfe-2000-ICS" NAME="Wolfe 2000 ICS" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2004</AU>
<TI>A randomized, double-blind, double-dummy, parallel-group, comparative trial of inhaled fluticasone propionate 100mcg BID and 200mcg QD via multi-dose powder inhaler, Beclomethasone Dipropionate 168mcg via metered-dose inhaler, and placebo in adolescent and adult subjects with mild to moderate asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanford R, Wightman D, Lincourt W, Edwards L, Crim C</AU>
<TI>Patient satisfaction with fluticasone propionate 250µg once daily</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A769</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, et al</AU>
<TI>Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>6 Pt 1</NO>
<PG>1153-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfe-2000-SABA" NAME="Wolfe 2000 SABA" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2003</AU>
<TI>A randomized, double-blind, double-dummy, parallel-group, comparative trial of inhaled fluticasone propionate 100mcg BID and 200mcg QD via multi-dose powder inhaler, Beclomethasone Dipropionate 168mcg via metered-dose inhaler, and placebo in adolescent and adult subjects with mild to moderate asthma</TI>
<SO>http://ctr.gsk.co.uk</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanford R, Wightman D, Lincourt W, Edwards L, Crim C</AU>
<TI>Patient satisfaction with fluticasone propionate 250µg once daily</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A769</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, et al</AU>
<TI>Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>6 Pt 1</NO>
<PG>1153-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ZuWallack-2000" MODIFIED="2008-07-09 11:28:15 +0100" MODIFIED_BY="[Empty name]" NAME="ZuWallack 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-07-08 10:28:44 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>FLTA2005</AU>
<TI>A randomized, double-blind, parallel group, comparative trial of inhaled fluticasone propionate via the multi-dose powder inhaler 250mcg BID, 500mcg QD and placebo in adolescent and adult subjects with mild to moderate asthma</TI>
<SO>http://www.clinicalstudyresults.org</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:28:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ</AU>
<TI>Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>4</NO>
<PG>1584-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:40:21 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;.&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:40:21 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>ZuWallack R, Adelglass J, Clifford D, Duke S, Wire PD, Faris M, et al</AU>
<TI>Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>2</NO>
<PG>303-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-09 11:30:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Acuna-2001" MODIFIED="2008-07-08 10:29:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Acuna 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-08 10:29:00 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Acuna AA, Gabrijelcic J, Uribe EM, Rabinovich R, Barbera JA, Roca J, et al</AU>
<TI>Fluticasone propionate protects against platelet-activating factor (PAF)-included gas exchange defects in mild asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Baitinger-2002" NAME="Baitinger 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE: COMPARISON WITH FPS&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baitinger L, Dorinsky P, House K, Matthews P, Scott C, VanerMeer A</AU>
<TI>Fluticasone propionate/salmeterol HFA MDI combination product demonstrates superior improvements in lung function regardless of baseline asthma severity</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A568</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bisgaard-1999" MODIFIED="2008-07-09 11:28:38 +0100" MODIFIED_BY="[Empty name]" NAME="Bisgaard 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H, Gillies J, Groenewald M, Maden C</AU>
<TI>The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<NO>1</NO>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-09 11:28:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H</AU>
<TI>Efficacy of inhaled fluticasone propionate in the treatment of young children with asthmatic symptoms: a dose comparison study</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3</NO>
<PG>A711</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Chervinsky-2001" MODIFIED="2008-07-08 10:29:07 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Chervinsky 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-08 10:29:06 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;EXCLUDE - COMPARISON BETWEEN FP AND MONTELUKAST&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:29:06 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Chervinsky P, Kalberg C, Goode-Sellers S, Edwards L, Lincourt W, Rickard K</AU>
<TI>A comparison of low dose fluticasone propionate and montelukast in patients stratified based on baseline asthma severity</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Cirule-2002" NAME="Cirule 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - NO CLEAR DIAGNOSIS OF ASTHMA&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cirule I, Mehra S, Kamin W, StickS , Kudzyte MDJ, Wixon C, et al</AU>
<TI>Efficacy of fluticasone (200 mcg/day) in pre-school children with chronic persistent asthma-like symptoms</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>B38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Dal-Negro-2001" MODIFIED="2008-07-08 10:29:12 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Dal Negro 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-08 10:29:12 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;EXCLUDE - FP AS ADJUNCTIVE RX WITH SAL&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:29:12 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dal Negro R, Micheletto C, Tognella S, Trevisan F, Pomari C</AU>
<TI>Short-term bronchodilation following salmeterol 50mcg and combined salmeterol + fluticasone propionate (50/250mcg) via diskus: a randomized, double blind cross-over study in reversible airway obstruction</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Benedictis-2001" NAME="de Benedictis 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - BDP versus FP&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Benedictis FM, Teper A, Green RJ, Boner AL, Williams L, Medley H, et al</AU>
<TI>Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>11</NO>
<PG>1248-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-den-Otter-2007" MODIFIED="2008-07-04 11:47:19 +0100" MODIFIED_BY="Toby J Lasserson" NAME="den Otter 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-07-04 11:47:19 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>den Otter JJ, van Schayck CP, Folgering HTM, van den Boom G, Akkermans RPM, van Weel C</AU>
<TI>Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: Results from the DIMCA programme</TI>
<SO>European Journal of General Practice</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>2</NO>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Dente-2001" NAME="Dente 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - NO PLA CONTROL&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dente FL, Scuotri L, Bacci E, DeSanctis M, Di Franco A, Giannini D, et al</AU>
<TI>Combined treatment with fluticasone plus salmeterol protects against allergen-induced asthmatic responses better than each drug alone</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>349s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Efthimiou-1998" MODIFIED="2008-07-09 11:28:58 +0100" MODIFIED_BY="[Empty name]" NAME="Efthimiou 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-07-09 11:28:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Efthimiou I, Westbroek J, Saarelainen S, Laher M, O'Brien J, Barnacle H</AU>
<TI>Oral steroid sparing effect of nebulised fluticasone propionate at two dose levels with placebo over a 3 month period in patients with severe chronic asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3</NO>
<PG>A404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Eliraz-2002" NAME="Eliraz 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE: FP V COMBINATION&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eliraz A, Fritscher CC, Perez CMR, Boonsawat W, Nang AN, Bardin P, et al</AU>
<TI>Symbicort® (Budesonide/Formoterol) achieves more rapid control of asthma that fluticasone in patients with mild asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A567</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falcoz-2000a" NAME="Falcoz 2000a" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Falcoz C, Horton J, Mackie A, Harding S, Daley-Yates PT</AU>
<TI>Pharmacokinetics of fluticasone propionate inhaled via the diskhaler and diskus powder devices in patients with mild-to-moderate asthma</TI>
<SO>Cinical Pharmacokinetics</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>Suppl 1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Faul-2002" NAME="Faul 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - COMPARISON BETWEEN FP AND MONTELUKAST&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Faul JL, Canfield JC, Gould MK, Wilson SR, Kischner WG</AU>
<TI>A randomized, double-blind, placebo-controlled, crossover study comparing the effects of inhaled fluticasone propionate (880 Micrograms per day) and montelukast (10 MG per day) on glucose control patients with diabetes and asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - COMPARISON BETWEEN FP AND MONTELUKAST&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Faul JL, Chu JW, Kuschner WG, Wilson SR</AU>
<TI>Effects of inhaled fluticasone propionate and oral montelukast on glucose control in diabetic subjects with asthma: a double-blind placebo-controlled crossover study</TI>
<SO>Chest International Conference, San Diego CA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fletcher-1999" NAME="Fletcher 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fletcher P, Alfaham MA, Barnacle H, Maslen TK</AU>
<TI>Effect of fluticasone propionate Nebules 0.5 mg bd for treating symptomatic asthma in children under 4 years</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>3 pt 2</NO>
<PG>A141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fowler-2002" NAME="Fowler 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - comparison between different propellants&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fowler SJ, Orr LC, Sims EJ, Wilson AM, Currie GP, McFarlane L, et al</AU>
<TI>Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>2</NO>
<PG>618-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2001" NAME="Harrison 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;WRONG COMPARISON (FP/BDP)&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison TW, Wisnieswki A, Honour J, Tattersfield AE</AU>
<TI>Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kanniess-2001" MODIFIED="2008-07-08 10:29:21 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Kanniess 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-08 10:29:21 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;EXLCUDE - COMPARISON WITH MONTELUKAST&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:29:21 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kanniess F, Richter K, Bohme S, Magnussen H</AU>
<TI>Comparison of the efficacy of fluticasone versus montelukast in patients with moderate asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2001" MODIFIED="2008-07-08 10:29:33 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Kelly 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-08 10:29:33 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;FP V FP - EXCLUDE VARYING DOSE OF FP; FP V PLA - EXCLUDE - SEQUENTIAL STUDY = NOT RANDOMISED ADEQUATELY&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:29:33 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kelly MM, Leigh R, Parameswaran K, Jayaram L, Belda J, Goodwin S, et al</AU>
<TI>Establishing dose response and relative potencies of inhaled corticosteroids</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lee-2002" NAME="Lee 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - FP COMPARED WITH TAA, DIFFERENT PROPELLANTS COMPARED&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee TA, Sullivan SD, Weiss K, Georges G</AU>
<TI>Comparison of the cost-effectiveness of inhaled triamcinolone acetonide HFA to inhaled fluticasone propionate CFC in adult asthmatics in a 12-month pragmatic trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leibman-2002" MODIFIED="2008-07-08 10:40:32 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Leibman 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-07-08 10:40:32 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;EXCLUDE - COMPARISON OF FP + MONTELUKAST WITH COMBINATION FP AND SAL&lt;/p&gt;" NOTES_MODIFIED="2008-07-08 10:40:32 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leibman CW, Stanford R, Emmett A, Dorinsky PM, Rickard KA</AU>
<TI>Cost-effectiveness of fluticasone propionate-salmeterol combination versus fluticasone + montelukast in the treatment of persistent asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>B4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Lipworth-1997" NAME="Lipworth 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipworth BJ, Clark DJ, McFarlane LC</AU>
<TI>Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>8</NO>
<PG>686-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lujik-2004" NAME="Lujik 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers J-WJ</AU>
<TI>Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>559-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Majer_x002d_Teboul-2001" MODIFIED="2008-07-09 11:29:24 +0100" MODIFIED_BY="[Empty name]" NAME="Majer-Teboul 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-09 11:29:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;WRONG COMPARISON FP/BDP)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-07-09 11:29:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Majer-Teboul C, Chemali-Hudry J, Texereau J, Granier C, Dinh-Xuan AT</AU>
<TI>Similar anti-inflammatory effects of flixotide&#8482; 500mug/day vs becotide&#8482; 1000mug/day on exhaled NO after 7-days treatment in asthma</TI>
<SO>Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1998" NAME="Moore 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore WC, Pearce SJ, Hmieleski RR, Rogenes PR, Reed KD, Bleecker ER</AU>
<TI>Matrix metalloproteinases (MMPs) in bronchoalveolar lavage (BAL) following allergen challenge: effect of fluticasone propionate (FP)</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A872</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Overbeek-2002" NAME="Overbeek 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - FP COMPARED WITH MONTELUKAST&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overbeek SE, O'Sullivan S, Leman K, Mulder PGM, Hoogsteden Prins JB</AU>
<TI>Treatment with montelukast is less effective in reducing eosinophilic airway inflammation than fluticasone propionate in atopic asthmatics</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A215</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pao-2002" NAME="Pao 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - WHEEZE AND NOT ASTHMA&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pao CS, McKenzie SA</AU>
<TI>Randomized controlled trial of fluticasone in preschool children with intermittent wheeze</TI>
<SO>Amercian Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>166</VL>
<PG>945-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Srebro-1998" NAME="Srebro 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;WRONG COMPARISON&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srebro SH, Rogenes PR, Edwards L, Lincourt WR</AU>
<TI>Comparison of efficacy and HPA effects of fluticasone propionate versus flunisolide in patients with mild to moderate asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2006" MODIFIED="2008-07-04 13:55:50 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Su 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-07-04 13:55:50 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su S-F, Yoon K, Levy A, Miller D, Matz P, Welch M, et al</AU>
<TI>Urine cortisol excretion in children 4-11 years old is not affected by therapeutic doses of fluticasone propionate HFA [Abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>Suppl 50</NO>
<PG>260s [P1512]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szefler-2005" MODIFIED="2008-07-08 10:40:55 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Szefler 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;EXCLUDE - INPATIENT STUDY&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D</AU>
<TI>Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>3</NO>
<PG>1104-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-07-08 10:40:55 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szefler SJ, Heron J, Lloyd M, Rohatagi S, Williams JE, Kundu S et al</AU>
<TI>High doses of the a novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>2</NO>
<PG>s216</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teper-1998" MODIFIED="2008-07-09 11:29:48 +0100" MODIFIED_BY="[Empty name]" NAME="Teper 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-07-09 11:29:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teper AM, Colom AJ, Cherry HR, Robaldo JF, Kofman CD, Maffey AF, et al</AU>
<TI>Effect of fluticasone propionate on asthmatic infants</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3</NO>
<PG>A711</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1997" NAME="Wilson 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AM, McFarlane LC, Lipworth BJ</AU>
<TI>Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1997</YR>
<VL>156</VL>
<NO>4 Pt 1</NO>
<PG>1274-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1998a" NAME="Wilson 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AM, Clark DJ, Devlin MM, McFarlane LC, Lipworth BJ</AU>
<TI>Adrenocortical activity with repeated administration of one-daily inhaled fluticasone propionate and budesonide in asthmatic adults</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>5</NO>
<PG>317-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1998b" NAME="Wilson 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AM, Sims EJ, Struthers AD, Lipworth BJ</AU>
<TI>Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone</TI>
<SO>Clinical Science</SO>
<YR>1998</YR>
<VL>95</VL>
<NO>4</NO>
<PG>513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-1997" MODIFIED="2008-07-09 11:30:01 +0100" MODIFIED_BY="[Empty name]" NAME="Wong 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-09 11:30:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wong J, Moon S, O'Callahan C, Simpson H</AU>
<TI>Inhaled steroids reduce the respiratory symptoms following bronchiolitis in infancy: a double-blind, randomised, placebo-controlled study</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>3</NO>
<PG>430S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-07-04 13:55:50 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Stanford-2004" NAME="Stanford 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanford R, Crim C, Wightman D, Edwards L, Rickard K</AU>
<TI>The impact of once daily fluticasone propionate on asthma specific quality of life in adolescents and adults with persistent asthma [Abstract]</TI>
<SO>Journal of Allergy, Asthma and Immunolgy</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>Suppl 1</NO>
<PG>Abstract No: 548</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wignarajah-2004" MODIFIED="2008-07-04 10:20:17 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Wignarajah 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-04 10:20:17 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wignarajah D, Zheng L, Reid D, Harding R, Walters EH</AU>
<TI>Fluticasone propionate decreases airway vascularity in asthma [Abstract]</TI>
<SO>Respirology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>Suppl 2</NO>
<PG>A24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-23 17:11:29 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-23 17:11:29 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Barnes-1998" MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Barnes 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PJ, Pedersen S, Busse WW</AU>
<TI>Efficacy and safety of inhaled corticosteroids</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<PG>S1-S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 1997" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society</AU>
<TI>The British guidelines on asthma management 1995 review and position statement</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>Suppl 1</NO>
<PG>S1-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-2003" MODIFIED="2008-07-23 17:11:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 2003" TYPE="JOURNAL_ARTICLE">
<AU>The British Thoracic Society/Scottish Intercollegiate Guidelines Network</AU>
<TI>British Guideline on the Management of Asthma</TI>
<SO>Thorax</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>Suppl 1</NO>
<PG>i1-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handbook" MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Cochrane Handbook" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GINA-1995" MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="GINA 1995" TYPE="OTHER">
<AU>National Asthma Education and Prevention Program</AU>
<TI>Global initiative for asthma management and prevention NHBLI/WHO workshop report</TI>
<SO>National Institute of Health, Bethseda, MD</SO>
<YR>1995</YR>
<NO>NIH Publication No. 95-3659</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-2001" MODIFIED="2008-07-14 12:01:14 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Harrison 2001" TYPE="JOURNAL_ARTICLE">
<AU>Harrison TW, Wisniewski A, Honour J, Tattersfield AE</AU>
<TI>Comparison of the systemic effects of fluticasone propionate and budesonide given by the dry powder inhaler in healthy and asthmatic subjects</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-23 17:11:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Current Controlled Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masoli-2005" MODIFIED="2008-07-23 17:11:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Masoli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Masoli M, Weatherall M, Beasley R</AU>
<TI>Fluticasone given once versus twice a day: Meta-analysis</TI>
<SO>Respirology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHBLI-1997" MODIFIED="2008-07-23 17:11:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NHBLI 1997" TYPE="OTHER">
<AU>National Asthma Education and Prevention Program</AU>
<TI>Guidelines for the Diagnosis and Managment of Asthma, Expert Panel Report No. 2</TI>
<SO>Bethesda MD: NIH/National Heart, Lung and Blood Institute</SO>
<YR>1997</YR>
<NO>NIH Publication No. 97-4051</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pedersen-1997" MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pedersen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen D, O'Byrne P</AU>
<TI>A comparison of the efficacy and safety of inhaled corticosteroids in asthma</TI>
<SO>Allergy: European Journal of Allergy &amp; Clincal Immunology</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>Suppl 39</NO>
<PG>S1-S34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorkness-1998" MODIFIED="2008-07-23 17:11:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Sorkness 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sorkness CA</AU>
<TI>Establishing a therapeutic index for the inhaled corticosteroids: part II</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1998</YR>
<VL>102</VL>
<PG>S52-S64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tattersfield-2004" MODIFIED="2008-07-23 17:11:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Tattersfield 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K</AU>
<TI>Safety of inhaled corticosteroids</TI>
<SO>Proceedings of the American Thoracic Society</SO>
<YR>2004</YR>
<VL>1</VL>
<PG>171-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-12 15:53:34 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-12 15:53:34 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:00 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Agertoft-1997">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:00 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Denmark, paediatric outpatient clinic<BR/>Design: crossover, 2 week washout<BR/>Length of intervention period: 2 weeks<BR/>Excluded: stated (none)<BR/>Withdrawals: stated (one child from low dose group due to sore throat)<BR/>Baseline characteristics: comparable between groups<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 children: 27M 21F <BR/>Age range: 6-12 years<BR/>Inclusion criteria: <BR/>Pre-pubertal children <BR/>Mild asthma requiring treatment with as needed beta2 agonists only<BR/>Exclusion criteria:<BR/>Inhaled or oral steroid use in last 2 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1 randomised to:</P>
<P>1. FP: 200mcg/d via Accuhaler DPI</P>
<P>2. BUD: 200 mcg/d via Turbuhaler DPI</P>
<P>3. Placebo</P>
<P>Group 2 randomised to:</P>
<P>1. FP: 400mcg/d via Accuhaler DPI</P>
<P>2. BUD: 400 mcg/d via Turbuhaler DPI</P>
<P>3. Placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>24 hour urinary cortisol excretion<BR/>Growth by lower leg knemometry<BR/>FEV1 <BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily asthma symptom score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:01 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Allen-1998">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, paediatric outpatient clinic<BR/>Length of intervention period: 12 months<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:23:11 +0100" MODIFIED_BY="Christopher J Cates">
<P>344 children enrolled, 325 randomised: 81M 244F<BR/>Age range: M 4-11 years, F 4-9 years )<BR/>Inclusion criteria:<BR/>Pre-pubescent children with mild to moderate asthma (ATS criteria 1987) for at least 3 months<BR/>FEV1 60 (% predicted) or greater<BR/>Exclusion criteria:<BR/>Systemic, intra-nasal or ophthalmic corticosteroids in last month<BR/>More than 60 days of systemic corticosteroid use in last 2 years</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 50 mcg 2xdaily (100 mcg/d) </P>
<P>2. 100 mcg 2xdaily (200 mcg/d) </P>
<P>Placebo: 2xdaily via </P>
<P>Delivery device: Diskhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Height assessment <BR/>Oral corticosteroids for asthma exacerbation (No. of courses or prednisolone)<BR/>Withdrawal due to asthma exacerbation<BR/>HRQOL: Functional Status IIR (FSII) questionnaire, Sleep Scale Children (SLP-C) questionnaire, Quality of Life of Parents of Asthmatic Children Questionnaire (QOL-PAC)<BR/>Oro-pharyngeal side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Authors confirmed use of allocation concealment </P>
<P>Criteria for withdrawal due to lack of efficacy: requirement for more than two seven day courses of oral corticosteroid</P>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:01 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Allen-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 months<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>111 adults randomised enrolled. Distribution between groups not clear. Mean FEV1: 61%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>i) FP 1000mcg BiD (2000); ii) FP500mcg BiD (1000); iii) Placebo. <BR/>Inhaler device: Diskus.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Steroid consumption; lung function; adverse events Steroid consumption; lung function; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Arets-2002">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, paediatric asthma hospital clinic, Europe<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:23:17 +0100" MODIFIED_BY="Christopher J Cates">
<P>88 children enrolled, 68 randomised. Mean age: FP: 6.86 (SD 1.5); PLA: 6.97 (SD 1.48); FEV1 (L): FP: 1.54 (SD 0.37); PLA: 1.53 (SD 0.39); FEV1 %: FP: 104.1 (SD 10.8); PLA: 99.8 (SD 17); Rescue medication free days: FP: 49.4 (SD 36.3); PLA: 45.8 (SD 38.3); am PEF L/min: FP: 213.4 (SD 63.9); PLA: 210.6 (SD 58.6); pm PEF: FP: 219.1 (SD 62.3); PLA: 219.8 (SD 58).</P>
<P>Inclusion criteria: Age 5-10; Physician diagnosed asthma</P>
<P>Exclusion criteria: Use of systemic steroids in last 2 months; ICS &gt;100mcg/d; Salbutamol &gt;1600mcg/d during &gt;30% days of last year; hospitalisation with asthma in last 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP500mcg/d versus Placebo. Inhaler device: MDI + spacer.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; PEF; Symptom-free days; wheeze score; parent global evaluation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Berger-2002-ICS">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Masking: double-blind<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT analysis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>401 adults randomised. Age range 12-84; FEV1 (L): FP: 2.47 (SEM 0.04); PLA: 2.47 (SEM 0.04); FEV1 (%): FP: 75.9 (SEM 8.6); PLA: 75.8 (SEM 8.3); am PEF (L/min): FP: 384.5 (SEM 7.5); PLA: 372.9 (SEM 6.1); pm PEF (L/min): FP: 401.2 (SEM 7.9); PLA: 391.1 (SEM 6.43); Composite asthma scores: FP: 1.45 (SEM 0.07); PLA: 1.36 (SEM 0.07); Symptom free days: FP: 25.7 (SEM 2.6); PLA: 28.1 (SEM 2.6); Rescue medication usage (puffs/day): FP: 1.87 (0.12); PLA: 1.82 (SEM 0.11); Rescue medication free days: FP: 41 (SEM 2.7); PLA: 39.3 (SEM 2.8); Night awakenings (in baseline week): FP: 0.68 (SEM 0.06); PLA: 0.54 (sem 0.06) </P>
<P>Inclusion criteria: &gt;12 years of age; asthma confirmed by ATS criteria; use of ICS for 3 months prior to study entry; stable low dose of ICS for 1 month prior to study entry (BDP: 168-504mcg/d; FP: 88-264mcg/d; Flunisolide: 500-1000mcg/d; TAA: 400-1000; BUD: 200-400mcg/d); FEV1: 60-90% predicted; &gt;12% reversibility &lt;30mins after inhalation of 180mcg SABA. </P>
<P>Exclusion criteria: Life-threatening/unstable asthma; other clinically significant uncontrolled disease; chicken-pox within 3 weeks; hypersensitivity to ß-agonists, sympathomimetics, or corticosteroids; respiratory infection; pregnancy; current tobacco usage or &gt;10 pack-year history of smoking; use of the investigational drugs; participants not allowed to use LABAs, sodium cromoglycate, nedocromil, anticholinergic agents, leukotriene antagonists</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP250 versus placebo. Inhaler device: Diskus.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; Symptoms; Rescue medication usage; Withdrawals; Tolerability; Exacerbations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Berger-2002-SABA">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT analysis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:23:28 +0100" MODIFIED_BY="Christopher J Cates">
<P>408 adults randomised. Age range: 12-74; FEV1 (L): FP: 2.52 (SEM 0.05); PLA: 2.51 (SEM 0.04); FEV1 (% pred): FP: 72 (SEM 7.3); PLA: 71.9 (SEM 6.9); am PEF (L/min): FP: 363.7 (SEM 7.3); PLA: 356.1 (SEM 6.7); pm PEF (L/min): FP: 394.2 (SEM 7.5); PLA: 380.9 (SEM 7.1); Composite asthma scores: FP: 2.45 (SEM 0.06); PLA: 2.40 (SEM 0.05); Symptom free days (%): FP: 3.1 (SEM 0.7); PLA: 3.5 (SEM 0.9); Rescue medication usage (% days): FP: 13.3 (SEM 1.6); PLA: 13.5 (SEM 1.5); Night awakenings (N during baseline week): FP: 0.94 (SEM 0.09); PLA: 0.82 (SEM 0.08).</P>
<P>Inclusion criteria: &gt;12 years of age; asthma confirmed by ATS criteria; requirement for pharmacotherapy for at least 6 mo; previous treatment with SABA; no ICS Rx for 1 mo prior to study entry; FEV1 between 60-85% predicted; &gt;12% reversibility &lt;30mins after inhalation of 180mcg SABA.</P>
<P>Exclusion criteria: Life-threatening/unstable asthma; other clinically significant uncontrolled disease; chicken-pox within 3 weeks; hypersensitivity to ß-agonists, sympathomimetics, or corticosteroids; respiratory infection; pregnancy; current tobacco usage or &gt;10 pack-year history of smoking; use of the investigational drugs; participants not allowed to use LABAs, sodium cromoglycate, nedocromil, anticholinergic agents, leukotriene antagonists</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP250 versus placebo. <BR/>Inhaler device: Diskus.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; Symptoms; Rescue medication usage; Withdrawals; Tolerability; Exacerbations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Bernstein-2004">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:02 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>531 adults randomised. Age range: &gt;/=12 years. </P>
<P>Inclusion criteria: &gt;12 years; FEV1 40-65% predicted. </P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 440 BID (880mcg/d)</P>
<P>Placebo </P>
<P>Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function; withdrawal due to lack of efficacy; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished conference abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Busse-2001">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>338 adults randomised. Age range: 12-75 years. Baseline pulmonary function 66-67% predicted across treatment groups; % participants with 70.1-80% FEV1 predicted: FP 51;Zaf: 55; Pla: 46; Participants with 50 - 70 % predicted FEV1: FP: 60; Zaf: 52; Pla: 65; Participants with asthma diagnosed &gt;/=10 years: 64-73% across treatment groups. </P>
<P>Inclusion criteria: &gt;12 years; asthma diagnosed according to ATS; use of SABA (scheduled or prn) for at least 6 weeks preceding the study FEV1 between 50-80% predicted; reversibility of FEV1 (12% increase within 30 minutes after inhaling 180mg albuterol). </P>
<P>Exclusion criteria: Life-threatening asthma; significant and uncontrolled disease (COPD/coronary disease); use of tobacco products in preceding year/smoking history of more than 10 pack-years; systemic steroid within 1 mo of screening; leukotriene modifier within 1 wk of screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 88mcg BID (176mcg/d) + oral placebo </P>
<P>Inhaled placebo + oral zafirlukast versus placebo.</P>
<P>Inhaler device: MDI </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function (Change in FEV1; am/pm PEF); Symptoms (symptom scores; symptom-free days; awakenings due to asthma); Medication usage (albuterol use (puffs day); albuterol-free days);</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study reported in abstract form only</P>
<P>Study also included a parallel treatment arm with oral zafirlukast 20 mcg 2xdaily</P>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Caffey-2005">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study (UK)<BR/>Length of intervention period: 4 weeks<BR/>Design: crossover group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 children. Age range 5-12 years. FEV1 88% predicted </P>
<P>Inclusion criteria: Mild to moderate asthma; clinically stable on one long-term controller drug.</P>
<P>Exclusion criteria: systemic steroids within one month of study entry.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 50mcg BID (100mcg/d)</P>
<P>Placebo</P>
<P>Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; Symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Casale-2001">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 3 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>134 adults randomised. Age range: 18-50. Mean FEV1 (SD): PLA: 3.0 (0.66); FP110: 3.3 (0.86); FP220: 3.2 (0.67); FP330: 3.0 (0.69); FP440: 3.2 (0.77). </P>
<P>Inclusion criteria: non-smokers; 18-50 years; diagnosis of persistent mild to moderate asthma confirmed within previous 12 months by response to SABA (increase in FEV1 &gt;/= 12%)/methacholine challenge &lt;8mg/mL); FEV1 &gt;/=65% predicted; no OCS/nasal/ICS use in previous 6 months. </P>
<P>Exclusion criteria: significant pulmonary disease (e.g. COPD); exacerbation within 6 weeks; URTI within 30 days screening; oestrogen usage; current condition that might confound data interpretation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PLA versus FP220 versus FP440 versus FP660 versus FP880. </P>
<P>Inhaler device: pMDI </P>
<P>Participants also randomised to flunisolide 500 bid, 1000 bid and prednisolone 7.5mg qd</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HPA function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Chervinsky-1994">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinic<BR/>Length of intervention period: 8 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>331 adults<BR/>Mean age: 48-59 years <BR/>Inclusion criteria:<BR/>Mild to moderate asthma (as defined by the Committee on Diagnostic standards for Non-Tuberculous Respiratory Diseases 1962)<BR/>Treatment with BDP for at least 1 month prior to study and daily beta2 agonist, or daily theophylline for at least 2 weeks prior to study<BR/>FEV1 60-90 (% predicted)<BR/>Exclusion criteria:<BR/>Not stated </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-08 10:33:13 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FP:<BR/>1. 25 mcg 1 puff 2xdaily (50 mcg/d)</P>
<P>2. 100 mcg 2xdaily (200mcg/d)</P>
<P>3. 500 mcg 2xdaily (1000 mcg/d)</P>
<P>Placebo: 2 x daily</P>
<P>Delivery device: MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Probability of remaining in study<BR/>All outcomes expressed as change compared to baseline: FEV1; FVC;<BR/>FEF25-75; Morning PEFR; Evening PEFR; Daily symptom score; Daily beta2 agonist use; Night awakenings; Morning plasma cortisol; Plasma cortisol 30-60 min post 250 mcg iv cosyntropin; Urinary free cortisol; Plasma cortisol 60 min post ACTH </P>
<P>Physician-rated global assessment of efficacy <BR/>Oropharyngeal side-effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
<P>Additional data sourced from www.clinicalstudyresults.org<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Chuchalin-2008">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study (28 countries in North &amp; South America, Asia, Europe, Africa &amp; Australia)<BR/>Length of intervention period: 52 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:33:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>1295 adolescents and adults with mild asthma (block randomisation 3:1)<BR/>Age range: 12-79 years</P>
<P>Inclusion criteria: 12-79 years; documented history of asthma &gt;/=6 months; SABA prn; pre-BD PEF &gt;/=80% predicted; symptom score &gt;/=1 on 3-6 days during last 7 days of run-in; reversibility of &gt;/=15% PEF<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 100 BID versus Placebo <BR/>Inhaler device: Diskus/Accuhaler</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>am PEF; symptoms; FEF25-75; FEV1; rescue medication use; adverse events; exacerbation rates</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Condemi-1997">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 24 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated (ITT)<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>378 adults enrolled, 291 randomised: 142M 149F<BR/>Age range: 12-74 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>Requirement or maintenance ICS for 4 weeks or longer<BR/>FEV1 50-80 (% predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>One or more urgent or emergency care visit due to asthma in last 12 months<BR/>During one week run-in: no more than 3 days of rescue beta2 agonist use 12 puffs/d, no more than 4 days when morning PEFR 20% lower than previous evening PEFR, no more than 3 nights with awakening due to asthma symptoms<BR/>Adequate compliance<BR/>Exclusion criteria:<BR/>Systemic of intranasal steroid in last month<BR/>Current use of nedocromil or cromolyn<BR/>Previous treatment with methotrexate or gold salts<BR/>Immunotherapy requiring change in dose regimen in last 12 weeks<BR/>Pregnancy or lactation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 250 mcg 2xdaily (500 mcg/d) </P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Change in FEV1 compared to baseline<BR/>Change in morning PEFR compared to baseline<BR/>Change in daily asthma symptom score compared to baseline<BR/>Change in % symptom free days compared to baseline<BR/>Change in No. night-time awakenings compared to baseline<BR/>Change in daily rescue beta2 agonist use compared to baseline <BR/>Change in % rescue beta2 agonist free days compared to baseline<BR/>Withdrawal due to lacy of efficacy<BR/>Probability of remaining in study<BR/>Oro-pharyngeal side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-08 10:17:50 +0100" MODIFIED_BY="Toby J Lasserson">
<P>No reply from author to clarify details of randomisation method</P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
<P>Study also included a TA treatment arm: results not considered in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Convery-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, Europe and North America<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>52 adults randomised. Age range 20-50. FEV1 % predicted: PLA: 99.5 (SD 13.57); FP: 102.86 (SD 12.41); PD20 mcg: PLA: 5.47 (SD 1.33); FP2000: 5.58 (SD 0.93). </P>
<P>Inclusion criteria: PD20 &lt;1600mcg from 2 baseline methacholine tests conducted within 2 weeks but separated by 48 hours; 20-50 years of age; nonsmokers and smokers who had smoked at least 5 cigarettes daily. </P>
<P>Exclusion criteria: Use of ß-blocking or antimuscarinic drugs; use of aspirin or nonsteroidal anti-inflammatory; RTI requiring antibiotics in preceding 4 weeks; uncontrolled systemic disease; history of alcohol abuse <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP2000 versus PLA. Delivery device: pMDI. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Expired levels of carbon monoxide; FEV1; PD20</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Participants recruited had not knowingly been diagnosed with asthma - Participants with positive PD20 tests were recruited.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Corsico-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre, Italy<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 adults randomised. Age: FP: 31 (SD 9); PLA: 31 (SD 12); FEV1 %: FP: 98 (SD 15); PLA: 102 (SD 14); FVC % pred: FP: 110 (SD 12); PLA: 112 (SD 12). Participants were described as suffering from mild asthma according to ATS criteria. All participants were on SABAs as needed. </P>
<P>Inclusion criteria: Positive response to inhalation challenge with methacholine; clinically stable for previous 2 months; FEV1 &gt;80% predicted; not to have suffered URTI in previous 4 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 1500mcg versus PLA. Inhaler device: Unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; FVC; IVC; Vmax 50; Vp50; log max dose of MCh mcg; log PD20 mg; FVC versus FEV1; Intercept; slope; IVC versus Vp50; Intercept; Slope; Vmax 50 versus Vp 50; Intercept; Slope</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Derom-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Belgium<BR/>Length of intervention period: 1 week<BR/>Randomisation: yes (method not stated)<BR/>Allocation concealment: not stated<BR/>Design: crossover study<BR/>Masking: double-blind<BR/>Excluded: not stated<BR/>Withdrawals: stated (non-ITT)</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:33:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>23 adults randomised; Age range: 19-57; FEV1: 2.95 (SD 0.83) (FEV1 % predicted: 80.0 (SD 21.4)); Mean FVC: 4.42 L (SD 0.94).</P>
<P>Inclusion criteria: either sex; 18-60 years of age; ATS defined asthma; &gt;/=40% predicted value; Either post-BD increase in FEV1 of at least 200ml or &gt;/=12% of baseline, OR diurnal variation of PEF &gt;/=15% on at least 2 days/week during run-in.</P>
<P>Exclusion criteria: Exacerbation 4 weeks before inclusion; use of oral steroids within 4 weeks; use of ICS within 6 months; other systemic steroids within 4 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 200mcg; FP 1000mcg; BUD: 200mcg; BUD 800mcg; Placebo. Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; PEFR; Serum cortisol; White blood cell count; Neutrophils; Basophils</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data reported for effects after 24 hours @ 1 week</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 15:53:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Derom-2005">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Belgium<BR/>Length of intervention period: unclear<BR/>Design: crossover study<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>25 adults randomised <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP500 versus FP1000 versus PLA; washout period: 3 weeks. Study duration: 6 treatment periods unclear duration. Inhaler device: unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cortisol suppression; PC20</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 15:53:34 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Ekroos-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Finland, hospital outpatient clinic<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: no details<BR/>Withdrawals: no details<BR/>Baseline characteristics: no demographic data presented<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 adults: 11M 15F<BR/>Age range: 21-59 years<BR/>Inclusion criteria:<BR/>Adult non-smoking asthmatics<BR/>Histamine BHR (PD15 FEV1) &lt; 0.6mg<BR/>Exclusion criteria:<BR/>Oral or inhaled steroid use in last 2 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 250 mcg 2xdaily (500 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exhaled nitric oxide concentration<BR/>Histamine BHR (PD15 FEV1)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study reported in abstract form only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Falcoz-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: multicentre study<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (non-ITT)</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>232 adults randomised; 230 evaluable. Age range: 18-72 years. Participants suffered from mild-to-moderate asthma </P>
<P>Inclusion criteria: Mild-to-moderate asthma (defined as FEV1 50-80%)</P>
<P>Exclusion criteria: Not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 100mcg versus FP 500mcg versus placebo. Duration 6 weeks. Inhaler device: DPI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Plasma concentrations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data taken only for study 1. Study 2 assessed equal dose of FP given via different inhalers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Faul-1998">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: two centre study UK and Ireland, hospital outpatient clinics<BR/>Length of intervention period: 8 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>27 adults randomised, 23 completed: 16M 7F<BR/>Age range: 19-45 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>FEV1 &gt; 40 (% predicted)<BR/>12.5% or greater improvement in FEV1 after inhaled beta2 agonist<BR/>Histamine BHR (PC20 FEV1) 8 mg/ml or less<BR/>Exclusion criteria:<BR/>Treatment with corticosteroids in last 3 months<BR/>Exacerbation of asthma within last 3 months<BR/>Pregnancy or serious concurrent illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-08 10:33:42 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FP: 250 mcg 4 puffs 2xdaily (2000 mcg/d)</P>
<P>Placebo: 4 puffs 2xdaily</P>
<P>Delivery device: MDI+Volumatic spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 (after:baseline ratio)<BR/>Change in FEV1 compared to baseline (after:baseline ratio)<BR/>FEV1/FVC ratio (after:baseline ratio)<BR/>FEF25-75 (after:baseline ratio)<BR/>Histamine bronchial responsiveness (PC20 FEV1) (after:baseline ratio)<BR/>Bronchial wall immunopathology:<BR/>Total T cells, primed T cells, CD4:CD8 ratios, CD68+ cells, inductive and suppressive macrophages, eosinophils, activated eosinophils.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>Non-parametric analyses for all outcomes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-FLIC15">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study in Italy<BR/>Design: parallel group<BR/>Length of intervention period: 4 weeks<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>33 participants. Mean age 37-44 years.</P>
<P>Inclusion criteria: M/F participants; age 18-60 years; persistent mild-moderate asthma (ATS).</P>
<P>Exclusion criteria: Preventer medication 4 weeks prior to study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>i) FP100mcg bid (200mcg/d)</P>
<P>ii) FP500mcg bid (1000mcg/d)</P>
<P>iii) Placebo</P>
<P>Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Withdrawals; FEV1; PEFR; FVC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished study downloaded from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-FLTA2007">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: 21 centres in USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>262 children <BR/>Mean age: 7.6-8<BR/>Inclusion criteria: <BR/>Age 4-11 years; asthma of at least 3 months duration requiring pharmacotherapy; PEF &lt;/=85% (ages 4-5); FEV1 50-85% predicted (ages 6-11); 15% variation in FEV1 in last 6 months /&gt;/=15% increase in FEV1 within 30mins of 2 puffs albuterol at screening visit. <BR/>Exclusion criteria: life threatening asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP50mcg BID (100mcg/d)</P>
<P>2. FP100mcg QD (100mcg/d)</P>
<P>3. Placebo</P>
<P>Delivery device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; clinic PEF; symptoms; day and night use of SABA; withdrawal; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-FLTA3014">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: 21 centres in USA<BR/>Length of intervention period: 26 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>379 adults and adolescents. <BR/>Mean age: 37-39<BR/>Inclusion criteria: &gt;/=12 years; 6 month history of asthma requiring pharmacotherapy; FEV1 50-85%; use of SABA and/or ICS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP 100mcg BID (without spacer)</P>
<P>2. FP250mcg BID (with spacer)</P>
<P>3. FP250mcg BID (without spacer)</P>
<P>4. Placebo (with or without spacer)</P>
<P>Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; withdrawals; SABA usage; symptoms; adverse events; withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-FLTA3020">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: 25 centres in USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>191 adults and adolescents<BR/>Mean age: 31-36 years.</P>
<P>Inclusion criteria: &gt;/=12 years; 6 month history of asthma requiring pharmacotherapy; FEV1 50-85%; use of SABA and/or ICS; pre-BD FEV1% predicted 60-90%; SABA prn or regular use only; effective use of MDI.</P>
<P>Exclusion criteria: ICS within 30 days of screening; hospitalisation due to asthma on 2+ occasions in 12 months prior to screening; significant other medication within 30 days of screening</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. HFA-FP 110mcg BID</P>
<P>2. HFA-FP 220mcg BID</P>
<P>3. CFC-FP 110mcg BID</P>
<P>4. CFC-FP 220mcg BID</P>
<P>5. Placebo</P>
<P>Inhaler device: MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; withdrawals; symptoms; rescue medication usage; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-FLTA3022">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: 39 centres in USA<BR/>Design: parallel group</P>
<P>Length of intervention period: 16 weeks (plus 2 week run-in)<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable between groups<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:23:39 +0100" MODIFIED_BY="Christopher J Cates">
<P>168 adolescents/adults: 78M/90F Age range: &gt;12 (mean age: 50 years)<BR/>Inclusion criteria: 12 years of age or older FEV1 40-85 (% predicted); oral steroid dependent asthma Exclusion criteria: History of life-threatening asthma; 3 or more hospitalisations in past year; therapy with anti leukotrienes, nedocromil and/or ipratropium bromide within 4 weeks of randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP440mcg CFC bid</P>
<P>2. FP880mcg CFC bid</P>
<P>3. FP440mcg HFA bid</P>
<P>4. FP880mcg HFA bid</P>
<P>5. Placebo </P>
<P>Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Oral steroid reduction<BR/>FEV1<BR/>am PEF <BR/>pm PEF <BR/>Symptoms<BR/>Rescue medication usage<BR/>AQLQ<BR/>Withdrawals<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-FLTA4030">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: 33 centres in USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:23:42 +0100" MODIFIED_BY="Christopher J Cates">
<P>324 adults and adolescents.<BR/>Mean age: 32-34<BR/>Inclusion criteria: Stable asthma controlled with SABA. Unstable asthma defined as: Fall in FEV1 to below 50% predicted, or greater than 20% decrease compared with pre-BD FEV1 at baseline; am PEF below stability limit on 3 or more occasions of 7 days immediately preceding clinic visit (defined as 20% decrease from the mean am PEF in run-in; Nocturnal awakenings due to asthma on &gt;/=3 nights during 7 days immediately preceding clinic visit; Use of &gt;12 puffs of SABA on more than 2 days during 7 days immediately preceding clinic visit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP 88mcg BID <BR/>2. Zafirlukast 20mg BID <BR/>3. Placebo </P>
<P>Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; rescue medication usage; symptoms; asthma exacerbations; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted for total population (including those deemed unstable according to pre-defined stability criteria)</P>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Galant-1996">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinic<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics:<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>353 adolescents/adults: 236M 117F<BR/>Age range: 12-75 years<BR/>Inclusion criteria: <BR/>12 years of age or older<BR/>FEV1 45-75 (% predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Significant asthma symptoms during run-in period: e.g. daily asthma symptoms with &gt; 8 puffs beta2 agonist/day or 2- 4 weekly nighttime awakenings due to asthma<BR/>Exclusion criteria:<BR/>History of life-threatening asthma<BR/>Smokers of 10 pack years or greater<BR/>Previous use of inhaled, oral, injectable or intra-nasal corticosteroids<BR/>Pregnancy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 25 mcg 2 puffs 2xdaily (100 mcg/d) </P>
<P>2. 50 mcg 2 puffs 2xdaily (200 mcg/d) </P>
<P>Placebo: 2 puffs 2xdaily</P>
<P>Delivery device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Probability of remaining in study</P>
<P>All outcomes expressed as change compared to baseline:</P>
<P>FEV1<BR/>Morning PEFR<BR/>Daily use of beta2 agonist <BR/>Daily asthma symptom score <BR/>Night-time awakenings per week </P>
<P>'Effective or very effective' Physician rated global assessment of efficacy (No. of patients)</P>
<P>Oro-pharyngeal side effects</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on diurnal variability in PEFR, night-time awakenings, rescue beta2 agonist use and FEV1 </P>
<P>Study also included an oral theophylline treatment arm: results not considered in this review<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:07 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Galant-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinic<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>229 adults and adolescents: 116M 113F<BR/>Age range: 13-76 years<BR/>Inclusion criteria:<BR/>12 years of age or older<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>FEV1 60-80 (% predicted)<BR/>15% or greater reversibility in FEV1 following inhaled beta2 agonist<BR/>15% or greater variability in FEV1 in previous 6 months<BR/>Exclusion criteria:<BR/>Pregnancy or severe concurrent disease<BR/>Use of methotrexate, gold salts, oral or injectable corticosteroids in last 4 weeks</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 500 mcg 2xdaily (1000 mcg/d) via Accuhaler DPI</P>
<P>2. 500 mcg 2xdaily (1000 mcg/d) via Diskhaler DPI </P>
<P>Placebo: via 2xdaily </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Probability of remaining in study </P>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily asthma symptom score<BR/>Daily use of beta2 agonist<BR/>Night-time awakenings per week</P>
<P>Morning plasma cortisol<BR/>Oro-pharyngeal side effects</P>
<P>Withdrawal due to lack of efficacy</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings, rescue beta2 agonist use or clinical exacerbation requiring emergency hospital treatment</P>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:07 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Giannini-2003">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Italy<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>27 randomised. Mean age: 38.67 (SD 16.97). M/F: 15/12; history of atopy: 18/6; FEV1: 3.23 (SD 0.91); FEV1 % predicted (median (range)): 96 (76-122); PD20: 0.220</P>
<P>Inclusion criteria: diurnal/nocturnal symptoms=0, low PEF variability [maximal amplitude(-MA) &lt;10%). </P>
<P>Exclusion criteria: no use of ß-agonists throughout run-in</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP100 versus FP250 versus PLA. Inhaler device: unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; PD20; Sputum eosinophils; max amplitude; PEF; Symptoms; Rescue medication use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:07 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Gross-1998">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: 24 centres in USA<BR/>Length of intervention period: 24 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:34:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Diagnosis: chronic asthma (American Thoracic Society criteria).<BR/>Asthma severity: baseline FEV1 for TAA and placebo groups were 68% (0.8%) versus 67%(0.9%), respectively.<BR/>N = 304 (204 to relevant treatment).<BR/>Age: &gt;12 yrs (mean 38).<BR/>Sex: M167 (116 to relevant treatment), F 137 (88 to relevant treatment).<BR/>History: patients had FEV1 of 50- 80% of predicted normal or required urgent care for their asthma within the past year, and were currently receiving either 400-600 mcg/day of beclomethasone dipropionate or 800-1200 mcg/day of TAA.<BR/>Excluded: pregnancy, lactation or use of methotrexate, gold salts, nedocromil or corticosteroid, having a significant concomitant illness or immunotherapy which requires change in dosage regimen within 12 weeks, taking any medication that might affect the course of asthma.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Inhaled triamcinolone acetonide 800 µg/d N=101.<BR/>2. Placebo N=103.<BR/>3. Fluticasone propionate 500 µg/d N=100.</P>
<P>Device: MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Lung function.<BR/>2. Albuterol use.<BR/>3. Night time awakenings.<BR/>4. Adverse events. <BR/>5. Rescue salbutamol use.<BR/>6. Quality of life based on AQLQ<BR/>- Activity limitation.<BR/>- Asthma symptoms.<BR/>- Emotional function.<BR/>- Environmental exposure.<BR/>- Global<BR/>7. Quality of life based on (SF-36):<BR/>- Physical functioning.<BR/>- Role - physical.<BR/>- Role - emotional.<BR/>- Social functioning.<BR/>- Mental health.<BR/>- Pain.<BR/>- Vitality.<BR/>- Health perceptions.<BR/>8. Leaving the study early. </P>
<P>Unable to use-<BR/>Symptom score (not validated scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Hart-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, UK<BR/>Length of intervention period: 14 weeks<BR/>Design: crossover study<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 adults randomised; Age years: 28 (SE 1.4); FEV1 L: 3.7 (SE 0.2); FEV1 (% pred): 98.5 (SE 2.8); log 10 PC20: -0.35 (SE 0.15). Participants described as suffering from mild, stable asthma </P>
<P>Inclusion criteria: &lt;15% improvement in FEV1 after 200mcg SABA; PC20 &lt;4mg/mL; Atopy (&lt;/=2 +ve skin prick test to common allergens; inhaled or oral steroids in preceding 6 months. </P>
<P>Exclusion criteria: Current smokers/ex-smokers of &lt;5 pack years; patients &lt;80% predicted</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP1000mcg daily versus placebo. Inhaler device: pMDI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cell count; BHR; protein expression; DNA-binding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No clinical outcomes reported. Lung function (FEV1 and PEF recorded but not presented)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Hoekstra-1996">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: The Netherlands, primary care and hospital outpatient clinic<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>34 children: 26M 8F<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1975)<BR/>Serum IgE greater than normal range (corrected for age)<BR/>At least one specific serum IgE against a major inhaled allergen<BR/>FEV1 &gt; 75 (%predicted)<BR/>Histamine BHR (PC20 FEV1) &lt; 8 mg/ml<BR/>10% or greater reversibility in spirometric measures after inhaled beta2 agonist<BR/>Exclusion criteria:<BR/>Use of inhaled corticosteroids in last 4 weeks<BR/>Need for systemic corticosteroids &gt; 3 times in last 6 months <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 100 mcg 2xdaily (200 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV (% predicted)<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Nocturnal (4 am) PEFR <BR/>Morning wheeze score<BR/>Histamine BHR (log 2 PC20 FEV1) <BR/>Change in % reversibility of FEV1 after inhaled beta2 agonist compared to baseline<BR/>Morning serum cortisol <BR/>Morning urine cortisol<BR/>Blood eosinophil count<BR/>Serum ECP<BR/>Serum EDN<BR/>Urinary EDN</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Hofstra-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: The Netherlands, paediatric outpatient clinic<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: no details<BR/>Withdrawals: no details<BR/>Baseline characteristics: no details<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>37 children<BR/>Age range: 6-14 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma <BR/>20% or greater fall in FEV1 after exercise test<BR/>Exclusion criteria:<BR/>ICS use in last 4 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 100 mcg 2xdaily (200 mcg/d)</P>
<P>2. 250 mcg 2xdaily (500 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>% fall in FEV1 post exercise test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients were randomised to receive FP or placebo and treated for 6 weeks. After 6 weeks patients receiving placebo were re-randomised to either dose of FP for a further 18 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Jayaram-2005">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: unclear<BR/>Length of intervention period: unclear<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 31 (PLA: N = 13; FP: N = 18)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP versus PLA (dosage unclear)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sputum eosinophils; symptoms; rescue medication usage; exacerbations; spirometry; am &amp; pm PEF; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Conference abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Jeffery-2002">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre teaching hospital<BR/>Length of intervention period: 6 weeks<BR/>Design: crossover study<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 adults randomised; Mean age: 31.3 years; Mean FEV1 (L): 3; Mean FEV1 % pred: 75.6; Mean PC20: 0.29. </P>
<P>Inclusion criteria: Diagnosis of asthma; &gt;/=15% reversibility in FEV1; bronchial reactivity had to be &lt;4mg/mL; non-smoking; receiving SABA treatment only</P>
<P>Exclusion criteria: URTI/exacerbation of asthma within 4 weeks of study entry; asthma medication in last 2 weeks (apart from SABA); ICS in last two months; OCS in previous 3 months; females who were pregnant or lactating were excluded; skin prick +ve pts were recruited only if it was outside the season of their allergy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 500 mcg/day versus SAL 100mcg per day versus PLA. All interventions given via Diskus. Study duration: 3 x 6 week treatment arms (no washout)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Inflammatory cell markers; symptoms; FEV1; PEF; FVC; PC20; erythema</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Katz-1998">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: multicentre study, Europe, Middle East and Asia, hospital outpatient clinics<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>263 children: 166M 97F<BR/>Age range: 4-11 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (not otherwise defined) <BR/>Recurrent episodes of bronchoconstriction and cough<BR/>Able to use delivery device and peak flow meter satisfactorily<BR/>PEFR 75 (% predicted)or less, or PEFR 75-90 (% predicted) with asthma symptoms during run-in period<BR/>Exclusion criteria:<BR/>Treatment with inhaled corticosteroids within last 3 months<BR/>Oral steroids in last month<BR/>Continuous treatment with oral steroids over 2 months or more in past<BR/>Hospital admission due to asthma in last 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 50 mcg 2xdaily (100 mcg/d) </P>
<P>2. 100 mcg 2xdaily (200 mcg/d) </P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1 <BR/>FVC <BR/>FEF 25-75 <BR/>Morning PEFR <BR/>Evening PEFR <BR/>Daily asthma symptom score Night-time wakening score <BR/>Daily use of beta2 agonists </P>
<P>Probability of remaining in study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reply from author but unable to clarify details of randomisation method. Detail of randomisation obtained from FDA website (31/08/2005)</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, PEFR, sleep disturbance or rescue beta2 agonist use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Kavuru-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: yes<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>527 adults and adolescents screened, 356 randomised (four arm study; PLA: N = 82; FP: N = 90), Age range: 12-67; Mean baseline FEV1 (% predicted): PLA: 64; FP: 64. Reversibility (%): PLA: 32; FP: 30; Therapy @ baseline: PLA: ICS - 55, SAL - 27; FP: ICS - 63, SAL - 27 </P>
<P>Inclusion criteria: &gt;/= 12 years of age; medical history of asthma (ATS criteria); at least 6 months duration; FEV1 between 40-85% predicted; &gt;/= 15% reversibility post SAB; Participants treated with ICS prior to enrolment had to have been treated with BDP 252-420mcg/d (6-10 puffs/d), TRA 600-1000mcg/d (6-10 puffs/d); FLU: 1000mcg/d (250 QID); FP 176mcg/d (44 QID) for at least 1 month prior to enrolment without change in regimen; If participants using SAL, they had to do so for at least 1 week prior to screening, and demonstrated FEV1 &lt;/= 85% predicted post SABA and not received concurrent ICS for 1 month prior to screening; provision of signed consent</P>
<P>Exclusion criteria: Female participants had -ve pregnancy test, and were sterile, post-menopausal or using acceptable birth control measures; history of life-threatening asthma; hypersensitivity to ICSor beta-agonists; smoking history (&gt;10 pack years); use of oral, inhaled (external to guidelines above) or IM CS therapy, intranasal CS (except for 'Flonase'); use of OCS in previous 6 months; use of over the counter medicines that might affect course of asthma; abnormal chest x-ray; abnormal ECG; significant concurrent disease. During screening period, participants not eligible if they had &gt;3 awakenings requiring asthma during 7 days immediately preceding randomisation. ICS patients not eligible if using &gt;12 puffs SABA per day for more than 3 days, SAL patients not eligible using &gt;6 puffs SABA per day for more than 3 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP200 versus PLA. Inhaler device: Diskus. Single-blind run-in with a placebo (2 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; adverse events; symptoms; ECG; rescue medication usage; withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Kemp-2004">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 2 years<BR/>Design: parallel group<BR/>Excluded: yes<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:34:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>190 adults and adolescents screened, 160 randomised (three arm study; PLA: N = 54; FP400: N = 55; FP1000: 51), Age range: 18-50; Mean baseline FEV1 (% predicted): PLA: 83; FP100: 82; FP500: 85</P>
<P>Inclusion criteria: 18-50 years (F: 18-40); mild asthma (6 months); FEV1: 50-100% predicted</P>
<P>Exclusion criteria: Significant co-morbidity of bone; alterations in body weight; reversal of nocturnal sleeping hours; substance abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP200 BID (400) versus FP1000 BID (1000) versus PLA. Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Bome mineral density; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Laforce-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study,USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>242 children screened, 192 randomised. Age range: 4-11; FEV1 (% predicted) (mean (SEM)): FP200: 70 (0.8); FP100: 70 (1.0); Placebo: 73 (0.8); FEV1 (L) (mean (SEM)): FP200: 1.40 (0.04); FP100: 1.36 (0.04); Placebo: 1.51 (0.04); Clinic am PEF (Mean (SEM)): FP200: 208 (7); FP100: 208 (6); Placebo: 219 (7); Diary am PEF L/min (mean (SEM)): FP200: 220 (8); FP100: 222 (7); Placebo: 234 (8); Asthma symptom scores (mean (SEM)): FP200: 0.88 (0.06); FP100: 0.93 (0.07); Placebo: 0.85 (0.06); Albuterol use (puffs/day) (mean (SEM)): FP200: 2.1 (0.3); FP100: 2.0 (0.3); Placebo: 1.7 (0.2); Nighttime awakenings/night (mean (SEM)): FP200: 0.10 (0.02); FP100: 0.10 (0.02); Placebo: 0.08 (0.02) </P>
<P>Inclusion criteria: male and premenarchal females; ATS-diagnosed asthma; Requirement for pharmacotherapy for 3 mo prior to start of the trial; Baseline PEF &gt;/= 85% predicted; Baseline FEV1 50-85% predicted; &gt;/= 15% reversibility to albuterol or 15% variability in FEV1 within 6 months prior to the study (patients aged 6-11); Stable asthma (no more than 3 days from preceding 7 where &gt;/-12 puffs of albuterol per day/6 doses of albuterol power per day; no more than 3 am PEFs more than 20% below previous pm PEF; no more than 3 nights awakening resulting from asthma</P>
<P>Exclusion criteria: History of life threatening asthma or other severe chronic disease; any RTI within 2 weeks prior to study; chickenpox 3 weeks prior to study; oral and parenteral steroids within 1 mo prior to study; use of methotrexate/gold salts; use Pf prescription or over the counter medication which may have affected course of asthma; participation in previous Diskus trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP200mcg QD (+ placebo for evening) versus FP 100mcg BD versus placebo. Inhaler device: Diskus. Single blind run-in 7 days (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function (predose am FEV1; clinic PEF - measurements taken between 7am and 10am; diary PEF (am and pm); Symptoms; Rescue medication use; nighttime awakenings requiring albuterol; Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Langley-2002">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, UK<BR/>Length of intervention period: 4 weeks<BR/>Design: crossover study<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>59 adults randomised. 48 completed; mean age: 32.6 (SD 9.2); M/F: 18/30; FEV1 (L): 3.2 (SD 0.7); Duration of reversible obstruction &gt;15 years: 32; Patients using a spacer: 4; % predicted FEV1: 93.5 (11.8); Never smoked: 28; current smoker: 3. </P>
<P>Inclusion criteria: Patients &gt;/=18 years; resting FEV1: &gt;/=60%; PD20 &lt;/=3.2MG; no significant asthma medication 4 weeks prior to study (steroids - ICS, OCS, parenteral); LABA, oral beta-agonists; methylxanthine; leukotriene antagonists); No change to regular medication in this period</P>
<P>Exclusion criteria: Inability to perform methacholine test (recent MI/CVA in last 3 months); Females of child-bearing age except if using appropriate contraception; -ve pregnancy test</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>HFA FP100mcg BID (200mcg) via either: 1) pMDI or 2)Diskhaler. Placebo given via two inhalers. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; rescue medication usage; side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lanz-2001">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, USA<BR/>Length of intervention period: 4 weeks<BR/>Design: crossover study<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>Statistical analysis: paired t test.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 adults randomised. Age range: 17-63; FEV1% pre-SABA: 75 (50-85); Reversibility %: 25 (12-50); M/F: 6/12; Caucasian/Hispanic: 3/15; Medications: SABA: 18; LABAs: 3; IGC in past year: 4; LT/Theo in past year: 4 </P>
<P>Inclusion criteria: ATS diagnosed asthma; &gt;/=12% reversibility</P>
<P>Exclusion criteria: Use of inhaled/nasal/oral steroids; nasal/inhaled cromolyn; LTRA/theophylline in past 4 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP44 BID versus placebo. arms; Washout period: 4 weeks. Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exhaled NO; FEV1 %; PEF %; QoL; Symptoms; SABA usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lawrence-1997">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:23:58 +0100" MODIFIED_BY="Christopher J Cates">
<P>261 adults<BR/>Age range: 18-71 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>Treatment with ICS for 3 months or longer<BR/>Treatment with BDP 336 mcg/d or TA 800 mcg/d at stable dose for 2 weeks<BR/>FEV1 50-80 (% predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Exclusion criteria:<BR/>Systemic, intra-nasal or ophthalmic corticosteroids in last 2 months<BR/>Oral corticosteroids for &gt; 2 months in last 6 months<BR/>Pregnancy<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: <BR/>1.100 mcg 2xdaily (200 mcg/d)</P>
<P>2. 500 mcg 2xdaily (1000 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Probability of remaining in study</P>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1 <BR/>Morning PEFR<BR/>Daily asthma symptom score<BR/>Daily use of beta2 agonist <BR/>Morning plasma cortisol</P>
<P>Oro-pharyngeal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>Results for continuous outcomes expressed as change to endpoint (point of withdrawal)</P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Levy-2006">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Not stated<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:34:42 +0100" MODIFIED_BY="Toby J Lasserson">
<P>241 children with asthma. Most children had NHLBI moderate-severe persistent asthma (77-9%)</P>
<P>Inclusion criteria: 4-11 years of age; &gt;/=6 months diagnosis of asthma requiring treatment; PEF &gt;/=85% predicted</P>
<P>Exclusion criteria: systemic steroids &gt;/=10 weeks prior to study entry</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP 100 2 x daily (200mcg/d)</P>
<P>2. Placebo</P>
<P>Inhaler device: HFA-MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Am PEF; symptoms; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished conference abstract</P>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Li-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>128 adults randomised. Age range: 18-53; Ethnic origin (%) (White/Other): PLA: 94/6; FP88: 95/5; FP220: 88/13; FEV1 % Predicted: PLA: 89.1; FP88: 82.5; FP220: 88.2; Concurrent medication: Salmeterol: PLA: 0; FP88: 0; FP220: 1; Theophylline: PLA: 2; FP88: 0; FP220: 3; Cromolyn: PLA: 0; FP88: 1; FP220: 1; Nedocromil: PLA: 0; FP88: 0; FP220: 1 </P>
<P>Inclusion criteria: Non-smokers; asthma according to ATS criteria; duration of disease &gt;6 months; FEV1 &gt;/=50% predicted. </P>
<P>Exclusion criteria: Pregnancy/lactation; use of methotrexate/gold salts; use of inhaled cromolyn/nedocromil; use of oral, intranasal, inhaled or injectable steroids &lt;4 weeks of study commencement; use of &gt;/= 140mg prednisone or equivalent dosage in past year; significant concomitant illness; immunotherapy requiring change in dosage regimen within 12 weeks; reversal of nocturnal sleeping hours; concurrent use of over-the-counter medication that might affect course of asthma or interact with sympathomimetic amines or confound cortisol assay.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP88 versus FP220 versus Placebo. Inhaler device: pMDI + spacer.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HPA axis function; plasma concentration; area under the curve; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Li-1999a">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Australia<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: yes<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>71 adults enrolled. 50 randomised (45 completed). Age range: 18-55; Atopy (+/-): FP: 11/5; PLA: 12/4; Median PD20: FP: 0.021; PLA: 0.011; Median FEV1 % pred: FP: 80; PLA: 83; Symptom scores: FP: 1.39; PLA: 1.07; SABA (median puffs/day): FP: 1.82; PLA: 1.07; median am PEF (mL): FP: 420; PLA: 404; median pm PEF (mL): FP: 471; PLA: 445 </P>
<P>Inclusion criteria: 20-70 years of age; non-smoker; diagnosed asthma for previous 12 months with ICS (daily does up to 500mcg BDP/BUD; baseline FEV1 &gt;/=60% predicted; symptomatic post run-in i.e. symptom score &gt;2 on 7 of last 14 days; SABA more than 7 of last 14 days; variation of &gt;/=15% PEF over 24hrs on at least 7 of last 14 days and some degree of symptoms and SABA use during that time.</P>
<P>Exclusion criteria: Acute RTI, change in asthma medication, admission to hospital with airways disease in previous 4 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP200mcg/day versus placebo via diskhaler. Study duration 12 weeks. Inhaler device: unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>am PEF; FEV1; symptom; SABA usage; BAL;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Li-1999b">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 2 years<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 adults: 55M 9F<BR/>Age range: 18-50 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>FEV1 60 (% predicted) or greater<BR/>Exclusion criteria:<BR/>Inhaled steroid use in last month<BR/>4 or more weeks of cumulative oral steroid use prior to study<BR/>More than one year of cumulative corticosteroid use via any route prior to study<BR/>Life threatening asthma or other serious concurrent disease<BR/>Glaucoma, posterior subcapsular cataracts, abnormal HPA function, abnormal lumbar spine bone mineral density<BR/>Postmenopausal or pregnant women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FP: 500 mcg 2xdaily (1000 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morning plasma cortisol <BR/>8 hour area under curve (AUC) plasma cortisol during 6 hour 250 mcg co-syntropin infusion <BR/>Peak plasma cortisol during 6 hour 250 mcg co-syntropin infusion <BR/>Lumbar spine bone mineral density by dual energy x-ray absorptiometry <BR/>Serum osteocalcin <BR/>Urinary N-telopeptide/creatinine ratio <BR/>Incidence of posterior subcapsular cataracts<BR/>Change in FEV1 compared to baseline <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>ITT analysis undertaken using endpoint data </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lindqvist-2003">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: dual centre study, Finland<BR/>Length of intervention period: 16 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>83 adults enrolled, 80 randomised (four treatment arms; SAL, DCSG, FP &amp; PLA); age range: 18-60; asthma duration: &lt;2 years; FEV1 % predicted: 81 (SEM 1.2). </P>
<P>Inclusion criteria: 18-60 years of age; newly diagnosed symptomatic ATS defined asthma (within previous 2 years); FEV1 60-100%; moderate-severe BHR; non-smoker; </P>
<P>Exclusion criteria: Rx with LABA or cromones in previous 4 weeks; ICS/OCS in 2 months prior to study; RTI or exacerbation of asthma; seasonal allergy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>SAL, FP250 BID (1000mcg/d); DSCG 5mg BID; PLA. Inhaler device: not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Eosinophils; lymphocytes; Tenascin; PD15; amPEF; Symptoms; rescue medication usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lipworth-2005">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Seting: multicentre study in USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>82 adults with mild to moderate asthma. Mean age: 36 years; FEV1: 81.7%. </P>
<P>Inclusion criteria: &gt;/-18 years; mild to moderate persistent asthma; acceptable inhaler technique; SABA only for 6 months (at least 2 x daily); FEV1 &gt;/=70% predicted</P>
<P>Exclusion criteria: systemic steroid use within 6 months of screening; inhaled steroids within 2 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP880mcg/d <BR/>2. Placebo </P>
<P>Inhaler device: MDI without a spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hypothalmic pituitary axis function; serum cortisol; safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lumry-2006">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 10:24:19 +0100" MODIFIED_BY="Christopher J Cates">
<P>415 adults and adolescents randomised; Mean FEV1 % predicted: PLA: 65.6; FP172: 65.3; FP440: 65.5; FP880: 66.2; mean am PEF (l/min): PLA: 346; FP172: 334; FP440: 329; FP880: 333.1</P>
<P>Inclusion criteria: &gt;/=12 years; asthma for &gt;6 months requiring Rx with ICS for &gt;/=3 months; FEV1: 45-80% predicted; &gt;/=12% reversibility</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>HFA FP88 BID (172 mcg/d) versus HFA FP220 BID (440) versus HFA FP440 BID (880). Study duration: 12 weeks. Inhaler device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>am PEF; FEV1 (% predicted)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-MacKenzie-1993">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study Europe and South Africa, hospital outpatient clinics<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated (ITT analysis)<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>258 children: 170M 88F<BR/>Age range: 6-14 years<BR/>Inclusion criteria:<BR/>Asthma judged to require regular therapy with either a bronchodilator or a prophylactic agent<BR/>Experienced a worsening of asthma i.e.. marked deterioration in lung function leading to a change in medication or hospitalisation in the last month<BR/>20% or greater diurnal variation in PEFR or symptoms during 4 out of 7 days of run-in period<BR/>Exclusion criteria:<BR/>Use of inhaled corticosteroids in previous 6 months<BR/>Course of oral steroids on more than 2 occasions in the previous 3 months<BR/>Lower respiratory tract infection in the last 2 weeks<BR/>Unstable concurrent disease </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 50 mcg 1 actuation 2xdaily (100 mcg/d) </P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-07 13:30:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FEV1<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Clinic PEFR<BR/>Daily asthma symptom score<BR/>Serum cortisol<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-07 13:30:19 +0100" MODIFIED_BY="Toby J Lasserson"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Micheletto-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Single centre study<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 adults randomised. Age range: 19-51; FEV1% predicted: FP: 73.1 (SD 5.3); PLA: 74.2 (SD 13.2)</P>
<P>Inclusion criteria: not reported</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP250 BID versus PLA BID via Diskhaler.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exhaled NO; FEV1 % predicted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished conference. Pending confirmation from trialists of randomisation. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:12 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Nathan-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>330 adults and adolescents randomised. Gender (% M:F): PLA: 56:44; FP100: 65:35; FP200: 56:44; FP500: 55:45; Age range: 12-75; FEV1 L: PLA: 2.22 (SEM 0.06); FP100: 2.40 (0.07); FP200: 2.21 (SEM 0.07); FP500: 2.26 (SEM 0.05); FEV1 % predicted: PLA: 62.6 (SEM 1.07); FP100: 64.3 (SEM 0.89); FP200: 63.3 (SEM 1.03); FP500: 63.7 (SEM 0.96); am PEF (L/min): PLA: 394 (SEM 10); FP100: 397 (SEM 10); FP200: 395 (SEM 10); FP500: 379 (SEM 10); pm PEF (L/min): PLA: 412 (SEM 10); FP100: 420 (SEM 10); FP200: 414 (SEM 10); FP500: 404 (SEM 10); Asthma symptom scores: PLA: 1.10 (SEM 0.07); FP100: 1.18 (SEM 0.06); FP200: 1.03 (SEM 0.07); FP500: 1.08 (SEM 0.07); Albuterol use (puffs/d): PLA: 3.05 (SEM 0.26); FP100: 3.43 (SEM 0.26); FP200: 2.62 (SEM 0.24); FP500: 3.18 (SEM 0.26); Nighttime awakenings, No. (%): PLA: 0.09 (SEM 0.02); FP100: 0.08 (SEM 0.02); FP200: 0.12 (SEM 0.02); FP500: 0.10 (SEM 0.02)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Inhaled FP100mcg QD versus FP200mcg QD versus FP500mcg QD versus placebo. Diskus inhaler.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function (FEV1; am PEF; pm PEF); asthma symptoms; albuterol use; nighttime awakenings; withdrawals; safety; HPA axis function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:12 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Nathan-2006">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>365 adults and adolescents randomised. Age range: 12-82 years. Unclear distribution between the treatment groups. Age range: 12-82 years. M/F (%): 40/60; Caucasian: 84%; mean FEV1 68%; Reversibility: 28% </P>
<P>Inclusion criteria: FP440-660 mcg/d for at least 3 months prior to study entry; FEV1 40-85%; reversibility &gt;=15%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Combination HFA FP/SAL 110/42 BID (220/84) versus CFC SAL 42 BID (84) versus CFC FP 110 BID (220) versus HFA PLA. Inhaler devices: MDI. Run-in: 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Remaining in study; AUC; withdrawals due to deterioration; FEV1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:12 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Nelson-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 16 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>111 adults: 44M 67F <BR/>Age range: 12-77 years<BR/>Inclusion criteria:<BR/>12 years of age or older<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>Dependent on oral corticosteroids for asthma control for 6 months or longer<BR/>Requiring 5-40 mg/day oral prednisolone<BR/>FEV1 40-80 (% predicted) 15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Exclusion criteria:<BR/>Life-threatening asthma or other severe concurrent disease<BR/>Use of intra-nasal, injectable, topical corticosteroids<BR/>Methotrexate, cyclosporin, azathioprine, troleandomycin within last 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FP:<BR/>1. 500 mcg 2xdaily (1000 mcg/d)</P>
<P>2. 1000 mcg 2xdaily (2000 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Accuhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>100% reduction in daily dose oral prednisolone (% of patients)</P>
<P>Outcomes reported as a change compared to baseline:</P>
<P>Daily dose oral prednisolone <BR/>FEV1<BR/>Morning PEFR <BR/>Evening PEFR <BR/>Daily asthma symptom score <BR/>Daily beta2 agonist use <BR/>Night-time awakenings <BR/>Health status: Asthma Quality of Life Questionnaire (AQLQ) </P>
<P>Oro-pharyngeal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>No reply from author to clarify details of randomisation method</P>
<P>Usual ICS discontinued at randomisation</P>
<P>A priori criteria for prednisolone dose reduction based on FEV1 (% predicted), PEFR (% predicted), number of night-time awakenings, beta-2 agonist use compared to run in period values</P>
<P>Patients were withdrawn from the study if they experienced asthma exacerbation requiring hospital admission, or 3 bursts of oral prednisolone due to exacerbation</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:13 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Noonan-1995">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:13 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 16 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>96 adults: 46M 50F<BR/>Mean age: 50-52 years<BR/>Inclusion criteria:<BR/>12 years of age or older<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>Dependent on oral corticosteroids for asthma control for 6 months or longer<BR/>FEV1 40-80 (% predicted) <BR/>Documented evidence of previous attempts to reduce oral steroid dose<BR/>Exclusion criteria:<BR/>Use of methotrexate, gold salts or troleandomycin in last 3 months<BR/>Nasal corticosteroid use<BR/>10 pack year history of smoking or greater <BR/>Pregnancy or lactation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 750 mcg 2xdaily (1500 mcg/d)</P>
<P>2. 1000 mcg 2xdaily (2000 mcg/d) </P>
<P>Placebo: 2xdaily </P>
<P>Delivery device: MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>100% reduction in daily oral steroid use (% patients) </P>
<P>Outcomes expressed as change compared to baseline:</P>
<P>Daily oral prednisolone dose<BR/>FEV1<BR/>Morning PEFR <BR/>Evening PEFR <BR/>Daily use of beta2 agonists <BR/>Daily asthma symptom score<BR/>Health Status: Medical Outcomes Study Short Form (SF-36)</P>
<P>Oro-pharyngeal side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-08 10:35:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>No reply from author to clarify details of randomisation method</P>
<P>Usual ICS discontinued at randomisation</P>
<P>Daily dose oral prednisolone reduced according to pre-defined criteria</P>
<P>An uncontrolled one year open label study was undertaken following the randomised 16 week trial, when all patients received FP 2000 mcg/d. Results not considered in this review<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Noonan-1998">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinic<BR/>Length of intervention period: 8 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>138 adults: 84M 54F<BR/>Age range: 12-59 years<BR/>Inclusion criteria: <BR/>12 years of age or older<BR/>Diagnosis of asthma (ATS criteria 1987) 6 months or longer<BR/>FEV1 60 (% predicted) or greater<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Methacholine BHR (PD20 FEV1) &lt; 18 mg<BR/>Asthma stability during run in period based on a priori defined criteria related to PEFR, medication requirement and symptoms<BR/>Exclusion criteria:<BR/>Recent hospitalisation due to asthma exacerbation<BR/>Treatment with corticosteroids, theophylline, sodium cromoglycate, nedocromil<BR/>Pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 50 mcg 2xdaily (100 mcg/d) </P>
<P>2. 100 mcg 2xdaily (200 mcg/d) </P>
<P>Placebo: 2xdaily </P>
<P>Delivery device: MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1 <BR/>Morning PEFR <BR/>Evening PEFR <BR/>Methacholine BHR (log e PD20 FEV1) <BR/>Daily asthma symptom score <BR/>Daily use of beta2 agonist <BR/>Night-time awakenings </P>
<P>Probability of remaining in study</P>
<P>Oro-pharyngeal side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-08 10:35:34 +0100" MODIFIED_BY="Toby J Lasserson">
<P>No reply from author to clarify details of randomisation method</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported</P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
<P>MDI's used for all interventions. Formulations of FP with 1% lecithin and 10% lecithin used. Only data for 1% formulation included in meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-O_x0027_Shaughnessy-1993">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: UK, hospital outpatient clinic<BR/>Length of intervention period: 2 weeks<BR/>Design: crossover, 3 week washout<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no demographic data presented<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>11 subjects: 6M 5F<BR/>Age range: 21 to 39 years<BR/>Inclusion criteria:<BR/>Adult patients with mild asthma<BR/>Non-smokers<BR/>FEV1 60 (% predicted) or greater<BR/>Histamine BHR (PC20 FEV1) 8mg/ml or less<BR/>Skin prick test positive to either grass pollen or Dermatophagoides<BR/>Exclusion criteria:<BR/>Use of inhaled steroids within last 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 1000 mcg/d </P>
<P>Placebo</P>
<P>Delivery device: MDI+spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Histamine bronchial responsiveness (change in doubling dose log 2 PC20 FEV1) <BR/>Histamine bronchial responsiveness (change in doubling dose log 2 PC20 FEV1) following inhaled allergen challenge<BR/>Maximal % fall in FEV1 within 2 hours compared to test baseline following inhaled allergen challenge: Early asthmatic response<BR/>Maximal % fall in FEV1 compared to test baseline 2 to 10 hours following inhaled allergen challenge: Late asthmatic response<BR/>Urinary leukotriene E4 excretion index<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Olivieri-1997">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Italy, hospital outpatient clinic<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 adults<BR/>Age range: 18-50 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>FEV1 &gt; 80 (% predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Free of asthma attacks for at least 2 months<BR/>Rescue beta2 agonist &lt; 2 puffs/d and &lt; 10% variability in FEV1 during 2 week run in period<BR/>Exclusion criteria:<BR/>ICS in last 6 months<BR/>Respiratory tract infection in last month<BR/>Smokers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 250 mcg 2xdaily (500 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Methacholine BHR (PC20 FEV1)<BR/>BAL differential cell count, ICAM-1 and Mac-1 expression<BR/>BAL tryptase and ECP levels<BR/>Bronchial biopsy differential cell count and basement membrane thickness<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Overbeek-1996">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: The Netherlands, hospital outpatient clinic<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>33 subjects: 23 male 10 female<BR/>Age range: 18-56 years<BR/>Inclusion criteria:<BR/>Adult asthmatic patients<BR/>At least one positive skin-prick test to a panel of common aero-allergens<BR/>Methacholine BHR (PC20 FEV1) 8 mg/ml or less<BR/>9% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Exclusion criteria:<BR/>Exacerbation of asthma or respiratory tract infection in last month<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: 500 mcg 2xdaily (1000 mcg/d) </P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Methacholine BHR (log 2 PC20 FEV1) </P>
<P>Change in FEV1 as percentage of initial FEV1, per doubling dose methacholine post methacholine challenge </P>
<P>% fall in FEV1 post methacholine challenge compared to test baseline FEV1</P>
<P>Daily asthma symptom score</P>
<P>FEV1<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Parameswaren-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Single centre study, Canada<BR/>Length of intervention period: 2 weeks<BR/>Design: crossover study<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 adults randomised (6 male). Mean age: 25 (SD 9.14); mean FEV1 (% predicted): 90.2 (SD 14.33); Mean PC20: 2.56 (SD 1.76). All patients were non-smokers. Study took place out of allergy season. Beta-agonist withheld at least 8 hours before each visit. Participants instructed to refrain from rigorous exercise and caffeine in am before visits to laboratory. </P>
<P>Inclusion criteria: Mild stable asthma: Few or no symptoms, inhaled SABA prn, FEV1 &lt;/= 70% predicted; moderate to borderline methacholine airway hyperresponsiveness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Four visit run-in period: control inhalation test and allergen inhalation test; Randomisation to either: Pretreatment with FP 250mcg 30 mins before allergen challenge followed by 2 weeks of FP 250mcg BID, and allergen inhalation test at end of treatment or Treatment 2: Pretreatment with placebo 30 mins before allergen inhalation test followed by 2 weeks treatment with placebo. Three week washout period before crossover. Inhaler device not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; PC20; Sputum inflammatory markers</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Investigator may have noted effects of active treatment on airway responses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pauwels-2002">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Belgium<BR/>Length of intervention period: 1 weeks<BR/>Design: crossover study<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=26, Other details not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ciclesonide (400mcg QID; 800mcg QID; 800mcg QID), FP500 BID &amp; FP1000 BID or PLA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>% Cortisol suppression; PC20</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished conference abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pearlman-1997">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: multicentre study USA, hospital outpatient clinic<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>342 subjects randomised <BR/>Age range: 12-72 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987)<BR/>Required maintenance inhaled corticosteroids for at least 3 months<BR/>FEV1 50-80 (%predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>During last 7 days of run-in period:<BR/>No more than 12 puffs per day of albuterol<BR/>No more than 4 morning PEFR 20% less than previous evenings<BR/>No more than 2 nights wakening due to asthma requiring inhaled albuterol<BR/>adequate compliance with study medication<BR/>Exclusion criteria:<BR/>Previous use of gold or methotrexate for control of asthma<BR/>Inhaled cromoglycate or oral steroids in the last 4 weeks<BR/>Significant co-existent illness <BR/>Pregnancy or lactation</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 50 mcg 1 actuation 2xdaily (100 mcg/d)</P>
<P>2. 100mcg 1 actuation 2xdaily (200 mcg/d)</P>
<P>3. 250 mcg 1 actuation 2xdaily (500 mcg/d) </P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: Diskhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1<BR/>Morning PEFR <BR/>Evening PEFR<BR/>Daily asthma symptom score<BR/>Night-time awakenings<BR/>Daily use of beta2 agonist<BR/>Medical Outcomes Study Short Form-36, acute version (SF-36A)<BR/>Living with Asthma Questionnaire (LWA-20)<BR/>Validated sleep scale</P>
<P>Probability of remaining in study</P>
<P>Physician global assessment of efficacy</P>
<P>Plasma cortisol <BR/>Plasma cortisol 30-60 min post 250 mcg iv cosyntropin <BR/>Oro-pharyngeal side effects</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pearlman-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: multicentre study, USA<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 136 (PLA: 23; FP88: 23; FP220: 23; SAL: 21; SAL/FP88: 25; SAL/FP220: 21).Mean age (range): PLA: 35 (12-62); SAL: 29 (15-57); FP88: 27 (13-50); FP220: 32 (14-61); SAL/FP88: 33 (14-60); SAL/FP220: 26 (13-52); Gender (M:F %): PLA: 43:57; SAL42: 67:33; FP88: 74:26; FP220: 57:43; SAL/FP88: 40:60; SAL/FP220: 67:33; Mean FEV1 (% predicted): PLA: 68; SAL: 70; FP88: 69; FP220: 65; SAL/FP88: 67; SAL/FP220: 69. </P>
<P>Inclusion criteria: &gt;/=12 years of age; ATS defined asthma (at least 6 months), requiring medical treatment; FEV1 between 50-80% predicted; &gt;/=15% increase in FEV1 post-SABA; treatment with prn SABA; female participants had -ve pregnancy tests and either surgically sterile, postmenopausal at 1 year or using acceptable birth control for 1 month prior to participation</P>
<P>Exclusion criteria: History of life-threatening asthma; hypersensitivity reaction to beta-agonists/corticosteroids; smoking within previous year/history &gt;10 pack years; use of OCS/ICS or parenteral steroids (except for Flonase); use of steroid therapy in previous month; OCS treatment in previous 6 months; use of OTC medication that may affect the course of asthma; abnormal CXR; clinically significant abnormal 12-lead ECG; history of concurrent disease (glaucoma, diabetes + hypertension)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PLA versus FP88mcg versus FP220mcg versus SAL42mcg/FP88mcg versus SAL42mcg/FP220mcg daily. Inhaler device: MDI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; Am PEF; Symptoms; % days without asthma; % nights awakening due to asthma; rescue medication use; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pearlman-2004">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 360. No details on distribution between the groups provided. Participants described as symptomatic. Baseline medication: prn SABA alone: 142; SAL: 84; ICS: 134)</P>
<P>Inclusion criteria: FEV1 40-85% predicted; Reversibility: &gt;/=15%. No other details provided</P>
<P>Exclusion criteria: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>CFC FP88 BID (176mcg/d) versus HFA PLA. Inhaler device: MDI. 2 week run-in.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>am PEF; probability of remaining in the study; withdrawals due to worsening asthma; FEV1; AUC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished conference abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Peden-1998">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, paediatric outpatient clinic<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>437 children: 268M 169F<BR/>Age range: 4-11 years<BR/>Inclusion criteria:<BR/>History of chronic asthma (ATS criteria 1987)<BR/>Symptoms requiring maintenance therapy for 3 months or more<BR/>PEFR 85 (% predicted) or greater<BR/>FEV1 50-85 (% predicted)<BR/>15% or greater improvement in FEV1 after inhaled beta2 agonist<BR/>Asthma stability during run-in period, based on a priori beta2 agonist use and morning PEFR<BR/>Exclusion criteria:<BR/>Life-threatening asthma<BR/>Severe concurrent disease<BR/>Systemic steroids in last month<BR/>Previous treatment with methotrexate or gold <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 50mcg 2xdaily (100 mcg/d) via Accuhaler DPI </P>
<P>2. 100mcg 2xdaily (200mcg/d) via Accuhaler DPI </P>
<P>3. 50 mcg 2xdaily (100 mcg/d) via Diskhaler DPI</P>
<P>4. 100 mcg 2xdaily (200 mcg/d) via Diskhaler DPI</P>
<P>Placebo: 2xdaily, Diskhaler and Diskus/Accuhaler </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1 <BR/>FEV1 (% predicted)<BR/>Morning PEFR <BR/>Morning PEFR (% predicted)<BR/>Evening PEFR <BR/>Daily asthma symptom score <BR/>Daily use of beta2 agonist <BR/>Night-time awakening score </P>
<P>Morning plasma cortisol <BR/>Total urinary free cortisol excretion (mcg/24 hours) </P>
<P>Probability of remaining in study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-07 13:32:30 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported</P>
<P>Only data concerning FP v placebo delivered via Accuhaler has been included in the meta-analysis</P>
<P>Additional data sourced from www.clinicalstudyresults.org<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Phillips-2004">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single-centre study, UK<BR/>Design: crossover<BR/>Length of intervention period: 4 weeks<BR/>Excluded: stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 adults with mild asthma.<BR/>Age range: 18-65 years<BR/>Inclusion criteria: diagnosis and symptoms consistent with asthma<BR/>Exclusion criteria: inhaled steroids within 4 weeks of study entry; recent exacerbation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 750mcg BID (1500mcg/d)</P>
<P>BUD 800mcg BID (1600mcg/d)</P>
<P>Placebo</P>
<P>Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PD20; FEV1; am PEF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pinnas-2005">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA.<BR/>Length of intervention period: 12 weeks.<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>397 adults randomised, 312 completed: 212F<BR/>Age range: &gt;/=12 years<BR/>Inclusion criteria: treatment with SABA only for 6 months previously; am pre-SABA FEV1 of 45-80% predicted; &gt;/=12% reversibility.</P>
<P>No run-in period described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FP:<BR/>1. 88mcg 2 x daily</P>
<P>2. 110mcg 2 x daily</P>
<P>2. 220mcg 2 x daily</P>
<P>3. Placebo</P>
<P>Inhaler device: MDI </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Change in FEV1; am PEF; rescue medication usage; symptoms; quality of life; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Conference abstract </P>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Qaquandah-2006">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: Stated<BR/>Withdrawals: stated (ITT analysis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-04 14:07:55 +0100" MODIFIED_BY="Toby J Lasserson">
<P>359 children: 221M 138F<BR/>Age range: 1-4 years<BR/>Inclusion criteria:<BR/>Children with history of symptomatic asthma; requirement for SABA during run-in<BR/>FEV1 not stipulated <BR/>Exclusion criteria:<BR/>Recent ICS exposure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-04 13:58:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>FP: 200 mcg/d</P>
<P>Placebo</P>
<P>Delivery device: MDI+spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-04 13:59:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Symptoms; rescue medication use; am PEF (limited number of participants); adverse events;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-04 11:53:40 +0100" MODIFIED_BY="Toby J Lasserson"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-SAS30021">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study in North &amp; South America.<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>608 children. Mean age: 7.6-7 years; am PEF: 75.2-76.6% predicted. </P>
<P>Inclusion criteria: 4-11 years; diagnosis of asthma for 6 months; treated with SABA or non-ICS controller only for 1 month prior to screening; am PEF: 50-85% predicted; &gt;/=15% reversibility post SABA; symptoms on 4 days of previous week/use of SABA on 4 days of previous week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP 100 once daily <BR/>2. Placebo </P>
<P>Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>am &amp; pm PEF; symptoms; SABA usage; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-SAS30022">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study in North America<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>FP and PLA groups: 224 adults randomised. Mean age: 32-33 years; Baseline am PEF: 72-3% predicted</P>
<P>Inclusion criteria: &gt;/=12 years; diagnosis of asthma for at least 3 months; FEV1 50-85%; &gt;/=15% reversibility to SABA; symptoms on 4 days of week preceding randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. FP250 1 x daily <BR/>2. PLA 1 x daily</P>
<P>Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>am &amp; pm PEF; symptoms; SABA usage; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-SAS30023">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study in Australia, France, UK, Hungary, Ukraine, Italy, Philippines, Thailand, Russia<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT analysis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>464 adults with mild asthma randomised to three treatment groups (two groups of relevance to the review: FP100: 155; PLA: 158). Age range: 12-80 (mean 33-34 years); Mean baseline FEV1: 3.2-3.3L</P>
<P>Inclusion criteria: 12-80 years; documented history of asthma &gt;/=6 months; receiving SABA prn alone</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP100 OD versus placebo via HFA MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-08 10:35:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>mean am &amp; pm PEF; FEV1; adverse events; rescue medication usage; symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Shapiro-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>484 adults and adolescents screened. 349 randomised (four treatment arm study; PLA: 93; FP: 84. Data from 13 participants excluded from the analysis due to poor procedure at one site). M/F %: PLA: 41/59; FP250: 54/46; age range: 12-69; FEV1 mean % predicted (% reversibility): PLA: 68 (29); FP250: 66 (28); FEV1 L: PLA: 2.19 (SE 0.07); FP250: 2.12 (0.06); Symptom scores: PLA: 1.6 (SE 0.12); FP250: 1.6 (SE 0.12); SABA usage (puffs/d): PLA: 3.8 (0.3); FP250: 3.2 (0.3)</P>
<P>Inclusion criteria: &gt;/=12 years; ATS defined asthma of &gt;/=6 mo duration requiring pharmacotherapy for at least 6 months; FEV1 between 40 and 85% predicted; &gt;/=15% increase in FEV1 30 mins after 2 puffs of albuterol; use of ICS 12 weeks prior to the study. </P>
<P>Exclusion criteria: Females with negative pregnancy tests; life-threatening asthma; hypersensitivity to sympathomimetic drugs/steroids; smoking within previous year; smoking history of &gt;10 pack years; use of oral/injectable steroid therapy within 1 month of study; use of daily oral steroids within 6 months prior to the study; use of any prescription or over the counter medication that could have affected asthma or course of treatment; abnormal CXR; clinically significant abnormal 12-lead ECGs history of concurrent disease.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PLA versus FP250 BID (500mcg/d) via Diskus inhaler. Duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; PEF; AUC; Symptoms; Rescue medication usage; Adverse Effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Sheffer-1996">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>307 patients: 185M 122F<BR/>Age range: 12-72 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma requiring at least 3 months of regular therapy <BR/>FEV1 45-75 (% predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>Exclusion criteria:<BR/>More than 1 month's use of oral steroids in the past<BR/>Any oral, topical or inhaled steroid or cromoglycate in last month<BR/>Previous history of life threatening asthma<BR/>Pregnancy or lactation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 25 mcg 1 puff 2xdaily (50 mcg/d)</P>
<P>2. 50 mcg 1 puff 2xdaily (100 mcg/d)</P>
<P>3. 50 mcg 2 puffs 2xdaily (200 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1<BR/>Morning PEFR<BR/>Evening PEFR <BR/>Night-time awakenings<BR/>Daily wheeze score<BR/>Daily cough score<BR/>Daily breathlessness score <BR/>Daily use of beta2 agonists</P>
<P>Probability of remaining in study<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Randomisation details confirmed by author</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning and evening PEFR, diurnal variability in PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Sorkness-1999a">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>168 adults randomised (N for treatment groups considered by the review: Placebo: 30; FP100: 27; FP500: 30); Mean age (SE): PLA: 27.9 (1.6); FP100: 27.7 (1.7); FP500: 28.2 (1.6); Gender (M/F): PLA: 26/4; FP100: 26/1; FP500: 24/6; Race (White/other %): PLA: 67/33; FP100: 81/19; FP500: 77/23; FEV1 % predicted (SE): PLA: 87 (2.5); FP100: 88 (3.1); FP500: 83 (3.9) </P>
<P>Inclusion criteria: 18-51 years of age; documented diagnosis of asthma (&gt;/=6 months according to ATS criteria; FEV1 at least 50% predicted</P>
<P>Exclusion criteria: Pregnancy or lactation; corticosteroid/immunosuppressive therapy for 3 months prior to study entry; use of 140mg prednisone or equivalent in any dosage or form in previous year; current/prior use of antiasthma medication other than beta-agonists, theophylline or cromolyn sodium; historical or current evidence of significant concomitant disease; use of oral contraceptives or other hormonal therapy; current use of prescription or over the counter medication known to interact with corticosteroids or to cause an abnormal response to exogenous glucocorticoids or reversal of normal nocturnal sleeping hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP100 versus FP500 versus Placebo. Delivery device: Rotadisk.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUC; Plasma cortisol; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Sorkness-1999b">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>119 adults randomised (N for treatment groups considered by the review: PLA: 31; FP100: 29; FP250: 30); Mean age (SE): PLA: 32.1 (1.7); FP100: 31.4 (1.8); FP250: 33 (1.6); Gender (M/F): PLA: 25/6; FP100: 26/3; FP250: 26/4; Race (White/other %): PLA: 94/6; FP100: 93/7; FP250: 90/10; FEV1 % predicted (SE): PLA: 87 (2.7); FP100: 86 (2.7); FP250: 88 (3) </P>
<P>Inclusion criteria: 18-51 years of age; documented diagnosis of asthma (&gt;/=6 months according to ATS criteria; FEV1 at least 50% predicted </P>
<P>Exclusion criteria: Pregnancy or lactation; corticosteroid/immunosuppressive therapy for 3 months prior to study entry; use of 140mg prednisone or equivalent in any dosage or form in previous year; current/prior use of antiasthma medication other than beta-agonists, theophylline or cromolyn sodium; historical or current evidence of significant concomitant disease; use of oral contraceptives or other hormonal therapy; current use of prescription or over the counter medication known to interact with corticosteroids or to cause an abnormal response to exogenous glucocorticoids or reversal of normal nocturnal sleeping hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP100 versus FP500 versus Placebo. Delivery device: Rotadisk.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUC; Plasma cortisol; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Sovij_x00e4_rvi-2003">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Finland<BR/>Length of intervention period: 6 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: not stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 adults randomised. Age range: 21-59; M/F: FP: 4/9; PLA: 7/6; Atopic asthma: FP: 9/13; PLA: 10/13; Mean duration of reversible airway obstruction (years): FP: 12.9 (0.1-37); PLA: 8 (0.1-33); FEV1 % pred: FP: 79.3 (70-88); PLA: 84.3 (69-100); am PEF: FP: 81 (64-99); PLA: 92 (71-112); pm PEF: FP: 83 (63-99); PLA: 95 (72-116); Symptoms (DAY): FP: 0.12; PLA: 0.27; Symptoms (NIGHT): FP: 0.46; PLA: 0.51. Rescue medication usage (puffs/week): FP: 3.8; PLA: 4.6</P>
<P>Inclusion criteria: &gt;/=18 years; improvement by 15% in FEV1/PEF; FEV1 &gt;/=65% predicted; 15% fall in FEV1 at a dose of &lt;/=0.6mg </P>
<P>Exclusion criteria: Seasonal/unstable angina; RTI; exacerbation of asthma during 4 weeks prior to study entry; current smoking/cessation of smoking within year preceding study; history of pulmonary disease other than asthma; use of ICS/OCS, inhaled cromones, anti-leux for 2 months prior to study; use of antihistamines within 2 weeks, and LABAs within 4 weeks of study entry; pregnancy or breast feeding; severe/chronic disease; alcohol or drug abuse<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP250 BID (500) versus placebo. Inhaler device: MDI + spacer. Run-in: 1-2 weeks (usual asthma medication and monitoring symptoms)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PD15; FEV1 % predicted; PEF; Symptoms; rescue medication usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Subburao-2005">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre<BR/>Design: crossover study<BR/>Length of intervention period: 1 week (3 week washout)<BR/>Excluded: not stated<BR/>Withdrawals: Stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 adults with mild asthma. Age range: 20-52<BR/>Stable asthma<BR/>Inclusion criteria: mild asthma (beta-agonist less than twice weekly)<BR/>Exclusion criteria: recent exacerbation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP200mcg BID (400mcg/d)</P>
<P>BUD200mcg BID (400mcg/d)</P>
<P>Placebo</P>
<P>Inhaler device: DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EAR; LAR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-van-Grunsven-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Single centre study<BR/>Design: parallel group<BR/>Length of intervention period: 12 months<BR/>Excluded: yes<BR/>Withdrawals: stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:36:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>45 adults screened, 29 randomised (N for FP500mcg or Placebo not reported); Age range: 30-70; 10M, 19F; FEV1 % predicted: 93 (SD 11); Pack years (mean): 7 (0-31); PC20 histamine (mg/mL): 5.3 (SD 3.5); Reversibility FEV1 % predicted: 5 (SD 3); Symptoms: 0.6 (SD 0.9); Bronchodilators y/n: 2/27</P>
<P>Inclusion criteria: Bronchial hyperresponsiveness (concentration of Methcholine causing a 20% reduction in FEV1 histamine &lt;/= 8mg/mL and/or reversibility of obstruction (increase in FEV1 by 10% as percentage of FEV1 predicted after application of 800mcg inhaled salbutamol</P>
<P>Exclusion criteria: Not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP500 or placebo via diskhaler.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Compliance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No outcomes of interest measured adequately in published trial report.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-van-Rensen-1999">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Single centre study, Netherlands<BR/>Length of intervention period: 4 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>25 adults randomised (FP 1500: 12; Placebo: 13); Mean age: FP 1500: 23.3 (SD 2.4); Placebo: 25.1 (SD 3.9); FEV % predicted: FP1500: 96.2 (SD 9); Placebo: 95.6 (SD 10.6); PC20: FP1500: 0.91 (SD 1.62); Placebo: 0.52 (SD 1.38); Eosinophils %: FP1500: 2.85 (SD 2.46); Placebo: 4.91 (SD 8.98); NO (ppb): FP1500: 6.30 (SD 3.34); Placebo: 7.47 (SD 4.37) </P>
<P>Inclusion criteria: Stable (symptom free and free from RTI) for two weeks previously; Atopic disease (&gt;3 mm weal); FEV1 % predicted &gt;75% predicted; hyperresponsiveness to inhaled histamine<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP 500mcg per day versus Placebo. Inhaler device: unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PC20; Sputum eosinophils; Exhaled NO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-van-Schoor-2002">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Belgium, hospital outpatient clinic<BR/>Length of intervention period: 2 weeks<BR/>Design: crossover, one month washout<BR/>Excluded: no details<BR/>Withdrawals: no details<BR/>Baseline characteristics: no demographic data presented<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=11. Mean FEV1: 3.2 (SEM 0.16); FEV1 % pred: 88 (SEM 3.44). Mean methacholine log2 PC20: -5.96 (SEM 0.2). Mean NKA (neurokronin A) log2 PC20 : -12.71 (SEM 0.63); Gender: 4M 11F; mean age: 27.5 years</P>
<P>Inclusion criteria: Adults (no age threshold defined - all participants recruited were over 18 years); mild to moderate asthma (NHLBI 1997 guideline definition); non- or ex-smokers (&lt;/=5 pack years, and ceased smoking &gt;/=1 year prior to study entry); females of child-bearing required to be using reliable contraception</P>
<P>Exclusion criteria: pregnant/lactating women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Inhaled FP500 BID versus PLA. Inhaler devices: Diskhaler. Study duration: 2 x 14 day treatment periods. Washout: 4 weeks. Only prn SABAs allowed as concomitant therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; Methacholine BHR (PC20 FEV1); Neurokinin A BHR (log 10 PC20 FEV1)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data on FEV1 presented at end of 1st arm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Ward-2001">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: single centre study, Australia<BR/>Length of intervention period:<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>35 adults enrolled, 34 randomised. Age range: 20-70; Mean FEV1 % pred: 91.3 (SEM 3). No patients had received LABAs or ICS for at least 3 months prior to the study. 34/35 patients had not had OCS treatment in previous 12 months. 1 patient had received OCS treatment within 3 months before the study.</P>
<P>Inclusion criteria: mild-moderate symptomatic asthma</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Inhaled FP 1500 versus PLA. Inhaler device: MDI. Study duration: 12 months (preceded by 14-day run in)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, MMFEF25-75, withdrawals, adverse events, PD20, BAL inflammatory cell counts, membrane thickening</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wasserman-1996">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, primary care and hospital outpatient clinics<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>331 adults randomised, 265 completed: 265M 66F <BR/>Age range 12-74 years<BR/>Inclusion criteria:<BR/>Diagnosis of asthma (ATS criteria 1987) for at least 6 months <BR/>FEV1 50-80 (% predicted)<BR/>15% or greater reversibility in FEV1 after inhaled beta2 agonist<BR/>During run-in:<BR/>12 or less puffs/day albuterol <BR/>4 or less mornings when PEFR decreased 20% or less than previous night PEFR<BR/>2 or less nights wakening requiring albuterol<BR/>Good compliance <BR/>Exclusion criteria:<BR/>Smoking<BR/>Use of any oral, inhaled or topical steroid within last month of study<BR/>Oral steroids for 2 months or longer within last 6 month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP: <BR/>1. 50 mcg 1 actuation 2xdaily (100 mcg/d) </P>
<P>2. 100 mcg 1 actuation 2xdaily (200 mcg/d) </P>
<P>3. 250 mcg 1 actuation 2xdaily (500 mcg/d)</P>
<P>Placebo: 1 actuation 2xdaily</P>
<P>Delivery device: Diskhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1<BR/>FVC<BR/>FEF 25-75%<BR/>Morning PEFR<BR/>Evening PEFR <BR/>Daily asthma score<BR/>Change in night time awakenings<BR/>Daily use of beta2 agonist </P>
<P>Probability of remaining in study</P>
<P>Physician global assessment of efficacy</P>
<P>Oro-pharyngeal side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wolfe-1996">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study USA, hospital outpatient clinics<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>304 adults: 169M 135F<BR/>Age range: 12-87 years<BR/>Inclusion criteria:<BR/>12 years of age or older<BR/>Diagnosis of moderate asthma, for at least 6 months<BR/>Current treatment with inhaled corticosteroids and regular/as needed beta2 agonists<BR/>Exclusion criteria:<BR/>During run-in period:<BR/>More than 12 puffs albuterol daily for 3 or more days<BR/>Diurnal variation in PEFR &gt; 20% for 4 or more days<BR/>Awakening more than 2 nights due to asthma symptoms<BR/>And:<BR/>Systemic steroids in last month<BR/>Significant concurrent disease<BR/>Pregnancy or lactation</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP:<BR/>1. 100 mcg 2xdaily (200 mcg/d)</P>
<P>2. 250 mcg 2xdaily (500 mcg/d)</P>
<P>3. 500 mcg 2xdaily (1000 mcg/d)</P>
<P>Placebo: 2xdaily</P>
<P>Delivery device: MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes expressed as change compared to baseline:</P>
<P>FEV1 <BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily use of beta2 agonist<BR/>Daily cough score<BR/>Daily wheezing score <BR/>Daily breathlessness score<BR/>Daily asthma symptom score</P>
<P>Probability of remaining in the study</P>
<P>Physician related global assessment of efficacy</P>
<P>Oro-pharyngeal side effects</P>
<P>Morning plasma cortisol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method</P>
<P>For continuous outcomes change scores from baseline to endpoint (i.e. point of withdrawal) were reported </P>
<P>A priori criteria for withdrawal due to lack of efficacy were established based on FEV1, morning PEFR, night-time awakenings or clinical exacerbation requiring emergency hospital treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:20 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wolfe-2000-ICS">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>358 adults and adolescents screened. 199 randomised; PLA: 69; FP100BID: 65; FP200QD: 65. Gender M/F (%): PLA: 58/42; FP100BID: 48/52; FP200QD: 60/40; Mean age: PLA: 36; FP100BID: 39; FP200QID: 36; FEV1 L: PLA: 2.35 (SEM 0.07); FP100BID: 2.26 (SEM 0.07); FP200QD: 2.38 (SEM 0.08); FEV1 (% predicted): PLA: 67.87 (SEM 1.17); FP100BID: 65.93 (SEM 1.19); FP200QD: 66.6 (SEM 1.02); am PEF (L/min): PLA: 408 (SEM 12); FP100BID: 396 (SEM 11); FP200QD: 421 (SEM 11); pm PEF (L/min): PLA: 426 (SEM 12); FP100BID: 411 (SEM 11); FP200QD: 438 (SEM 11); Symptoms: PLA: 2.62 (SEM 0.3); FP100BID: 2.91 (SEM 0.34); FP200QD: 2.82 (SEM 0.32); Nocturnal awakenings: 0.08 (SEM 0.02); FP100BID: 0.06 (SEM 0.01); FP200QD: 0.07 (SEM 0.02)</P>
<P>Inclusion criteria: ICS &gt;/=8 puffs day of BDP (42mcg/puff) or TAA (100mcg/puff) for three months; asthma stability defined as 0 days with &gt;/= 12 puffs of SABA prn; &lt;/=4 mornings when PEF decreased by &gt;/= 20% from previous pm's PEF; &lt;/=2 nights with awakenings caused by asthma requiring inhaled SABA; FEV1 between 50 &amp; 80% predicted &amp; +/-15% screening value; adequate compliance during run-in. </P>
<P>Exclusion criteria: Exclusion criteria: pregnancy/lactation; use of methotrexate/gold; use inhaled cromolyn; use of oral, intranasal or parenteral steroids within 4 weeks of study start; significant concomitant illness; immunotherapy requiring change in dose within 12 weeks; concurrent use of prescription/over the counter medication that may affect course of asthma/interact with sympathomimetic amines. Use of loratadine/intranasal cromolyn for allergic rhinitis permitted if treatment started before screening visit and continued without change <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>FP100BID versus FP200QD versus PLA. Inhaler device: Diskus. Run-in period: 2 weeks (ICS dosage regimen maintained).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; symptoms; rescue medication usage; nocturnal awakenings; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:21 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wolfe-2000-SABA">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: stated<BR/>Withdrawals: stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-10 12:18:21 +0100" MODIFIED_BY="Toby J Lasserson"/>
<CHAR_INTERVENTIONS>
<P>FP100BID (200mcg/d) versus FP200QD (200mcg/d) versus PLA. Inhaler device: Diskus. Study duration: 12 weeks, preceded by run-in period - placebo device for 2 weeks; prn SABA, SAL and XANTH continued (if SAL and XANTH used pre-run-in)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1; am PEF; pm PEF; symptoms; rescue medication usage; nocturnal awakenings; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional data sourced from www.clinicalstudyresults.org</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-10 12:18:22 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-ZuWallack-2000">
<CHAR_METHODS MODIFIED="2008-07-10 12:18:22 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Setting: Multicentre study, USA<BR/>Length of intervention period: 12 weeks<BR/>Design: parallel group<BR/>Excluded: not stated<BR/>Withdrawals: stated (ITT)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-08 10:36:29 +0100" MODIFIED_BY="Toby J Lasserson">
<P>253 adults and adolescents randomised; Gender: M:F (%): FP500: 51:49; FP1000: 59:41; PLA: 58:42; Age range: 12-69; FEV1 (L)*: FP500: 2.44 (SEM: 0.07); FP1000: 2.51 (SEM 0.08); PLA: 2.46 (SEM 0.06); FEV1 (% predicted): FP500: 68 (SEM: 0.9); FP1000: 66 (SEM 1); PLA: 67 (SEM 1); am PEF (L/min)*: FP500: 410 (SEM 9); FP1000: 402 (SEM 10); PLA: 418 (SEM 11); pm PEF (L/min)*: FP500: 434 (SEM 10); FP1000: 429 (SEM 10); PLA: 441 (SEM 11); Asthma symptom scores*: FP500: 1.13 (SEM 0.05); FP1000: 1.06 (SEM 0.06); PLA: 1.08 (SEM 0.07); ß-2 agonist use (puffs/d)*: FP500: 2.82 (SEM 0.24); FP1000 2.67 (SEM 0.27) ; PLA: 3.04 (SEM 0.28); Nighttime awakenings/night*: FP500: 0.08 (SEM 0.02); FP1000: 0.11 (SEM 0.02); PLA 0.15 (0.02)</P>
<P>*denotes efficacy population</P>
<P>Inclusion criteria: Chronic asthma (ATS diagnosis); requirement of daily pharmacotherapy over 6 mo prior to study; FEV1 50-80% predicted; &gt;/= 15% increase in FEV1 &lt;15 minutes after 2 puffs of ß-2 agonist OR documented &gt;/=15% variation in FEV1 within 6 mo prior to study. Open label extension: Participants completing DB phase eligible</P>
<P>Exclusion criteria: History of life-threatening asthma or other severe chronic disease; use of oral/intranasal/parenteral steroids; inhaled nedocromil or cromolyn sodium within 1 mo prior to start of study; ise of methotrexate/gold salts, any prescription/over the counter medication which could affect course of asthma; participation in previous study with Diskus device</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Inhaled FP 250mcg versus FP 500mcg versus placebo BID. Identical inhaler devices used (Diskus powder inhaler). Participants in FP500mcg given placebo inhaler for pm dose. Double-blind phase duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function (FEV1, PEF); Probability of remaining in study; Symptoms; Medication use; Safety; HPA axis function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACTH: adrenocorticotropic hormone; ATS: American Thoracic Society; BAL: bronchoalveolar lavage; BDP: beclomethasone dipropionate; BID: twice daily; BHR: bronchial hyperresponsiveness; BUD: budesonide; DPI: dry powder inhaler; ECP: eosinophil cationic protein; EDN: eosinophil derived neurotoxin; FEF25-75: forced expiratory flow at 25 to 75% of FVC; FEV1: forced expired volume in one second; FP: fluticasone propionate; FVC: forced vital capacity; HPA: hypothalamo-pituitary-adrenal; ICAM-1: intercellular adhesion molecule-1; ICS: inhaled corticosteroid; ITT: intension-to-treat; mcg/d: micrograms per day; MDI: metered dose inhaler; PD15 FEV1: provocative dose of inhalant required to produce a 15% fall in FEV1; PC20 FEV1: provocative concentration of inhalant required to produce a 20% fall in FEV1; PD20 FEV1: provocative dose of inhalant required to produce a 20% fall in FEV1; PEFR: peak expiratory flow rate; TA: triamcinolone acetonide<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-08 10:36:44 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Acuna-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised study of the acute effects of inhalation of FP in mild asthmatics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baitinger-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison with combination product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bisgaard-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study assessed a group of young children including infants under the age of two years<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chervinsky-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between FP and LTRA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cirule-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clear diagnosis of asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dal-Negro-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>FP as additional treatment to SAL</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Benedictis-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between FP and BDP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-04 11:49:14 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-den-Otter-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-04 11:49:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Administration of fluticasone to people without asthma or COPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dente-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No PLA control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Efthimiou-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nebuliser delivery device</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eliraz-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison with combination product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falcoz-2000a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Wrong comparison (FP versus FP via different inhalers)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faul-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between FP and LTRA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fletcher-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nebuliser delivery device</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fowler-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between different propellants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harrison-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between FP and BDP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanniess-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between FP and LTRA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kelly-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison with TAA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leibman-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison between SAL and LTRA as add on to FP<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipworth-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Crossover study with intervention periods of only 4 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lujik-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of inadequate duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Majer_x002d_Teboul-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison with BDP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moore-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Wrong outcomes assessed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Overbeek-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compaison with LTRA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pao-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants had wheeze and not asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Srebro-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Wrong comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-04 13:56:12 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Su-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-04 13:56:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Treatments not given in random order </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Szefler-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study conducted in participants admitted as in patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teper-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study assesses infants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo was not a randomised intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1998a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Crossover design study with intervention periods of 4 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1998b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo was not a randomised intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wong-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Infant age group<BR/>Assessing the effects of fluticasone in infants discharged from hospital following recent acute bronchiolitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>FP: fluticasone; SAL: salmeterol; BUD: budesonide; F: formoterol; TAA: triamcinolone; LTRA: anti-leukotriene agent; PLA: placebo<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-07-04 13:55:50 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Stanford-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wignarajah-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Agertoft-1997">
<DESCRIPTION>
<P>Computer generated random sequence with balanced blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:33:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Allen-1998">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Allen-2000">
<DESCRIPTION>
<P>Described as randomised; method not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Arets-2002">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Berger-2002-ICS">
<DESCRIPTION>
<P>Computer-generated blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Berger-2002-SABA">
<DESCRIPTION>
<P>Computer-generated blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-2004">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:34:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Busse-2001">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-2005">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Casale-2001">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:49:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chervinsky-1994">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chuchalin-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Condemi-1997">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Convery-2000">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Corsico-2000">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Derom-1999">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Derom-2005">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Ekroos-1999">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:42 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLIC15">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:50 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA2007">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:57 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3014">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:07 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3020">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3022">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA4030">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Falcoz-2000">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Faul-1998">
<DESCRIPTION>
<P>Described as randomised; information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Galant-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:43 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Galant-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Giannini-2003">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1998">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hart-2000">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hoekstra-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hofstra-2000">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jayaram-2005">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jeffery-2002">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:37:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Katz-1998">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:28:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Kavuru-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:28:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Kemp-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Laforce-2000">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Langley-2002">
<DESCRIPTION>
<P>PACT (computer-generated package)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lanz-2001">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1997">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:29:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Levy-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Li-1999a">
<DESCRIPTION>
<P>Computer-generated randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999b">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lindqvist-2003">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lipworth-2005">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:29:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lumry-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:30:10 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-MacKenzie-1993">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Micheletto-2000">
<DESCRIPTION>
<P>Described as randomised; information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:30:45 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nathan-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:30:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nathan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:31:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nelson-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Noonan-1995">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Noonan-1998">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Shaughnessy-1993">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Overbeek-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Parameswaren-2000">
<DESCRIPTION>
<P>Computer generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pauwels-2002">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-1997">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:31:58 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:08 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Peden-1998">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Phillips-2004">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:48 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pinnas-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 14:08:42 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Qaquandah-2006">
<DESCRIPTION>
<P>'Randomization was stratified according to age (12 to<BR/>23 months and 24 to 47 months) and by pharmacokinetic<BR/>sampling (1 sample or 3 samples).'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30021">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:06 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30022">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30023">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Shapiro-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sheffer-1996">
<DESCRIPTION>
<P>Computer generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sorkness-1999a">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sorkness-1999b">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sovij_x00e4_rvi-2003">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Subburao-2005">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Ward-2001">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wasserman-1996">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wolfe-1996">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:34:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-2000-ICS">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:34:43 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-2000-SABA">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:34:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-ZuWallack-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Grunsven-2000">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensen-1999">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Schoor-2002">
<DESCRIPTION>
<P>Described as randomised; no other information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Agertoft-1997">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Allen-1998">
<DESCRIPTION>
<P>Randomisation code generated off site and concealed using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Allen-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Arets-2002">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:33:50 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Berger-2002-ICS">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:34:04 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Berger-2002-SABA">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-2004">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:34:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Busse-2001">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-2005">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Casale-2001">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:49:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chervinsky-1994">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:10 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chuchalin-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Condemi-1997">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Convery-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Corsico-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Derom-1999">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Derom-2005">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Ekroos-1999">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:43 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLIC15">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:35:52 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA2007">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:00 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3014">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:10 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3020">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3022">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA4030">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Falcoz-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Faul-1998">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Galant-1996">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:36:45 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Galant-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Giannini-2003">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gross-1998">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hart-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hoekstra-1996">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hofstra-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jayaram-2005">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jeffery-2002">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 12:37:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Katz-1998">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:28:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Kavuru-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:29:01 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Kemp-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Laforce-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Langley-2002">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lanz-2001">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1997">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:29:37 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Levy-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999a">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Li-1999b">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lindqvist-2003">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lipworth-2005">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:29:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lumry-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:30:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-MacKenzie-1993">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Micheletto-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:30:47 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nathan-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:30:58 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nathan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:31:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nelson-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Noonan-1995">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Noonan-1998">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Shaughnessy-1993">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Overbeek-1996">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Parameswaren-2000">
<DESCRIPTION>
<P>Off-site </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pauwels-2002">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-1997">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:01 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Peden-1998">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Phillips-2004">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:32:51 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pinnas-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 14:09:06 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Qaquandah-2006">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:01 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30021">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:09 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30022">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30023">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:33:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Shapiro-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sheffer-1996">
<DESCRIPTION>
<P>Off site by third party </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sorkness-1999a">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sorkness-1999b">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sovij_x00e4_rvi-2003">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Subburao-2005">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Ward-2001">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wasserman-1996">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wolfe-1996">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:34:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-2000-ICS">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:34:46 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-2000-SABA">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 13:34:58 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-ZuWallack-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Grunsven-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensen-1999">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Schoor-2002">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Agertoft-1997">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Allen-1998">
<DESCRIPTION>
<P>Double blind; identical inhaler devices </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Allen-2000">
<DESCRIPTION>
<P>Double-blind; identical inhaler devices </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Arets-2002">
<DESCRIPTION>
<P>Double-blind; identical inhalers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Berger-2002-ICS">
<DESCRIPTION>
<P>Double blind; identical inhaler devices </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Berger-2002-SABA">
<DESCRIPTION>
<P>Double blind; identical inhaler devices</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Bernstein-2004">
<DESCRIPTION>
<P>double-blind, double-dummy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Busse-2001">
<DESCRIPTION>
<P>Double dummy design </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-2005">
<DESCRIPTION>
<P>Double-blind </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Casale-2001">
<DESCRIPTION>
<P>Double-blind </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chervinsky-1994">
<DESCRIPTION>
<P>Identical inhaler devices </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:13 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chuchalin-2008">
<DESCRIPTION>
<P>Double-dummy design </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Condemi-1997">
<DESCRIPTION>
<P>Double-dummy design </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Convery-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Corsico-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Derom-1999">
<DESCRIPTION>
<P>Identical inhaler devices </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Derom-2005">
<DESCRIPTION>
<P>Double-dummy design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Ekroos-1999">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLIC15">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA2007">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3014">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3020">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA3022">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-FLTA4030">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:15 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Falcoz-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Faul-1998">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Galant-1996">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Galant-1999">
<DESCRIPTION>
<P>Double-dummy design </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Giannini-2003">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Gross-1998">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:17 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Hart-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Hoekstra-1996">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hofstra-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jayaram-2005">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Jeffery-2002">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Katz-1998">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Kavuru-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Kemp-2004">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Laforce-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Langley-2002">
<DESCRIPTION>
<P>Double dummy design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lanz-2001">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lawrence-1997">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Levy-2006">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Li-1999a">
<DESCRIPTION>
<P>Triple dummy (identical inhalers)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Li-1999b">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lindqvist-2003">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lipworth-2005">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lumry-2006">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-MacKenzie-1993">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Micheletto-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nathan-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nathan-2006">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nelson-1999">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Noonan-1995">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:23 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Noonan-1998">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-O_x0027_Shaughnessy-1993">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Olivieri-1997">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Overbeek-1996">
<DESCRIPTION>
<P>Identical inhaler devices </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Parameswaren-2000">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pauwels-2002">
<DESCRIPTION>
<P>Double-dummy design used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-1997">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-1999">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pearlman-2004">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Peden-1998">
<DESCRIPTION>
<P>Double dummy design used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Phillips-2004">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Pinnas-2005">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Qaquandah-2006">
<DESCRIPTION>
<P>Identical inhaler devices</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30021">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30022">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:26 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-SAS30023">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Shapiro-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sheffer-1996">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sorkness-1999a">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Sorkness-1999b">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sovij_x00e4_rvi-2003">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Subburao-2005">
<DESCRIPTION>
<P>Double-dummy design used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Ward-2001">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wasserman-1996">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-1996">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-2000-ICS">
<DESCRIPTION>
<P>Double-dummy design used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfe-2000-SABA">
<DESCRIPTION>
<P>Double-dummy design used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-ZuWallack-2000">
<DESCRIPTION>
<P>Double-dummy design used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-van-Grunsven-2000">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-Rensen-1999">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-07 15:20:29 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-van-Schoor-2002">
<DESCRIPTION>
<P>Identical inhaler devices used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-07-07 10:57:09 +0100" MODIFIED_BY="Toby J Lasserson"/>
<ADDITIONAL_TABLES MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Incomplete data not included in meta-analysis</TITLE>
<TABLE COLS="2" ROWS="21">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Data</P>
</TH>
</TR>
<TR>
<TD>
<P>Allen 1997</P>
</TD>
<TD>
<P>Medical Outcomes Study Short Form (SF-36A)<BR/>Living with asthma questionnaire<BR/>No SD values available for above outcomes<BR/>
<BR/>Sleep scale<BR/>No numerical data available for above outcome</P>
</TD>
</TR>
<TR>
<TD>
<P>Chervinsky 1994</P>
</TD>
<TD>
<P>Change in urinary free cortisol compared to baseline<BR/>Change in urinary 17-hydroxy steroids compared to baseline<BR/>Change in morning plasma cortisol compared to baseline<BR/>Change in plasma cortisol 60 min post cosyntropin<BR/>No SD values available for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Ekroos 1998</P>
</TD>
<TD>
<P>Histamine bronchial hyperresponsiveness (PD15 FEV1)<BR/>Log transformed data not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Faul 1998</P>
</TD>
<TD>
<P>FEV1 (after treatment: baseline ratio)<BR/>FEV1/FVC (after treatment: baseline ratio)<BR/>FEF 25-75 (after treatment: baseline ratio)<BR/>Histamine bronchial responsiveness PC20 FEV1 (after treatment: baseline ratio)<BR/>Results expressed using medians and ranges for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Galant 1999</P>
</TD>
<TD>
<P>Morning plasma cortisol<BR/>No numerical data available</P>
</TD>
</TR>
<TR>
<TD>
<P>Hart 2000</P>
</TD>
<TD>
<P>FEV1(reported as non-significant)<BR/>am PEF<BR/>
<BR/>Both outcomes recorded but no data presented.</P>
</TD>
</TR>
<TR>
<TD>
<P>Hofstra 2000</P>
</TD>
<TD>
<P>PD20<BR/>
<BR/>Unable to ascertain distribution around geometric mean</P>
</TD>
</TR>
<TR>
<TD>
<P>Hoekstra 1997</P>
</TD>
<TD>
<P>Night-time (4am) PEFR<BR/>Morning serum cortisol<BR/>Morning urine cortisol (collection time frame not specified)<BR/>No SD values available for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Jayaram 2002</P>
</TD>
<TD>
<P>All outcomes reported in study could not be entered as dosage was unclear.</P>
</TD>
</TR>
<TR>
<TD>
<P>Jeffery 2002</P>
</TD>
<TD>
<P>FEV1; am PEF<BR/>
<BR/>Recorded but not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Katz 1998</P>
</TD>
<TD>
<P>Change in FEV1 compared to baseline<BR/>Change in FVC compared to baseline<BR/>Change in FEF25-75 compared to baseline<BR/>Change in evening PEFR compared to baseline<BR/>Change in night-time awakening score compared to baseline<BR/>No SD values available for above outcomes<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Langley 2002</P>
</TD>
<TD>
<P>Rescue medication usage<BR/>
<BR/>Median values reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Lindqvist 2003</P>
</TD>
<TD>
<P>FEV1 - change from baseline in L/min<BR/>Symptoms - change from baseline<BR/>Medication usage - change from baseline<BR/>
<BR/>No SDs presented<BR/>
<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>MacKenzie 1993</P>
</TD>
<TD>
<P>FEV1<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Clinic PEFR<BR/>No SD values available for above outcomes<BR/>
<BR/>Daily asthma symptom score<BR/>Morning plasma cortisol<BR/>No numerical data available for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Noonan 1998</P>
</TD>
<TD>
<P>Change in log e methacholine bronchial responsiveness PD20 FEV1<BR/>Error bars plotted on graphical display of results, but unclear whether these represent SD or SEM values</P>
</TD>
</TR>
<TR>
<TD>
<P>Olivieri 1997</P>
</TD>
<TD>
<P>Methacholine bronchial responsiveness PC20 FEV1<BR/>Randomised treatment groups were not compared: results expressed as change compared to baseline for each individual treatment group.</P>
</TD>
</TR>
<TR>
<TD>
<P>Overbeek 1996</P>
</TD>
<TD>
<P>Daily asthma symptom score<BR/>No numerical data available for above outcome</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 1997</P>
</TD>
<TD>
<P>Change in evening PEFR compared to baseline<BR/>No SD values available for above outcome<BR/>
<BR/>Morning serum cortisol<BR/>Plasma cortisol 30-60 min post 250 mcg iv cosyntropin<BR/>No numerical data available for above outcome<BR/>
<BR/>Physician rated global assessment of efficacy<BR/>Data not presented in a form suitable for meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Wasserman 1996</P>
</TD>
<TD>
<P>Physician-rated global assessment of effectiveness<BR/>Data not presented in a form suitable for meta-analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolfe 1996</P>
</TD>
<TD>
<P>Change FEV1 compared to baseline<BR/>No SD values available for above outcome<BR/>
<BR/>Change in morning PEFR compared to baseline<BR/>Change in evening PEFR compared to baseline<BR/>Daily wheeze, cough, shortness of breath scores<BR/>Daily beta2 agonist use<BR/>Morning plasma cortisol<BR/>No numerical data available for above outcomes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<TITLE>Search history detail</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Issue of CLIB</P>
</TH>
<TH>
<P>Time frame of search</P>
</TH>
<TH>
<P>Search detail</P>
</TH>
</TR>
<TR>
<TD>
<P>Issue 3, 2001</P>
</TD>
<TD>
<P>All years to March 1999</P>
</TD>
<TD>
<P>Stage 1 electronic search: 6494 citations retrieved, 2162 unique citations imported to Inhaled Steroid Register; Stage 2 electronic search: Fluticasone Register: 258 citations (180 excluded on basis of abstract: 150 not RCT; 30 not chronic asthma in humans). 78 papers retrieved in full text form - 50 excluded on full paper: 6 not RCT, 38 no randomised placebo arm, 2 treatment period &lt; 1 week; 1 infants; 3 nebuliser delivery device; 28 papers meeting inclusion criteria; 21 unique studies meeting inclusion criteria. Other sources: Two studies (Galant 1999; Li 1999) were identified by GSK. These studies were published after the date of the final electronic search (March 1999). Five studies (Ekroos 1999; Hofstra 2000; Nathan 1999; Busse 2001; Van Schoor 2002) were identified as a result of searching respiratory society meeting abstracts.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Issue 2, 2005</P>
</TD>
<TD>
<P>March 1999 to January 2004</P>
</TD>
<TD>
<P>From handsearching the updated inhaled steroids search results (1301 additional references), a 'fluticasone' register was created consisting of 197 citations (121 references excluded from abstracts as irrelevant comparisons). Three studies reported data from two different trials each, and so two study identities were created for each study (Berger 2002 BD; Berger 2002 ICS; Sorkness 1999; Sorkness 1999a; Wolfe 2000 BD; Wolfe 2000 ICS). Seventy-five references, pertaining to 55 studies were retrieved in full. We excluded studies for the following reasons: Wrong comparison (11); no clear diagnosis of asthma (2); acute asthma (1); not randomised (1). One study was a full published version of a previously included abstract (Busse 2001). Forty new studies were included in the January 2004 update:<BR/>
<BR/>Allen 2000; Arets 2002; Berger 2002 BD; Berger 2002 ICS; Casale 2001; Convery 2000; Corsico 2000; Derom 1999; Derom 2005; Falcoz 2000; Giannini 2003; Hart 2000; Jayaram 2002; Jeffery 2002; Kavuru 2000; Laforce 2000; Langley 2002; Lanz 2001; Li 1999a; Li 1999b; Lindqvist 2003; Micheletto 2000; Nathan 2000; Nielsen 2002; Parameswaren 2000; Pauwels 2002; Pearlman 1999; Pearlman 2002; Rooklin 2001; Shapiro 2000; Sorkness 1999; Sorkness 1999a; Sovijärvi 2003; van Grunsven 2000; van Rensen 1999; Ward 2001; Weinstein 2001 (now Pearlman 2004); Wolfe 2000 BD; Wolfe 2000 ICS; ZuWallack 2000.</P>
</TD>
</TR>
<TR>
<TD>
<P>Issue 4, 2005</P>
</TD>
<TD>
<P>January 2004-2005</P>
</TD>
<TD>
<P>Seven new trials were included, giving a total of 75 studies. The new trials were:<BR/>Lipworth 2005, Given 2004 (now Levy 2006); SAS30021; SAS30022; SAS30023; SAS30024 (now Chuchalin 2008); Kemp 2004.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="3">
<TITLE>What's New Archive</TITLE>
<TABLE COLS="2" ROWS="2">
<TR>
<TH>
<P>Date of search</P>
</TH>
<TH>
<P>Detail</P>
</TH>
</TR>
<TR>
<TD>
<P>January 2005</P>
</TD>
<TD>
<P>7 new trials were included, giving a total of 75 studies. The new trials are: <BR/>Lipworth 2005, Boonsawat 2004; Given 2004; SAS30021; SAS30024; Dorinksy 2004; Kemp 2004. <BR/>
<BR/>Impact of the new studies<BR/>The effects of these studies was to tighten confidence intervals around the significant effects already obtained in the review. Some subgroup analyses based on severity are now starting to show a more pronounced effect in moderately severe patients, than in milder patients. This observation should be tempered with some caution, as other variables could explain these differences.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="4">
<TITLE>Criteria for trial withdrawal due to lack of efficacy</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>FEV1</P>
</TH>
<TH>
<P>PEFR</P>
</TH>
<TH>
<P>Beta2 agonist use</P>
</TH>
<TH>
<P>Night-time awakening</P>
</TH>
<TH>
<P>Exacerbations</P>
</TH>
</TR>
<TR>
<TD>
<P>Chervinsky 1994</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% decrease in morning or evening PEFR on 4 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more nights with 2 awakening out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Galant 1996</P>
</TD>
<TD>
<P>15% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>3 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Katz 1997</P>
</TD>
<TD>
<P>15% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>15% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>8 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more nights with awakening out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kavuru 2000</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease from mean am PEF compared to baseline on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Nathan 2000</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>12 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 1997</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Peden 1997</P>
</TD>
<TD>
<P>15% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>3 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Shapiro 2000</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline on 3+ days out of preceding 7 prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Sheffer 1996</P>
</TD>
<TD>
<P>15% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease in morning PEFR on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 3 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>3 or more nights with awakening out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolfe 2000 (BD and ICS studies)</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>12 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>ZuWallack 2000</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline</P>
</TD>
<TD>
<P>20% or greater decrease compared to baseline on 3+ days out of preceding 7 prior to clinic visit</P>
</TD>
<TD>
<P>12 or more puffs on 2 or more days out of 7 in week prior to clinic visit</P>
</TD>
<TD>
<P>2 or more awakening in week prior to clinic visit</P>
</TD>
<TD>
<P>Any clinical exacerbation requiring emergency treatment, hospital admission or additional asthma medication other than rescue beta 2 agonist</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="5">
<TITLE>Asthma severity: characteristics of included patients at baseline</TITLE>
<TABLE COLS="8" ROWS="89">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>FEV1: incl. criteria</P>
</TH>
<TH>
<P>FEV1: mean baseline</P>
</TH>
<TH>
<P>Symptom frequency</P>
</TH>
<TH>
<P>OCS treatment</P>
</TH>
<TH>
<P>ICS treatment</P>
</TH>
<TH>
<P>Author opinion</P>
</TH>
<TH>
<P>Overall estimation</P>
</TH>
</TR>
<TR>
<TD>
<P>Agertoft 1997</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Allen 1998</P>
</TD>
<TD>
<P>&gt;60</P>
</TD>
<TD>
<P>88-89</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Approx. 50% patients ICS naive at baseline, 50% previous regular ICS use</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Allen 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>61%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Severe</P>
</TD>
</TR>
<TR>
<TD>
<P>Arets 2002</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>99-104</P>
</TD>
<TD>
<P>SABA &gt;1600mcg/d during &gt;30% days of last year excluded</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Only ICS &lt;100mcg/d</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Berger 2002 BD</P>
</TD>
<TD>
<P>60-85%</P>
</TD>
<TD>
<P>72-71.9%</P>
</TD>
<TD>
<P>&gt;/=2 puffs BD on 2 of last 7 days of run-in; symptom scores &gt;/=2 of last 7 days</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not within 1 month of study</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Berger 2002 ICS</P>
</TD>
<TD>
<P>60-90%</P>
</TD>
<TD>
<P>75.9-75.8%</P>
</TD>
<TD>
<P>&lt;/=30 puffs over past 7 days</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>For three months prior to randomisation</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Boonsawat 2004</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Requirement for SABAs alone</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Busse 2001</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>68-69</P>
</TD>
<TD>
<P>Symptomatic despite treatment with short acting beta2 agonist</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Busse 2005</P>
</TD>
<TD>
<P>40-65</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Caffey 2005</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>88%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not clear - one 'preventer' medication allowed per participant</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Casale 2001</P>
</TD>
<TD>
<P>&gt;/=65%</P>
</TD>
<TD>
<P>3 Litres</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Chervinsky 1994</P>
</TD>
<TD>
<P>60-90</P>
</TD>
<TD>
<P>71-73</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes: at least 1 month regular treatment with BDP prior to study</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Condemi 1997</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>66-68</P>
</TD>
<TD>
<P>"&lt; 3 days needing &gt; 12 puffs beta2 agonist in 7 days&lt; 4 days with diurnal PEFR variability of &gt; 20% in 7 days"</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes: ICS for at least 1 month prior to study</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Convery 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>100-103</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Corsico 2000</P>
</TD>
<TD>
<P>&gt;80%</P>
</TD>
<TD>
<P>98-102</P>
</TD>
<TD>
<P>Stable asthma for previous 2 months</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Derom 1999</P>
</TD>
<TD>
<P>&gt;/=40%</P>
</TD>
<TD>
<P>80%</P>
</TD>
<TD>
<P>Exacerbation free for 1 month</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Derom 2005</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Dorinsky 2004</P>
</TD>
<TD>
<P>50-85%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>4 days of week preceding randomisation; pre-treatment with SABA only</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Ekroos 1999</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Falcoz 2000</P>
</TD>
<TD>
<P>50-80%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Falcoz 2000a</P>
</TD>
<TD>
<P>50-80%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Faul 1998</P>
</TD>
<TD>
<P>&gt;40</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>FLIC15</P>
</TD>
<TD>
<P>&gt;/=60% predicted</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>FLTA2007</P>
</TD>
<TD>
<P>50-85%</P>
</TD>
<TD>
<P>74%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>FLTA3014</P>
</TD>
<TD>
<P>50-85%</P>
</TD>
<TD>
<P>2.47-2.5L</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>FLTA3020</P>
</TD>
<TD>
<P>60-90% predicted</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>FLTA4030</P>
</TD>
<TD>
<P>50-80%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Stable during 7 day run-in, controlled with SABA alone</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Galant 1999</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>65-67</P>
</TD>
<TD>
<P>"Mean beta2 agonist use 3.5 puffs/dMean night awakenings/week 0.05 to 0.08"</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>24-30% of patients ICS treated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Galant 1996</P>
</TD>
<TD>
<P>45-75</P>
</TD>
<TD>
<P>60-62</P>
</TD>
<TD>
<P>&gt; 8 puffs/d beta2 agonist or 2-4 night-time awakenings in week run-in</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Giannini 2003</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>3.23 L<BR/>96 % predicted</P>
</TD>
<TD>
<P>Use of ß-agonist during run-in (unspecified)</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Given 2004</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>85%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes - 49%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Gross 1998</P>
</TD>
<TD>
<P>50-80%</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>&lt;4 days usage of &gt;<BR/>12 puffs/d</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>100%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Hart 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>98.5%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Hoekstra 1996</P>
</TD>
<TD>
<P>&gt;75</P>
</TD>
<TD>
<P>88-92</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Hofstra 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>96.6-93.2%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Jayaram 2002</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Jeffery 2002</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>75.6%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No - SABA treatment only</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Katz 1998</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>PEFR 75 (% predicted) or less</P>
</TD>
<TD>
<P>Asthma symptoms on at least 4 out of 10 days of run in period or at least one night-time awakening in 10 days or 4 or puffs beta2 agonist on at least 4 days</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Kavuru 2000</P>
</TD>
<TD>
<P>40-85% predicted</P>
</TD>
<TD>
<P>64% predicted</P>
</TD>
<TD>
<P>Participants excluded if excessive use of SABA during run-in, and frequent nocturnal awakenings</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Kemp 2004</P>
</TD>
<TD>
<P>50-100% predicted</P>
</TD>
<TD>
<P>82-85% predicted</P>
</TD>
<TD>
<P>Mild stable asthma</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>LaForce 2000</P>
</TD>
<TD>
<P>50-85% predicted</P>
</TD>
<TD>
<P>70-73% predicted</P>
</TD>
<TD>
<P>Participants had to have stable asthma during run-in</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Pharmacotherapy required for at least 3 months prior to the study (irrespective of whether ICS or not)</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Langley 2002</P>
</TD>
<TD>
<P>&gt;/=60%</P>
</TD>
<TD>
<P>93.5%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Lanz 2001</P>
</TD>
<TD>
<P>50-85%</P>
</TD>
<TD>
<P>75%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Lawrence 1997</P>
</TD>
<TD>
<P>50-80%</P>
</TD>
<TD>
<P>65-68</P>
</TD>
<TD>
<P>"Mean beta2 agonist use 3.2 - 4.2 puffs/d "</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes: 3 months treatment or longer prior to study</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 1999</P>
</TD>
<TD>
<P>&gt;60</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 1999a</P>
</TD>
<TD>
<P>&gt;60%</P>
</TD>
<TD>
<P>80-83%</P>
</TD>
<TD>
<P>Use of SABA on 50% days in run-in</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes - 12 months with BDP up to 500mcg/d</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 1999b</P>
</TD>
<TD>
<P>&gt;/=50%</P>
</TD>
<TD>
<P>82-89%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Prednisolone &lt;/=140mg in past year or equivalent</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Lindqvist 2003</P>
</TD>
<TD>
<P>60-100%</P>
</TD>
<TD>
<P>79-83%</P>
</TD>
<TD>
<P>Participants were to have been 'symptomatic'</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Lipworth 2005</P>
</TD>
<TD>
<P>&gt;/=70%</P>
</TD>
<TD>
<P>82%</P>
</TD>
<TD>
<P>Use of SABA 2 x per week for 6 months</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Lumry 2006</P>
</TD>
<TD>
<P>45-80%</P>
</TD>
<TD>
<P>65%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>ICS for &gt;/=3 months</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>MacKenzie 1993</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>"Patients had experienced a worsening of asthma with deterioration in lung function leading to change in medication or hospitalisation in last month; symptoms on at least 4 out of 7 days "</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Michelletto 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>73-74%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Nathan 2000</P>
</TD>
<TD>
<P>45-75% predicted</P>
</TD>
<TD>
<P>63.3-64.3</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Nelson 1999</P>
</TD>
<TD>
<P>40-80</P>
</TD>
<TD>
<P>60-62</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Almost 100% of patients receiving ICS</P>
</TD>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>Severe</P>
</TD>
</TR>
<TR>
<TD>
<P>Nielsen 2002</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Noonan 1998</P>
</TD>
<TD>
<P>60-85</P>
</TD>
<TD>
<P>73-76</P>
</TD>
<TD>
<P>"No more than 12 puffs/d beta2 agonist and no more than 3 nights with awakening due to asthma"</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Noonan 1995</P>
</TD>
<TD>
<P>40-80</P>
</TD>
<TD>
<P>56-57.4</P>
</TD>
<TD>
<P>Requirement for rescue beta2 agonist for 2 weeks prior to study due to symptoms</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>87% of patients receiving ICS</P>
</TD>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>Severe</P>
</TD>
</TR>
<TR>
<TD>
<P>Olivieri 1997</P>
</TD>
<TD>
<P>&gt; 80</P>
</TD>
<TD>
<P>98</P>
</TD>
<TD>
<P>&lt; 2 puffs/d beta2 agonist</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Shaughnessy 1993</P>
</TD>
<TD>
<P>&gt; 60</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Overbeek 1996</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>84-86</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Parameswaren 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>90.2</P>
</TD>
<TD>
<P>Few or no symptoms</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Pauwels 2002</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 1997</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>66-67</P>
</TD>
<TD>
<P>"Mean beta2 agonist use 3.4-4.1 puffs/dNo more than 12 puffs/d beta2 agonist and no more than 2 nights with awakening due to asthma symptoms in last 7 days"</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes: at least 3 months</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 1999</P>
</TD>
<TD>
<P>50-80% predicted</P>
</TD>
<TD>
<P>65-69</P>
</TD>
<TD>
<P>No more than 12 puffs of SABA on more than 2 days during run-in</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not in previous month</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 2002</P>
</TD>
<TD>
<P>45-80% predicted</P>
</TD>
<TD>
<P>65.3-65.6</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 2004</P>
</TD>
<TD>
<P>40-85%</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Described as symptomatic</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Requirement for pharmacotherapy</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Peden 1998</P>
</TD>
<TD>
<P>50-85</P>
</TD>
<TD>
<P>72-73</P>
</TD>
<TD>
<P>"No more than 12 puffs/d beta2 agonist and no more than 3 nights with awakening due to asthmaMean awakenings per night due to asthma 0.05 to 0.09Mean beta2 agonist use 1.4 to 2.0 puffs/d"</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Some patients: amount and type of ICS not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Pinnas 2005</P>
</TD>
<TD>
<P>45-80%</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>Not specified</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Moderate to severe</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Qaquandah 2006</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Requirement for rescue beta2 agonist for 2 weeks prior to study due to symptoms</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Rooklin 2001</P>
</TD>
<TD>
<P>40-85%</P>
</TD>
<TD>
<P>68%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>SAS30021</P>
</TD>
<TD>
<P>Not stated (am PEF 50-85% predicted)</P>
</TD>
<TD>
<P>Not stated (am PEF 75.2-76.7% predicted)</P>
</TD>
<TD>
<P>Symptoms on &gt;/=4 days of week prior to randomisation</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>SAS30024</P>
</TD>
<TD>
<P>Not stated (pre-BD PEF had to be &gt;80% predicted)</P>
</TD>
<TD>
<P>3.1 Litres</P>
</TD>
<TD>
<P>0.57 puffs rescue medication per day</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Shapiro 2000</P>
</TD>
<TD>
<P>40-85%</P>
</TD>
<TD>
<P>66-68%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Sheffer 1996</P>
</TD>
<TD>
<P>45-75</P>
</TD>
<TD>
<P>62-64</P>
</TD>
<TD>
<P>"During 7 day run-in:&gt; 2 night-time awakenings due to asthma in last 7 days20% or greater PEFR diurnal variability at least one day in which 8 puffs beta2 agonist used "</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Sorkness 1999</P>
</TD>
<TD>
<P>&gt;/=50%</P>
</TD>
<TD>
<P>83-88%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Sorkness 1999a</P>
</TD>
<TD>
<P>&gt;/=50%</P>
</TD>
<TD>
<P>83-88%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Sovijärvi 2003</P>
</TD>
<TD>
<P>&gt;/=65%</P>
</TD>
<TD>
<P>79-84</P>
</TD>
<TD>
<P>Stable asthma</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>MIld</P>
</TD>
</TR>
<TR>
<TD>
<P>Subbarao 2005</P>
</TD>
<TD>
<P>&gt;70%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Stable asthma</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>van Grunsven 2000</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>93%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>van Rensen 1999</P>
</TD>
<TD>
<P>&gt;75%</P>
</TD>
<TD>
<P>95.6-96.2%</P>
</TD>
<TD>
<P>Stable asthma</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Schoor 2002</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>Mild</P>
</TD>
</TR>
<TR>
<TD>
<P>Ward 2001</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>91.3%</P>
</TD>
<TD>
<P>Mild to moderate symptomatic asthma</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
<TD>
<P>Mild to moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Wasserman 1996</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>"Mean beta2 agonist use 3.1 to 3.3 puffs/dDuring last 7 days run-in no more than 12 puffs/d beta2 agonist and no more than 2 nights with awakening due to asthma"</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Weinstein 2002</P>
</TD>
<TD>
<P>45-80</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>Not stated - no run-in period described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolfe 1996</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>64-66</P>
</TD>
<TD>
<P>During 2 week run-in period no more than 12 puffs/d beta2 agonist and no more than 2 nights with awakening due to asthma</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolfe 2000 BD</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>During 2 week run-in: 0 days with &gt;/= 12 puffs of SABA prn</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Mild-moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolfe 2000 ICS</P>
</TD>
<TD>
<P>50-80</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>During 2 week run-in: 0 days with &gt;/= 12 puffs of SABA prn</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes - for 3 months prior to study entry</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>ZuWallack 2000</P>
</TD>
<TD>
<P>50-80%</P>
</TD>
<TD>
<P>66-68%</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2009-05-21 10:45:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="6">
<TITLE>Definitions of exacerbation leading to study withdrawal</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Definition</P>
</TH>
</TR>
<TR>
<TD>
<P>Allen 1998</P>
</TD>
<TD>
<P>Requirement for more than two 7-day courses of oral corticosteroid for asthma exacerbation</P>
</TD>
</TR>
<TR>
<TD>
<P>Berger 2002</P>
</TD>
<TD>
<P>Requirement for treatment with oral or parenteral steroids</P>
</TD>
</TR>
<TR>
<TD>
<P>Hoekstra 1996</P>
</TD>
<TD>
<P>Treatment with oral steroids</P>
</TD>
</TR>
<TR>
<TD>
<P>Oliveri 1997</P>
</TD>
<TD>
<P>Not given</P>
</TD>
</TR>
<TR>
<TD>
<P>Overbeek 1996</P>
</TD>
<TD>
<P>Not given</P>
</TD>
</TR>
<TR>
<TD>
<P>Pearlman 1999</P>
</TD>
<TD>
<P>Not given</P>
</TD>
</TR>
<TR>
<TD>
<P>Shapiro 2000</P>
</TD>
<TD>
<P>Requirement for emergency treatment, hospitalisation or usage of medication not allowed by study protocol</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-05-21 10:59:47 +0100" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2009-05-21 09:13:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (all ages)</NAME>
<CONT_OUTCOME CHI2="65.00373106855557" CI_END="0.2991634528358149" CI_START="0.21584903448072115" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.257506243658268" ESTIMABLE="YES" I2="87.69301412627703" I2_Q="97.54801187102179" ID="CMP-001.01" MODIFIED="2008-07-23 16:30:10 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="4.817857224281852E-11" P_Q="1.7009182950999957E-10" P_Z="8.73002630614657E-34" Q="40.78323170417282" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="885" TOTAL_2="877" UNITS="" WEIGHT="200.0" Z="12.115621121264038">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3762700441035288" CI_END="0.16629524983790733" CI_START="0.040165185714042706" DF="1.0" EFFECT_SIZE="0.10323021777597502" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.5396065397611987" P_Z="0.0013355183845870063" STUDIES="4" TAU2="0.0" TOTAL_1="359" TOTAL_2="360" WEIGHT="100.0" Z="3.2082360436833532">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.17739909130993015" CI_START="-0.017399091309930143" EFFECT_SIZE="0.08" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.05" ORDER="1" SD_1="0.25" SD_2="0.33" SE="0.049694327078559475" STUDY_ID="STD-FLTA2007" TOTAL_1="72" TOTAL_2="68" WEIGHT="41.924455560062455"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.17" MEAN_2="0.07" ORDER="2" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Katz-1998" TOTAL_1="69" TOTAL_2="76" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.17" MEAN_2="0.04" ORDER="4" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.20275456800702413" CI_START="0.03724543199297588" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.22" MEAN_2="0.1" ORDER="3" SD_1="0.28" SD_2="0.28" SE="0.04222249421917014" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="58.075544439937545"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="23.84422932027922" CI_END="0.43240825164463154" CI_START="0.32143889404426457" DF="6.0" EFFECT_SIZE="0.37692357284444805" ESTIMABLE="YES" I2="74.83667884834057" ID="CMP-001.01.02" NO="2" P_CHI2="5.578568997659517E-4" P_Z="1.9037453124310863E-40" STUDIES="7" TAU2="0.0" TOTAL_1="526" TOTAL_2="517" WEIGHT="100.0" Z="13.314605827669217">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.5122458618655239" CI_START="0.1877541381344761" EFFECT_SIZE="0.35" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="-0.26" ORDER="5" SD_1="0.53" SD_2="0.51" SE="0.08278002205412881" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="11.694964152190908"/>
<CONT_DATA CI_END="0.6095701980962813" CI_START="0.33042980190371873" EFFECT_SIZE="0.47000000000000003" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="0.19" ORDER="6" SD_1="0.48" SD_2="0.47" SE="0.07121059325436242" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="15.803772261393078"/>
<CONT_DATA CI_END="0.2558097869870334" CI_START="-0.07580978698703338" EFFECT_SIZE="0.09000000000000001" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.11" ORDER="7" SD_1="0.53" SD_2="0.55" SE="0.0845983846105948" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="11.19762269392143"/>
<CONT_DATA CI_END="0.6026337673929649" CI_START="0.15736623260703514" EFFECT_SIZE="0.38" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.08" ORDER="8" SD_1="0.41" SD_2="0.54" SE="0.11359074408972389" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="6.211036501775683"/>
<CONT_DATA CI_END="0.8173991126069012" CI_START="0.4826008873930988" EFFECT_SIZE="0.65" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="-0.22" ORDER="9" SD_1="0.56" SD_2="0.52" SE="0.08540927992928647" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="10.986006449084012"/>
<CONT_DATA CI_END="0.5353669584342065" CI_START="0.2046330415657936" EFFECT_SIZE="0.37" ESTIMABLE="YES" MEAN_1="0.51" MEAN_2="0.14" ORDER="10" SD_1="0.53" SD_2="0.51" SE="0.084372447523832" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="11.257674185936953"/>
<CONT_DATA CI_END="0.4468082799188252" CI_START="0.25319172008117474" EFFECT_SIZE="0.35" ESTIMABLE="YES" MEAN_1="0.59" MEAN_2="0.24" ORDER="11" SD_1="0.35" SD_2="0.27" SE="0.04939288715631338" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="32.84892375569793"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="97.03019425527307" CI_END="0.21357113745535522" CI_START="0.14829853858236375" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_SIZE="0.18093483801885948" ESTIMABLE="YES" I2="88.66332270647577" I2_Q="95.51470906208033" ID="CMP-001.02" LOG_CI_END="-0.6704574393346331" LOG_CI_START="-0.8288631287338731" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.7424778040486333" MODIFIED="2008-07-14 10:07:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="7.771561172376096E-16" P_Q="2.3380627374169904E-6" P_Z="1.6739409813501175E-27" Q="22.29509777271683" RANDOM="NO" SCALE="1.2695253092204082" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1039" TOTAL_2="1032" WEIGHT="200.0" Z="10.865991922754294">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.38192244216223614" CI_END="0.14848108838160684" CI_START="0.05618497277713826" DF="3.0" EFFECT_SIZE="0.10233303057937256" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.8283288576904498" LOG_CI_START="-1.2503798252252962" LOG_EFFECT_SIZE="-0.9899841641079714" NO="1" P_CHI2="0.9439510597264991" P_Z="1.3851127990646825E-5" STUDIES="4" TAU2="0.0" TOTAL_1="359" TOTAL_2="360" WEIGHT="100.0" Z="4.346207921120692">
<NAME>Children</NAME>
<IV_DATA CI_END="0.17995816321154276" CI_START="-0.019958163211542757" EFFECT_SIZE="0.08" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="12" SE="0.051" STUDY_ID="STD-FLTA2007" TOTAL_1="72" TOTAL_2="68" WEIGHT="21.314263064811446"/>
<IV_DATA CI_END="0.2293576229796436" CI_START="-0.02935762297964359" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="69" TOTAL_2="76" WEIGHT="12.726905011839888"/>
<IV_DATA CI_END="0.18035852336614222" CI_START="0.019641476633857777" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15" SE="0.041" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" WEIGHT="32.97941596167433"/>
<IV_DATA CI_END="0.20035852336614224" CI_START="0.03964147663385777" EFFECT_SIZE="0.12" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="14" SE="0.041" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="32.97941596167433"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="74.35317404039401" CI_END="0.3057432362714543" CI_START="0.2134205569877461" DF="7.0" EFFECT_SIZE="0.2595818966296002" ESTIMABLE="YES" I2="90.58547252307332" ID="CMP-001.02.02" LOG_CI_END="-0.514643141756847" LOG_CI_START="-0.6707637510017083" LOG_EFFECT_SIZE="-0.5857255987284433" MODIFIED="2008-07-10 10:59:09 +0100" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="1.942890293094024E-13" P_Z="3.007138227426284E-28" STUDIES="8" TAU2="0.0" TOTAL_1="680" TOTAL_2="672" WEIGHT="100.0" Z="11.021585863407596">
<NAME>Adults</NAME>
<IV_DATA CI_END="0.5107170467322845" CI_START="0.18928295326771552" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17" SE="0.082" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="8.24960056447376"/>
<IV_DATA CI_END="0.6099414284961598" CI_START="0.3300585715038401" EFFECT_SIZE="0.47" ESTIMABLE="YES" ESTIMATE="0.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="18" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="10.880884549019916"/>
<IV_DATA CI_END="0.2599288774596227" CI_START="-0.07992887745962271" EFFECT_SIZE="0.09" ESTIMABLE="YES" ESTIMATE="0.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="19" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="7.379423431169217"/>
<IV_DATA CI_END="0.5999079590653941" CI_START="0.16009204093460594" EFFECT_SIZE="0.38" ESTIMABLE="YES" ESTIMATE="0.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20" SE="0.1122" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="4.406308619024594"/>
<IV_DATA CI_END="0.8199288774596227" CI_START="0.4800711225403773" EFFECT_SIZE="0.65" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21" SE="0.0867" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="7.379423431169217"/>
<IV_DATA CI_END="0.09935852336614223" CI_START="-0.061358523366142226" EFFECT_SIZE="0.019" ESTIMABLE="YES" ESTIMATE="0.019" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-10 10:59:09 +0100" MODIFIED_BY="Christopher J Cates" ORDER="16" SE="0.041" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="32.99840225789504"/>
<IV_DATA CI_END="0.5399288774596227" CI_START="0.2000711225403773" EFFECT_SIZE="0.37" ESTIMABLE="YES" ESTIMATE="0.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="22" SE="0.0867" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="7.379423431169217"/>
<IV_DATA CI_END="0.44995816321154275" CI_START="0.2500418367884572" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="23" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="21.32653371607904"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-07-10 12:19:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FEV1 - Litres (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.7247431863090052" CI_START="-0.10474318630900525" EFFECT_SIZE="0.81" ESTIMABLE="YES" MEAN_1="3.61" MEAN_2="2.8" ORDER="24" SD_1="1.0" SD_2="0.98" SE="0.4667142832849903" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-07 15:35:24 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="100" TOTAL_2="99" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="99" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="8.439945976810082" CI_START="2.5600540231899185" EFFECT_SIZE="5.5" ESTIMABLE="YES" ESTIMATE="5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="147" SE="1.5" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="33.00608639092679" CI_END="26.514516293154745" CI_START="19.073419001363273" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="22.79396764725901" ESTIMABLE="YES" I2="72.73230187486253" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-07-10 12:20:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="5" P_CHI2="1.332269940028663E-4" P_Q="0.3455848447186203" P_Z="3.2359348328409855E-33" Q="0.8896036630900994" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="855" TOTAL_2="850" UNITS="" WEIGHT="200.0" Z="12.0077332418921">
<NAME>Change in morning PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9484333028702774" CI_END="34.793298000588734" CI_START="18.02562545357451" DF="1.0" EFFECT_SIZE="26.40946172708162" ESTIMABLE="YES" I2="48.6767138230044" ID="CMP-001.05.01" NO="1" P_CHI2="0.16275606355840466" P_Z="6.659416208818197E-10" STUDIES="2" TAU2="0.0" TOTAL_1="175" TOTAL_2="178" WEIGHT="100.0" Z="6.173974794776871">
<NAME>Children</NAME>
<CONT_DATA CI_END="45.48695036062515" CI_START="20.51304963937485" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="17.0" ORDER="25" SD_1="46.0" SD_2="38.0" SE="6.371010109941112" STUDY_ID="STD-Katz-1998" TOTAL_1="85" TOTAL_2="92" WEIGHT="45.07884772568019"/>
<CONT_DATA CI_END="32.31287447359108" CI_START="9.687125526408918" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="13.0" ORDER="26" SD_1="28.0" SD_2="46.0" SE="5.77198079292558" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="54.9211522743198"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="30.168049424966412" CI_END="26.059089590236248" CI_START="17.755568235515078" DF="7.0" EFFECT_SIZE="21.907328912875663" ESTIMABLE="YES" I2="76.79664368950895" ID="CMP-001.05.02" NO="2" P_CHI2="8.84508521560301E-5" P_Z="4.54865889605383E-25" STUDIES="8" TAU2="0.0" TOTAL_1="680" TOTAL_2="672" WEIGHT="100.0" Z="10.34201607545601">
<NAME>Adults</NAME>
<CONT_DATA CI_END="42.02231755384202" CI_START="17.977682446157978" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="-19.0" ORDER="28" SD_1="40.0" SD_2="37.0" SE="6.1339481993916865" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="11.925819509861437"/>
<CONT_DATA CI_END="51.45359258008002" CI_START="18.54640741991998" EFFECT_SIZE="35.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="19.0" ORDER="29" SD_1="57.0" SD_2="55.0" SE="8.394844349112462" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="6.367121598875575"/>
<CONT_DATA CI_END="27.10055090089393" CI_START="4.89944909910607" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="-15.0" ORDER="30" SD_1="35.6" SD_2="36.7" SE="5.663650448913173" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="13.988642049121253"/>
<CONT_DATA CI_END="53.53592213848753" CI_START="4.464077861512472" EFFECT_SIZE="29.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="0.0" ORDER="31" SD_1="65.0" SD_2="36.0" SE="12.518557653111868" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="2.8632538469061917"/>
<CONT_DATA CI_END="56.58465554647255" CI_START="31.415344453527457" EFFECT_SIZE="44.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="-24.0" ORDER="32" SD_1="46.0" SD_2="35.0" SE="6.420860610571776" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="10.883835181806248"/>
<CONT_DATA CI_END="16.361418126608793" CI_START="0.8385818733912105" EFFECT_SIZE="8.600000000000001" ESTIMABLE="YES" MEAN_1="21.8" MEAN_2="13.2" ORDER="27" SD_1="34.75" SD_2="34.86" SE="3.9599799730147422" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="28.614256200822737"/>
<CONT_DATA CI_END="30.29992732516264" CI_START="-0.2999273251626384" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="12.0" ORDER="33" SD_1="53.3" SD_2="42.7" SE="7.806228811267203" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="7.36352705176931"/>
<CONT_DATA CI_END="35.787549001447125" CI_START="16.212450998552875" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="7.0" ORDER="34" SD_1="26.6" SD_2="36.2" SE="4.9937392108477825" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="17.993544560837254"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-07 15:35:23 +0100" MODIFIED_BY="Toby J Lasserson" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="304" TOTAL_2="300" WEIGHT="0.0" Z="0.0">
<NAME>Change in am PEF (predicted)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="304" TOTAL_2="300" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<IV_DATA CI_END="6.185569026704447" CI_START="2.8144309732955533" EFFECT_SIZE="4.5" ESTIMABLE="YES" ESTIMATE="4.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" SE="0.86" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="21.811072381132547" CI_END="14.737342486116301" CI_START="8.186124921216209" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.461733703666255" ESTIMABLE="YES" I2="67.90620893058298" I2_Q="84.94303229604495" ID="CMP-001.07" MODIFIED="2008-07-10 12:20:21 +0100" MODIFIED_BY="Toby J Lasserson" NO="7" P_CHI2="0.002738059036943241" P_Q="0.009963356171826088" P_Z="6.9762630238275984E-12" Q="6.641443480929613" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="898" TOTAL_2="896" UNITS="" WEIGHT="199.99999999999997" Z="6.858140501983872">
<NAME>Change in evening PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7902412383612154" CI_END="11.708731962993987" CI_START="2.257561799317112" DF="1.0" EFFECT_SIZE="6.983146881155549" ESTIMABLE="YES" I2="44.14160624992648" ID="CMP-001.07.01" NO="1" P_CHI2="0.18089691066243896" P_Z="0.0037759014247877765" STUDIES="2" TAU2="0.0" TOTAL_1="394" TOTAL_2="386" WEIGHT="99.99999999999999" Z="2.896300912752462">
<NAME>Children</NAME>
<CONT_DATA CI_END="25.31287447359108" CI_START="2.687125526408918" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="12.0" ORDER="36" SD_1="28.0" SD_2="46.0" SE="5.77198079292558" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="17.448786837124107"/>
<CONT_DATA CI_END="10.701083867576287" CI_START="0.29891613242371395" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="8.5" ORDER="37" SD_1="31.7" SD_2="33.48" SE="2.6536629798311457" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" WEIGHT="82.55121316287588"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.379387661841719" CI_END="20.14826492221063" CI_START="11.059188376013411" DF="5.0" EFFECT_SIZE="15.60372664911202" ESTIMABLE="YES" I2="62.62908194027369" ID="CMP-001.07.02" NO="2" P_CHI2="0.020071408269261015" P_Z="1.7017708963874346E-11" STUDIES="6" TAU2="0.0" TOTAL_1="504" TOTAL_2="510" WEIGHT="99.99999999999999" Z="6.729559840633745">
<NAME>Adults</NAME>
<CONT_DATA CI_END="40.692644639550615" CI_START="19.307355360449385" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="-23.0" ORDER="39" SD_1="38.0" SD_2="30.0" SE="5.455531185211988" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="18.063806118602937"/>
<CONT_DATA CI_END="35.85952830303906" CI_START="8.140471696960939" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="-15.0" ORDER="40" SD_1="44.44" SD_2="45.83" SE="7.0713178468386415" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="10.751835996313345"/>
<CONT_DATA CI_END="22.012616590794977" CI_START="-6.012616590794975" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="8.0" ORDER="41" SD_1="23.0" SD_2="36.0" SE="7.149425551349263" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="10.518190986597478"/>
<CONT_DATA CI_END="15.315565817214049" CI_START="-1.3155658172140487" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="17.7" MEAN_2="10.7" ORDER="38" SD_1="37.23" SD_2="37.35" SE="4.242713581885265" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="29.867296957267804"/>
<CONT_DATA CI_END="25.539038203240395" CI_START="0.4609617967596069" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="8.0" ORDER="42" SD_1="35.5" SD_2="42.7" SE="6.397586028185582" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="13.135635220273217"/>
<CONT_DATA CI_END="28.813210195463363" CI_START="7.186789804536639" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="8.0" ORDER="43" SD_1="34.0" SD_2="36.0" SE="5.517045354280274" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="17.663234720945212"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="26.007909834170317" CI_END="15.300753437567842" CI_START="8.866074531280514" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="12.083413984424178" ESTIMABLE="YES" I2="69.24012713436412" I2_Q="88.07680836125576" ID="CMP-001.08" LOG_CI_END="1.1847128168124832" LOG_CI_START="0.9477313778078685" LOG_DATA="NO" LOG_EFFECT_SIZE="1.0821896549079146" MODIFIED="2008-07-10 12:20:37 +0100" MODIFIED_BY="Toby J Lasserson" NO="8" P_CHI2="0.001047032859664232" P_Q="0.0037791177528626596" P_Z="1.8244385891201482E-13" Q="8.387016080078038" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="983" TOTAL_2="971" WEIGHT="200.0" Z="7.3610685364947415">
<NAME>Change in evening PEFR compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.792119140576554" CI_END="11.700522905034479" CI_START="2.260690427835839" DF="1.0" EFFECT_SIZE="6.9806066664351585" ESTIMABLE="YES" I2="44.2001384083045" ID="CMP-001.08.01" LOG_CI_END="1.0682052711219259" LOG_CI_START="0.3542410954335922" LOG_EFFECT_SIZE="0.8438931676712964" NO="1" P_CHI2="0.18066831855994525" P_Z="0.003746837555479319" STUDIES="2" TAU2="0.0" TOTAL_1="394" TOTAL_2="386" WEIGHT="100.00000000000001" Z="2.898724673239817">
<NAME>Children</NAME>
<IV_DATA CI_END="25.30899219079611" CI_START="2.691007809203887" EFFECT_SIZE="14.0" ESTIMABLE="YES" ESTIMATE="14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="44" SE="5.77" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="17.418901958060697"/>
<IV_DATA CI_END="10.693904559031143" CI_START="0.3060954409688561" EFFECT_SIZE="5.5" ESTIMABLE="YES" ESTIMATE="5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="45" SE="2.65" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" WEIGHT="82.58109804193931"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="15.828774613515726" CI_END="20.909528694064868" CI_START="12.115099655899472" DF="6.0" EFFECT_SIZE="16.51231417498217" ESTIMABLE="YES" I2="62.09434939532984" ID="CMP-001.08.02" LOG_CI_END="1.3203442438232322" LOG_CI_START="1.0833269908902996" LOG_EFFECT_SIZE="1.2178079432200737" NO="2" P_CHI2="0.01470313689905045" P_Z="1.8389699982138252E-13" STUDIES="7" TAU2="0.0" TOTAL_1="589" TOTAL_2="585" WEIGHT="100.0" Z="7.360009602425909">
<NAME>Adults</NAME>
<IV_DATA CI_END="40.6818037157433" CI_START="19.318196284256704" EFFECT_SIZE="30.0" ESTIMABLE="YES" ESTIMATE="30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="47" SE="5.45" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="16.94595777745562"/>
<IV_DATA CI_END="35.858905334682724" CI_START="8.141094665317278" EFFECT_SIZE="22.0" ESTIMABLE="YES" ESTIMATE="22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" SE="7.071" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="10.066939301593317"/>
<IV_DATA CI_END="22.007862597507767" CI_START="-6.007862597507769" EFFECT_SIZE="8.0" ESTIMABLE="YES" ESTIMATE="8.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="49" SE="7.147" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="9.853977364722498"/>
<IV_DATA CI_END="47.52207802178808" CI_START="12.477921978211917" EFFECT_SIZE="30.0" ESTIMABLE="YES" ESTIMATE="30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" SE="8.94" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="6.297730718897492"/>
<IV_DATA CI_END="15.31024729444983" CI_START="-1.3102472944498302" EFFECT_SIZE="7.0" ESTIMABLE="YES" ESTIMATE="7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="46" SE="4.24" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="27.9980259258675"/>
<IV_DATA CI_END="25.543769501056346" CI_START="0.4562304989436523" EFFECT_SIZE="13.0" ESTIMABLE="YES" ESTIMATE="13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="51" SE="6.4" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="12.288508566525282"/>
<IV_DATA CI_END="28.8092013747384" CI_START="7.190798625261602" EFFECT_SIZE="18.0" ESTIMABLE="YES" ESTIMATE="18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" SE="5.515" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="16.54886034493829"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-07 15:35:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="304" TOTAL_2="300" WEIGHT="0.0" Z="0.0">
<NAME>Change in evening PEF (predicted)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="304" TOTAL_2="300" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<IV_DATA CI_END="5.763967586086049" CI_START="2.236032413913951" EFFECT_SIZE="4.0" ESTIMABLE="YES" ESTIMATE="4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" SE="0.9" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2008-07-07 15:35:18 +0100" MODIFIED_BY="Toby J Lasserson" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Peak flow - L/min (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="292.13233367643625" CI_START="57.86766632356375" EFFECT_SIZE="175.0" ESTIMABLE="YES" MEAN_1="504.0" MEAN_2="329.0" ORDER="54" SD_1="140.0" SD_2="112.0" SE="59.76249288270659" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2008-07-07 15:35:17 +0100" MODIFIED_BY="Toby J Lasserson" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="90" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in clinic PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="44.30900764870204" CI_START="13.69099235129796" EFFECT_SIZE="29.0" ESTIMABLE="YES" MEAN_1="51.0" MEAN_2="22.0" ORDER="55" SD_1="47.0" SD_2="56.0" SE="7.810861714530236" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2008-07-07 15:35:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FVC compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.4850909646878311" CI_START="0.09490903531216888" EFFECT_SIZE="0.29" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="-0.31" ORDER="56" SD_1="0.59" SD_2="0.66" SE="0.09953803550814389" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.430941582021203" CI_END="0.34291723615466085" CI_START="0.04842700404759123" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19567212010112603" ESTIMABLE="YES" I2="77.43143344390825" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2008-07-07 15:35:14 +0100" MODIFIED_BY="Toby J Lasserson" NO="13" P_CHI2="0.03529307165617945" P_Q="1.0" P_Z="0.009198945240271435" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="235" UNITS="" WEIGHT="100.0" Z="2.604570653721159">
<NAME>Change in FEF25-75 compared to baseline (L/second)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.430941582021203" CI_END="0.34291723615466085" CI_START="0.04842700404759123" DF="1.0" EFFECT_SIZE="0.19567212010112603" ESTIMABLE="YES" I2="77.43143344390825" ID="CMP-001.13.02" NO="2" P_CHI2="0.03529307165617945" P_Z="0.009198945240271435" STUDIES="2" TAU2="0.0" TOTAL_1="232" TOTAL_2="235" WEIGHT="100.0" Z="2.604570653721159">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.6061364561917615" CI_START="0.15386354380823855" EFFECT_SIZE="0.38" ESTIMABLE="YES" MEAN_1="0.22" MEAN_2="-0.16" ORDER="58" SD_1="0.73" SD_2="0.72" SE="0.11537786305028916" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="42.39753753160188"/>
<CONT_DATA CI_END="0.2540083284448593" CI_START="-0.1340083284448593" EFFECT_SIZE="0.060000000000000005" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="-0.05" ORDER="57" SD_1="0.87" SD_2="0.87" SE="0.09898565992802533" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="57.602462468398116"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.416877416926376" CI_END="-0.4596587410269314" CI_START="-0.6878178861407024" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5737383135838169" ESTIMABLE="YES" I2="43.62511793458011" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2008-07-07 15:35:11 +0100" MODIFIED_BY="Toby J Lasserson" NO="14" P_CHI2="0.08765657632566559" P_Q="0.5447949643697327" P_Z="6.379676714623315E-23" Q="0.3667252877827476" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="622" TOTAL_2="616" UNITS="" WEIGHT="99.99999999999997" Z="9.85721112002148">
<NAME>Change in daily asthma symptom score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3727947201081433" CI_END="-0.3060435121210895" CI_START="-0.7307525261174043" DF="1.0" EFFECT_SIZE="-0.5183980191192469" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="0.5414851216579493" P_Z="1.712877287026623E-6" STUDIES="2" TAU2="0.0" TOTAL_1="175" TOTAL_2="178" WEIGHT="28.859765957285227" Z="4.784647434581865">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.2837171618467706" CI_START="-0.8861997272937581" EFFECT_SIZE="-0.5849584445702644" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="-0.01" ORDER="59" SD_1="0.65" SD_2="0.77" SE="0.15369735622677078" STUDY_ID="STD-Katz-1998" TOTAL_1="85" TOTAL_2="92" WEIGHT="14.341242982743477"/>
<CONT_DATA CI_END="-0.15325387268775598" CI_START="-0.7520468011666821" EFFECT_SIZE="-0.45265033692721907" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.02" ORDER="60" SD_1="0.66" SD_2="0.83" SE="0.15275610501063497" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="14.51852297454175"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.677357409035485" CI_END="-0.46093441162209164" CI_START="-0.7314424880213337" DF="5.0" EFFECT_SIZE="-0.5961884498217127" ESTIMABLE="YES" I2="57.182093303651094" ID="CMP-001.14.02" NO="2" P_CHI2="0.03948644114719346" P_Z="5.653038972485697E-18" STUDIES="6" TAU2="0.0" TOTAL_1="447" TOTAL_2="438" WEIGHT="71.14023404271475" Z="8.639356763047063">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.21436514393851652" CI_START="-0.8493273304101423" EFFECT_SIZE="-0.5318462371743294" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="0.1" ORDER="61" SD_1="0.39" SD_2="0.5" SE="0.16198312608806245" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="12.91159920022"/>
<CONT_DATA CI_END="-0.40170706152560975" CI_START="-1.0078411191911252" EFFECT_SIZE="-0.7047740903583675" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.2" ORDER="62" SD_1="0.57" SD_2="0.56" SE="0.15462887646064508" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="14.168973494815594"/>
<CONT_DATA CI_END="-0.15445983849434852" CI_START="-0.7772874538300663" EFFECT_SIZE="-0.4658736461622074" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="0.12" ORDER="63" SD_1="0.53" SD_2="0.73" SE="0.15888751534428758" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="13.419614528828761"/>
<CONT_DATA CI_END="0.007060292984225114" CI_START="-0.936657675672329" EFFECT_SIZE="-0.464798691344052" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-0.02" ORDER="64" SD_1="0.41" SD_2="0.48" SE="0.24074880357508635" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="5.845091491196954"/>
<CONT_DATA CI_END="-0.7134056587231075" CI_START="-1.3692639244038305" EFFECT_SIZE="-1.041334791563469" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.21" ORDER="65" SD_1="0.28" SD_2="0.35" SE="0.16731385649278488" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="78" WEIGHT="12.101961565432893"/>
<CONT_DATA CI_END="0.005916113929369193" CI_START="-0.634490557621672" EFFECT_SIZE="-0.3142872218461514" ESTIMABLE="YES" MEAN_1="-0.37" MEAN_2="-0.19" ORDER="66" SD_1="0.62" SD_2="0.51" SE="0.16337205086483406" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="12.692993762220548"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2008-07-07 15:35:09 +0100" MODIFIED_BY="Toby J Lasserson" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptoms - absolute scores</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-5.443311333677613" CI_START="-7.956688666322387" EFFECT_SIZE="-6.7" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="6.8" ORDER="67" SD_1="0.3" SD_2="1.9" SE="0.6411794687223782" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.679457508604336" CI_END="-0.11738482066008091" CI_START="-0.38114545933542854" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.24926513999775474" ESTIMABLE="YES" I2="25.143621415974188" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2008-07-07 15:35:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="16" P_CHI2="0.24559172488949688" P_Q="0.766911089265936" P_Z="2.1180776584425528E-4" Q="0.08786347993464627" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="458" TOTAL_2="437" UNITS="" WEIGHT="100.0" Z="3.7045004095419345">
<NAME>Change in night-time wakening score</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.007597629307914133" CI_START="-0.5866642736520122" DF="0.0" EFFECT_SIZE="-0.289533322172049" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="1.0" P_Z="0.056152817158666574" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="86" WEIGHT="19.699907766634983" Z="1.9098477656230162">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.007597629307914133" CI_START="-0.5866642736520122" EFFECT_SIZE="-0.289533322172049" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.07" ORDER="68" SD_1="0.28" SD_2="0.4" SE="0.1516002099139036" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="19.699907766634983"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.5915940286696895" CI_END="-0.09221529641222312" CI_START="-0.386557111513644" DF="4.0" EFFECT_SIZE="-0.23938620396293356" ESTIMABLE="YES" I2="39.31665113776315" ID="CMP-001.16.02" NO="2" P_CHI2="0.1591100150111716" P_Z="0.0014323534082163363" STUDIES="5" TAU2="0.0" TOTAL_1="368" TOTAL_2="351" WEIGHT="80.30009223336502" Z="3.1880508584989324">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.019065314953918444" CI_START="-0.6081485711859522" EFFECT_SIZE="-0.29454162811601686" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.14" ORDER="69" SD_1="0.43" SD_2="0.38" SE="0.16000648253928482" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="17.684331278047868"/>
<CONT_DATA CI_END="0.2938852365854385" CI_START="-0.2938852365854385" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.2" ORDER="70" SD_1="0.38" SD_2="0.47" SE="0.14994420249737636" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="20.137448407299754"/>
<CONT_DATA CI_END="0.5133039955025128" CI_START="-0.4173497187959669" EFFECT_SIZE="0.04797713835327299" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="-0.02" ORDER="71" SD_1="0.23" SD_2="0.18" SE="0.2374160243859983" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="8.032370667517696"/>
<CONT_DATA CI_END="-0.1234889028628916" CI_START="-0.7520483221099071" EFFECT_SIZE="-0.43776861248639937" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.21" ORDER="72" SD_1="0.39" SD_2="0.43" SE="0.16034973708828631" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="17.60869997218109"/>
<CONT_DATA CI_END="-0.07598179773768349" CI_START="-0.7187797875125785" EFFECT_SIZE="-0.397380792625131" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="0.0" ORDER="73" SD_1="0.36" SD_2="0.34" SE="0.16398209223363375" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="16.83724190831862"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2008-07-07 15:35:07 +0100" MODIFIED_BY="Toby J Lasserson" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="79" TOTAL_2="84" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Nighttime awakenings/night</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.003923131300769364" CI_START="-0.21607686869923065" EFFECT_SIZE="-0.11" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.11" ORDER="74" SD_1="0.18" SD_2="0.46" SE="0.05412184587877708" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.385287689461697" CI_END="-0.050294464511038854" CI_START="-0.17260946645300532" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11145196548202209" ESTIMABLE="YES" I2="31.5894369436853" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2008-07-07 15:35:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="18" P_CHI2="0.22275367125991208" P_Q="1.0" P_Z="3.545477141951315E-4" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="412" TOTAL_2="397" UNITS="" WEIGHT="100.0" Z="3.5717914382179616">
<NAME>Change in number night-time wakenings per week</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.385287689461697" CI_END="-0.050294464511038854" CI_START="-0.17260946645300532" DF="3.0" EFFECT_SIZE="-0.11145196548202209" ESTIMABLE="YES" I2="31.5894369436853" ID="CMP-001.18.02" NO="2" P_CHI2="0.22275367125991208" P_Z="3.545477141951315E-4" STUDIES="5" TAU2="0.0" TOTAL_1="412" TOTAL_2="397" WEIGHT="100.0" Z="3.5717914382179616">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.0066493606587904736" CI_START="-0.2466493606587905" EFFECT_SIZE="-0.12000000000000001" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.14" ORDER="75" SD_1="0.43" SD_2="0.38" SE="0.06461820811901875" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="23.31811598918515"/>
<CONT_DATA CI_END="0.12589460092439736" CI_START="-0.12589460092439736" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.2" ORDER="76" SD_1="0.38" SD_2="0.47" SE="0.0642331195457865" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="23.5985463037024"/>
<CONT_DATA CI_END="-0.052154671236420064" CI_START="-0.30784532876357995" EFFECT_SIZE="-0.18" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.21" ORDER="77" SD_1="0.39" SD_2="0.43" SE="0.065228407140135" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="22.883883762606114"/>
<CONT_DATA CI_END="-0.02871152641353894" CI_START="-0.2512884735864611" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="0.0" ORDER="78" SD_1="0.36" SD_2="0.34" SE="0.05678087682441634" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="30.199453944506338"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.35" MEAN_2="0.14" ORDER="79" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.925315117860933" CI_END="-0.7386735007391059" CI_START="-1.1386490861115963" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9386612934253511" ESTIMABLE="YES" I2="72.34256578570469" I2_Q="92.75510221252541" ID="CMP-001.19" MODIFIED="2008-07-07 15:35:04 +0100" MODIFIED_BY="Toby J Lasserson" NO="19" P_CHI2="3.268115837584684E-4" P_Q="2.0303427365875315E-4" P_Z="3.6037918791081436E-20" Q="13.80281722854474" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1005" TOTAL_2="995" UNITS="" WEIGHT="100.00000000000001" Z="9.199273136044797">
<NAME>Change in daily use of beta2 agonist compared to baseline (puffs/d)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.551233117299144" CI_END="-0.3266303863721067" CI_START="-0.8656803661579144" DF="2.0" EFFECT_SIZE="-0.5961553762650106" ESTIMABLE="YES" I2="21.606536602296284" ID="CMP-001.19.01" NO="1" P_CHI2="0.2792588495377042" P_Z="1.4563175803413374E-5" STUDIES="3" TAU2="0.0" TOTAL_1="479" TOTAL_2="478" WEIGHT="55.05653775191192" Z="4.335193805715854">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.3253371755797366" CI_START="-1.3746628244202634" EFFECT_SIZE="-0.85" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="0.15" ORDER="80" SD_1="1.66" SD_2="1.9" SE="0.2676900333673153" STUDY_ID="STD-Katz-1998" TOTAL_1="85" TOTAL_2="92" WEIGHT="14.529356778438085"/>
<CONT_DATA CI_END="-0.19472718169521674" CI_START="-1.4652728183047832" EFFECT_SIZE="-0.83" ESTIMABLE="YES" MEAN_1="-0.75" MEAN_2="0.08" ORDER="81" SD_1="2.2" SD_2="2.1" SE="0.324124740717551" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="9.910291461111395"/>
<CONT_DATA CI_END="-0.038571035454890545" CI_START="-0.7614289645451098" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.7" ORDER="82" SD_1="2.44" SD_2="2.08" SE="0.18440592143325854" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" WEIGHT="30.61688951236243"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.571264772017049" CI_END="-1.0599254550423536" CI_START="-1.6565487687828095" DF="5.0" EFFECT_SIZE="-1.3582371119125816" ESTIMABLE="YES" I2="60.22675450182445" ID="CMP-001.19.02" NO="2" P_CHI2="0.027745492816995232" P_Z="4.502535467052092E-19" STUDIES="7" TAU2="0.0" TOTAL_1="526" TOTAL_2="517" WEIGHT="44.943462248088096" Z="8.923874614033029">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.2780255206624287" CI_START="-1.3819744793375714" EFFECT_SIZE="-0.8300000000000001" ESTIMABLE="YES" MEAN_1="-0.63" MEAN_2="0.2" ORDER="83" SD_1="1.55" SD_2="1.97" SE="0.2816248072370082" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="13.127105543490742"/>
<CONT_DATA CI_END="-0.6056542273870985" CI_START="-2.1943457726129014" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.3" ORDER="84" SD_1="2.9" SD_2="2.5" SE="0.4052859026383135" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="6.33851900385968"/>
<CONT_DATA CI_END="-0.7391884068713636" CI_START="-2.0008115931286365" EFFECT_SIZE="-1.37" ESTIMABLE="YES" MEAN_1="-0.51" MEAN_2="0.86" ORDER="85" SD_1="1.69" SD_2="2.38" SE="0.32184856359830993" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="10.05096224279451"/>
<CONT_DATA CI_END="-0.09770186914550716" CI_START="-1.982298130854493" EFFECT_SIZE="-1.04" ESTIMABLE="YES" MEAN_1="-0.93" MEAN_2="0.11" ORDER="86" SD_1="1.95" SD_2="2.1" SE="0.48077318679691067" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="4.504331183010324"/>
<CONT_DATA CI_END="-1.763004436965494" CI_START="-3.436995563034506" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="1.7" ORDER="87" SD_1="2.8" SD_2="2.6" SE="0.4270463996464323" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="5.709008143072883"/>
<CONT_DATA CI_END="-0.6541347558031546" CI_START="-2.4058652441968453" EFFECT_SIZE="-1.53" ESTIMABLE="YES" MEAN_1="-1.81" MEAN_2="-0.28" ORDER="88" SD_1="3.02" SD_2="2.48" SE="0.44687823404182864" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="5.213536131859955"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-1.31" MEAN_2="-0.19" ORDER="89" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2008-07-07 15:35:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Rescue medication usage - puffs/d (absolute scores)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="6.7" ORDER="90" SD_1="0.0" SD_2="1.0" SE="0.0" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2008-07-07 15:35:02 +0100" MODIFIED_BY="Toby J Lasserson" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: AQLQ</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2009-05-21 09:13:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="104" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Functional Status IIR questionnaire (short version)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="6.93532641129039" CI_START="1.4646735887096152" EFFECT_SIZE="4.200000000000003" ESTIMABLE="YES" MEAN_1="95.7" MEAN_2="91.5" ORDER="91" SD_1="7.7" SD_2="11.5" SE="1.3956003441217764" STUDY_ID="STD-Allen-1998" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.23" MODIFIED="2008-07-07 15:34:59 +0100" MODIFIED_BY="Toby J Lasserson" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="104" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.07624777533678762" CI_START="-0.38375222466321235" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="1.59" MEAN_2="1.82" ORDER="92" SD_1="0.5" SD_2="0.6" SE="0.07844645405527362" STUDY_ID="STD-Allen-1998" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.24" MODIFIED="2008-07-07 15:34:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="104" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.18418194315145844" CI_START="-0.20418194315145802" EFFECT_SIZE="-0.009999999999999787" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.34" ORDER="93" SD_1="0.7" SD_2="0.7" SE="0.09907424048765212" STUDY_ID="STD-Allen-1998" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.25" MODIFIED="2008-07-07 15:34:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="104" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.25.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.10644166555839271" CI_START="-0.22644166555839282" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="1.67" MEAN_2="1.73" ORDER="94" SD_1="0.6" SD_2="0.6" SE="0.08492077756084468" STUDY_ID="STD-Allen-1998" TOTAL_1="104" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.25.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2008-07-07 15:34:53 +0100" MODIFIED_BY="Toby J Lasserson" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="104" TOTAL_2="95" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Sleep Scale Children questionnaire</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.26.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="15.390403336311685" CI_START="5.009596663688321" EFFECT_SIZE="10.200000000000003" ESTIMABLE="YES" MEAN_1="89.4" MEAN_2="79.2" ORDER="95" SD_1="15.1" SD_2="21.4" SE="2.64821362905284" STUDY_ID="STD-Allen-1998" TOTAL_1="104" TOTAL_2="95" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.26.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.177474057774231" CI_END="6.976701122860784" CI_START="3.755255879250939" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.1185249739939325" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="76" I2="58.20256575151851" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.8436501184969056" LOG_CI_START="0.5746395347251654" LOG_EFFECT_SIZE="0.7091448266110354" METHOD="PETO" MODIFIED="2008-07-07 15:34:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="27" P_CHI2="0.06645124407719294" P_Q="1.0" P_Z="4.975957503441697E-25" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="327" WEIGHT="99.99999999999997" Z="10.333409938695066">
<NAME>Physician-rated efficacy: effective or very effective</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.177474057774231" CI_END="6.976701122860784" CI_START="3.755255879250939" DF="3.0" EFFECT_SIZE="5.1185249739939325" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="76" I2="58.20256575151851" ID="CMP-001.27.02" LOG_CI_END="0.8436501184969056" LOG_CI_START="0.5746395347251654" LOG_EFFECT_SIZE="0.7091448266110354" NO="2" P_CHI2="0.06645124407719294" P_Z="4.975957503441697E-25" STUDIES="4" TAU2="0.0" TOTAL_1="337" TOTAL_2="327" WEIGHT="99.99999999999997" Z="10.333409938695066">
<NAME>Adults</NAME>
<DICH_DATA CI_END="9.667092667415108" CI_START="2.6483896068847836" EFFECT_SIZE="5.059864400275393" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="14" LOG_CI_END="0.9852958816997612" LOG_CI_START="0.4229818749042486" LOG_EFFECT_SIZE="0.7041388783020048" ORDER="96" O_E="14.860759493670887" SE="0.3303060310909094" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" VAR="9.165728585468809" WEIGHT="22.886581629263123"/>
<DICH_DATA CI_END="9.588466737837177" CI_START="2.8493950454508274" EFFECT_SIZE="5.22698092748226" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="15" LOG_CI_END="0.9817491660305405" LOG_CI_START="0.45475266481186233" LOG_EFFECT_SIZE="0.7182509154212015" ORDER="97" O_E="17.258426966292134" SE="0.3095603534906048" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" VAR="10.43540556212942" WEIGHT="26.05693142722769"/>
<DICH_DATA CI_END="16.74175347631197" CI_START="4.962396124251913" EFFECT_SIZE="9.114779896631157" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="13" LOG_CI_END="1.2238009426181269" LOG_CI_START="0.6956914289628376" LOG_EFFECT_SIZE="0.9597461857904822" ORDER="98" O_E="22.964071856287426" SE="0.3102141425053705" STUDY_ID="STD-Pearlman-1997" TOTAL_1="89" TOTAL_2="78" VAR="10.39146582385334" WEIGHT="25.947215063989713"/>
<DICH_DATA CI_END="5.172709441006594" CI_START="1.5026882403345023" EFFECT_SIZE="2.788004599649697" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="34" LOG_CI_END="0.7137180841095411" LOG_CI_START="0.17686888774156626" LOG_EFFECT_SIZE="0.4452934859255537" ORDER="99" O_E="10.310559006211179" SE="0.3153478753929291" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" VAR="10.055882296207708" WEIGHT="25.109271879519454"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-07 15:34:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="111" TOTAL_2="106" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to clinical asthma exacerbation (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="24" I2="0.0" ID="CMP-001.28.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="106" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.31688073466522226" CI_START="0.061746614575090585" EFFECT_SIZE="0.13987963607918424" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="24" LOG_CI_END="-0.4991041637220347" LOG_CI_START="-1.2093868487834727" LOG_EFFECT_SIZE="-0.8542455062527538" ORDER="100" O_E="-11.299539170506913" SE="0.41722356516108433" STUDY_ID="STD-Allen-1998" TOTAL_1="111" TOTAL_2="106" VAR="5.744633684205559" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.28.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.753824869653634" CI_END="0.34253309024671064" CI_START="0.21929338597401063" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2740715986167529" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="350" I2="62.11136501432313" I2_Q="71.87060708598433" ID="CMP-001.29" LOG_CI_END="-0.465297467332486" LOG_CI_START="-0.6589744667187705" LOG_EFFECT_SIZE="-0.5621359670256283" METHOD="PETO" MODIFIED="2008-07-07 15:34:47 +0100" MODIFIED_BY="Toby J Lasserson" NO="29" P_CHI2="0.004707961213595402" P_Q="0.05936644837519944" P_Z="5.421760756178267E-30" Q="3.5550002911784944" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="957" TOTAL_2="951" WEIGHT="100.00000000000001" Z="11.377357696330053">
<NAME>Withdrawal due to lack of treatment efficacy (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6790363250509803" CI_END="0.5178312655821762" CI_START="0.25106640883680803" DF="3.0" EFFECT_SIZE="0.3605690450290157" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="128" I2="18.456907327262417" ID="CMP-001.29.01" LOG_CI_END="-0.2858117313057733" LOG_CI_START="-0.6002113893686984" LOG_EFFECT_SIZE="-0.4430115603372359" NO="1" P_CHI2="0.298273436224993" P_Z="3.3239117779539335E-8" STUDIES="4" TAU2="0.0" TOTAL_1="391" TOTAL_2="391" WEIGHT="37.94826860708795" Z="5.523458316370648">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.890946633428801" CI_START="0.2312919605570993" EFFECT_SIZE="0.45394800759282405" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="29" LOG_CI_END="-0.05014830887166239" LOG_CI_START="-0.6358394625444201" LOG_EFFECT_SIZE="-0.3429938857080413" ORDER="101" O_E="-6.672514619883042" SE="0.3440378828853466" STUDY_ID="STD-FLTA2007" TOTAL_1="88" TOTAL_2="83" VAR="8.448652878613228" WEIGHT="10.934999489900841"/>
<DICH_DATA CI_END="0.789050687698104" CI_START="0.2428410749415439" EFFECT_SIZE="0.4377372695852753" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="58" LOG_CI_END="-0.10289509732224683" LOG_CI_START="-0.6146778533804277" LOG_EFFECT_SIZE="-0.3587864753513373" ORDER="102" O_E="-9.141242937853107" SE="0.3006237242740755" STUDY_ID="STD-Katz-1998" TOTAL_1="85" TOTAL_2="92" VAR="11.065053000560038" WEIGHT="14.321377698347371"/>
<DICH_DATA CI_END="16.327729865242134" CI_START="0.06318210703741031" EFFECT_SIZE="1.0156871447565188" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2129258065656088" LOG_CI_START="-1.1994058950585678" LOG_EFFECT_SIZE="0.006759955753520527" ORDER="103" O_E="0.007751937984496138" SE="1.4170155827685502" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" VAR="0.4980245453484748" WEIGHT="0.6445877499748299"/>
<DICH_DATA CI_END="0.4178457779992873" CI_START="0.11561585774062216" EFFECT_SIZE="0.21979444494046066" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="40" LOG_CI_END="-0.3789839816764785" LOG_CI_START="-0.9369825944888086" LOG_EFFECT_SIZE="-0.6579832880826435" ORDER="104" O_E="-14.102272727272727" SE="0.32777114730364326" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" VAR="9.308046782762691" WEIGHT="12.047303668864908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.51978825342416" CI_END="0.307571592978136" CI_START="0.17461387028294062" DF="5.0" EFFECT_SIZE="0.23174612453933646" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="222" I2="69.73326822779573" ID="CMP-001.29.02" LOG_CI_END="-0.5120537780466232" LOG_CI_START="-0.7579212615004928" LOG_EFFECT_SIZE="-0.634987519773558" NO="2" P_CHI2="0.00550660787171664" P_Z="4.334026068242677E-24" STUDIES="6" TAU2="0.0" TOTAL_1="566" TOTAL_2="560" WEIGHT="62.05173139291207" Z="10.123767908675857">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.37907242790652684" CI_START="0.10797906503008481" EFFECT_SIZE="0.20231630271441547" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="50" LOG_CI_END="-0.42127780313231705" LOG_CI_START="-0.9666604373207206" LOG_EFFECT_SIZE="-0.6939691202265188" ORDER="106" O_E="-15.569620253164558" SE="0.3203604590098475" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" VAR="9.74366144573026" WEIGHT="12.611114987164157"/>
<DICH_DATA CI_END="0.32229411760153237" CI_START="0.09176396748327662" EFFECT_SIZE="0.17197379721236122" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="45" LOG_CI_END="-0.49174762100491154" LOG_CI_START="-1.037327817656432" LOG_EFFECT_SIZE="-0.7645377193306717" ORDER="107" O_E="-17.140449438202246" SE="0.3204765081786323" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" VAR="9.736606082522538" WEIGHT="12.601983307334727"/>
<DICH_DATA CI_END="0.9968747902265803" CI_START="0.2799768449563107" EFFECT_SIZE="0.5283009166981655" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="37" LOG_CI_END="-0.0013593866517637968" LOG_CI_START="-0.552877884813239" LOG_EFFECT_SIZE="-0.2771186357325014" ORDER="108" O_E="-6.079754601226995" SE="0.3239646958806463" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" VAR="9.528063198129816" WEIGHT="12.332068521247413"/>
<DICH_DATA CI_END="0.2085481840425722" CI_START="0.05890631999617711" EFFECT_SIZE="0.11083684434263452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="51" LOG_CI_END="-0.6807935874711056" LOG_CI_START="-1.2298381077218963" LOG_EFFECT_SIZE="-0.955315847596501" ORDER="109" O_E="-21.148148148148145" SE="0.32251146900952204" STUDY_ID="STD-Pearlman-1997" TOTAL_1="84" TOTAL_2="78" VAR="9.614122979662431" WEIGHT="12.443454760057426"/>
<DICH_DATA CI_END="379.7309113467643" CI_START="0.1494560070881723" EFFECT_SIZE="7.533463066733661" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.579475951579904" LOG_CI_START="-0.8254866246674161" LOG_EFFECT_SIZE="0.8769946634562441" ORDER="105" O_E="0.5047923322683706" SE="2.0000918721242598" STUDY_ID="STD-SAS30023" TOTAL_1="155" TOTAL_2="158" VAR="0.2499770335514295" WEIGHT="0.3235425544930764"/>
<DICH_DATA CI_END="0.5915703658703266" CI_START="0.160968734587775" EFFECT_SIZE="0.30858440209085997" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" LOG_CI_END="-0.22799358968079284" LOG_CI_START="-0.7932584700215881" LOG_EFFECT_SIZE="-0.5106260298511905" ORDER="110" O_E="-10.664473684210527" SE="0.3320393888184681" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" VAR="9.070281972904551" WEIGHT="11.739567262615266"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.763196187453076" CI_END="2.1166213312404616" CI_START="0.3743645465560704" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8901617745672645" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.3256431686181603" LOG_CI_START="-0.4267052869748571" LOG_EFFECT_SIZE="-0.05053105917834841" METHOD="MH" MODIFIED="2008-07-07 15:34:44 +0100" MODIFIED_BY="Toby J Lasserson" NO="30" P_CHI2="0.5982025034934475" P_Q="0.0" P_Z="0.7923349678500985" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="689" TOTAL_2="689" WEIGHT="100.0" Z="0.26327974851004454">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7814093946254084" CI_END="2.201576438838247" CI_START="0.2397831435040134" DF="1.0" EFFECT_SIZE="0.726567904031692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="43.86467237587022" ID="CMP-001.30.01" LOG_CI_END="0.34273376878230216" LOG_CI_START="-0.6201813505970669" LOG_EFFECT_SIZE="-0.13872379090738235" NO="1" P_CHI2="0.18197648776770747" P_Z="0.572257278142877" STUDIES="2" TAU2="0.0" TOTAL_1="432" TOTAL_2="430" WEIGHT="68.2700226829746" Z="0.5647302207749714">
<NAME>Children</NAME>
<DICH_DATA CI_END="2.7720172774871035" CI_START="0.007248065366305253" EFFECT_SIZE="0.14174541411895497" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.44279593282790985" LOG_CI_START="-2.139777898651102" LOG_EFFECT_SIZE="-0.8484909829115962" ORDER="111" O_E="0.0" SE="1.5170166525574142" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" VAR="2.3013395241365027" WEIGHT="31.831783223066186"/>
<DICH_DATA CI_END="4.653539270733827" CI_START="0.329061966120811" EFFECT_SIZE="1.2374581939799332" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6677833832302971" LOG_CI_START="-0.4827223117451663" LOG_EFFECT_SIZE="0.09253053574256537" ORDER="112" O_E="0.0" SE="0.6758127403236266" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" VAR="0.4567228599837296" WEIGHT="36.43823945990841"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8748398386660516" CI_END="5.130174003043558" CI_START="0.30075684862337393" DF="2.0" EFFECT_SIZE="1.2421493332304854" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.30.02" LOG_CI_END="0.7101320955757706" LOG_CI_START="-0.5217844744271032" LOG_EFFECT_SIZE="0.09417381057433374" NO="2" P_CHI2="0.6457002550169186" P_Z="0.7644374822932113" STUDIES="3" TAU2="0.0" TOTAL_1="257" TOTAL_2="259" WEIGHT="31.7299773170254" Z="0.2996587293442459">
<NAME>Adults</NAME>
<DICH_DATA CI_END="60.84318375773472" CI_START="0.08948322734265718" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7842119314203941" LOG_CI_START="-1.0482583608312055" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="114" O_E="0.0" SE="1.6638070706226633" STUDY_ID="STD-Li-1999" TOTAL_1="23" TOTAL_2="17" VAR="2.768253968253968" WEIGHT="4.929085784561189"/>
<DICH_DATA CI_END="24.25413891033368" CI_START="0.19162354274747004" EFFECT_SIZE="2.155844155844156" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3847858605688086" LOG_CI_START="-0.7175511348336621" LOG_EFFECT_SIZE="0.33361736286757326" ORDER="115" O_E="0.0" SE="1.234923157835376" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" VAR="1.5250352057580974" WEIGHT="8.692931657680102"/>
<DICH_DATA CI_END="5.643559160418848" CI_START="0.04545636270091805" EFFECT_SIZE="0.5064935064935064" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7515530820357286" LOG_CI_START="-1.3424053183276938" LOG_EFFECT_SIZE="-0.2954261181459827" ORDER="113" O_E="0.0" SE="1.2300015296347249" STUDY_ID="STD-SAS30023" TOTAL_1="155" TOTAL_2="158" VAR="1.512903762903763" WEIGHT="18.10795987478411"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1029456172307863" CI_END="1.5938057467486924" CI_START="-1.0457469076274486" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.27402941956062193" ESTIMABLE="YES" I2="9.333698382088537" I2_Q="9.333698382088537" ID="CMP-001.31" MODIFIED="2008-07-07 15:34:42 +0100" MODIFIED_BY="Toby J Lasserson" NO="31" P_CHI2="0.29362107752115896" P_Q="0.29362107752115896" P_Z="0.6840420321630053" Q="1.1029456172307863" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="90" UNITS="" WEIGHT="100.00000000000001" Z="0.40695364962906994">
<NAME>Morning plasma cortisol (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2407097665067557" CI_START="-0.8407097665067569" DF="0.0" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.31.01" NO="1" P_CHI2="1.0" P_Z="0.373206973683483" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="73" WEIGHT="73.37683872253892" Z="0.8904823082213001">
<NAME>Children</NAME>
<CONT_DATA CI_END="2.2407097665067557" CI_START="-0.8407097665067569" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.3" ORDER="116" SD_1="5.6" SD_2="4.3" SE="0.7860908560869884" STUDY_ID="STD-Peden-1998" TOTAL_1="86" TOTAL_2="73" WEIGHT="73.37683872253892"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6578232026648356" CI_START="-3.4578232026648363" DF="0.0" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.31.02" NO="2" P_CHI2="1.0" P_Z="0.49042297363621723" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="26.62316127746109" Z="0.6896362439156397">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.6578232026648356" CI_START="-3.4578232026648363" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="13.4" ORDER="117" SD_1="3.21" SD_2="4.54" SE="1.3050358184337156" STUDY_ID="STD-Li-1999b" TOTAL_1="21" TOTAL_2="17" WEIGHT="26.62316127746109"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.32" MODIFIED="2008-07-07 15:34:39 +0100" MODIFIED_BY="Toby J Lasserson" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total urinary free cortisol excretion (mcg/24 hours)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.32.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="4.47840290335345" CI_START="-1.878402903353452" EFFECT_SIZE="1.299999999999999" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="9.8" ORDER="118" SD_1="8.8" SD_2="6.9" SE="1.6216639328193208" STUDY_ID="STD-Peden-1998" TOTAL_1="61" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.32.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.014321442139009" CI_END="2.2922429605345007" CI_START="0.7813767855426251" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.338321873162491" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.33" LOG_CI_END="0.36026064768770943" LOG_CI_START="-0.10713949567138535" LOG_EFFECT_SIZE="0.12656057600816206" METHOD="PETO" MODIFIED="2008-07-07 15:34:38 +0100" MODIFIED_BY="Toby J Lasserson" NO="33" P_CHI2="0.756044417161867" P_Q="0.8727416127671952" P_Z="0.2884986195113769" Q="0.025656693443734113" RANDOM="NO" SCALE="264.2862613568521" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="975" TOTAL_2="953" WEIGHT="100.0" Z="1.0614210301945344">
<NAME>Sore throat or pharyngitis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8163480550227962" CI_END="2.910783119979441" CI_START="0.6679620696522837" DF="3.0" EFFECT_SIZE="1.3943789718474668" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-001.33.01" LOG_CI_END="0.46400984772493986" LOG_CI_START="-0.175248198315488" LOG_EFFECT_SIZE="0.1443808247047259" NO="1" P_CHI2="0.6113840499843557" P_Z="0.3759718459015924" STUDIES="4" TAU2="0.0" TOTAL_1="631" TOTAL_2="619" WEIGHT="53.45954726833385" Z="0.8853426819802828">
<NAME>Children</NAME>
<DICH_DATA CI_END="19.035191630369944" CI_START="0.552300893789092" EFFECT_SIZE="3.242399320086895" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2795572532855746" LOG_CI_START="-0.2578242539565572" LOG_EFFECT_SIZE="0.5108664996645086" ORDER="119" O_E="1.4423963133640552" SE="0.9030655075152242" STUDY_ID="STD-Allen-1998" TOTAL_1="111" TOTAL_2="106" VAR="1.2262005044820565" WEIGHT="9.243030306426395"/>
<DICH_DATA CI_END="4.6794001045109415" CI_START="0.04919400635937226" EFFECT_SIZE="0.47978999416344487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6701901804245814" LOG_CI_START="-1.3080878070622253" LOG_EFFECT_SIZE="-0.3189488133188219" ORDER="120" O_E="-0.5438596491228069" SE="1.162050282483722" STUDY_ID="STD-FLTA2007" TOTAL_1="88" TOTAL_2="83" VAR="0.740542791447142" WEIGHT="5.58216983236586"/>
<DICH_DATA CI_END="7.295456614274495" CI_START="0.14144053435976742" EFFECT_SIZE="1.0158116370279897" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8630524790744052" LOG_CI_START="-0.8494261115712456" LOG_EFFECT_SIZE="0.0068131837515797876" ORDER="121" O_E="0.015503875968992276" SE="1.0059184010509927" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" VAR="0.9882674571758797" WEIGHT="7.4495044033520665"/>
<DICH_DATA CI_END="3.7157623302979106" CI_START="0.5408341522785807" EFFECT_SIZE="1.4176075514666793" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5700479276194709" LOG_CI_START="-0.26693589162667136" LOG_EFFECT_SIZE="0.1515560179963997" ORDER="122" O_E="1.443708609271523" SE="0.4916484385619089" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" VAR="4.137049064575811" WEIGHT="31.184842726189526"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1723166936724785" CI_END="2.8096773936171804" CI_START="0.5801303436538279" DF="4.0" EFFECT_SIZE="1.2767063530489406" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-001.33.02" LOG_CI_END="0.44865645719509645" LOG_CI_START="-0.2364744182131939" LOG_EFFECT_SIZE="0.10609101949095126" NO="2" P_CHI2="0.5294139689503712" P_Z="0.543856036390129" STUDIES="5" TAU2="0.0" TOTAL_1="344" TOTAL_2="334" WEIGHT="46.54045273166614" Z="0.6069922835151368">
<NAME>Adults</NAME>
<DICH_DATA CI_END="18.630259087039192" CI_START="0.30505336371761393" EFFECT_SIZE="2.3839511742969797" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2702188945789616" LOG_CI_START="-0.5156241818306028" LOG_EFFECT_SIZE="0.3772973563741794" ORDER="123" O_E="0.7894736842105261" SE="1.049013063148777" STUDY_ID="STD-Li-1999" TOTAL_1="21" TOTAL_2="17" VAR="0.908736991839485" WEIGHT="6.85000823718551"/>
<DICH_DATA CI_END="2.2192159541194565" CI_START="0.31444081455029893" EFFECT_SIZE="0.8353514663160297" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.34619956591789824" LOG_CI_START="-0.5024610873669315" LOG_EFFECT_SIZE="-0.07813076072451655" ORDER="124" O_E="-0.7239263803680984" SE="0.49850746867749457" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" VAR="4.023987855520845" WEIGHT="30.332593703328723"/>
<DICH_DATA CI_END="107.12772688349759" CI_START="0.40719277945612053" EFFECT_SIZE="6.604667808944486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0299018898239796" LOG_CI_START="-0.3901999317276979" LOG_EFFECT_SIZE="0.8198509790481407" ORDER="125" O_E="0.9341317365269461" SE="1.421579789676678" STUDY_ID="STD-Pearlman-1997" TOTAL_1="89" TOTAL_2="78" VAR="0.4948317058977781" WEIGHT="3.7300135153065948"/>
<DICH_DATA CI_END="358.25644999819065" CI_START="0.14083075353024563" EFFECT_SIZE="7.103064536544487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5541940181158753" LOG_CI_START="-0.8513024969689142" LOG_EFFECT_SIZE="0.8514457605734804" ORDER="126" O_E="0.4899328859060402" SE="2.000405510440429" STUDY_ID="STD-Sheffer-1996" TOTAL_1="76" TOTAL_2="73" VAR="0.2498986532138192" WEIGHT="1.8837219661446252"/>
<DICH_DATA CI_END="16.75183304420607" CI_START="0.06434611580372847" EFFECT_SIZE="1.0382270411558392" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.224062335995384" LOG_CI_START="-1.1914776637700062" LOG_EFFECT_SIZE="0.01629233611268881" ORDER="127" O_E="0.018633540372670843" SE="1.418900152978031" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" VAR="0.4967024806141738" WEIGHT="3.7441153097006903"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9806246812145212" CI_END="16.369457252374477" CI_START="1.5258577888755975" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.997745876712995" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.34" LOG_CI_END="1.214034280132379" LOG_CI_START="0.18351405892383288" LOG_EFFECT_SIZE="0.6987741695281059" METHOD="PETO" MODIFIED="2008-07-07 15:34:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="34" P_CHI2="0.9641133511430053" P_Q="0.7129320875139962" P_Z="0.00786009900868178" Q="0.13536601254733327" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="613" TOTAL_2="602" WEIGHT="100.0" Z="2.658021021646336">
<NAME>Hoarseness or dysphonia (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.93399119384196" CI_START="0.7400032579230424" DF="0.0" EFFECT_SIZE="7.193843292914048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.34.01" LOG_CI_END="1.8446883145122088" LOG_CI_START="-0.1307663682489087" LOG_EFFECT_SIZE="0.8569609731316501" NO="1" P_CHI2="1.0" P_Z="0.0890402843933211" STUDIES="2" TAU2="0.0" TOTAL_1="196" TOTAL_2="199" WEIGHT="27.213154882624732" Z="1.700482079545167">
<NAME>Children</NAME>
<DICH_DATA CI_END="69.93399119384196" CI_START="0.7400032579230429" EFFECT_SIZE="7.193843292914048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8446883145122088" LOG_CI_START="-0.13076636824890842" LOG_EFFECT_SIZE="0.8569609731316501" ORDER="128" O_E="1.4654377880184333" SE="1.160391859312268" STUDY_ID="STD-Allen-1998" TOTAL_1="111" TOTAL_2="106" VAR="0.7426610602617739" WEIGHT="27.213154882624732"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="129" O_E="0.0" SE="0.0" STUDY_ID="STD-Katz-1998" TOTAL_1="85" TOTAL_2="93" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8452586686671879" CI_END="17.521886778895063" CI_START="1.0856339185862451" DF="4.0" EFFECT_SIZE="4.361462438769405" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.34.02" LOG_CI_END="1.2435808697283603" LOG_CI_START="0.03568340357644304" LOG_EFFECT_SIZE="0.6396321366524017" NO="2" P_CHI2="0.9322795971091151" P_Z="0.037915643526871004" STUDIES="5" TAU2="0.0" TOTAL_1="417" TOTAL_2="403" WEIGHT="72.78684511737526" Z="2.0757655120959373">
<NAME>Adults</NAME>
<DICH_DATA CI_END="376.9811116035596" CI_START="0.1484058037118573" EFFECT_SIZE="7.479718233444067" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5763195907048675" LOG_CI_START="-0.8285491147527566" LOG_EFFECT_SIZE="0.8738852379760556" ORDER="130" O_E="0.503030303030303" SE="2.0000367319577244" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="82" TOTAL_2="83" VAR="0.24999081726354455" WEIGHT="9.160354828660106"/>
<DICH_DATA CI_END="18.27964246152227" CI_START="0.19253138775103906" EFFECT_SIZE="1.8760077107276776" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2619676969499736" LOG_CI_START="-0.7154984588003429" LOG_EFFECT_SIZE="0.2732346190748153" ORDER="131" O_E="0.4662921348314606" SE="1.1615734085030756" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" VAR="0.7411509632194191" WEIGHT="27.157820751215027"/>
<DICH_DATA CI_END="331.9099805041748" CI_START="0.12847065065232754" EFFECT_SIZE="6.529984008661328" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5210203118021575" LOG_CI_START="-0.89119607634501" LOG_EFFECT_SIZE="0.8149121177285736" ORDER="132" O_E="0.46706586826347307" SE="2.004352797141178" STUDY_ID="STD-Pearlman-1997" TOTAL_1="89" TOTAL_2="78" VAR="0.2489153429667611" WEIGHT="9.120946476483496"/>
<DICH_DATA CI_END="116.23880312185152" CI_START="0.4457842164797599" EFFECT_SIZE="7.198432035813053" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0653511295052827" LOG_CI_START="-0.35087531229609775" LOG_EFFECT_SIZE="0.8572379086045925" ORDER="133" O_E="0.9798657718120805" SE="1.4193033724279145" STUDY_ID="STD-Sheffer-1996" TOTAL_1="76" TOTAL_2="73" VAR="0.49642029760042466" WEIGHT="18.190212424382796"/>
<DICH_DATA CI_END="387.0614038344298" CI_START="0.15218871539117784" EFFECT_SIZE="7.675049043951953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5877798674248043" LOG_CI_START="-0.8176175487811701" LOG_EFFECT_SIZE="0.8850811593218171" ORDER="134" O_E="0.5093167701863355" SE="2.0003472992684657" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" VAR="0.24991319779329502" WEIGHT="9.15751063663385"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.600667402955188" CI_END="9.259335206961348" CI_START="1.2891129765114806" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.4548992994244405" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.35" LOG_CI_END="0.9665798067345774" LOG_CI_START="0.11029098013497941" LOG_EFFECT_SIZE="0.5384353934347784" METHOD="PETO" MODIFIED="2008-07-07 15:34:33 +0100" MODIFIED_BY="Toby J Lasserson" NO="35" P_CHI2="0.5959504927822784" P_Q="0.3880217536324655" P_Z="0.013706863512018436" Q="0.7451324278289744" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="653" TOTAL_2="645" WEIGHT="100.00000000000001" Z="2.4648551898652453">
<NAME>Oral Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1893620643757696" CI_END="9.850809292500877" CI_START="0.39651072304227897" DF="2.0" EFFECT_SIZE="1.9763480247975365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="37.29153480755892" ID="CMP-001.35.01" LOG_CI_END="0.9934719113940009" LOG_CI_START="-0.4017450633397692" LOG_EFFECT_SIZE="0.2958634240271159" NO="1" P_CHI2="0.20297339056392727" P_Z="0.4058367939075732" STUDIES="3" TAU2="0.0" TOTAL_1="324" TOTAL_2="329" WEIGHT="37.666654752688125" Z="0.8312422597159134">
<NAME>Children</NAME>
<DICH_DATA CI_END="69.93399119384196" CI_START="0.7400032579230429" EFFECT_SIZE="7.193843292914048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8446883145122088" LOG_CI_START="-0.13076636824890842" LOG_EFFECT_SIZE="0.8569609731316501" ORDER="135" O_E="1.4654377880184333" SE="1.160391859312268" STUDY_ID="STD-Allen-1998" TOTAL_1="111" TOTAL_2="106" VAR="0.7426610602617739" WEIGHT="18.789118762343282"/>
<DICH_DATA CI_END="17.691139800503574" CI_START="0.06775200214791705" EFFECT_SIZE="1.094810550626372" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2477558144316376" LOG_CI_START="-1.1690778663731947" LOG_EFFECT_SIZE="0.039338974029221624" ORDER="136" O_E="0.0449438202247191" SE="1.4196600676244238" STUDY_ID="STD-Katz-1998" TOTAL_1="85" TOTAL_2="93" VAR="0.496170873819647" WEIGHT="12.552985437700135"/>
<DICH_DATA CI_END="6.927024590559979" CI_START="0.002726705600506778" EFFECT_SIZE="0.1374334629772824" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8405467293613299" LOG_CI_START="-2.5643617498388522" LOG_EFFECT_SIZE="-0.8619075102387614" ORDER="137" O_E="-0.49612403100775193" SE="2.000060095250986" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" VAR="0.24998497686437113" WEIGHT="6.324550552644708"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.666172910750444" CI_END="16.877352799244104" CI_START="1.3890828666681232" DF="3.0" EFFECT_SIZE="4.841904750007302" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.35.02" LOG_CI_END="1.2273043288513599" LOG_CI_START="0.14272815463842056" LOG_EFFECT_SIZE="0.6850162417448902" NO="2" P_CHI2="0.8811300916484013" P_Z="0.013293094101971914" STUDIES="4" TAU2="0.0" TOTAL_1="329" TOTAL_2="316" WEIGHT="62.33334524731189" Z="2.475819024181087">
<NAME>Adults</NAME>
<DICH_DATA CI_END="376.9811116035596" CI_START="0.1484058037118573" EFFECT_SIZE="7.479718233444067" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5763195907048675" LOG_CI_START="-0.8285491147527566" LOG_EFFECT_SIZE="0.8738852379760556" ORDER="138" O_E="0.503030303030303" SE="2.0000367319577244" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="82" TOTAL_2="83" VAR="0.24999081726354455" WEIGHT="6.324698313123291"/>
<DICH_DATA CI_END="107.12772688349759" CI_START="0.40719277945612053" EFFECT_SIZE="6.604667808944486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0299018898239796" LOG_CI_START="-0.3901999317276979" LOG_EFFECT_SIZE="0.8198509790481407" ORDER="139" O_E="0.9341317365269461" SE="1.421579789676678" STUDY_ID="STD-Pearlman-1997" TOTAL_1="89" TOTAL_2="78" VAR="0.4948317058977781" WEIGHT="12.51910486084877"/>
<DICH_DATA CI_END="18.586995368815355" CI_START="0.3534250428209238" EFFECT_SIZE="2.5630274353069025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2692091907289935" LOG_CI_START="-0.4517026807103875" LOG_EFFECT_SIZE="0.40875325500930304" ORDER="140" O_E="0.9210526315789473" SE="1.010872151934643" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" VAR="0.9786052356405129" WEIGHT="24.758440933229238"/>
<DICH_DATA CI_END="76.83172217222375" CI_START="0.8072886909896224" EFFECT_SIZE="7.875619367319174" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.885540567946796" LOG_CI_START="-0.09297113134564769" LOG_EFFECT_SIZE="0.8962847183005742" ORDER="141" O_E="1.5279503105590062" SE="1.1621875659552452" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" VAR="0.7403678484626365" WEIGHT="18.73110114011059"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4238393228395276" CI_END="1.1555996086963531" CI_START="0.613957319179276" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.842311603742839" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-001.36" LOG_CI_END="0.06280738611345102" LOG_CI_START="-0.2118618189063877" LOG_EFFECT_SIZE="-0.07452721639646834" METHOD="MH" MODIFIED="2008-07-07 15:34:29 +0100" MODIFIED_BY="Toby J Lasserson" NO="36" P_CHI2="0.6583235220836989" P_Q="0.0" P_Z="0.2875047549315314" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="649" TOTAL_2="642" WEIGHT="100.0" Z="1.0636114812692643">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03710960370426779" CI_END="1.0850148622997475" CI_START="0.5186309381124371" DF="1.0" EFFECT_SIZE="0.7501481692975427" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="78" I2="0.0" ID="CMP-001.36.01" LOG_CI_END="0.035435687097508294" LOG_CI_START="-0.28514157964004805" LOG_EFFECT_SIZE="-0.1248529462712699" NO="1" P_CHI2="0.847242140279614" P_Z="0.1268439753869679" STUDIES="2" TAU2="0.0" TOTAL_1="392" TOTAL_2="383" WEIGHT="77.95680097557607" Z="1.5266664448526566">
<NAME>Children</NAME>
<DICH_DATA CI_END="2.2427883644012456" CI_START="0.30143253525239927" EFFECT_SIZE="0.8222222222222222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.35078829431006625" LOG_CI_START="-0.5208098737267637" LOG_EFFECT_SIZE="-0.0850107897083487" ORDER="142" O_E="0.0" SE="0.5119810783853488" STUDY_ID="STD-FLTA2007" TOTAL_1="88" TOTAL_2="83" VAR="0.2621246246246246" WEIGHT="10.051453395755235"/>
<DICH_DATA CI_END="1.0998227142610901" CI_START="0.4971984640364711" EFFECT_SIZE="0.7394796577614807" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="69" LOG_CI_END="0.041322684773379255" LOG_CI_START="-0.3034702216665862" LOG_EFFECT_SIZE="-0.1310737684466035" ORDER="143" O_E="0.0" SE="0.20253305999524876" STUDY_ID="STD-SAS30021" TOTAL_1="304" TOTAL_2="300" VAR="0.04101964039103903" WEIGHT="67.90534757982084"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2468460687593743" CI_END="2.1737895984719517" CI_START="0.6278493882613866" DF="2.0" EFFECT_SIZE="1.1682518861998812" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" I2="0.0" ID="CMP-001.36.02" LOG_CI_END="0.3372175063350807" LOG_CI_START="-0.20214452456182866" LOG_EFFECT_SIZE="0.06753649088662601" NO="2" P_CHI2="0.5361065090770913" P_Z="0.623542607842366" STUDIES="3" TAU2="0.0" TOTAL_1="257" TOTAL_2="259" WEIGHT="22.04319902442392" Z="0.49083577336686823">
<NAME>Adults</NAME>
<DICH_DATA CI_END="123.81083110743664" CI_START="0.28840701284189657" EFFECT_SIZE="5.975609756097561" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0927586389040984" LOG_CI_START="-0.5399941836145041" LOG_EFFECT_SIZE="0.7763822276447969" ORDER="145" O_E="0.0" SE="1.5464920402840814" STUDY_ID="STD-Li-1999" TOTAL_1="23" TOTAL_2="17" VAR="2.3916376306620206" WEIGHT="0.5825954014355155"/>
<DICH_DATA CI_END="3.199359296976584" CI_START="0.35748139348834673" EFFECT_SIZE="1.0694444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5050630153051338" LOG_CI_START="-0.4467465578227068" LOG_EFFECT_SIZE="0.0291582287412134" ORDER="146" O_E="0.0" SE="0.5590976547886671" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" VAR="0.3125901875901876" WEIGHT="7.3813433832632"/>
<DICH_DATA CI_END="2.279004112009812" CI_START="0.45752434392017177" EFFECT_SIZE="1.0211267605633803" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.35774510877912935" LOG_CI_START="-0.3395857930752925" LOG_EFFECT_SIZE="0.009079657851918398" ORDER="144" O_E="0.0" SE="0.40961562359292225" STUDY_ID="STD-SAS30023" TOTAL_1="155" TOTAL_2="158" VAR="0.16778495909141855" WEIGHT="14.079260239725203"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-14 12:22:42 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 100 mcg/d or less (subgroups)</NAME>
<IV_OUTCOME CHI2="0.38192244216223614" CI_END="0.14848108838160687" CI_START="0.05618497277713828" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.10233303057937257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.8283288576904497" LOG_CI_START="-1.250379825225296" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.9899841641079714" MODIFIED="2008-07-14 12:09:44 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.9439510597264991" P_Q="0.9445855608424727" P_Z="1.3851127990646773E-5" Q="0.00483131040110335" RANDOM="NO" SCALE="0.2451734780869471" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="359" TOTAL_2="360" WEIGHT="200.0" Z="4.346207921120693">
<NAME>Paediatric studies: change in FEV1 compared to baseline; duration</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.18035852336614222" CI_START="0.019641476633857777" DF="0.0" EFFECT_SIZE="0.1" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.7438633290128469" LOG_CI_START="-1.7068258653357502" LOG_EFFECT_SIZE="-1.0" MODIFIED="2008-07-07 15:40:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.0" P_Z="0.014726974236882427" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="100.0" Z="2.4390243902439024">
<NAME>1-4 weeks</NAME>
<IV_DATA CI_END="0.18035852336614222" CI_START="0.019641476633857777" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2727" SE="0.041" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.3770911317611328" CI_END="0.15985123304087212" CI_START="0.04711089840829112" DF="2.0" EFFECT_SIZE="0.10348106572458161" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.7962840093717655" LOG_CI_START="-1.3268786136551438" LOG_EFFECT_SIZE="-0.9851391072465486" MODIFIED="2008-07-14 12:07:44 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.8281628197136349" P_Z="3.206889284294338E-4" STUDIES="3" TAU2="0.0" TOTAL_1="231" TOTAL_2="230" WEIGHT="100.0" Z="3.5979875802743844">
<NAME>1-5 months</NAME>
<IV_DATA CI_END="0.17995816321154276" CI_START="-0.019958163211542757" EFFECT_SIZE="0.08" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2729" SE="0.051" STUDY_ID="STD-FLTA2007" TOTAL_1="72" TOTAL_2="68" WEIGHT="31.80256240772671"/>
<IV_DATA CI_END="0.2293576229796436" CI_START="-0.02935762297964359" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="69" TOTAL_2="76" WEIGHT="18.989546561638463"/>
<IV_DATA CI_END="0.20035852336614224" CI_START="0.03964147663385777" EFFECT_SIZE="0.12" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="155" SE="0.041" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="49.207891030634826"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="74.35317404039402" CI_END="0.3057432362714544" CI_START="0.2134205569877462" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="0.2595818966296003" ESTIMABLE="YES" I2="90.58547252307334" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.5146431417568469" LOG_CI_START="-0.670763751001708" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.5857255987284431" MODIFIED="2008-07-14 12:21:58 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.9406698470447736E-13" P_Q="1.0" P_Z="3.007138227426155E-28" Q="0.0" RANDOM="NO" SCALE="2.45" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="680" TOTAL_2="672" WEIGHT="100.00000000000003" Z="11.0215858634076">
<NAME>Adult studies: change in FEV1; duration</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 12:06:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="74.35317404039402" CI_END="0.3057432362714544" CI_START="0.2134205569877462" DF="7.0" EFFECT_SIZE="0.2595818966296003" ESTIMABLE="YES" I2="90.58547252307334" ID="CMP-002.02.02" LOG_CI_END="-0.5146431417568469" LOG_CI_START="-0.670763751001708" LOG_EFFECT_SIZE="-0.5857255987284431" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.9406698470447736E-13" P_Z="3.007138227426155E-28" STUDIES="8" TAU2="0.0" TOTAL_1="680" TOTAL_2="672" WEIGHT="100.00000000000003" Z="11.0215858634076">
<NAME>1-5 months</NAME>
<IV_DATA CI_END="0.5107170467322845" CI_START="0.18928295326771552" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2525" SE="0.082" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="8.249600564473761"/>
<IV_DATA CI_END="0.6099414284961598" CI_START="0.3300585715038401" EFFECT_SIZE="0.47" ESTIMABLE="YES" ESTIMATE="0.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2523" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="10.880884549019918"/>
<IV_DATA CI_END="0.2599288774596227" CI_START="-0.07992887745962271" EFFECT_SIZE="0.09" ESTIMABLE="YES" ESTIMATE="0.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2532" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="7.379423431169218"/>
<IV_DATA CI_END="0.5999079590653941" CI_START="0.16009204093460594" EFFECT_SIZE="0.38" ESTIMABLE="YES" ESTIMATE="0.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2524" SE="0.1122" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="4.406308619024595"/>
<IV_DATA CI_END="0.8199288774596227" CI_START="0.4800711225403773" EFFECT_SIZE="0.65" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2533" SE="0.0867" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="7.379423431169218"/>
<IV_DATA CI_END="0.09935852336614223" CI_START="-0.061358523366142226" EFFECT_SIZE="0.019" ESTIMABLE="YES" ESTIMATE="0.019" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2528" SE="0.041" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="32.998402257895044"/>
<IV_DATA CI_END="0.5399288774596227" CI_START="0.2000711225403773" EFFECT_SIZE="0.37" ESTIMABLE="YES" ESTIMATE="0.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2531" SE="0.0867" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="7.379423431169218"/>
<IV_DATA CI_END="0.44995816321154275" CI_START="0.2500418367884572" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-14 12:19:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2526" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="21.32653371607904"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.38192244216223614" CI_END="0.14848108838160687" CI_START="0.05618497277713828" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.10233303057937257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.8283288576904497" LOG_CI_START="-1.250379825225296" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.9899841641079714" MODIFIED="2008-07-14 12:11:59 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.9439510597264991" P_Q="1.0" P_Z="1.3851127990646773E-5" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="359" TOTAL_2="360" WEIGHT="100.0" Z="4.346207921120693">
<NAME>Paediatric studies: change in FEV1 compared to baseline; inhaler device</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 12:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.38192244216223614" CI_END="0.14848108838160687" CI_START="0.05618497277713828" DF="3.0" EFFECT_SIZE="0.10233303057937257" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.8283288576904497" LOG_CI_START="-1.250379825225296" LOG_EFFECT_SIZE="-0.9899841641079714" MODIFIED="2008-07-14 12:11:36 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.9439510597264991" P_Z="1.3851127990646773E-5" STUDIES="4" TAU2="0.0" TOTAL_1="359" TOTAL_2="360" WEIGHT="100.0" Z="4.346207921120693">
<NAME>DPI</NAME>
<IV_DATA CI_END="0.17995816321154276" CI_START="-0.019958163211542757" EFFECT_SIZE="0.08" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2540" SE="0.051" STUDY_ID="STD-FLTA2007" TOTAL_1="72" TOTAL_2="68" WEIGHT="21.314263064811446"/>
<IV_DATA CI_END="0.2293576229796436" CI_START="-0.02935762297964359" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2544" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="69" TOTAL_2="76" WEIGHT="12.726905011839888"/>
<IV_DATA CI_END="0.18035852336614222" CI_START="0.019641476633857777" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2543" SE="0.041" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" WEIGHT="32.97941596167433"/>
<IV_DATA CI_END="0.20035852336614224" CI_START="0.03964147663385777" EFFECT_SIZE="0.12" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2541" SE="0.041" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="32.97941596167433"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="74.35317404039402" CI_END="1.3576336707079988" CI_START="1.2379051514475383" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="1.2963879491680192" ESTIMABLE="YES" I2="90.58547252307334" I2_Q="93.82691247911139" ID="CMP-002.04" LOG_CI_END="0.1327826003919348" LOG_CI_START="0.09268737022449665" LOG_DATA="YES" LOG_EFFECT_SIZE="0.11273498530821575" MODIFIED="2008-07-14 12:22:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="1.9406698470447736E-13" P_Q="5.70140616296122E-5" P_Z="3.007138227426155E-28" Q="16.199349136330575" RANDOM="NO" SCALE="2.68" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="680" TOTAL_2="672" WEIGHT="200.0" Z="11.0215858634076">
<NAME>Adult studies: change in FEV1 compared to baseline; inhaler device</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.4835580313090455" CI_END="1.6230445232023778" CI_START="1.3747374465253672" DF="3.0" EFFECT_SIZE="1.4937402998594564" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.21033043351439748" LOG_CI_START="0.13821976259312108" LOG_EFFECT_SIZE="0.17427509805375924" MODIFIED="2008-07-14 12:10:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.6860703206627337" P_Z="2.7042708928604373E-21" STUDIES="4" TAU2="0.0" TOTAL_1="283" TOTAL_2="276" WEIGHT="100.0" Z="9.473574749025756">
<NAME>MDI</NAME>
<IV_DATA CI_END="1.666485714767611" CI_START="1.208382819981923" EFFECT_SIZE="1.4190675485932571" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.22180159520975637" LOG_CI_START="0.08220454212251994" LOG_EFFECT_SIZE="0.1520030686661381" ORDER="2555" SE="0.082" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="26.683732103432412"/>
<IV_DATA CI_END="1.840323605103746" CI_START="1.3910496019448468" EFFECT_SIZE="1.5999941932173602" ESTIMABLE="YES" ESTIMATE="0.47" LOG_CI_END="0.264894196680069" LOG_CI_START="0.14334261630898762" LOG_EFFECT_SIZE="0.20411840649452834" ORDER="2556" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="35.19474744083507"/>
<IV_DATA CI_END="1.8219510985909917" CI_START="1.1736188870000175" EFFECT_SIZE="1.4622845894342245" ESTIMABLE="YES" ESTIMATE="0.38" LOG_CI_END="0.2605367162719426" LOG_CI_START="0.06952708997452887" LOG_EFFECT_SIZE="0.16503190312323568" ORDER="2557" SE="0.1122" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="14.25241838513156"/>
<IV_DATA CI_END="1.7158848197575503" CI_START="1.2214896305164087" EFFECT_SIZE="1.4477346146633243" ESTIMABLE="YES" ESTIMATE="0.37" LOG_CI_END="0.23448813210093117" LOG_CI_START="0.08688978450747514" LOG_EFFECT_SIZE="0.16068895830420313" ORDER="2554" SE="0.0867" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="23.869102070600952"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="56.670266872754404" CI_END="1.2862178944582907" CI_START="1.150998720932577" DF="3.0" EFFECT_SIZE="1.2167313390235681" ESTIMABLE="YES" I2="94.7062186830069" ID="CMP-002.04.02" LOG_CI_END="0.10931454739449584" LOG_CI_START="0.06107484101273492" LOG_EFFECT_SIZE="0.0851946942036154" MODIFIED="2008-07-14 12:11:46 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="3.0212499169124385E-12" P_Z="4.425937104695122E-12" STUDIES="4" TAU2="0.0" TOTAL_1="397" TOTAL_2="396" WEIGHT="100.00000000000001" Z="6.922866859576192">
<NAME>DPI</NAME>
<IV_DATA CI_END="1.2968378489834445" CI_START="0.9231820031010631" EFFECT_SIZE="1.0941742837052104" ESTIMABLE="YES" ESTIMATE="0.09" LOG_CI_END="0.11288567716802068" LOG_CI_START="-0.03471267042543533" LOG_EFFECT_SIZE="0.039086503371292686" ORDER="2552" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="10.68184619920722"/>
<IV_DATA CI_END="2.270338359558464" CI_START="1.616189345597301" EFFECT_SIZE="1.9155408290138962" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.35609058703384167" LOG_CI_START="0.20849223944038567" LOG_EFFECT_SIZE="0.28229141323711376" ORDER="2549" SE="0.0867" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="10.68184619920722"/>
<IV_DATA CI_END="1.104462204091316" CI_START="0.940485993120156" EFFECT_SIZE="1.019181648617408" ESTIMABLE="YES" ESTIMATE="0.019" LOG_CI_END="0.04315085842797084" LOG_CI_START="-0.026647668115647293" LOG_EFFECT_SIZE="0.008251595156161737" ORDER="2546" SE="0.041" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="47.765772085876705"/>
<IV_DATA CI_END="1.568246573717532" CI_START="1.2840791373112146" EFFECT_SIZE="1.4190675485932571" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.19541434737009575" LOG_CI_START="0.10859178996218052" LOG_EFFECT_SIZE="0.1520030686661381" ORDER="2553" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="30.87053551570887"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.38192244216223614" CI_END="0.14848108838160687" CI_START="0.05618497277713828" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.10233303057937257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.8283288576904497" LOG_CI_START="-1.250379825225296" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.9899841641079714" MODIFIED="2008-07-14 12:17:57 +0100" MODIFIED_BY="Toby J Lasserson" NO="5" P_CHI2="0.9439510597264991" P_Q="1.0" P_Z="1.3851127990646773E-5" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="359" TOTAL_2="360" WEIGHT="99.99999999999999" Z="4.346207921120693">
<NAME>Paediatric studies: change in FEV1 compared to baseline (litres); severity</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 12:16:46 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mild</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 12:16:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mild to moderate</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.38192244216223614" CI_END="0.14848108838160687" CI_START="0.05618497277713828" DF="3.0" EFFECT_SIZE="0.10233303057937257" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="-0.8283288576904497" LOG_CI_START="-1.250379825225296" LOG_EFFECT_SIZE="-0.9899841641079714" MODIFIED="2008-07-14 12:16:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.9439510597264991" P_Z="1.3851127990646773E-5" STUDIES="4" TAU2="0.0" TOTAL_1="359" TOTAL_2="360" WEIGHT="99.99999999999999" Z="4.346207921120693">
<NAME>Moderate</NAME>
<IV_DATA CI_END="0.17995816321154276" CI_START="-0.019958163211542757" EFFECT_SIZE="0.08" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2568" SE="0.051" STUDY_ID="STD-FLTA2007" TOTAL_1="72" TOTAL_2="68" WEIGHT="21.314263064811446"/>
<IV_DATA CI_END="0.2293576229796436" CI_START="-0.02935762297964359" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2567" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="69" TOTAL_2="76" WEIGHT="12.726905011839888"/>
<IV_DATA CI_END="0.18035852336614222" CI_START="0.019641476633857777" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2561" SE="0.041" STUDY_ID="STD-MacKenzie-1993" TOTAL_1="128" TOTAL_2="130" WEIGHT="32.97941596167433"/>
<IV_DATA CI_END="0.20035852336614224" CI_START="0.03964147663385777" EFFECT_SIZE="0.12" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2566" SE="0.041" STUDY_ID="STD-Peden-1998" TOTAL_1="90" TOTAL_2="86" WEIGHT="32.97941596167433"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="74.35317404039401" CI_END="0.30574323627145433" CI_START="0.21342055698774615" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="0.25958189662960024" ESTIMABLE="YES" I2="90.58547252307332" I2_Q="96.11823555355191" ID="CMP-002.06" LOG_CI_END="-0.5146431417568469" LOG_CI_START="-0.6707637510017082" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.5857255987284432" MODIFIED="2008-07-14 12:22:42 +0100" MODIFIED_BY="Toby J Lasserson" NO="6" P_CHI2="1.942890293094024E-13" P_Q="6.485811887557702E-12" P_Z="3.00713822742622E-28" Q="51.522961467434" RANDOM="NO" SCALE="1.02" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="680" TOTAL_2="672" WEIGHT="300.0" Z="11.021585863407598">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); severity</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.09935852336614223" CI_START="-0.061358523366142226" DF="0.0" EFFECT_SIZE="0.019" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-1.0027948714619952" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.7212463990471711" MODIFIED="2008-07-14 12:15:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.0" P_Z="0.6430671925586295" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="155" WEIGHT="100.0" Z="0.46341463414634143">
<NAME>Mild</NAME>
<IV_DATA CI_END="0.09935852336614223" CI_START="-0.061358523366142226" EFFECT_SIZE="0.019" ESTIMABLE="YES" ESTIMATE="0.019" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2570" SE="0.041" STUDY_ID="STD-SAS30023" TOTAL_1="154" TOTAL_2="155" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.5107170467322845" CI_START="0.18928295326771552" DF="0.0" EFFECT_SIZE="0.35" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-0.29181964600541466" LOG_CI_START="-0.7228884966285146" LOG_EFFECT_SIZE="-0.4559319556497244" MODIFIED="2008-07-14 12:15:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.0" P_Z="1.9697477444870384E-5" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="4.268292682926829">
<NAME>Mild to moderate</NAME>
<IV_DATA CI_END="0.5107170467322845" CI_START="0.18928295326771552" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2571" SE="0.082" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="22.83021257296001" CI_END="0.44223381151362284" CI_START="0.3217865078173875" DF="5.0" EFFECT_SIZE="0.38201015966550517" ESTIMABLE="YES" I2="78.09919647475391" ID="CMP-002.06.03" LOG_CI_END="-0.35434805598518904" LOG_CI_START="-0.49243216938334994" LOG_EFFECT_SIZE="-0.4179250867532301" MODIFIED="2008-07-14 12:17:12 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="3.637500521581627E-4" P_Z="1.7426205139469445E-35" STUDIES="6" TAU2="0.0" TOTAL_1="448" TOTAL_2="437" WEIGHT="100.00000000000001" Z="12.432426989998072">
<NAME>Moderate</NAME>
<IV_DATA CI_END="0.6099414284961598" CI_START="0.3300585715038401" EFFECT_SIZE="0.47" ESTIMABLE="YES" ESTIMATE="0.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2574" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="91" TOTAL_2="87" WEIGHT="18.520024972295964"/>
<IV_DATA CI_END="0.2599288774596227" CI_START="-0.07992887745962271" EFFECT_SIZE="0.09" ESTIMABLE="YES" ESTIMATE="0.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2577" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="79" TOTAL_2="84" WEIGHT="12.560293752837403"/>
<IV_DATA CI_END="0.5999079590653941" CI_START="0.16009204093460594" EFFECT_SIZE="0.38" ESTIMABLE="YES" ESTIMATE="0.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2576" SE="0.1122" STUDY_ID="STD-Noonan-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="7.499844823491754"/>
<IV_DATA CI_END="0.8199288774596227" CI_START="0.4800711225403773" EFFECT_SIZE="0.65" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2572" SE="0.0867" STUDY_ID="STD-Pearlman-1997" TOTAL_1="85" TOTAL_2="75" WEIGHT="12.560293752837403"/>
<IV_DATA CI_END="0.5399288774596227" CI_START="0.2000711225403773" EFFECT_SIZE="0.37" ESTIMABLE="YES" ESTIMATE="0.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2575" SE="0.0867" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="12.560293752837403"/>
<IV_DATA CI_END="0.44995816321154275" CI_START="0.2500418367884572" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2581" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="36.2992489457001"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="3">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (all ages)</NAME>
<CONT_OUTCOME CHI2="154.58215978147052" CI_END="0.25761560158064273" CI_START="0.2132810076740942" CI_STUDY="95" CI_TOTAL="95" DF="27.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.23544830462736846" ESTIMABLE="YES" I2="82.53356012222282" I2_Q="83.3975507754595" ID="CMP-003.01" MODIFIED="2009-05-21 09:45:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Q="0.01411901714215702" P_Z="0.0" Q="6.023207699511431" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3287" TOTAL_2="2653" UNITS="" WEIGHT="200.0" Z="20.817612461428023">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.6259233300819087" CI_END="0.22853925454148027" CI_START="0.12449430392649208" DF="2.0" EFFECT_SIZE="0.17651677923398618" ESTIMABLE="YES" I2="44.841635690216854" ID="CMP-003.01.01" NO="1" P_CHI2="0.16317023381269513" P_Z="2.9244034920030715E-11" STUDIES="3" TAU2="0.0" TOTAL_1="264" TOTAL_2="260" WEIGHT="100.0" Z="6.650328111468822">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.24324372727493843" CI_START="0.07675627272506158" EFFECT_SIZE="0.16" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.09" ORDER="426" SD_1="0.3" SD_2="0.29" SE="0.04247206986023943" STUDY_ID="STD-Allen-1998" TOTAL_1="97" TOTAL_2="96" WEIGHT="39.055211143159276"/>
<CONT_DATA CI_END="0.38070782997103986" CI_START="0.15929217002896018" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="-0.04" ORDER="427" SD_1="0.36" SD_2="0.35" SE="0.05648462463815105" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="22.08133615796487"/>
<CONT_DATA CI_END="0.22344884344902743" CI_START="0.05655115655097252" EFFECT_SIZE="0.13999999999999999" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.1" ORDER="428" SD_1="0.28" SD_2="0.28" SE="0.04257672289249256" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="38.86345269887585"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="144.93302875187717" CI_END="0.27302548272733385" CI_START="0.224019185067256" DF="24.0" EFFECT_SIZE="0.24852233389729492" ESTIMABLE="YES" I2="83.44062757352047" ID="CMP-003.01.02" MODIFIED="2009-05-21 09:45:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="3.3306690738754696E-16" P_Z="0.0" STUDIES="25" TAU2="0.0" TOTAL_1="3023" TOTAL_2="2393" WEIGHT="100.00000000000001" Z="19.878866474311916">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.23094538742078363" CI_START="0.08905461257921639" EFFECT_SIZE="0.16" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="-0.08" ORDER="430" SD_1="0.29" SD_2="0.42" SE="0.036197291368816865" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="11.92876454786614"/>
<CONT_DATA CI_END="0.21249062743139513" CI_START="0.04750937256860489" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.1" ORDER="429" SD_1="0.42" SD_2="0.43" SE="0.04208782818565578" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="8.823371841641112"/>
<CONT_DATA CI_END="0.46407091274831724" CI_START="0.25592908725168273" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="0.21" ORDER="431" SD_1="0.4" SD_2="0.4" SE="0.05309838015862299" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="5.543512979699051"/>
<CONT_DATA CI_END="0.5504998391079464" CI_START="0.24950016089205365" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="-0.26" ORDER="432" SD_1="0.46" SD_2="0.51" SE="0.07678704317786954" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="2.65076803264319"/>
<CONT_DATA CI_END="0.1561995191798652" CI_START="0.04380048082013481" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="-0.02" ORDER="448" SD_1="0.43" SD_2="0.44" SE="0.02867375095826241" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="19.00984588147992"/>
<CONT_DATA CI_END="0.6010599033817746" CI_START="0.3189400966182253" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="-0.09" ORDER="433" SD_1="0.39" SD_2="0.58" SE="0.07197066093787292" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="3.0174260246669276"/>
<CONT_DATA CI_END="0.35835052492485453" CI_START="-0.13835052492485456" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.07" ORDER="434" SD_1="0.55" SD_2="0.59" SE="0.12671177985096246" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="0.9734499591916203"/>
<CONT_DATA CI_END="0.20874135954016093" CI_START="-0.06874135954016092" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.3" ORDER="435" SD_1="0.5" SD_2="0.54" SE="0.07078770866941181" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="3.119118711682618"/>
<CONT_DATA CI_END="0.6015814578891971" CI_START="0.3184185421108029" EFFECT_SIZE="0.46" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="0.19" ORDER="436" SD_1="0.48" SD_2="0.47" SE="0.07223676506607958" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="2.9952359230606516"/>
<CONT_DATA CI_END="0.43771016012807495" CI_START="0.10228983987192511" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.01" ORDER="437" SD_1="0.46" SD_2="0.61" SE="0.08556798056033235" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="2.134641992596922"/>
<CONT_DATA CI_END="0.4041926074508927" CI_START="-0.08419260745089271" EFFECT_SIZE="0.16" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="-0.05" ORDER="438" SD_1="0.62" SD_2="0.37" SE="0.12459035440296497" STUDY_ID="STD-Kemp-2004" TOTAL_1="32" TOTAL_2="39" WEIGHT="1.0068824504741574"/>
<CONT_DATA CI_END="0.6565555904561159" CI_START="0.26344440954388415" EFFECT_SIZE="0.46" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.19" ORDER="439" SD_1="0.48" SD_2="0.64" SE="0.1002853072844814" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="1.554078651808336"/>
<CONT_DATA CI_END="0.4630856624843958" CI_START="0.23691433751560415" EFFECT_SIZE="0.35" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="-0.25" ORDER="444" SD_1="0.41" SD_2="0.41" SE="0.05769782678477825" STUDY_ID="STD-Lumry-2006" TOTAL_1="100" TOTAL_2="102" WEIGHT="4.6949254724385705"/>
<CONT_DATA CI_END="0.3263222073995546" CI_START="-0.006322207399554525" EFFECT_SIZE="0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="0.11" ORDER="440" SD_1="0.54" SD_2="0.55" SE="0.08485982840066598" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="2.1704176641555333"/>
<CONT_DATA CI_END="0.4357232753398906" CI_START="0.18427672466010941" EFFECT_SIZE="0.31" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.12" ORDER="447" SD_1="0.38" SD_2="0.47" SE="0.06414570692705567" STUDY_ID="STD-Nathan-2006" TOTAL_1="90" TOTAL_2="88" WEIGHT="3.7985025505790904"/>
<CONT_DATA CI_END="0.7229137918708373" CI_START="0.19708620812916272" EFFECT_SIZE="0.46" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="-0.08" ORDER="441" SD_1="0.58" SD_2="0.54" SE="0.13414215462358886" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.8685944662047432"/>
<CONT_DATA CI_END="0.8707564321297505" CI_START="0.5092435678702494" EFFECT_SIZE="0.69" ESTIMABLE="YES" MEAN_1="0.47" MEAN_2="-0.22" ORDER="442" SD_1="0.63" SD_2="0.52" SE="0.09222436409828659" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="1.8376223952585526"/>
<CONT_DATA CI_END="0.4940301198323841" CI_START="0.04596988016761591" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="0.0" ORDER="443" SD_1="0.34" SD_2="0.43" SE="0.11430318189492517" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="1.1962748528681046"/>
<CONT_DATA CI_END="0.35888254082683013" CI_START="0.08111745917316981" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.14" ORDER="445" SD_1="0.47" SD_2="0.47" SE="0.0708597412617364" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="3.112780443885908"/>
<CONT_DATA CI_END="0.321430860142703" CI_START="0.09856913985729704" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.13" MODIFIED="2009-05-21 09:45:51 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="446" SD_1="0.4" SD_2="0.4" SE="0.05685352436149612" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="4.835404719483651"/>
<CONT_DATA CI_END="0.45994173572993025" CI_START="0.1000582642700697" EFFECT_SIZE="0.27999999999999997" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.14" ORDER="449" SD_1="0.62" SD_2="0.51" SE="0.09180869503179023" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="1.8542999431984626"/>
<CONT_DATA CI_END="0.398984252104636" CI_START="0.20101574789536408" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.24" ORDER="450" SD_1="0.36" SD_2="0.27" SE="0.05050309744740776" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="6.127898789692739"/>
<CONT_DATA CI_END="0.8558541128361845" CI_START="0.5441458871638154" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="-0.31" ORDER="451" SD_1="0.51" SD_2="0.48" SE="0.07951886568607477" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="2.4717654706792254"/>
<CONT_DATA CI_END="0.5159362018839917" CI_START="0.1840637981160084" EFFECT_SIZE="0.35000000000000003" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.08" ORDER="453" SD_1="0.48" SD_2="0.5" SE="0.08466288319217864" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.180527183706988"/>
<CONT_DATA CI_END="0.4493343499527517" CI_START="0.1106656500472484" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="0.49" MEAN_2="0.21" ORDER="452" SD_1="0.43" SD_2="0.6" SE="0.0863966640654825" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="2.0938890510377792"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="152.49962932065174" CI_END="0.2565599273302419" CI_START="0.2129051630135717" CI_STUDY="95" CI_TOTAL="95" DF="28.0" EFFECT_SIZE="0.2347325451719068" ESTIMABLE="YES" I2="81.63929963322987" I2_Q="87.13179291538775" ID="CMP-003.02" LOG_CI_END="-0.5908111760920864" LOG_CI_START="-0.6718138066635275" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.629426692213556" MODIFIED="2009-05-21 09:47:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="5.551115123125783E-16" P_Q="0.005308913962662198" P_Z="0.0" Q="7.771090358001743" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3360" TOTAL_2="2731" WEIGHT="200.0" Z="21.077531478536724">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.743456058048142" CI_END="0.22261009906889745" CI_START="0.1288729806494764" DF="3.0" EFFECT_SIZE="0.17574153985918692" ESTIMABLE="YES" I2="19.860151862869305" ID="CMP-003.02.01" LOG_CI_END="-0.6524551370794566" LOG_CI_START="-0.8898381267494384" LOG_EFFECT_SIZE="-0.7551255726006394" NO="1" P_CHI2="0.2905322634232659" P_Z="1.993752167353667E-13" STUDIES="4" TAU2="0.0" TOTAL_1="334" TOTAL_2="336" WEIGHT="100.0" Z="7.349214367149822">
<NAME>Children</NAME>
<IV_DATA CI_END="0.23996653056923423" CI_START="0.08003346943076578" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="454" SE="0.0408" STUDY_ID="STD-Allen-1998" TOTAL_1="97" TOTAL_2="96" WEIGHT="34.35157846922552"/>
<IV_DATA CI_END="0.3093576229796436" CI_START="0.0506423770203564" EFFECT_SIZE="0.18" ESTIMABLE="YES" ESTIMATE="0.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="455" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="70" TOTAL_2="76" WEIGHT="13.127413127413126"/>
<IV_DATA CI_END="0.37995397953269705" CI_START="0.16004602046730299" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="456" SE="0.0561" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="18.169429934135817"/>
<IV_DATA CI_END="0.21996653056923424" CI_START="0.06003346943076579" EFFECT_SIZE="0.14" ESTIMABLE="YES" ESTIMATE="0.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="457" SE="0.0408" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="34.35157846922552"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="140.98508290460185" CI_END="0.27573623440390976" CI_START="0.2264051863949554" DF="24.0" EFFECT_SIZE="0.2510707103994326" ESTIMABLE="YES" I2="82.97692244771761" ID="CMP-003.02.02" LOG_CI_END="-0.5595061596553064" LOG_CI_START="-0.6451136287341587" LOG_EFFECT_SIZE="-0.6002039485927037" MODIFIED="2009-05-21 09:47:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="-4.440892098500626E-16" P_Z="0.0" STUDIES="25" TAU2="0.0" TOTAL_1="3026" TOTAL_2="2395" WEIGHT="99.99999999999999" Z="19.950500539394664">
<NAME>Adults</NAME>
<IV_DATA CI_END="0.22997071424807997" CI_START="0.09002928575192005" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="459" SE="0.0357" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="12.426478655483537"/>
<IV_DATA CI_END="0.20996653056923423" CI_START="0.05003346943076578" EFFECT_SIZE="0.13" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="458" SE="0.0408" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="9.514022720604583"/>
<IV_DATA CI_END="0.45995816321154276" CI_START="0.2600418367884572" EFFECT_SIZE="0.36" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="460" SE="0.051" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="6.088974541186935"/>
<IV_DATA CI_END="0.5499372448173142" CI_START="0.25006275518268584" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="461" SE="0.0765" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="2.7062109071941927"/>
<IV_DATA CI_END="0.15997489792692565" CI_START="0.040025102073074345" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="477" SE="0.0306" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="16.913818169963708"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="462" SE="0.0714" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="3.1066196638708843"/>
<IV_DATA CI_END="0.35989540802885694" CI_START="-0.13989540802885692" EFFECT_SIZE="0.11" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="463" SE="0.1275" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="0.9742359265899094"/>
<IV_DATA CI_END="0.2099414284961599" CI_START="-0.06994142849615989" EFFECT_SIZE="0.07" ESTIMABLE="YES" ESTIMATE="0.07" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="464" SE="0.0714" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="3.1066196638708843"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="465" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="3.1066196638708843"/>
<IV_DATA CI_END="0.4399288774596227" CI_START="0.10007112254037731" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="466" SE="0.0867" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="2.106911605947036"/>
<IV_DATA CI_END="0.39911560611388663" CI_START="-0.0791156061138866" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="467" SE="0.122" STUDY_ID="STD-Kemp-2004" TOTAL_1="32" TOTAL_2="39" WEIGHT="1.0640568920738522"/>
<IV_DATA CI_END="0.6599163264230855" CI_START="0.26008367357691453" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="468" SE="0.102" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="1.5222436352967337"/>
<IV_DATA CI_END="0.459757983134243" CI_START="0.24024201686575694" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="473" SE="0.056" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="5.050198591080107"/>
<IV_DATA CI_END="0.32992887745962274" CI_START="-0.009928877459622704" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="469" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="2.106911605947036"/>
<IV_DATA CI_END="0.4399456121750056" CI_START="0.18005438782499442" EFFECT_SIZE="0.31" ESTIMABLE="YES" ESTIMATE="0.31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="476" SE="0.0663" STUDY_ID="STD-Nathan-2006" TOTAL_1="90" TOTAL_2="88" WEIGHT="3.602943515495227"/>
<IV_DATA CI_END="0.7402748497892278" CI_START="0.1797251502107723" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="470" SE="0.143" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.7744839738680237"/>
<IV_DATA CI_END="0.8703166865776849" CI_START="0.509683313422315" EFFECT_SIZE="0.69" ESTIMABLE="YES" ESTIMATE="0.69" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="471" SE="0.092" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="1.8711510847858241"/>
<IV_DATA CI_END="0.4899079590653941" CI_START="0.05009204093460595" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="472" SE="0.1122" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="1.2580525911543252"/>
<IV_DATA CI_END="0.3599414284961599" CI_START="0.0800585715038401" EFFECT_SIZE="0.22" ESTIMABLE="YES" ESTIMATE="0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="474" SE="0.0714" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="3.1066196638708843"/>
<IV_DATA CI_END="0.319953979532697" CI_START="0.10004602046730296" EFFECT_SIZE="0.21" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:47:19 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="475" SE="0.0561" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="5.032210364617301"/>
<IV_DATA CI_END="0.45992469378077705" CI_START="0.10007530621922303" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="478" SE="0.0918" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="1.879313129995967"/>
<IV_DATA CI_END="0.39995816321154276" CI_START="0.20004183678845722" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="479" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="6.088974541186935"/>
<IV_DATA CI_END="0.8599330611384683" CI_START="0.5400669388615316" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="480" SE="0.0816" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="2.3785056801511457"/>
<IV_DATA CI_END="0.5199288774596227" CI_START="0.18007112254037727" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="482" SE="0.0867" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.106911605947036"/>
<IV_DATA CI_END="0.44992887745962273" CI_START="0.11007112254037732" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="481" SE="0.0867" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="2.106911605947036"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="21.452912778541407" CI_END="8.289828913542708" CI_START="5.593549078738713" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="6.94168899614071" ESTIMABLE="YES" I2="62.70902658961016" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.9185455676225232" LOG_CI_START="0.7476874530064034" LOG_DATA="NO" LOG_EFFECT_SIZE="0.8414651523654193" NO="3" P_CHI2="0.006036829993831816" P_Q="0.7098821372630726" P_Z="5.9921046718721E-24" Q="0.1383948133100894" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="624" TOTAL_2="698" WEIGHT="100.0" Z="10.092024016715492">
<NAME>Change in FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="12.500791997667465" CI_END="8.936641034480186" CI_START="4.209837986408048" DF="2.0" EFFECT_SIZE="6.573239510444116" ESTIMABLE="YES" I2="84.00101369278698" ID="CMP-003.03.01" LOG_CI_END="0.9511743136160953" LOG_CI_START="0.6242653825428234" LOG_EFFECT_SIZE="0.8177794570436647" NO="1" P_CHI2="0.0019297027247698884" P_Z="5.003840942861456E-8" STUDIES="3" TAU2="0.0" TOTAL_1="170" TOTAL_2="229" WEIGHT="32.538304086923354" Z="5.4511738996532655">
<NAME>Children</NAME>
<IV_DATA CI_END="14.095906359804141" CI_START="3.9040936401958586" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="484" SE="2.6" STUDY_ID="STD-Hoekstra-1996" TOTAL_1="15" TOTAL_2="19" WEIGHT="6.998855999434799"/>
<IV_DATA CI_END="18.952703478567344" CI_START="8.447296521432653" EFFECT_SIZE="13.7" ESTIMABLE="YES" ESTIMATE="13.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="485" SE="2.68" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="6.587250300203169"/>
<IV_DATA CI_END="6.2967430955732855" CI_START="0.10325690442671442" EFFECT_SIZE="3.2" ESTIMABLE="YES" ESTIMATE="3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="483" SE="1.58" STUDY_ID="STD-Levy-2006" TOTAL_1="75" TOTAL_2="132" WEIGHT="18.952197787285385"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="8.813725967563851" CI_END="8.760769959681694" CI_START="5.478031098800539" DF="5.0" EFFECT_SIZE="7.119400529241116" ESTIMABLE="YES" I2="43.27030340629005" ID="CMP-003.03.02" LOG_CI_END="0.9425422767783944" LOG_CI_START="0.738624493416141" LOG_EFFECT_SIZE="0.8524434265296577" NO="2" P_CHI2="0.11672877780887736" P_Z="1.874843893859101E-17" STUDIES="6" TAU2="0.0" TOTAL_1="454" TOTAL_2="469" WEIGHT="67.46169591307665" Z="8.501296764788966">
<NAME>Adults</NAME>
<IV_DATA CI_END="10.367471784962593" CI_START="-3.587471784962593" EFFECT_SIZE="3.39" ESTIMABLE="YES" ESTIMATE="3.39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="486" SE="3.56" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="3.733135538140642"/>
<IV_DATA CI_END="13.812339133872692" CI_START="7.187660866127308" EFFECT_SIZE="10.5" ESTIMABLE="YES" ESTIMATE="10.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="488" SE="1.69" STUDY_ID="STD-Lumry-2006" TOTAL_1="100" TOTAL_2="102" WEIGHT="16.565339643632665"/>
<IV_DATA CI_END="8.690319325369721" CI_START="-0.09031932536972231" EFFECT_SIZE="4.3" ESTIMABLE="YES" ESTIMATE="4.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="487" SE="2.24" STUDY_ID="STD-Nathan-2000" TOTAL_1="80" TOTAL_2="83" WEIGHT="9.429262307911998"/>
<IV_DATA CI_END="8.349745796732781" CI_START="2.4502542032672188" EFFECT_SIZE="5.4" ESTIMABLE="YES" ESTIMATE="5.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="489" SE="1.505" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="20.888187351653627"/>
<IV_DATA CI_END="14.20972651598822" CI_START="4.4702734840117815" EFFECT_SIZE="9.34" ESTIMABLE="YES" ESTIMATE="9.34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="491" SE="2.4846" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="7.664093461813356"/>
<IV_DATA CI_END="11.939118244905924" CI_START="3.0408817550940768" EFFECT_SIZE="7.49" ESTIMABLE="YES" ESTIMATE="7.49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="490" SE="2.27" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="9.181677609924362"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="26.498507019041988" CI_END="8.885197476788576" CI_START="4.915856801404981" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.900527139096779" ESTIMABLE="YES" I2="81.13101241361646" I2_Q="89.27721865502356" ID="CMP-003.04" NO="4" P_CHI2="7.141040507707697E-5" P_Q="0.002259337514406101" P_Z="9.450977959183514E-12" Q="9.325938558548462" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="491" TOTAL_2="447" UNITS="" WEIGHT="100.0" Z="6.8146252856786464">
<NAME>Change in FEV1 (%)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.295090951028953" CI_START="0.10490904897104691" DF="0.0" EFFECT_SIZE="3.2" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.04272406082104134" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="75" WEIGHT="41.11780539321172" Z="2.026397559801306">
<NAME>Children</NAME>
<CONT_DATA CI_END="6.295090951028953" CI_START="0.10490904897104691" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-2.4" ORDER="492" SD_1="9.35" SD_2="11.72" SE="1.579157053620697" STUDY_ID="STD-Levy-2006" TOTAL_1="132" TOTAL_2="75" WEIGHT="41.11780539321172"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.172568460493526" CI_END="12.071032552310959" CI_START="6.898224296244615" DF="4.0" EFFECT_SIZE="9.484628424277787" ESTIMABLE="YES" I2="76.70703710279433" ID="CMP-003.04.02" NO="2" P_CHI2="0.0017892668083888674" P_Z="6.603503544803007E-13" STUDIES="5" TAU2="0.0" TOTAL_1="359" TOTAL_2="372" WEIGHT="58.88219460678828" Z="7.18740351395346">
<NAME>Adults</NAME>
<CONT_DATA CI_END="10.369814875090253" CI_START="-3.589814875090254" EFFECT_SIZE="3.3899999999999997" ESTIMABLE="YES" MEAN_1="5.31" MEAN_2="1.92" ORDER="493" SD_1="17.26" SD_2="14.43" SE="3.56119547611392" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="8.085166162487136"/>
<CONT_DATA CI_END="20.990005918286073" CI_START="11.009994081713927" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="-11.6" ORDER="495" SD_1="18.27" SD_2="18.36" SE="2.5459681696432193" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="15.81884010903614"/>
<CONT_DATA CI_END="8.693477092543642" CI_START="-0.09347709254364034" EFFECT_SIZE="4.300000000000001" ESTIMABLE="YES" MEAN_1="7.49" MEAN_2="3.19" ORDER="494" SD_1="14.4" SD_2="14.21" SE="2.2416111353059684" STUDY_ID="STD-Nathan-2000" TOTAL_1="80" TOTAL_2="83" WEIGHT="20.40610068292719"/>
<CONT_DATA CI_END="22.953267969017144" CI_START="7.446732030982857" EFFECT_SIZE="15.200000000000001" ESTIMABLE="YES" MEAN_1="11.89" MEAN_2="-3.31" ORDER="497" SD_1="23.46" SD_2="22.26" SE="3.9558216529354273" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="6.552502104611934"/>
<CONT_DATA CI_END="18.308295683401827" CI_START="4.291704316598174" EFFECT_SIZE="11.3" ESTIMABLE="YES" MEAN_1="19.39" MEAN_2="8.09" ORDER="496" SD_1="16.75" SD_2="25.55" SE="3.575726767778576" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="8.019585547725882"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="5.6699369649703" CI_END="7.501062709064561" CI_START="0.9444879152731969" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="4.222775312168879" ESTIMABLE="YES" I2="47.08935886704845" I2_Q="73.57012905603392" ID="CMP-003.05" LOG_CI_END="0.8751227961900532" LOG_CI_START="-0.02480359450630004" LOG_DATA="NO" LOG_EFFECT_SIZE="0.625597973851802" NO="5" P_CHI2="0.1288206582381929" P_Q="0.05175730204987683" P_Z="0.011581766441750805" Q="3.7835977410563153" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="80" WEIGHT="100.0" Z="2.524637569754612">
<NAME>FEV1 (% predicted - absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.8863392239139847" CI_END="9.623157502933195" CI_START="2.224505845860993" DF="2.0" EFFECT_SIZE="5.923831674397094" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.9833175939823096" LOG_CI_START="0.34723355138405665" LOG_EFFECT_SIZE="0.7726027095522255" NO="1" P_CHI2="0.38939172217360907" P_Z="0.0016978946561258526" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="64" WEIGHT="78.53240159398459" Z="3.1385439592084867">
<NAME>Children</NAME>
<IV_DATA CI_END="8.813922566761116" CI_START="0.3860774332388832" EFFECT_SIZE="4.6" ESTIMABLE="YES" ESTIMATE="4.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="498" SE="2.15" STUDY_ID="STD-Arets-2002" TOTAL_1="35" TOTAL_2="33" WEIGHT="60.52306959157025"/>
<IV_DATA CI_END="19.133850535841226" CI_START="2.8661494641587737" EFFECT_SIZE="11.0" ESTIMABLE="YES" ESTIMATE="11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="499" SE="4.15" STUDY_ID="STD-Hoekstra-1996" TOTAL_1="15" TOTAL_2="19" WEIGHT="16.24432510884212"/>
<IV_DATA CI_END="29.275946565359284" CI_START="-20.07594656535928" EFFECT_SIZE="4.6" ESTIMABLE="YES" ESTIMATE="4.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="500" SE="12.59" STUDY_ID="STD-Hofstra-2000" TOTAL_1="11" TOTAL_2="12" WEIGHT="1.7650068935722116"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="5.075469984189596" CI_START="-9.075469984189596" DF="0.0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.7054762637457538" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.5795674736460164" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="21.467598406015412" Z="0.554016620498615">
<NAME>Adults</NAME>
<IV_DATA CI_END="5.075469984189596" CI_START="-9.075469984189596" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="501" SE="3.61" STUDY_ID="STD-Li-1999a" TOTAL_1="16" TOTAL_2="16" WEIGHT="21.467598406015412"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>FEV1 (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="1.491583432888425" CI_START="-0.31158343288842505" EFFECT_SIZE="0.59" ESTIMABLE="YES" ESTIMATE="0.59" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="502" SE="0.46" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="63.330979523667736" CI_END="28.529893787780523" CI_START="24.060654819756714" CI_STUDY="95" CI_TOTAL="95" DF="28.0" EFFECT_SIZE="26.29527430376862" ESTIMABLE="YES" I2="55.78783052054962" I2_Q="84.64114164157348" ID="CMP-003.07" LOG_CI_END="1.4553001548513738" LOG_CI_START="1.3813074426520857" LOG_DATA="NO" LOG_EFFECT_SIZE="1.4198777055922112" MODIFIED="2009-05-21 09:34:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="7" P_CHI2="1.5031449526081708E-4" P_Q="0.010721548591134056" P_Z="0.0" Q="6.510900593411343" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3413" TOTAL_2="2707" WEIGHT="199.99999999999997" Z="23.063340746702917">
<NAME>Change in morning PEFR compared with baseline (L/min - generic inverse variance))</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="20.804873654842275" CI_END="25.572724081765248" CI_START="16.00665746222909" DF="4.0" EFFECT_SIZE="20.78969077199717" ESTIMABLE="YES" I2="80.7737356815478" ID="CMP-003.07.01" LOG_CI_END="1.407776992815756" LOG_CI_START="1.2043006512655527" LOG_EFFECT_SIZE="1.3178480296386341" NO="1" P_CHI2="3.4616154140132416E-4" P_Z="1.6082521898756238E-17" STUDIES="5" TAU2="0.0" TOTAL_1="421" TOTAL_2="354" WEIGHT="100.0" Z="8.519080366767279">
<NAME>Children</NAME>
<IV_DATA CI_END="62.481205270558995" CI_START="19.518794729441005" EFFECT_SIZE="41.0" ESTIMABLE="YES" ESTIMATE="41.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="504" SE="10.96" STUDY_ID="STD-Hoekstra-1996" TOTAL_1="15" TOTAL_2="19" WEIGHT="4.957805905065734"/>
<IV_DATA CI_END="52.42617166198394" CI_START="27.573828338016057" EFFECT_SIZE="40.0" ESTIMABLE="YES" ESTIMATE="40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="505" SE="6.34" STUDY_ID="STD-Katz-1998" TOTAL_1="86" TOTAL_2="92" WEIGHT="14.816039014368343"/>
<IV_DATA CI_END="29.799819922700273" CI_START="10.200180077299729" EFFECT_SIZE="20.0" ESTIMABLE="YES" ESTIMATE="20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="506" SE="5.0" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="23.821583112237764"/>
<IV_DATA CI_END="17.993067823262" CI_START="3.6069321767380016" EFFECT_SIZE="10.8" ESTIMABLE="YES" ESTIMATE="10.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="503" SE="3.67" STUDY_ID="STD-Levy-2006" TOTAL_1="153" TOTAL_2="79" WEIGHT="44.21590314026714"/>
<IV_DATA CI_END="40.700148251934976" CI_START="13.29985174806502" EFFECT_SIZE="27.0" ESTIMABLE="YES" ESTIMATE="27.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="507" SE="6.99" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="12.188668828061015"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="36.01520527541412" CI_END="30.35995128993074" CI_START="25.30512695872899" DF="23.0" EFFECT_SIZE="27.832539124329866" ESTIMABLE="YES" I2="36.13808438931483" ID="CMP-003.07.02" LOG_CI_END="1.4823010704338755" LOG_CI_START="1.4032085205555795" LOG_EFFECT_SIZE="1.444552828230688" MODIFIED="2009-05-21 09:34:11 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.04110618081528028" P_Z="0.0" STUDIES="24" TAU2="0.0" TOTAL_1="2992" TOTAL_2="2353" WEIGHT="99.99999999999997" Z="21.58364790058666">
<NAME>Adults</NAME>
<IV_DATA CI_END="25.609828926565257" CI_START="6.990171073434743" EFFECT_SIZE="16.3" ESTIMABLE="YES" ESTIMATE="16.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="509" SE="4.75" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="7.37002128198703"/>
<IV_DATA CI_END="32.75828414792882" CI_START="11.441715852071187" EFFECT_SIZE="22.1" ESTIMABLE="YES" ESTIMATE="22.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="508" SE="5.438" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="5.6231226289044525"/>
<IV_DATA CI_END="55.099311516165834" CI_START="23.700688483834163" EFFECT_SIZE="39.4" ESTIMABLE="YES" ESTIMATE="39.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="510" SE="8.01" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="2.5917370012645295"/>
<IV_DATA CI_END="45.62258642832252" CI_START="22.37741357167748" EFFECT_SIZE="34.0" ESTIMABLE="YES" ESTIMATE="34.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="511" SE="5.93" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="4.728752397272063"/>
<IV_DATA CI_END="25.499700777407853" CI_START="14.700299222592152" EFFECT_SIZE="20.1" ESTIMABLE="YES" ESTIMATE="20.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="526" SE="2.755" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="21.908505594491764"/>
<IV_DATA CI_END="46.85968932027654" CI_START="19.140310679723463" EFFECT_SIZE="33.0" ESTIMABLE="YES" ESTIMATE="33.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="512" SE="7.0714" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="3.3254096506661988"/>
<IV_DATA CI_END="59.5676020291676" CI_START="16.252397970832394" EFFECT_SIZE="37.91" ESTIMABLE="YES" ESTIMATE="37.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="513" SE="11.05" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="1.3618566792230489"/>
<IV_DATA CI_END="39.19935335295429" CI_START="8.000646647045711" EFFECT_SIZE="23.6" ESTIMABLE="YES" ESTIMATE="23.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="514" SE="7.959" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="2.625058292053603"/>
<IV_DATA CI_END="46.68909332835857" CI_START="13.310906671641437" EFFECT_SIZE="30.0" ESTIMABLE="YES" ESTIMATE="30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="515" SE="8.515" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="2.293436165115443"/>
<IV_DATA CI_END="53.759365539355755" CI_START="28.240634460644245" EFFECT_SIZE="41.0" ESTIMABLE="YES" ESTIMATE="41.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="516" SE="6.51" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="3.9236836433805578"/>
<IV_DATA CI_END="43.909668401882314" CI_START="16.09033159811769" EFFECT_SIZE="30.0" ESTIMABLE="YES" ESTIMATE="30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="517" SE="7.0969" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="3.301555404002561"/>
<IV_DATA CI_END="53.839473041991155" CI_START="26.960526958008845" EFFECT_SIZE="40.4" ESTIMABLE="YES" ESTIMATE="40.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="522" SE="6.857" STUDY_ID="STD-Lumry-2006" TOTAL_1="100" TOTAL_2="102" WEIGHT="3.5366140038952016"/>
<IV_DATA CI_END="37.09339615249671" CI_START="14.906603847503293" EFFECT_SIZE="26.0" ESTIMABLE="YES" ESTIMATE="26.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="518" SE="5.66" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="5.19066617059872"/>
<IV_DATA CI_END="40.818750173930354" CI_START="17.981249826069643" EFFECT_SIZE="29.4" ESTIMABLE="YES" ESTIMATE="29.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="525" SE="5.826" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="87" WEIGHT="4.899085293361954"/>
<IV_DATA CI_END="55.06961283380558" CI_START="12.930387166194418" EFFECT_SIZE="34.0" ESTIMABLE="YES" ESTIMATE="34.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="519" SE="10.75" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="1.438927897672968"/>
<IV_DATA CI_END="54.18033942814729" CI_START="25.819660571852708" EFFECT_SIZE="40.0" ESTIMABLE="YES" ESTIMATE="40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="520" SE="7.235" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="3.1767196563742415"/>
<IV_DATA CI_END="31.834417155660777" CI_START="-9.834417155660777" EFFECT_SIZE="11.0" ESTIMABLE="YES" ESTIMATE="11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="521" SE="10.63" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="1.4715988241697988"/>
<IV_DATA CI_END="40.22981419413462" CI_START="12.170185805865383" EFFECT_SIZE="26.2" ESTIMABLE="YES" ESTIMATE="26.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="523" SE="7.1582" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="3.2452510894693716"/>
<IV_DATA CI_END="46.929706419626996" CI_START="13.670293580373002" EFFECT_SIZE="30.3" ESTIMABLE="YES" ESTIMATE="30.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:34:11 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="524" SE="8.4847" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="2.3098457486819823"/>
<IV_DATA CI_END="48.30731871925782" CI_START="17.69268128074218" EFFECT_SIZE="33.0" ESTIMABLE="YES" ESTIMATE="33.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="527" SE="7.81" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="2.7261760206772627"/>
<IV_DATA CI_END="47.549649393009965" CI_START="22.450350606990035" EFFECT_SIZE="35.0" ESTIMABLE="YES" ESTIMATE="35.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="528" SE="6.403" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="4.055916052128569"/>
<IV_DATA CI_END="46.75975753215266" CI_START="21.240242467847338" EFFECT_SIZE="34.0" ESTIMABLE="YES" ESTIMATE="34.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="531" SE="6.5102" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="3.923442567937493"/>
<IV_DATA CI_END="45.309670676039275" CI_START="14.690329323960727" EFFECT_SIZE="30.0" ESTIMABLE="YES" ESTIMATE="30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="530" SE="7.8112" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.7253384643636056"/>
<IV_DATA CI_END="46.859610195013545" CI_START="13.140389804986452" EFFECT_SIZE="30.0" ESTIMABLE="YES" ESTIMATE="30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="529" SE="8.602" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="2.247279472307559"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="54.54544638910326" CI_END="29.66637479733571" CI_START="24.6274254920141" CI_STUDY="95" CI_TOTAL="95" DF="25.0" EFFECT_MEASURE="MD" EFFECT_SIZE="27.146900144674905" ESTIMABLE="YES" I2="54.16665981306491" I2_Q="91.55893767990297" ID="CMP-003.08" MODIFIED="2009-05-21 09:33:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="8" P_CHI2="5.643325801820698E-4" P_Q="5.775991594777485E-4" P_Z="0.0" Q="11.84685010107242" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2443" TOTAL_2="2380" UNITS="" WEIGHT="100.0" Z="21.118270239105776">
<NAME>Change in morning PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="17.176580266787877" CI_END="24.653883302883095" CI_START="14.829657613661816" DF="3.0" EFFECT_SIZE="19.741770458272455" ESTIMABLE="YES" I2="82.53435810036814" ID="CMP-003.08.01" NO="1" P_CHI2="6.500350068764371E-4" P_Z="3.35091302682206E-15" STUDIES="4" TAU2="0.0" TOTAL_1="406" TOTAL_2="335" WEIGHT="26.307726401697" Z="7.87709083917388">
<NAME>Children</NAME>
<CONT_DATA CI_END="18.006783096727546" CI_START="3.593216903272454" EFFECT_SIZE="10.8" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="7.2" ORDER="532" SD_1="32.16" SD_2="23.11" SE="3.676997717087524" STUDY_ID="STD-Levy-2006" TOTAL_1="153" TOTAL_2="79" WEIGHT="12.221853803423521"/>
<CONT_DATA CI_END="52.44234526644513" CI_START="27.55765473355487" EFFECT_SIZE="40.0" ESTIMABLE="YES" MEAN_1="57.0" MEAN_2="17.0" ORDER="533" SD_1="46.0" SD_2="38.0" SE="6.348251990643074" STUDY_ID="STD-Katz-1998" TOTAL_1="86" TOTAL_2="92" WEIGHT="4.1002986465040685"/>
<CONT_DATA CI_END="29.80095862074706" CI_START="10.199041379252941" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="14.0" ORDER="534" SD_1="35.78" SD_2="26.5" SE="5.000580979066845" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="6.608195390510654"/>
<CONT_DATA CI_END="40.70945285234023" CI_START="13.29054714765977" EFFECT_SIZE="27.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="13.0" ORDER="535" SD_1="46.0" SD_2="46.0" SE="6.994747332338065" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="3.3773785612587544"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="25.522016021242962" CI_END="32.72542828247419" CI_START="26.855551143751818" DF="21.0" EFFECT_SIZE="29.790489713113004" ESTIMABLE="YES" I2="17.718098826829014" ID="CMP-003.08.02" MODIFIED="2009-05-21 09:33:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.22526351737788408" P_Z="0.0" STUDIES="23" TAU2="0.0" TOTAL_1="2037" TOTAL_2="2045" WEIGHT="73.692273598303" Z="19.8942109143433">
<NAME>Adults</NAME>
<CONT_DATA CI_END="46.86061365312789" CI_START="13.139386346872108" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="1.0" ORDER="77" SD_1="59.81" SD_2="42.72" SE="8.6025119778334" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="2.232920356093178"/>
<CONT_DATA CI_END="32.762772649517416" CI_START="11.43722735048258" EFFECT_SIZE="22.099999999999998" ESTIMABLE="YES" MEAN_1="34.3" MEAN_2="12.2" ORDER="536" SD_1="61.91" SD_2="46.37" SE="5.4402900939119325" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="5.58315504297875"/>
<CONT_DATA CI_END="25.6118008591503" CI_START="6.988199140849693" EFFECT_SIZE="16.299999999999997" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="-10.7" ORDER="537" SD_1="44.39" SD_2="50.4" SE="4.751006106541039" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="7.320700297949606"/>
<CONT_DATA CI_END="55.10018502930648" CI_START="23.69981497069353" EFFECT_SIZE="39.400000000000006" ESTIMABLE="YES" MEAN_1="46.7" MEAN_2="7.3" ORDER="538" SD_1="69.1" SD_2="49.98" SE="8.010445678159156" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="2.575196927920617"/>
<CONT_DATA CI_END="45.62218980152437" CI_START="22.377810198475625" EFFECT_SIZE="34.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="-19.0" ORDER="539" SD_1="38.0" SD_2="37.0" SE="5.929797635670209" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="4.699417823681187"/>
<CONT_DATA CI_END="46.85893116688106" CI_START="19.141068833118943" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="1.0" ORDER="540" SD_1="48.73" SD_2="48.48" SE="7.071013179935211" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="3.3049166526828624"/>
<CONT_DATA CI_END="59.56953879062149" CI_START="16.250461209378503" EFFECT_SIZE="37.91" ESTIMABLE="YES" MEAN_1="40.19" MEAN_2="2.28" ORDER="541" SD_1="55.97" SD_2="41.31" SE="11.05098816175663" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="1.3530740891041781"/>
<CONT_DATA CI_END="39.19804959823847" CI_START="8.00195040176153" EFFECT_SIZE="23.6" ESTIMABLE="YES" MEAN_1="35.13" MEAN_2="11.53" ORDER="542" SD_1="58.19" SD_2="58.55" SE="7.95833480679946" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="2.609031923164902"/>
<CONT_DATA CI_END="46.69415183644512" CI_START="13.305848163554877" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="19.0" ORDER="543" SD_1="57.0" SD_2="55.0" SE="8.517580918897725" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="2.2776724491912863"/>
<CONT_DATA CI_END="53.762964225114054" CI_START="28.237035774885946" EFFECT_SIZE="41.0" ESTIMABLE="YES" MEAN_1="17.3" MEAN_2="-23.7" ORDER="544" SD_1="40.57" SD_2="42.12" SE="6.511836097901128" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="3.8968786606759753"/>
<CONT_DATA CI_END="43.91392573846852" CI_START="16.086074261531483" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="-15.0" ORDER="545" SD_1="40.0" SD_2="40.0" SE="7.09907215041694" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="3.2788430208462853"/>
<CONT_DATA CI_END="37.08713902577375" CI_START="14.912860974226247" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="-15.0" ORDER="546" SD_1="36.0" SD_2="36.66" SE="5.656807529744266" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="5.163937772973609"/>
<CONT_DATA CI_END="55.06659625741978" CI_START="12.933403742580218" EFFECT_SIZE="34.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="0.0" ORDER="547" SD_1="52.0" SD_2="36.0" SE="10.748460902134124" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="1.4303135167149827"/>
<CONT_DATA CI_END="54.178728608364686" CI_START="25.821271391635314" EFFECT_SIZE="40.0" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="-24.0" ORDER="548" SD_1="54.0" SD_2="35.0" SE="7.234178138070234" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="3.157514889653308"/>
<CONT_DATA CI_END="31.835511785509112" CI_START="-9.835511785509112" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="-1.0" ORDER="549" SD_1="38.37" SD_2="33.57" SE="10.630558494878972" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="1.4622163704947284"/>
<CONT_DATA CI_END="53.8443041728172" CI_START="26.955695827182794" EFFECT_SIZE="40.4" ESTIMABLE="YES" MEAN_1="20.4" MEAN_2="-20.0" ORDER="550" SD_1="49.0" SD_2="48.48" SE="6.859464907959615" STUDY_ID="STD-Lumry-2006" TOTAL_1="100" TOTAL_2="102" WEIGHT="3.511909594923774"/>
<CONT_DATA CI_END="40.230840521633844" CI_START="12.169159478366154" EFFECT_SIZE="26.2" ESTIMABLE="YES" MEAN_1="27.2" MEAN_2="1.0" ORDER="551" SD_1="50.94" SD_2="43.84" SE="7.158723646101318" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="3.2244274539543984"/>
<CONT_DATA CI_END="46.93105587629842" CI_START="13.668944123701586" EFFECT_SIZE="30.300000000000004" ESTIMABLE="YES" MEAN_1="41.7" MEAN_2="11.4" MODIFIED="2009-05-21 09:33:03 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="552" SD_1="59.7" SD_2="59.7" SE="8.485388510953296" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="2.2949875905622172"/>
<CONT_DATA CI_END="40.82088058290984" CI_START="17.979119417090157" EFFECT_SIZE="29.4" ESTIMABLE="YES" MEAN_1="13.9" MEAN_2="-15.5" ORDER="553" SD_1="39.4" SD_2="38.34" SE="5.827086963330086" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="87" WEIGHT="4.86654569747025"/>
<CONT_DATA CI_END="48.29992732516264" CI_START="17.70007267483736" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="12.0" ORDER="554" SD_1="53.3" SD_2="42.7" SE="7.806228811267203" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="2.711697564758845"/>
<CONT_DATA CI_END="47.55412276166867" CI_START="22.445877238331327" EFFECT_SIZE="35.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="7.0" ORDER="555" SD_1="44.2" SD_2="36.2" SE="6.405282372887457" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="4.027608462408517"/>
<CONT_DATA CI_END="45.30667456090534" CI_START="14.693325439094657" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="-12.0" ORDER="557" SD_1="48.37" SD_2="41.53" SE="7.809671341740174" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.709307440099547"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="25.0" MEAN_2="-9.0" ORDER="558" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.681115852761252" CI_END="6.050044019614279" CI_START="2.922774412557934" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="4.486409216086106" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.7817585345542917" LOG_CI_START="0.4657952966567784" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6518988840892829" MODIFIED="2008-07-10 14:05:14 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.40920311137779963" P_Q="0.40920311137779963" P_Z="1.8705735140158728E-8" Q="0.681115852761252" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="372" TOTAL_2="293" WEIGHT="100.0" Z="5.623564059585041">
<NAME>Change in am PEF (% predicted)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="9.919927969080108" CI_START="2.0800720309198915" DF="0.0" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.9965085186516978" LOG_CI_START="0.3180783744288121" LOG_EFFECT_SIZE="0.7781512503836436" NO="1" P_CHI2="1.0" P_Z="0.002699796063251122" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="81" WEIGHT="15.911623115894805" Z="3.0">
<NAME>Children</NAME>
<IV_DATA CI_END="9.919927969080108" CI_START="2.0800720309198915" EFFECT_SIZE="6.0" ESTIMABLE="YES" ESTIMATE="6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="559" SE="2.0" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" WEIGHT="15.911623115894805"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="5.905168666549847" CI_START="2.4948313334501533" DF="0.0" EFFECT_SIZE="4.2" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.7712323066753175" LOG_CI_START="0.39704118986804976" LOG_EFFECT_SIZE="0.6232492903979004" NO="2" P_CHI2="1.0" P_Z="1.3819787136403385E-6" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="212" WEIGHT="84.0883768841052" Z="4.827586206896552">
<NAME>Adults</NAME>
<IV_DATA CI_END="5.905168666549847" CI_START="2.4948313334501533" EFFECT_SIZE="4.2" ESTIMABLE="YES" ESTIMATE="4.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="560" SE="0.87" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" WEIGHT="84.0883768841052"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="37.458021540614546" CI_END="24.95301835588114" CI_START="19.405287736514403" CI_STUDY="95" CI_TOTAL="95" DF="19.0" EFFECT_MEASURE="MD" EFFECT_SIZE="22.179153046197772" ESTIMABLE="YES" I2="49.27655220818616" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2009-05-21 09:41:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="10" P_CHI2="0.006950833291283098" P_Q="0.6996911120412366" P_Z="2.3731003158060404E-55" Q="0.14879354947197498" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1996" TOTAL_2="2011" UNITS="" WEIGHT="200.0" Z="15.671395805123469">
<NAME>Change in evening PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0612125344805225" CI_END="28.465999190931353" CI_START="13.064669823754809" DF="1.0" EFFECT_SIZE="20.76533450734308" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" NO="1" P_CHI2="0.8045896463434962" P_Z="1.255893404293721E-7" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="164" WEIGHT="100.0" Z="5.285168155426631">
<NAME>Children</NAME>
<CONT_DATA CI_END="29.80095862074706" CI_START="10.199041379252941" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="14.0" ORDER="561" SD_1="35.78" SD_2="26.5" SE="5.000580979066845" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="61.73327463284612"/>
<CONT_DATA CI_END="34.448515465366796" CI_START="9.551484534633206" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="12.0" ORDER="562" SD_1="37.0" SD_2="46.0" SE="6.351400109164809" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="38.26672536715388"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="37.248015456662046" CI_END="25.363422441211984" CI_START="19.41647819726194" DF="17.0" EFFECT_SIZE="22.389950319236963" ESTIMABLE="YES" I2="54.35998457480386" ID="CMP-003.10.02" MODIFIED="2009-05-21 09:41:08 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.0031141729444554844" P_Z="2.7191294685797506E-49" STUDIES="18" TAU2="0.0" TOTAL_1="1829" TOTAL_2="1847" WEIGHT="100.0" Z="14.758334513053212">
<NAME>Adults</NAME>
<CONT_DATA CI_END="25.588076659827877" CI_START="6.411923340172125" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="-11.0" ORDER="564" SD_1="45.82" SD_2="51.8" SE="4.891965737869369" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="9.617556510046606"/>
<CONT_DATA CI_END="24.97636475615701" CI_START="4.423635243842989" EFFECT_SIZE="14.700000000000001" ESTIMABLE="YES" MEAN_1="26.1" MEAN_2="11.4" ORDER="563" SD_1="60.51" SD_2="43.47" SE="5.243139586857547" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="8.372375924386041"/>
<CONT_DATA CI_END="40.56177986813948" CI_START="15.43822013186052" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="5.0" ORDER="565" SD_1="53.0" SD_2="43.0" SE="6.409189131649967" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="5.603061443778179"/>
<CONT_DATA CI_END="45.438073375960585" CI_START="24.561926624039415" EFFECT_SIZE="35.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="-23.0" ORDER="566" SD_1="37.0" SD_2="30.0" SE="5.325645500782041" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="8.114972477984882"/>
<CONT_DATA CI_END="44.549087536709195" CI_START="19.450912463290805" EFFECT_SIZE="32.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="-5.0" ORDER="568" SD_1="48.73" SD_2="38.78" SE="6.402713333354488" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="5.614401212745427"/>
<CONT_DATA CI_END="53.5057496119033" CI_START="15.894250388096708" EFFECT_SIZE="34.7" ESTIMABLE="YES" MEAN_1="36.85" MEAN_2="2.15" ORDER="569" SD_1="49.7" SD_2="32.6" SE="9.594946519548648" STUDY_ID="STD-FLTA3020" TOTAL_1="37" TOTAL_2="42" WEIGHT="2.500037041204361"/>
<CONT_DATA CI_END="25.79812724730224" CI_START="-3.9181272473022393" EFFECT_SIZE="10.940000000000001" ESTIMABLE="YES" MEAN_1="29.96" MEAN_2="19.02" ORDER="570" SD_1="58.39" SD_2="52.22" SE="7.580816466272468" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="4.004973025947176"/>
<CONT_DATA CI_END="43.776252688238145" CI_START="18.82374731176186" EFFECT_SIZE="31.3" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="-13.3" ORDER="571" SD_1="42.41" SD_2="38.61" SE="6.365552013531488" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="5.68014494146695"/>
<CONT_DATA CI_END="44.788203703084015" CI_START="19.011796296915982" EFFECT_SIZE="31.9" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="-11.7" ORDER="579" SD_1="47.7" SD_2="46.9" SE="6.575734964899622" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="5.3228344480979315"/>
<CONT_DATA CI_END="38.550601447268015" CI_START="13.449398552731987" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="-15.0" ORDER="572" SD_1="36.0" SD_2="45.83" SE="6.403485750894177" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="5.613046825280119"/>
<CONT_DATA CI_END="33.81342700542571" CI_START="12.786572994574296" EFFECT_SIZE="23.3" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="-14.3" ORDER="574" SD_1="33.77" SD_2="37.59" SE="5.364091936563261" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="87" WEIGHT="7.999063320730764"/>
<CONT_DATA CI_END="40.69452606200883" CI_START="1.3054739379911666" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="8.0" ORDER="573" SD_1="47.0" SD_2="36.0" SE="10.048412224590217" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="2.2794846591415006"/>
<CONT_DATA CI_END="33.83817012451463" CI_START="3.361829875485366" EFFECT_SIZE="18.599999999999998" ESTIMABLE="YES" MEAN_1="25.4" MEAN_2="6.8" MODIFIED="2009-05-21 09:41:08 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1155" SD_1="54.7" SD_2="54.7" SE="7.774719456434594" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="3.8076945853530098"/>
<CONT_DATA CI_END="11.018117497241184" CI_START="-11.218117497241183" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="13.2" ORDER="567" SD_1="59.84" SD_2="56.93" SE="5.672613162761905" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" WEIGHT="7.152621164045063"/>
<CONT_DATA CI_END="42.29992732516264" CI_START="11.700072674837362" EFFECT_SIZE="27.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="8.0" ORDER="575" SD_1="53.3" SD_2="42.7" SE="7.806228811267203" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="3.7770175809173843"/>
<CONT_DATA CI_END="34.66664790354376" CI_START="9.33335209645624" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="8.0" ORDER="576" SD_1="45.0" SD_2="36.0" SE="6.462694214514482" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="5.510669244271456"/>
<CONT_DATA CI_END="35.85829627531074" CI_START="8.14170372468926" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="-7.0" ORDER="578" SD_1="40.31" SD_2="41.53" SE="7.070689249712348" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="4.603711060610912"/>
<CONT_DATA CI_END="34.13324065792395" CI_START="5.866759342076051" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="5.0" ORDER="577" SD_1="51.26" SD_2="34.18" SE="7.210969573627448" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="4.426334533992237"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="38.57335074731159" CI_END="25.16252717181759" CI_START="19.69147353192346" CI_STUDY="95" CI_TOTAL="95" DF="20.0" EFFECT_SIZE="22.427000351870525" ESTIMABLE="YES" I2="48.15073201439748" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="1.4007542568709412" LOG_CI_START="1.2942782160283546" LOG_DATA="NO" LOG_EFFECT_SIZE="1.3507711898670705" MODIFIED="2009-05-21 09:42:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="11" P_CHI2="0.007530272922728454" P_Q="0.6509175727285668" P_Z="4.234775550740342E-58" Q="0.20474526812510163" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2082" TOTAL_2="2090" WEIGHT="99.99999999999999" Z="16.06860976482181">
<NAME>Change in evening PEFR compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.06123464349955988" CI_END="28.464895787862748" CI_START="13.065970299626247" DF="1.0" EFFECT_SIZE="20.765433043744498" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="1.454309598165518" LOG_CI_START="1.1161416666562511" LOG_EFFECT_SIZE="1.3173409923468191" NO="1" P_CHI2="0.8045550742596689" P_Z="1.250074006918999E-7" STUDIES="2" TAU2="0.0" TOTAL_1="167" TOTAL_2="164" WEIGHT="12.622957222041233" Z="5.286018290069422">
<NAME>Children</NAME>
<IV_DATA CI_END="29.799819922700273" CI_START="10.200180077299729" EFFECT_SIZE="20.0" ESTIMABLE="YES" ESTIMATE="20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="580" SE="5.0" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="7.791942938279424"/>
<IV_DATA CI_END="34.445771301829346" CI_START="9.554228698170656" EFFECT_SIZE="22.0" ESTIMABLE="YES" ESTIMATE="22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="581" SE="6.35" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="4.83101428376181"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="38.30737083568693" CI_END="25.59349736575614" CI_START="19.740581225384137" DF="18.0" EFFECT_SIZE="22.667039295570138" ESTIMABLE="YES" I2="53.01165387411213" ID="CMP-003.11.02" LOG_CI_END="1.4081296365267324" LOG_CI_START="1.2953599355302223" LOG_EFFECT_SIZE="1.3553947975165612" MODIFIED="2009-05-21 09:42:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.003526350527005895" P_Z="4.7247163704059025E-52" STUDIES="19" TAU2="0.0" TOTAL_1="1915" TOTAL_2="1926" WEIGHT="87.37704277795875" Z="15.181007070655868">
<NAME>Adults</NAME>
<IV_DATA CI_END="25.588143812369946" CI_START="6.411856187630054" EFFECT_SIZE="16.0" ESTIMABLE="YES" ESTIMATE="16.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="583" SE="4.892" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="8.139783905414415"/>
<IV_DATA CI_END="24.978051134928045" CI_START="4.421948865071956" EFFECT_SIZE="14.7" ESTIMABLE="YES" ESTIMATE="14.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="582" SE="5.244" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="7.083704010750784"/>
<IV_DATA CI_END="40.55944921293267" CI_START="15.440550787067332" EFFECT_SIZE="28.0" ESTIMABLE="YES" ESTIMATE="28.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="584" SE="6.408" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="4.743957241752116"/>
<IV_DATA CI_END="45.439748163652595" CI_START="24.5602518363474" EFFECT_SIZE="35.0" ESTIMABLE="YES" ESTIMATE="35.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="585" SE="5.3265" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="6.865970125356088"/>
<IV_DATA CI_END="43.83818246662193" CI_START="20.16181753337807" EFFECT_SIZE="32.0" ESTIMABLE="YES" ESTIMATE="32.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="587" SE="6.04" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="5.339638981212052"/>
<IV_DATA CI_END="53.496054611739126" CI_START="15.903945388260883" EFFECT_SIZE="34.7" ESTIMABLE="YES" ESTIMATE="34.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="588" SE="9.59" STUDY_ID="STD-FLTA3020" TOTAL_1="42" TOTAL_2="37" WEIGHT="2.118110230144861"/>
<IV_DATA CI_END="25.79848696679815" CI_START="-3.9184869667981523" EFFECT_SIZE="10.94" ESTIMABLE="YES" ESTIMATE="10.94" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="589" SE="7.581" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="3.389477683701432"/>
<IV_DATA CI_END="43.77909068956653" CI_START="18.820909310433475" EFFECT_SIZE="31.3" ESTIMABLE="YES" ESTIMATE="31.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="590" SE="6.367" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="4.805250940823114"/>
<IV_DATA CI_END="44.79656301827356" CI_START="19.00343698172644" EFFECT_SIZE="31.9" ESTIMABLE="YES" ESTIMATE="31.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="599" SE="6.58" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="4.499186386327399"/>
<IV_DATA CI_END="38.54984538940842" CI_START="13.450154610591579" EFFECT_SIZE="26.0" ESTIMABLE="YES" ESTIMATE="26.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="591" SE="6.4031" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="4.751220687521336"/>
<IV_DATA CI_END="33.80971887790068" CI_START="12.790281122099323" EFFECT_SIZE="23.3" ESTIMABLE="YES" ESTIMATE="23.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="594" SE="5.3622" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="87" WEIGHT="6.77485111446114"/>
<IV_DATA CI_END="40.689602192290934" CI_START="1.3103978077090694" EFFECT_SIZE="21.0" ESTIMABLE="YES" ESTIMATE="21.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="592" SE="10.0459" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="1.9302255973998173"/>
<IV_DATA CI_END="49.61965785313052" CI_START="12.380342146869484" EFFECT_SIZE="31.0" ESTIMABLE="YES" ESTIMATE="31.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="593" SE="9.5" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="2.158432946891807"/>
<IV_DATA CI_END="33.8396999617912" CI_START="3.360300038208809" EFFECT_SIZE="18.6" ESTIMABLE="YES" ESTIMATE="18.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:42:19 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1156" SE="7.7755" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="3.2220265943438617"/>
<IV_DATA CI_END="11.018875684295729" CI_START="-11.218875684295728" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="586" SE="5.673" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" WEIGHT="6.05285409096809"/>
<IV_DATA CI_END="42.29967485971812" CI_START="11.700325140281883" EFFECT_SIZE="27.0" ESTIMABLE="YES" ESTIMATE="27.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="595" SE="7.8061" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="3.1968153444331096"/>
<IV_DATA CI_END="34.66959918886382" CI_START="9.330400811136181" EFFECT_SIZE="22.0" ESTIMABLE="YES" ESTIMATE="22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="596" SE="6.4642" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="4.661827531491222"/>
<IV_DATA CI_END="35.85968932027654" CI_START="8.140310679723461" EFFECT_SIZE="22.0" ESTIMABLE="YES" ESTIMATE="22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="598" SE="7.0714" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="3.8956054411689447"/>
<IV_DATA CI_END="34.129772357346155" CI_START="5.870227642653841" EFFECT_SIZE="20.0" ESTIMABLE="YES" ESTIMATE="20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="597" SE="7.2092" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="82" WEIGHT="3.748103923797161"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.12" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="87" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in clinic PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="41.41482964110306" CI_START="10.585170358896937" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="22.0" ORDER="600" SD_1="47.0" SD_2="56.0" SE="7.864853519091816" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.12.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.4986941702447876" CI_END="128.24527132016982" CI_START="7.886108432829175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="68.06568987649949" ESTIMABLE="YES" I2="59.97909580498866" I2_Q="0.0" ID="CMP-003.13" NO="13" P_CHI2="0.11394101781967825" P_Q="1.0" P_Z="0.02663652910064895" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="2.2168033997658063">
<NAME>Peak flow L/min (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4986941702447876" CI_END="128.24527132016982" CI_START="7.886108432829175" DF="1.0" EFFECT_SIZE="68.06568987649949" ESTIMABLE="YES" I2="59.97909580498866" ID="CMP-003.13.02" NO="2" P_CHI2="0.11394101781967825" P_Z="0.02663652910064895" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="2.2168033997658063">
<NAME>Adults</NAME>
<CONT_DATA CI_END="272.2182254941696" CI_START="31.781774505830384" EFFECT_SIZE="152.0" ESTIMABLE="YES" MEAN_1="481.0" MEAN_2="329.0" ORDER="601" SD_1="146.0" SD_2="112.0" SE="61.33695641472784" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="25.058651675445972"/>
<CONT_DATA CI_END="109.51658216881215" CI_START="-29.51658216881215" EFFECT_SIZE="40.0" ESTIMABLE="YES" MEAN_1="451.0" MEAN_2="411.0" ORDER="602" SD_1="108.0" SD_2="92.0" SE="35.4682957019364" STUDY_ID="STD-Li-1999a" TOTAL_1="16" TOTAL_2="16" WEIGHT="74.94134832455403"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.14" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="80" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FVC compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.14.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.14.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.5796714576729997" CI_START="0.20032854232700034" EFFECT_SIZE="0.39" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="-0.31" ORDER="603" SD_1="0.56" SD_2="0.66" SE="0.09677293009927933" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.758078885814215" CI_END="0.3392789336632863" CI_START="0.15726073748316785" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2482698355732271" ESTIMABLE="YES" I2="73.39065968586387" I2_Q="0.0" ID="CMP-003.15" MODIFIED="2008-07-10 11:05:39 +0100" MODIFIED_BY="Christopher J Cates" NO="15" P_CHI2="0.05255296398280507" P_Q="1.0" P_Z="8.95636464189873E-8" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1035" TOTAL_2="388" UNITS="" WEIGHT="100.0" Z="5.346717486307632">
<NAME>Change in FEF25-75 compared to baseline (L/second)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.15.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.758078885814215" CI_END="0.3392789336632863" CI_START="0.15726073748316785" DF="1.0" EFFECT_SIZE="0.2482698355732271" ESTIMABLE="YES" I2="73.39065968586387" ID="CMP-003.15.02" NO="2" P_CHI2="0.05255296398280507" P_Z="8.95636464189873E-8" STUDIES="2" TAU2="0.0" TOTAL_1="1035" TOTAL_2="388" WEIGHT="100.0" Z="5.346717486307632">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.6926090013079389" CI_START="0.22739099869206097" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.16" ORDER="604" SD_1="0.78" SD_2="0.72" SE="0.1186802426691149" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="15.307934229290822"/>
<CONT_DATA CI_END="0.3088925208225678" CI_START="0.11110747917743224" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="-0.05" ORDER="605" SD_1="0.77" SD_2="0.77" SE="0.05045629491287562" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="84.69206577070918"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.16" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Histamine BHR (log base 2 PC20 FEV1 mg/ml)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.16.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="2.157845100996403" CI_START="0.30215489900359715" EFFECT_SIZE="1.23" ESTIMABLE="YES" MEAN_1="3.15" MEAN_2="1.92" ORDER="606" SD_1="1.24" SD_2="1.52" SE="0.4733990564699793" STUDY_ID="STD-Hoekstra-1996" TOTAL_1="15" TOTAL_2="19" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.16.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="53.23461985731092" CI_END="-0.38438634984698805" CI_START="-0.4965734920587742" CI_STUDY="95" CI_TOTAL="95" DF="25.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.44047992095288113" ESTIMABLE="YES" I2="53.03807922925056" I2_Q="68.30124613022255" ID="CMP-003.17" MODIFIED="2009-05-21 10:15:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="17" P_CHI2="8.341990099951513E-4" P_Q="0.0757090179634613" P_Z="1.8869288983685892E-53" Q="3.1546981439968533" RANDOM="NO" SCALE="1.415839254442743" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2631" TOTAL_2="2462" UNITS="" WEIGHT="100.0" Z="15.390797268922645">
<NAME>Change in daily asthma symptom score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.44646045189307" CI_END="-0.21695660143281653" CI_START="-0.46426997434416756" DF="4.0" EFFECT_SIZE="-0.34061328788849204" ESTIMABLE="YES" I2="61.7095185644901" ID="CMP-003.17.01" MODIFIED="2008-07-04 14:32:15 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.03354256746414541" P_Z="6.711212838149492E-8" STUDIES="5" TAU2="0.0" TOTAL_1="631" TOTAL_2="452" WEIGHT="20.577422250646382" Z="5.398735774442036">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.2666675468409141" CI_START="-0.8665536394446367" EFFECT_SIZE="-0.5666105931427754" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="-0.01" ORDER="608" SD_1="0.74" SD_2="0.77" SE="0.15303497853418419" STUDY_ID="STD-Katz-1998" TOTAL_1="86" TOTAL_2="92" WEIGHT="3.4974263935194476"/>
<CONT_DATA CI_END="-0.22972143784018562" CI_START="-0.8653482707105195" EFFECT_SIZE="-0.5475348542753525" ESTIMABLE="YES" MEAN_1="-0.38" MEAN_2="-0.01" ORDER="609" SD_1="0.72" SD_2="0.62" SE="0.16215268185642112" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="3.115169809401161"/>
<CONT_DATA CI_END="0.06242293984055167" CI_START="-0.49246439830842004" EFFECT_SIZE="-0.2150207292339342" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.16" ORDER="607" SD_1="0.97" SD_2="0.84" SE="0.14155549350035312" STUDY_ID="STD-Levy-2006" TOTAL_1="144" TOTAL_2="77" WEIGHT="4.087676710917936"/>
<CONT_DATA CI_END="-0.21807347517869846" CI_START="-0.8244052747619771" EFFECT_SIZE="-0.5212393749703378" ESTIMABLE="YES" MEAN_1="-0.41" MEAN_2="-0.02" ORDER="610" SD_1="0.65" SD_2="0.83" SE="0.15467932175436552" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="3.423461741820603"/>
<CONT_DATA CI_END="0.11881345617331432" CI_START="-0.3227967642093167" EFFECT_SIZE="-0.10199165401800117" ESTIMABLE="YES" MEAN_1="-0.93" MEAN_2="-0.77" MODIFIED="2008-07-04 14:32:15 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="3008" SD_1="1.68" SD_2="1.31" SE="0.1126577385773402" STUDY_ID="STD-Qaquandah-2006" TOTAL_1="234" TOTAL_2="119" WEIGHT="6.453687594987235"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="39.633461261421" CI_END="-0.4034120674522684" CI_START="-0.529296230259136" DF="20.0" EFFECT_SIZE="-0.4663541488557022" ESTIMABLE="YES" I2="49.53758929082509" ID="CMP-003.17.02" MODIFIED="2009-05-21 10:15:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.005556111577318501" P_Z="8.806184828513628E-48" STUDIES="21" TAU2="0.0" TOTAL_1="2000" TOTAL_2="2010" WEIGHT="79.42257774935362" Z="14.521879725257104">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.20337550404530638" CI_START="-0.5989336325125054" EFFECT_SIZE="-0.4011545682789059" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="0.28" ORDER="612" SD_1="0.86" SD_2="0.98" SE="0.10090954006994798" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="8.043879268142932"/>
<CONT_DATA CI_END="-0.1282934542905032" CI_START="-0.5191495505526039" EFFECT_SIZE="-0.32372150242155356" ESTIMABLE="YES" MEAN_1="-0.64" MEAN_2="-0.34" ORDER="611" SD_1="0.98" SD_2="0.87" SE="0.09971002001698086" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="8.238580510702462"/>
<CONT_DATA CI_END="-0.01363795925725031" CI_START="-0.5364905795739685" EFFECT_SIZE="-0.2750642694156094" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.43" ORDER="613" SD_1="0.74" SD_2="0.85" SE="0.13338322143695316" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="4.603918136156361"/>
<CONT_DATA CI_END="-0.3689208219940863" CI_START="-1.0072423624195908" EFFECT_SIZE="-0.6880815922068385" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="0.1" ORDER="614" SD_1="0.39" SD_2="0.5" SE="0.1628401198849834" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="3.088923623924315"/>
<CONT_DATA CI_END="-0.22675482815371079" CI_START="-0.8218468919388431" EFFECT_SIZE="-0.524300860046277" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="0.0" ORDER="616" SD_1="0.49" SD_2="0.37" SE="0.15181198952611952" STUDY_ID="STD-FLTA3014" TOTAL_1="94" TOTAL_2="86" WEIGHT="3.554003518318138"/>
<CONT_DATA CI_END="-0.0035478004156422327" CI_START="-0.9008230498961165" EFFECT_SIZE="-0.45218542515587934" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="-0.07" ORDER="617" SD_1="0.96" SD_2="0.66" SE="0.22890095342518202" STUDY_ID="STD-FLTA3020" TOTAL_1="36" TOTAL_2="43" WEIGHT="1.5632728803446778"/>
<CONT_DATA CI_END="0.11891439470348375" CI_START="-0.4163934351482197" EFFECT_SIZE="-0.14873952022236797" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.51" ORDER="618" SD_1="0.9" SD_2="0.97" SE="0.13656062919373602" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="4.392168357741983"/>
<CONT_DATA CI_END="-0.2253362610438357" CI_START="-0.831959476497397" EFFECT_SIZE="-0.5286478687706163" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.2" ORDER="619" SD_1="0.57" SD_2="0.56" SE="0.1547536639036553" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="3.420173336673742"/>
<CONT_DATA CI_END="-0.3813418899200984" CI_START="-1.0170250074189031" EFFECT_SIZE="-0.6991834486695008" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.4" ORDER="620" SD_1="0.83" SD_2="0.88" SE="0.16216704044385308" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="3.1146181873485506"/>
<CONT_DATA CI_END="-0.16328217533916706" CI_START="-0.8708737390103201" EFFECT_SIZE="-0.5170779571747436" ESTIMABLE="YES" MEAN_1="-0.17" MEAN_2="0.06" ORDER="621" SD_1="0.4" SD_2="0.48" SE="0.18051136889569017" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="2.513743020133534"/>
<CONT_DATA CI_END="-0.4065715977377068" CI_START="-0.9676366335560745" EFFECT_SIZE="-0.6871041156468907" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="0.38" ORDER="626" SD_1="1.01" SD_2="1.02" SE="0.14313146574222207" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="3.9981562229461787"/>
<CONT_DATA CI_END="-0.2126124543640449" CI_START="-0.8336460015867933" EFFECT_SIZE="-0.523129227975419" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.12" ORDER="622" SD_1="0.45" SD_2="0.73" SE="0.15842983649734935" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="3.263292847162102"/>
<CONT_DATA CI_END="0.04840647199906417" CI_START="-0.9002036072424209" EFFECT_SIZE="-0.4258985676216783" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.02" ORDER="623" SD_1="0.34" SD_2="0.48" SE="0.24199681390168395" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="1.3986553172786185"/>
<CONT_DATA CI_END="-0.7321593853300525" CI_START="-1.3976581028624406" EFFECT_SIZE="-1.0649087440962466" ESTIMABLE="YES" MEAN_1="-0.17" MEAN_2="0.21" ORDER="624" SD_1="0.36" SD_2="0.35" SE="0.16977320062556175" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="78" WEIGHT="2.8417883179671373"/>
<CONT_DATA CI_END="0.7843777889596709" CI_START="-0.3748539794358613" EFFECT_SIZE="0.20476190476190478" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="625" SD_1="0.48" SD_2="0.48" SE="0.2957278239649821" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.9365816006928536"/>
<CONT_DATA CI_END="-0.02203036692814664" CI_START="-0.6168624826213044" EFFECT_SIZE="-0.3194464247747255" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.0" ORDER="627" SD_1="0.94" SD_2="0.93" SE="0.15174567501880584" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="3.557110473294927"/>
<CONT_DATA CI_END="0.0010286260408032821" CI_START="-0.5588830321710714" EFFECT_SIZE="-0.2789272030651341" ESTIMABLE="YES" MEAN_1="-0.61" MEAN_2="-0.33" MODIFIED="2009-05-21 10:15:27 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1161" SD_1="1.0" SD_2="1.0" SE="0.14283723135434795" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="4.014645014869228"/>
<CONT_DATA CI_END="-0.2854996102385349" CI_START="-0.6716992756820018" EFFECT_SIZE="-0.47859944296026835" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="615" SD_1="1.46" SD_2="1.46" SE="0.09852213318452804" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" WEIGHT="8.438444220174947"/>
<CONT_DATA CI_END="-0.379064614741295" CI_START="-1.0355359584144326" EFFECT_SIZE="-0.7073002865778638" ESTIMABLE="YES" MEAN_1="-0.56" MEAN_2="-0.19" ORDER="628" SD_1="0.53" SD_2="0.51" SE="0.16747025681372205" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="2.920482608993459"/>
<CONT_DATA CI_END="-0.24468613092271996" CI_START="-0.9373066932398046" EFFECT_SIZE="-0.5909964120812623" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="0.14" ORDER="630" SD_1="0.58" SD_2="0.66" SE="0.17669216571844873" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.623586630888131"/>
<CONT_DATA CI_END="-0.17064201660701706" CI_START="-0.8298193972342458" EFFECT_SIZE="-0.5002307069206314" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.12" ORDER="629" SD_1="0.6" SD_2="0.51" SE="0.16816058504817838" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="2.8965536555993414"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.77514770930788" CI_END="-0.32075388767784996" CI_START="-0.5891492944340154" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4549515910559327" ESTIMABLE="YES" I2="66.15939076635993" I2_Q="0.0" ID="CMP-003.18" MODIFIED="2009-05-21 10:15:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="18" P_CHI2="0.011367580448939929" P_Q="0.7439483396879552" P_Z="3.040620346188714E-11" Q="0.10668667743604487" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="447" TOTAL_2="437" UNITS="" WEIGHT="100.0" Z="6.644590113935244">
<NAME>Change in night-time wakening score</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.10879158704439568" CI_START="-0.7112291156809589" DF="0.0" EFFECT_SIZE="-0.41001035136267727" ESTIMABLE="YES" I2="0.0" ID="CMP-003.18.01" NO="1" P_CHI2="1.0" P_Z="0.007633905441606871" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="86" WEIGHT="19.84842825477778" Z="2.667846818169449">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.10879158704439568" CI_START="-0.7112291156809589" EFFECT_SIZE="-0.41001035136267727" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="0.07" ORDER="657" SD_1="0.2" SD_2="0.4" SE="0.15368586703340303" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="19.84842825477778"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.668461031871836" CI_END="-0.316185006416725" CI_START="-0.6159763286498398" DF="4.0" EFFECT_SIZE="-0.46608066753328237" ESTIMABLE="YES" I2="72.73060894862287" ID="CMP-003.18.02" NO="2" P_CHI2="0.005440654671345024" P_Z="1.099531389513294E-9" STUDIES="5" TAU2="0.0" TOTAL_1="360" TOTAL_2="351" WEIGHT="80.15157174522223" Z="6.094247928532707">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.2106896946903462" CI_START="-0.8413786513775436" EFFECT_SIZE="-0.526034173033945" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.14" ORDER="658" SD_1="0.25" SD_2="0.38" SE="0.16089299641778917" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="18.11005232590987"/>
<CONT_DATA CI_END="0.2980315837465267" CI_START="-0.2980315837465267" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.2" ORDER="659" SD_1="0.37" SD_2="0.47" SE="0.1520597246160449" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="20.275220485394065"/>
<CONT_DATA CI_END="0.07844986897195533" CI_START="-0.8686078836660429" EFFECT_SIZE="-0.39507900734704376" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.02" ORDER="660" SD_1="0.17" SD_2="0.18" SE="0.2416008049403634" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="8.031510494758285"/>
<CONT_DATA CI_END="-0.40992076556818124" CI_START="-1.0594207263200577" EFFECT_SIZE="-0.7346707459441195" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.21" ORDER="661" SD_1="0.18" SD_2="0.43" SE="0.16569181012382098" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="17.076226237588592"/>
<CONT_DATA CI_END="-0.3982841027015313" CI_START="-1.0558758008710238" EFFECT_SIZE="-0.7270799517862776" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="0.0" ORDER="662" SD_1="0.26" SD_2="0.34" SE="0.1677560667840052" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="16.658562201571424"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.19" MODIFIED="2009-05-21 10:15:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="113" TOTAL_2="114" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in symptom free days</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.19.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.19.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="31.14477818006752" CI_START="12.655221819932477" EFFECT_SIZE="21.9" ESTIMABLE="YES" MEAN_1="28.8" MEAN_2="6.9" ORDER="663" SD_1="42.52" SD_2="26.69" SE="4.71681023375386" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.009712814241718" CI_END="11.949278421698894" CI_START="4.94232349932882" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.445800960513857" ESTIMABLE="YES" I2="62.545473607170635" I2_Q="0.0" ID="CMP-003.20" MODIFIED="2009-05-21 10:15:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="20" P_CHI2="0.04581151294998109" P_Q="1.0" P_Z="2.3026579619701E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="591" TOTAL_2="587" UNITS="" WEIGHT="100.0" Z="4.724867188842087">
<NAME>Change from baseline in symptom free days (%)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.20.01" MODIFIED="2008-07-04 14:37:24 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.009712814241718" CI_END="11.949278421698894" CI_START="4.94232349932882" DF="3.0" EFFECT_SIZE="8.445800960513857" ESTIMABLE="YES" I2="62.545473607170635" ID="CMP-003.20.02" NO="2" P_CHI2="0.04581151294998109" P_Z="2.3026579619701E-6" STUDIES="4" TAU2="0.0" TOTAL_1="591" TOTAL_2="587" WEIGHT="100.0" Z="4.724867188842087">
<NAME>Adults</NAME>
<CONT_DATA CI_END="17.275466969525628" CI_START="3.924533030474376" EFFECT_SIZE="10.600000000000001" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="-2.7" ORDER="665" SD_1="31.5" SD_2="36.4" SE="3.4059130791080126" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="27.544529165799908"/>
<CONT_DATA CI_END="9.020006698983291" CI_START="-1.020006698983292" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="8.1" ORDER="664" SD_1="28.14" SD_2="23.19" SE="2.561274971673186" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="48.7068521208246"/>
<CONT_DATA CI_END="20.95310885975809" CI_START="1.046891140241911" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="-3.8" ORDER="666" SD_1="37.71" SD_2="26.41" SE="5.078210078484575" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="12.390280764731079"/>
<CONT_DATA CI_END="29.895417467818966" CI_START="9.104582532181032" EFFECT_SIZE="19.5" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="-8.0" ORDER="667" SD_1="38.57" SD_2="37.73" SE="5.303881882430847" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="11.35833794864442"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.119438105000663" CI_END="16.461507788578736" CI_START="4.840360996834257" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.650934392706496" ESTIMABLE="YES" I2="87.683876801966" I2_Q="0.0" ID="CMP-003.21" MODIFIED="2009-05-21 10:15:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="21" P_CHI2="0.004379342141837106" P_Q="1.0" P_Z="3.273123720058475E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="3.5926657128594903">
<NAME>Percentage nights without awakening - change from baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.21.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.119438105000663" CI_END="16.461507788578736" CI_START="4.840360996834257" DF="1.0" EFFECT_SIZE="10.650934392706496" ESTIMABLE="YES" I2="87.683876801966" ID="CMP-003.21.02" NO="2" P_CHI2="0.004379342141837106" P_Z="3.273123720058475E-4" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="100" WEIGHT="100.0" Z="3.5926657128594903">
<NAME>Adults</NAME>
<CONT_DATA CI_END="27.021398752224737" CI_START="10.77860124777526" EFFECT_SIZE="18.9" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="-16.5" ORDER="668" SD_1="21.57" SD_2="30.01" SE="4.1436469324361545" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="51.18896090358875"/>
<CONT_DATA CI_END="10.316870989086013" CI_START="-6.316870989086013" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="2.0" ORDER="669" SD_1="14.39" SD_2="14.39" SE="4.24337949813794" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="48.81103909641124"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.720714334064844" CI_END="-0.12010649723361996" CI_START="-0.22533439648044093" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17272044685703045" ESTIMABLE="YES" I2="69.13807054809818" I2_Q="0.0" ID="CMP-003.22" MODIFIED="2009-05-21 10:28:24 +0100" MODIFIED_BY="Toby J Lasserson" NO="22" P_CHI2="0.02109565139420244" P_Q="1.0" P_Z="1.241691267262476E-10" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="397" UNITS="" WEIGHT="100.0" Z="6.43414641281402">
<NAME>Change in number night-time awakenings per week</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.720714334064844" CI_END="-0.12010649723361996" CI_START="-0.22533439648044093" DF="3.0" EFFECT_SIZE="-0.17272044685703045" ESTIMABLE="YES" I2="69.13807054809818" ID="CMP-003.22.02" NO="2" P_CHI2="0.02109565139420244" P_Z="1.241691267262476E-10" STUDIES="5" TAU2="0.0" TOTAL_1="405" TOTAL_2="397" WEIGHT="100.0" Z="6.43414641281402">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.07032566591634443" CI_START="-0.2696743340836556" EFFECT_SIZE="-0.17" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.14" ORDER="670" SD_1="0.25" SD_2="0.38" SE="0.05085518655948477" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="27.863465052179638"/>
<CONT_DATA CI_END="0.12597158192890642" CI_START="-0.12597158192890642" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.2" ORDER="671" SD_1="0.37" SD_2="0.47" SE="0.06427239629021461" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="17.44442435791584"/>
<CONT_DATA CI_END="-0.13508546331626758" CI_START="-0.3449145366837324" EFFECT_SIZE="-0.24" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.21" ORDER="672" SD_1="0.18" SD_2="0.43" SE="0.053528808443055534" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="25.149564852675518"/>
<CONT_DATA CI_END="-0.12319964581740996" CI_START="-0.31680035418259006" EFFECT_SIZE="-0.22" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="0.0" ORDER="673" SD_1="0.26" SD_2="0.34" SE="0.049388843339030146" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="29.54254573722901"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.21" MEAN_2="0.14" ORDER="674" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wasserman-1996" TOTAL_1="79" TOTAL_2="82" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.37706263985526" CI_END="-0.08194859456595274" CI_START="-0.15654564154462883" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11924711805529079" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.23" MODIFIED="2009-05-21 10:15:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="23" P_CHI2="0.6140508967885927" P_Q="0.3685848816866193" P_Z="3.6996200308894134E-10" Q="0.808430011475866" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="917" TOTAL_2="943" UNITS="" WEIGHT="99.99999999999999" Z="6.266201307281668">
<NAME>Change from baseline in nighttime awakenings/night</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.043862011817923256" CI_START="-0.15613798818207675" DF="0.0" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.01" NO="1" P_CHI2="1.0" P_Z="4.806172123049562E-4" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="78" WEIGHT="44.14378729933344" Z="3.4913327819713618">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.043862011817923256" CI_START="-0.15613798818207675" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="0.04" ORDER="675" SD_1="0.18" SD_2="0.18" SE="0.028642357015172745" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="44.14378729933344"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.568632628379394" CI_END="-0.08455196965464368" CI_START="-0.18436469019279744" DF="6.0" EFFECT_SIZE="-0.13445832992372056" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.02" NO="2" P_CHI2="0.6002022356425301" P_Z="1.2879028327541602E-7" STUDIES="7" TAU2="0.0" TOTAL_1="837" TOTAL_2="865" WEIGHT="55.856212700666546" Z="5.280559084073055">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.05619088840567296" CI_START="-0.443809111594327" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="-0.26" MEAN_2="-0.01" ORDER="677" SD_1="1.0" SD_2="0.98" SE="0.09888401681003763" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="3.7036922987591456"/>
<CONT_DATA CI_END="0.10125009475867677" CI_START="-0.34125009475867674" EFFECT_SIZE="-0.12" ESTIMABLE="YES" MEAN_1="-0.37" MEAN_2="-0.25" ORDER="676" SD_1="1.12" SD_2="1.16" SE="0.11288477569173172" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="2.8419494532676777"/>
<CONT_DATA CI_END="0.0029376594137796586" CI_START="-0.30293765941377965" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="-0.17" ORDER="678" SD_1="0.64" SD_2="0.53" SE="0.07803085190346985" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="5.947773222272645"/>
<CONT_DATA CI_END="0.09454788866610264" CI_START="-0.15454788866610264" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.02" ORDER="679" SD_1="0.24" SD_2="0.32" SE="0.06354600882899915" STUDY_ID="STD-FLTA3020" TOTAL_1="36" TOTAL_2="42" WEIGHT="8.968308529113946"/>
<CONT_DATA CI_END="0.09499792685889269" CI_START="-0.29499792685889276" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.3" ORDER="680" SD_1="0.8" SD_2="0.64" SE="0.09949056635581648" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="3.6586704420613048"/>
<CONT_DATA CI_END="-0.06689602775885685" CI_START="-0.23310397224114315" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="0.13" ORDER="682" SD_1="0.3" SD_2="0.31" SE="0.042400764961324125" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="20.143721773731343"/>
<CONT_DATA CI_END="-0.04539576519794861" CI_START="-0.27460423480205143" EFFECT_SIZE="-0.16" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="0.11" ORDER="681" SD_1="0.27" SD_2="0.46" SE="0.05847262281655937" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="10.592096981460482"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6864950530863512" CI_END="-0.023187129220540774" CI_START="-0.11112646558440575" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06715679740247327" ESTIMABLE="YES" I2="40.70542939512563" I2_Q="0.0" ID="CMP-003.24" MODIFIED="2009-05-21 10:15:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="24" P_CHI2="0.19406372510527914" P_Q="1.0" P_Z="0.0027576251504371216" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="142" UNITS="" WEIGHT="100.0" Z="2.9935387204033175">
<NAME>Change in nocturnal awakenings (unspecified time)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.24.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6864950530863512" CI_END="-0.023187129220540774" CI_START="-0.11112646558440575" DF="1.0" EFFECT_SIZE="-0.06715679740247327" ESTIMABLE="YES" I2="40.70542939512563" ID="CMP-003.24.02" NO="2" P_CHI2="0.19406372510527914" P_Z="0.0027576251504371216" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="142" WEIGHT="100.0" Z="2.9935387204033175">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.03412601122990286" CI_START="-0.14587398877009713" EFFECT_SIZE="-0.09" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.08" ORDER="684" SD_1="0.16" SD_2="0.17" SE="0.028507660962560553" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="61.92799567078879"/>
<CONT_DATA CI_END="0.041260738310911496" CI_START="-0.1012607383109115" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="-0.03" ORDER="683" SD_1="0.17" SD_2="0.26" SE="0.036358187636613276" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="38.07200432921121"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.25" MODIFIED="2009-05-21 10:15:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptoms (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.25.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.25.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-5.331479437646758" CI_START="-7.8685205623532415" EFFECT_SIZE="-6.6" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="6.8" ORDER="685" SD_1="0.4" SD_2="1.9" SE="0.6472162612982533" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="73.94006981826236" CI_END="-1.0051497101628675" CI_START="-1.2476430374966245" CI_STUDY="95" CI_TOTAL="95" DF="26.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.126396373829746" ESTIMABLE="YES" I2="64.83638700381873" I2_Q="86.1685294349444" ID="CMP-003.26" MODIFIED="2009-05-21 10:28:04 +0100" MODIFIED_BY="Toby J Lasserson" NO="26" P_CHI2="1.7415758869487874E-6" P_Q="0.007169988257942794" P_Z="4.434586921323393E-74" Q="7.229889224696336" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3776" TOTAL_2="2954" UNITS="" WEIGHT="99.99999999999999" Z="18.208305764918986">
<NAME>Change in daily use of beta2 agonist compared to baseline (puffs/d)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.191924434862996" CI_END="-0.5298866648498537" CI_START="-1.0663773625867046" DF="4.0" EFFECT_SIZE="-0.7981320137182791" ESTIMABLE="YES" I2="35.399728435340556" ID="CMP-003.26.01" MODIFIED="2008-07-04 14:39:14 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.18526657590120665" P_Z="5.488560698146685E-9" STUDIES="5" TAU2="0.0" TOTAL_1="636" TOTAL_2="453" WEIGHT="20.430321133630798" Z="5.831638864924183">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.645299666638082" CI_START="-1.6947003333619177" EFFECT_SIZE="-1.17" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="0.15" ORDER="687" SD_1="1.67" SD_2="1.9" SE="0.26770917093410246" STUDY_ID="STD-Katz-1998" TOTAL_1="86" TOTAL_2="92" WEIGHT="5.339700688219779"/>
<CONT_DATA CI_END="0.006526605259320806" CI_START="-1.4065266052593208" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="0.0" ORDER="688" SD_1="2.68" SD_2="1.77" SE="0.3604793816785984" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="2.944981378722884"/>
<CONT_DATA CI_END="0.017330359735063527" CI_START="-0.9173303597350635" EFFECT_SIZE="-0.44999999999999996" ESTIMABLE="YES" MEAN_1="-0.61" MEAN_2="-0.16" ORDER="686" SD_1="1.46" SD_2="1.81" SE="0.23843823836626882" STUDY_ID="STD-Levy-2006" TOTAL_1="149" TOTAL_2="77" WEIGHT="6.731186178932651"/>
<CONT_DATA CI_END="-0.5230201857814697" CI_START="-1.7169798142185306" EFFECT_SIZE="-1.12" ESTIMABLE="YES" MEAN_1="-1.04" MEAN_2="0.08" ORDER="689" SD_1="1.9" SD_2="2.1" SE="0.30458713472667404" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="4.1249653138341555"/>
<CONT_DATA CI_END="0.7977294370335974" CI_START="-1.3377294370335975" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.23" MODIFIED="2008-07-04 14:39:14 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="3011" SD_1="5.66" SD_2="4.38" SE="0.5447699271291263" STUDY_ID="STD-Qaquandah-2006" TOTAL_1="234" TOTAL_2="120" WEIGHT="1.2894875739213298"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="60.51825615870303" CI_END="-1.0747576214261225" CI_START="-1.3466055261482963" DF="21.0" EFFECT_SIZE="-1.2106815737872094" ESTIMABLE="YES" I2="65.29972716839426" ID="CMP-003.26.02" MODIFIED="2009-05-21 10:28:04 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.0657913226186366E-5" P_Z="3.018719784464483E-68" STUDIES="25" TAU2="0.0" TOTAL_1="3140" TOTAL_2="2501" WEIGHT="79.56967886636919" Z="17.45749913941238">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.5254346261584986" CI_START="-1.4145653738415014" EFFECT_SIZE="-0.97" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.85" ORDER="691" SD_1="2.15" SD_2="2.38" SE="0.22682323621667352" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="7.438208142445685"/>
<CONT_DATA CI_END="-0.2622158277805766" CI_START="-1.1377841722194235" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.9" ORDER="690" SD_1="2.81" SD_2="1.45" SE="0.22336337589497007" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="7.670425959944599"/>
<CONT_DATA CI_END="-0.8043449413496228" CI_START="-2.195655058650377" EFFECT_SIZE="-1.4999999999999998" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-1.3" ORDER="692" SD_1="2.87" SD_2="2.46" SE="0.35493257230113173" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="3.037747686974353"/>
<CONT_DATA CI_END="-0.29799083585097086" CI_START="-1.4020091641490293" EFFECT_SIZE="-0.8500000000000001" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="0.2" ORDER="693" SD_1="1.57" SD_2="1.97" SE="0.2816425038945649" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="4.824441210795056"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.46" MEAN_2="-0.28" ORDER="707" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.9343967436681324" CI_START="-2.2656032563318678" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="0.4" ORDER="695" SD_1="2.41" SD_2="2.12" SE="0.33959973835338875" STUDY_ID="STD-FLTA3014" TOTAL_1="93" TOTAL_2="85" WEIGHT="3.318247058047262"/>
<CONT_DATA CI_END="-0.32539533390551645" CI_START="-1.9346046660944833" EFFECT_SIZE="-1.13" ESTIMABLE="YES" MEAN_1="-1.18" MEAN_2="-0.05" ORDER="696" SD_1="1.64" SD_2="2.03" SE="0.41052012814577327" STUDY_ID="STD-FLTA3020" TOTAL_1="37" TOTAL_2="43" WEIGHT="2.2707770711906674"/>
<CONT_DATA CI_END="-0.2508778902239609" CI_START="-1.8291221097760393" EFFECT_SIZE="-1.04" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.46" ORDER="697" SD_1="2.91" SD_2="3.0" SE="0.4026207195645092" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="2.360756372097728"/>
<CONT_DATA CI_END="-1.376604589701302" CI_START="-3.0233954102986984" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-0.3" ORDER="698" SD_1="3.0" SD_2="2.5" SE="0.42010741870439255" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="2.1683166779944734"/>
<CONT_DATA CI_END="-1.4446877626515842" CI_START="-2.755312237348416" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="1.7" ORDER="699" SD_1="1.94" SD_2="2.28" SE="0.33434912198256456" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="3.4232848480127673"/>
<CONT_DATA CI_END="-0.7201922422397097" CI_START="-2.6798077577602903" EFFECT_SIZE="-1.7" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.7" ORDER="700" SD_1="2.38" SD_2="3.2" SE="0.4999111032084716" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="1.5312914109414981"/>
<CONT_DATA CI_END="1.0537451019300765" CI_START="-1.7537451019300767" EFFECT_SIZE="-0.35" ESTIMABLE="NO" MEAN_1="-0.5" MEAN_2="-0.15" MODIFIED="2009-05-21 10:28:04 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1165" SD_1="0.0" SD_2="0.0" SE="0.7162096410967951" STUDY_ID="STD-Li-1999a" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.7405171049005347"/>
<CONT_DATA CI_END="-0.681735634306851" CI_START="-1.818264365693149" EFFECT_SIZE="-1.25" ESTIMABLE="YES" MEAN_1="-0.16" MEAN_2="1.09" ORDER="705" SD_1="2.13" SD_2="2.04" SE="0.28993612646739725" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="4.552382519467934"/>
<CONT_DATA CI_END="-0.41935030597866907" CI_START="-1.680649694021331" EFFECT_SIZE="-1.05" ESTIMABLE="YES" MEAN_1="-0.19" MEAN_2="0.86" ORDER="701" SD_1="1.71" SD_2="2.38" SE="0.32176596049509854" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="3.696265981422642"/>
<CONT_DATA CI_END="-1.3994390720841687" CI_START="-2.800560927915831" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="1.6" ORDER="1163" SD_1="1.9" SD_2="2.8" SE="0.35743561281827957" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" WEIGHT="2.995351338612695"/>
<CONT_DATA CI_END="-0.46643118061647604" CI_START="-2.533568819383524" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.39" MEAN_2="0.11" ORDER="702" SD_1="2.3" SD_2="2.1" SE="0.527340720307201" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="1.376134224227593"/>
<CONT_DATA CI_END="-1.960417836948721" CI_START="-3.6395821630512786" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="1.7" ORDER="703" SD_1="2.75" SD_2="2.6" SE="0.4283661177826714" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="2.0855143725422054"/>
<CONT_DATA CI_END="-0.06773493924365159" CI_START="-1.7322650607563488" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.2" ORDER="704" SD_1="1.44" SD_2="1.44" SE="0.4246328337261037" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="2.1223463958081816"/>
<CONT_DATA CI_END="0.043029723532214015" CI_START="-1.243029723532214" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.2" ORDER="706" SD_1="2.45" SD_2="1.87" SE="0.32808241814867545" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="3.5553101883742073"/>
<CONT_DATA CI_END="0.0914388706421635" CI_START="-0.9114388706421633" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="-1.17" MEAN_2="-0.76" MODIFIED="2009-05-21 10:20:35 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1162" SD_1="1.8" SD_2="1.8" SE="0.25584085962673253" STUDY_ID="STD-Pinnas-2005" TOTAL_1="99" TOTAL_2="99" WEIGHT="5.846602940800277"/>
<CONT_DATA CI_END="-0.6255028566164943" CI_START="-1.574497143383506" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.4" ORDER="694" SD_1="2.77" SD_2="2.18" SE="0.24209482782657166" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" WEIGHT="6.529386690379924"/>
<CONT_DATA CI_END="-0.7368945555999695" CI_START="-2.4031054444000306" EFFECT_SIZE="-1.57" ESTIMABLE="YES" MEAN_1="-1.85" MEAN_2="-0.28" ORDER="708" SD_1="2.76" SD_2="2.48" SE="0.42506160877008964" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="2.118066780002655"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-1.57" MEAN_2="-0.19" ORDER="711" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.8858668927593181" CI_START="-2.554133107240682" EFFECT_SIZE="-1.72" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="1.29" ORDER="710" SD_1="2.26" SD_2="2.66" SE="0.4255859361805714" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.112851023262793"/>
<CONT_DATA CI_END="-0.7207084842279718" CI_START="-1.8592915157720282" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="-1.07" MEAN_2="0.22" ORDER="709" SD_1="1.62" SD_2="1.88" SE="0.29046019225992264" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="4.535969973024004"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.918886281516479" CI_END="16.317285266461944" CI_START="7.842987949490613" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.080136607976279" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.27" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="27" P_CHI2="0.5894118781809101" P_Q="1.0" P_Z="2.2987261374968658E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="607" TOTAL_2="625" UNITS="" WEIGHT="100.00000000000001" Z="5.587869246112141">
<NAME>Change from baseline in rescue medication free days (%)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.27.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.918886281516479" CI_END="16.317285266461944" CI_START="7.842987949490613" DF="3.0" EFFECT_SIZE="12.080136607976279" ESTIMABLE="YES" I2="0.0" ID="CMP-003.27.02" NO="2" P_CHI2="0.5894118781809101" P_Z="2.2987261374968658E-8" STUDIES="4" TAU2="0.0" TOTAL_1="607" TOTAL_2="625" WEIGHT="100.00000000000001" Z="5.587869246112141">
<NAME>Adults</NAME>
<CONT_DATA CI_END="16.923909779752513" CI_START="1.676090220247489" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="-1.0" ORDER="742" SD_1="38.66" SD_2="39.2" SE="3.889821364009206" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="30.88815059568492"/>
<CONT_DATA CI_END="18.058288103960546" CI_START="4.74171189603945" EFFECT_SIZE="11.399999999999999" ESTIMABLE="YES" MEAN_1="29.9" MEAN_2="18.5" ORDER="741" SD_1="35.18" SD_2="33.33" SE="3.3971481907220107" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="40.49694258338673"/>
<CONT_DATA CI_END="24.30519869921634" CI_START="3.2948013007836607" EFFECT_SIZE="13.8" ESTIMABLE="YES" MEAN_1="27.3" MEAN_2="13.5" ORDER="743" SD_1="43.21" SD_2="34.32" SE="5.359893744007546" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="16.268175921247956"/>
<CONT_DATA CI_END="31.05862278726984" CI_START="6.941377212730158" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="-10.7" ORDER="744" SD_1="44.66" SD_2="43.85" SE="6.152471618043352" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="12.346730899680399"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.28" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Rescue medication (absolute scores)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.28.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.28.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-5.89635139514692" CI_START="-7.303648604853081" EFFECT_SIZE="-6.6000000000000005" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="6.7" ORDER="745" SD_1="0.4" SD_2="1.0" SE="0.3590109871423003" STUDY_ID="STD-Giannini-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0050439271183746" CI_END="0.879600519179883" CI_START="0.4107759675572926" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6451882433685878" ESTIMABLE="YES" I2="50.12578096295436" I2_Q="0.0" ID="CMP-003.29" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="29" P_CHI2="0.15677711891675195" P_Q="1.0" P_Z="6.870042887632524E-8" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="173" TOTAL_2="170" UNITS="" WEIGHT="100.0" Z="5.394537107216478">
<NAME>HRQOL: AQLQ (absolute scores)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.29.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0050439271183746" CI_END="0.879600519179883" CI_START="0.4107759675572926" DF="1.0" EFFECT_SIZE="0.6451882433685878" ESTIMABLE="YES" I2="50.12578096295436" ID="CMP-003.29.02" NO="2" P_CHI2="0.15677711891675195" P_Z="6.870042887632524E-8" STUDIES="2" TAU2="0.0" TOTAL_1="173" TOTAL_2="170" WEIGHT="100.0" Z="5.394537107216478">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.1769687817116652" CI_START="0.48303121828833506" EFFECT_SIZE="0.8300000000000001" ESTIMABLE="YES" MEAN_1="5.47" MEAN_2="4.64" ORDER="747" SD_1="1.13" SD_2="1.21" SE="0.17702814156204424" STUDY_ID="STD-Nathan-2006" TOTAL_1="88" TOTAL_2="87" WEIGHT="45.64360099076106"/>
<CONT_DATA CI_END="0.8079472055408677" CI_START="0.17205279445913269" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="5.62" MEAN_2="5.13" ORDER="746" SD_1="1.01" SD_2="1.09" SE="0.1622209428585395" STUDY_ID="STD-Pearlman-2004" TOTAL_1="85" TOTAL_2="83" WEIGHT="54.35639900923895"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.30" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="101" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Functional Status IIR questionaire (short version)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.30.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="7.08160647631415" CI_START="0.518393523685845" EFFECT_SIZE="3.799999999999997" ESTIMABLE="YES" MEAN_1="95.3" MEAN_2="91.5" ORDER="748" SD_1="12.0" SD_2="11.5" SE="1.6743197845465758" STUDY_ID="STD-Allen-1998" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.30.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.31" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="101" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, burden dimension</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.31.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.05535837554214362" CI_START="-0.3646416244578563" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="1.61" MEAN_2="1.82" ORDER="749" SD_1="0.5" SD_2="0.6" SE="0.07890023779908699" STUDY_ID="STD-Allen-1998" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.31.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.32" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="101" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, subjective norms dimension</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.23248225813421025" CI_START="-0.13248225813420972" EFFECT_SIZE="0.050000000000000266" ESTIMABLE="YES" MEAN_1="2.39" MEAN_2="2.34" ORDER="750" SD_1="0.6" SD_2="0.7" SE="0.09310490375007231" STUDY_ID="STD-Allen-1998" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.33" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="33" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="101" TOTAL_2="96" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Quality of Life of Parents of Asthmatic Children questionnaire, social dimension</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.33.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="-0.005358375542143579" CI_START="-0.31464162445785626" EFFECT_SIZE="-0.15999999999999992" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.73" ORDER="751" SD_1="0.5" SD_2="0.6" SE="0.07890023779908699" STUDY_ID="STD-Allen-1998" TOTAL_1="101" TOTAL_2="96" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.33.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.34" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="34" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="101" TOTAL_2="95" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: Sleep Scale Children questionnaire</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.34.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="16.614445902835246" CI_START="6.185554097164736" EFFECT_SIZE="11.399999999999991" ESTIMABLE="YES" MEAN_1="90.6" MEAN_2="79.2" ORDER="752" SD_1="15.1" SD_2="21.4" SE="2.660480470032174" STUDY_ID="STD-Allen-1998" TOTAL_1="101" TOTAL_2="95" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.34.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="18.222796327051594" CI_END="5.545478424077576" CI_START="3.137330917326188" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.171091093613742" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="148" I2="83.53710404178462" I2_Q="0.0" ID="CMP-003.35" LOG_CI_END="0.7439390199123911" LOG_CI_START="0.49656032934138383" LOG_EFFECT_SIZE="0.6202496746268875" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="35" P_CHI2="3.956785905314675E-4" P_Q="1.0" P_Z="8.496689654105992E-23" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="385" TOTAL_2="399" WEIGHT="100.00000000000003" Z="9.828389186516802">
<NAME>Physician-rated efficacy: effective or very effective (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.35.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.222796327051594" CI_END="5.545478424077576" CI_START="3.137330917326188" DF="3.0" EFFECT_SIZE="4.171091093613742" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="148" I2="83.53710404178462" ID="CMP-003.35.02" LOG_CI_END="0.7439390199123911" LOG_CI_START="0.49656032934138383" LOG_EFFECT_SIZE="0.6202496746268875" NO="2" P_CHI2="3.956785905314675E-4" P_Z="8.496689654105992E-23" STUDIES="4" TAU2="0.0" TOTAL_1="385" TOTAL_2="399" WEIGHT="100.00000000000003" Z="9.828389186516802">
<NAME>Adults</NAME>
<DICH_DATA CI_END="8.695205702765387" CI_START="3.06925003358347" EFFECT_SIZE="5.166019782698073" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="38" LOG_CI_END="0.9392798605790078" LOG_CI_START="0.48703226926676985" LOG_EFFECT_SIZE="0.7131560649228889" ORDER="753" O_E="23.268722466960355" SE="0.2656524737984903" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" VAR="14.17007898464942" WEIGHT="29.920720538129224"/>
<DICH_DATA CI_END="18.36673893490868" CI_START="5.459526526999941" EFFECT_SIZE="10.013675570419515" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="13" LOG_CI_END="1.2640320529689815" LOG_CI_START="0.7371549805019162" LOG_EFFECT_SIZE="1.000593516735449" ORDER="754" O_E="24.05357142857143" SE="0.30949020045072556" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="85" TOTAL_2="83" VAR="10.44013694549676" WEIGHT="22.04479031234808"/>
<DICH_DATA CI_END="3.0750809528110006" CI_START="1.0582810020799622" EFFECT_SIZE="1.8039677802604543" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="49" LOG_CI_END="0.4878565532484573" LOG_CI_START="0.024600999881734576" LOG_EFFECT_SIZE="0.2562287765650959" ORDER="755" O_E="7.967592592592595" SE="0.2721186051995856" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="13.504656047628163" WEIGHT="28.515651888911194"/>
<DICH_DATA CI_END="7.2450692665182395" CI_START="1.9957700793969184" EFFECT_SIZE="3.8025639330950476" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="48" LOG_CI_END="0.8600425419014448" LOG_CI_START="0.3001105073918744" LOG_EFFECT_SIZE="0.5800765246466595" ORDER="756" O_E="12.346820809248555" SE="0.328906848779194" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" VAR="9.24387717598316" WEIGHT="19.51883726061152"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.36" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="36" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="113" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>Exacerbations requiring OCS treatment</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.36.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-003.36.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.2464896071473164" CI_START="0.16396154874210808" EFFECT_SIZE="0.4520800443271256" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.09568866183907981" LOG_CI_START="-0.7852579880929428" LOG_EFFECT_SIZE="-0.34478466312693146" ORDER="757" O_E="-2.964757709251101" SE="0.5174724229263166" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" VAR="3.7344408003260297" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7627874335672375" CI_END="0.39108974461827206" CI_START="0.1191453924039674" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.21586231974967612" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-003.37" LOG_CI_END="-0.4077235722199213" LOG_CI_START="-0.9239227480487354" LOG_EFFECT_SIZE="-0.6658231601343284" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="37" P_CHI2="0.8583455197160375" P_Q="0.4661613760923634" P_Z="4.2781199704910717E-7" Q="0.531060606888204" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="358" WEIGHT="100.0" Z="5.056146832627642">
<NAME>Withdrawal due to clinical asthma exacerbation (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07558391793565156" CI_END="0.3840713420080677" CI_START="0.08736977769095378" DF="1.0" EFFECT_SIZE="0.18318359033688347" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="28" I2="0.0" ID="CMP-003.37.01" LOG_CI_END="-0.415588097083938" LOG_CI_START="-1.0586387693324748" LOG_EFFECT_SIZE="-0.7371134332082063" NO="1" P_CHI2="0.7833736402910512" P_Z="7.012174612518576E-6" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="125" WEIGHT="64.4383216682515" Z="4.4933186262197955">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.4211708276219073" CI_START="0.0862701220233715" EFFECT_SIZE="0.1906159979949907" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.3755417178322119" LOG_CI_START="-1.064139587680916" LOG_EFFECT_SIZE="-0.719840652756564" ORDER="758" O_E="-10.130841121495328" SE="0.404485797363558" STUDY_ID="STD-Allen-1998" TOTAL_1="108" TOTAL_2="106" VAR="6.112142151537928" WEIGHT="56.19572309187632"/>
<DICH_DATA CI_END="1.1069203606599816" CI_START="0.0176252311617093" EFFECT_SIZE="0.13967722518089626" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.04411637591929072" LOG_CI_START="-1.7538651783594612" LOG_EFFECT_SIZE="-0.8548744012200853" ORDER="759" O_E="-1.7647058823529411" SE="1.0561432651355724" STUDY_ID="STD-Hoekstra-1996" TOTAL_1="15" TOTAL_2="19" VAR="0.8965083359547027" WEIGHT="8.242598576375187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.15614290874338194" CI_END="0.7873445798560481" CI_START="0.10728698346548747" DF="1.0" EFFECT_SIZE="0.29064037042478635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" ID="CMP-003.37.02" LOG_CI_END="-0.10383515788432797" LOG_CI_START="-0.9694529653781546" LOG_EFFECT_SIZE="-0.5366440616312412" NO="2" P_CHI2="0.6927329495794534" P_Z="0.015091374790844492" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="233" WEIGHT="35.561678331748496" Z="2.430178825363473">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.8586313492580606" CI_START="0.10934043791196542" EFFECT_SIZE="0.3064035374025863" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.06619325915818595" LOG_CI_START="-0.9612191910776307" LOG_EFFECT_SIZE="-0.5137062251179083" ORDER="760" O_E="-4.279411764705882" SE="0.5257426628592982" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" VAR="3.6178750116898906" WEIGHT="33.26315018488036"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="761" O_E="-0.5" SE="2.0" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" VAR="0.25" WEIGHT="2.2985281468681333"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="41.90050748704023" CI_END="0.25318754974213936" CI_START="0.186063398855349" CI_STUDY="95" CI_TOTAL="95" DF="22.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.21704593074480846" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="713" I2="47.49466935023503" I2_Q="0.0" ID="CMP-003.38" LOG_CI_END="-0.5965576541492676" LOG_CI_START="-0.7303390499670089" LOG_EFFECT_SIZE="-0.6634483520581382" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="38" P_CHI2="0.006426594335230074" P_Q="0.6542540480091441" P_Z="0.0" Q="0.20057882813229355" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2972" TOTAL_2="2232" WEIGHT="100.0" Z="19.439696643738518">
<NAME>Withdrawal due to lack of treatment efficacy (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.614599649135216" CI_END="0.35222752606334834" CI_START="0.15831316881387233" DF="2.0" EFFECT_SIZE="0.23614033072425278" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="108" I2="56.65929545210269" ID="CMP-003.38.01" LOG_CI_END="-0.45317670756721307" LOG_CI_START="-0.8004829581298971" LOG_EFFECT_SIZE="-0.6268298328485551" NO="1" P_CHI2="0.0995297997177903" P_Z="1.4964726420889667E-12" STUDIES="3" TAU2="0.0" TOTAL_1="333" TOTAL_2="259" WEIGHT="14.837688412669772" Z="7.074815928754447">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.4630851561754749" CI_START="0.14296968504930135" EFFECT_SIZE="0.2573074793499291" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="58" LOG_CI_END="-0.3343391397454732" LOG_CI_START="-0.8447560395385173" LOG_EFFECT_SIZE="-0.5895475896419953" ORDER="763" O_E="-15.10112359550562" SE="0.2998214135428367" STUDY_ID="STD-Katz-1998" TOTAL_1="86" TOTAL_2="92" VAR="11.1243515592179" WEIGHT="6.869756680323717"/>
<DICH_DATA CI_END="1.2979499697173893" CI_START="0.19581454632851855" EFFECT_SIZE="0.5041403420450747" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.11325795263814264" LOG_CI_START="-0.7081550492256586" LOG_EFFECT_SIZE="-0.297448548293758" ORDER="762" O_E="-2.9419087136929463" SE="0.4825020633547327" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="4.295380589177183" WEIGHT="2.6525788348159107"/>
<DICH_DATA CI_END="0.2823222969155989" CI_START="0.07421228024463887" EFFECT_SIZE="0.14474730193689472" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="40" LOG_CI_END="-0.5492548213039667" LOG_CI_START="-1.1295242240848442" LOG_EFFECT_SIZE="-0.8393895226944054" ORDER="764" O_E="-16.63583815028902" SE="0.34085311957335634" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" VAR="8.607270540278659" WEIGHT="5.315352897530144"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.08532900977272" CI_END="0.25272932638749074" CI_START="0.18100379819706214" DF="19.0" EFFECT_SIZE="0.2138807331012329" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="605" I2="48.766802109283915" ID="CMP-003.38.02" LOG_CI_END="-0.5973443601802771" LOG_CI_START="-0.7423123117677317" LOG_EFFECT_SIZE="-0.6698283359740045" NO="2" P_CHI2="0.00774225181319943" P_Z="2.556479081279394E-73" STUDIES="20" TAU2="0.0" TOTAL_1="2639" TOTAL_2="1973" WEIGHT="85.16231158733022" Z="18.112133060546828">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.2272096865872218" CI_START="0.06341099298854735" EFFECT_SIZE="0.12003162851145678" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="50" LOG_CI_END="-0.6435731573725367" LOG_CI_START="-1.1978354458972507" LOG_EFFECT_SIZE="-0.9207043016348937" ORDER="765" O_E="-20.0" SE="0.3255764119219941" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" VAR="9.433962264150944" WEIGHT="5.825869934177918"/>
<DICH_DATA CI_END="1.249267727667836" CI_START="0.049145230399223416" EFFECT_SIZE="0.24778125495394132" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0966555209913037" LOG_CI_START="-1.308518624562493" LOG_EFFECT_SIZE="-0.6059315517855947" ORDER="780" O_E="-2.0478764478764475" SE="0.8254062488225011" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="979" TOTAL_2="316" VAR="1.4677919284966958" WEIGHT="0.90642347578094"/>
<DICH_DATA CI_END="0.40138459737273996" CI_START="0.10558727509579498" EFFECT_SIZE="0.20586671878186236" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="36" LOG_CI_END="-0.39643929703131964" LOG_CI_START="-0.9763884178691705" LOG_EFFECT_SIZE="-0.6864138574502451" ORDER="767" O_E="-13.61904761904762" SE="0.34066498437460135" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="8.616780045351472" WEIGHT="5.321225418337562"/>
<DICH_DATA CI_END="0.8241074140613708" CI_START="0.08836054504963234" EFFECT_SIZE="0.26984918062856106" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.08401617872295004" LOG_CI_START="-1.0537416138585745" LOG_EFFECT_SIZE="-0.5688788962907623" ORDER="768" O_E="-4.037037037037037" SE="0.5696215208169867" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="3.0819615912208507" WEIGHT="1.9032413814939768"/>
<DICH_DATA CI_END="2.169101776309646" CI_START="0.15037792810664063" EFFECT_SIZE="0.5711261077676965" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3362799300006744" LOG_CI_START="-0.8228159031388772" LOG_EFFECT_SIZE="-0.2432679865691014" ORDER="769" O_E="-1.208333333333333" SE="0.6808586300030817" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="2.1571786175710597" WEIGHT="1.3321488573804243"/>
<DICH_DATA CI_END="0.44021028328385237" CI_START="0.12688672668345152" EFFECT_SIZE="0.2363405210671309" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="45" LOG_CI_END="-0.35633981657306135" LOG_CI_START="-0.8965838060347655" LOG_EFFECT_SIZE="-0.6264618113039134" ORDER="770" O_E="-14.323699421965319" SE="0.31734199366068266" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" VAR="9.929900765144176" WEIGHT="6.132132893604518"/>
<DICH_DATA CI_END="0.5416799740795961" CI_START="0.12160726183383402" EFFECT_SIZE="0.25665583655557467" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="26" LOG_CI_END="-0.26625721999243784" LOG_CI_START="-0.9150404901932494" LOG_EFFECT_SIZE="-0.5906488550928437" ORDER="771" O_E="-9.364197530864196" SE="0.38109850444493903" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" VAR="6.885341908378229" WEIGHT="4.251989279518929"/>
<DICH_DATA CI_END="2.560794268959026" CI_START="0.048056282314779986" EFFECT_SIZE="0.35080229808136315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4083746891889283" LOG_CI_START="-1.318249829716624" LOG_EFFECT_SIZE="-0.45493757026384796" ORDER="772" O_E="-1.018348623853211" SE="1.0142277893343332" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.9721403922228768" WEIGHT="0.6003377291822258"/>
<DICH_DATA CI_END="0.24410520708799913" CI_START="0.053119661612257486" EFFECT_SIZE="0.11387179632509778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="33" LOG_CI_END="-0.612422956406387" LOG_CI_START="-1.2747447002137853" LOG_EFFECT_SIZE="-0.9435838283100861" ORDER="773" O_E="-14.354330708661418" SE="0.3890510708579733" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" VAR="6.606733213466426" WEIGHT="4.079936649495683"/>
<DICH_DATA CI_END="0.28435931847291906" CI_START="0.08725573958974436" EFFECT_SIZE="0.15751819781406276" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="52" LOG_CI_END="-0.5461325353208757" LOG_CI_START="-1.059205996000073" LOG_EFFECT_SIZE="-0.8026692656604744" ORDER="776" O_E="-20.347826086956523" SE="0.3013818905575515" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="11.00945179584121" WEIGHT="6.798801226172273"/>
<DICH_DATA CI_END="0.8098306871683726" CI_START="0.22520127918059013" EFFECT_SIZE="0.4270537514997542" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" LOG_CI_END="-0.09160577039870062" LOG_CI_START="-0.647429146949049" LOG_EFFECT_SIZE="-0.3695174586738748" ORDER="774" O_E="-7.981818181818181" SE="0.3264934027557621" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="9.38104414432574" WEIGHT="5.793190761352053"/>
<DICH_DATA CI_END="0.28144871948303946" CI_START="0.08132567049791996" EFFECT_SIZE="0.15129112935905784" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="48" LOG_CI_END="-0.5506007229238893" LOG_CI_START="-1.089772347445477" LOG_EFFECT_SIZE="-0.8201865351846832" ORDER="779" O_E="-18.82777777777778" SE="0.31671208118656613" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="9.969439444099592" WEIGHT="6.156549696906646"/>
<DICH_DATA CI_END="0.2085481840425722" CI_START="0.05890631999617711" EFFECT_SIZE="0.11083684434263452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="51" LOG_CI_END="-0.6807935874711056" LOG_CI_START="-1.2298381077218963" LOG_EFFECT_SIZE="-0.955315847596501" ORDER="775" O_E="-21.148148148148145" SE="0.32251146900952204" STUDY_ID="STD-Pearlman-1997" TOTAL_1="84" TOTAL_2="78" VAR="9.614122979662431" WEIGHT="5.937126781134664"/>
<DICH_DATA CI_END="0.5320432048572233" CI_START="0.11544690012509734" EFFECT_SIZE="0.24783611264984884" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.27405309915380993" LOG_CI_START="-0.9376177238697058" LOG_EFFECT_SIZE="-0.6058354115117579" ORDER="777" O_E="-9.181818181818183" SE="0.38978114525598445" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" VAR="6.582007083825267" WEIGHT="4.064667220677592"/>
<DICH_DATA CI_END="1.3152429734330766" CI_START="0.23973493122355152" EFFECT_SIZE="0.5615244284786175" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.11900599029630714" LOG_CI_START="-0.6202686813090406" LOG_EFFECT_SIZE="-0.25063134550636673" ORDER="778" O_E="-3.060301507537689" SE="0.43425360156962484" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="5.302896391505265" WEIGHT="3.274762373041096"/>
<DICH_DATA CI_END="0.8440734702847141" CI_START="0.157475916427305" EFFECT_SIZE="0.36458365743003474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.07361974964148968" LOG_CI_START="-0.8027858556044524" LOG_EFFECT_SIZE="-0.43820280262297107" ORDER="766" O_E="-5.5" SE="0.42831578007308097" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" VAR="5.450945626477541" WEIGHT="3.3661890252422166"/>
<DICH_DATA CI_END="0.8256963106327092" CI_START="0.2290948236320304" EFFECT_SIZE="0.4349284431467074" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" LOG_CI_END="-0.08317965590964171" LOG_CI_START="-0.6399847235275065" LOG_EFFECT_SIZE="-0.3615821897185741" ORDER="781" O_E="-7.782894736842103" SE="0.3270700529482704" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" VAR="9.347994269505238" WEIGHT="5.772781068515271"/>
<DICH_DATA CI_END="0.18613979641942313" CI_START="0.052270298489501314" EFFECT_SIZE="0.0986386471907348" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="54" LOG_CI_END="-0.7301607654095661" LOG_CI_START="-1.2817450198568467" LOG_EFFECT_SIZE="-1.0059528926332064" ORDER="782" O_E="-22.064516129032256" SE="0.3240033214484274" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" VAR="9.525791586145383" WEIGHT="5.882578416902753"/>
<DICH_DATA CI_END="0.5531923960833044" CI_START="0.13247534430652896" EFFECT_SIZE="0.270710829371286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="33" LOG_CI_END="-0.25712379812483444" LOG_CI_START="-0.8778649430706149" LOG_EFFECT_SIZE="-0.5674943705977247" ORDER="784" O_E="-9.828358208955223" SE="0.3646264212593751" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" VAR="7.521487361754799" WEIGHT="4.644835950601526"/>
<DICH_DATA CI_END="0.5979246286176217" CI_START="0.10446183687570111" EFFECT_SIZE="0.24992059742769934" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.22335355754750263" LOG_CI_START="-0.981042341719712" LOG_EFFECT_SIZE="-0.6021979496336074" ORDER="783" O_E="-7.0" SE="0.44507014244272675" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" VAR="5.048275862068966" WEIGHT="3.117523447811952"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.43794007110079" CI_END="0.5049402203901869" CI_START="0.3582534260214334" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4253193669359557" ESTIMABLE="YES" EVENTS_1="353" EVENTS_2="485" I2="69.65893000714176" I2_Q="0.0" ID="CMP-003.39" LOG_CI_END="-0.2967600347356409" LOG_CI_START="-0.44580964769938586" LOG_EFFECT_SIZE="-0.3712848412175134" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="39" P_CHI2="1.4870986457027335E-5" P_Q="0.9050173901810924" P_Z="1.597412969632259E-22" Q="0.014238603318247556" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2072" TOTAL_2="1351" WEIGHT="100.00000000000001" Z="9.76459988485857">
<NAME>Withdrawals (any reason)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0837647704637705" CI_END="0.6468541885420874" CI_START="0.26604567519945327" DF="1.0" EFFECT_SIZE="0.41484064331532666" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="71" I2="7.7290545648504" ID="CMP-003.39.01" LOG_CI_END="-0.18919360534101937" LOG_CI_START="-0.5750437965110267" LOG_EFFECT_SIZE="-0.38211870092602307" NO="1" P_CHI2="0.2978573220681643" P_Z="1.0359277011407156E-4" STUDIES="2" TAU2="0.0" TOTAL_1="240" TOTAL_2="159" WEIGHT="14.921904829207985" Z="3.8820190258983263">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.613618607285894" CI_START="0.17580776546492044" EFFECT_SIZE="0.3284492596956638" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="46" LOG_CI_END="-0.21210147937351234" LOG_CI_START="-0.7549619459625809" LOG_EFFECT_SIZE="-0.4835317126680465" ORDER="786" O_E="-10.949367088607595" SE="0.3188789252770671" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" VAR="9.8344112337052" WEIGHT="7.538505812252913"/>
<DICH_DATA CI_END="0.9901276679276311" CI_START="0.2800001692856926" EFFECT_SIZE="0.5265319692423098" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="25" LOG_CI_END="-0.004308803481502174" LOG_CI_START="-0.5528417060869952" LOG_EFFECT_SIZE="-0.2785752547842487" ORDER="785" O_E="-6.178423236514526" SE="0.32221094227212604" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="9.63206556360944" WEIGHT="7.383399016955073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="48.33993669731877" CI_END="0.5145311955084785" CI_START="0.3546654821989052" DF="13.0" EFFECT_SIZE="0.4271843332349557" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="414" I2="73.10712241639932" ID="CMP-003.39.02" LOG_CI_END="-0.2885882892660145" LOG_CI_START="-0.4501810771610234" LOG_EFFECT_SIZE="-0.36938468321351897" NO="2" P_CHI2="5.728175675900893E-6" P_Z="3.230430525415825E-19" STUDIES="14" TAU2="0.0" TOTAL_1="1832" TOTAL_2="1192" WEIGHT="85.07809517079203" Z="8.960556779422896">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.9045129859216715" CI_START="0.4068900964150407" EFFECT_SIZE="0.6066608410391471" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="48" LOG_CI_END="-0.043585193675765" LOG_CI_START="-0.390522880617695" LOG_EFFECT_SIZE="-0.21705403714673" ORDER="796" O_E="-12.033872209391845" SE="0.2037929146789374" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="979" TOTAL_2="320" VAR="24.07807919709319" WEIGHT="18.45689951962548"/>
<DICH_DATA CI_END="0.902574666314666" CI_START="0.03443883177010262" EFFECT_SIZE="0.1763054652957965" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="-0.044516860527985445" LOG_CI_START="-1.4629515890535503" LOG_EFFECT_SIZE="-0.7537342247907677" ORDER="787" O_E="-2.5" SE="0.8331955809010619" STUDY_ID="STD-FLIC15" TOTAL_1="11" TOTAL_2="11" VAR="1.4404761904761902" WEIGHT="1.104187925058474"/>
<DICH_DATA CI_END="0.5740368054267686" CI_START="0.18274289153106682" EFFECT_SIZE="0.32388446345717803" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="55" LOG_CI_END="-0.2410602611189179" LOG_CI_START="-0.7381595075513614" LOG_EFFECT_SIZE="-0.48960988433513963" ORDER="788" O_E="-13.222222222222221" SE="0.29199855803537256" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="11.728395061728394" WEIGHT="8.990327152297342"/>
<DICH_DATA CI_END="1.1937217020823743" CI_START="0.22513710618953" EFFECT_SIZE="0.5184120461587154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.07690308949220927" LOG_CI_START="-0.6475529204358255" LOG_EFFECT_SIZE="-0.28532491547180805" ORDER="789" O_E="-3.6279069767441854" SE="0.4255490463468129" STUDY_ID="STD-FLTA4030" TOTAL_1="100" TOTAL_2="115" VAR="5.522055367134546" WEIGHT="4.232896661678692"/>
<DICH_DATA CI_END="4.045520913603115" CI_START="0.820262696657176" EFFECT_SIZE="1.821644832006254" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.6069744506300537" LOG_CI_START="-0.08604703854572539" LOG_EFFECT_SIZE="0.2604637060421642" ORDER="790" O_E="3.6190476190476204" SE="0.4070842532535507" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="50" VAR="6.034362462933893" WEIGHT="4.625602429981888"/>
<DICH_DATA CI_END="0.2787674899353282" CI_START="0.09173840687723411" EFFECT_SIZE="0.15991774578148732" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="64" LOG_CI_END="-0.5547578753550247" LOG_CI_START="-1.037448806066188" LOG_EFFECT_SIZE="-0.7961033407106063" ORDER="793" O_E="-22.80193236714976" SE="0.28353504205837926" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="12.43903008238232" WEIGHT="9.535059938661792"/>
<DICH_DATA CI_END="0.94234054989513" CI_START="0.27567039403647514" EFFECT_SIZE="0.5096816562386164" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" LOG_CI_END="-0.02579212033594489" LOG_CI_START="-0.5596098729838173" LOG_EFFECT_SIZE="-0.2927009966598811" ORDER="791" O_E="-6.854545454545452" SE="0.31356719034585256" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="10.17041725458577" WEIGHT="7.796069105180803"/>
<DICH_DATA CI_END="0.35410193182908667" CI_START="0.10858508450920276" EFFECT_SIZE="0.19608719538137448" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="55" LOG_CI_END="-0.45087170390999465" LOG_CI_START="-0.9642298263146166" LOG_EFFECT_SIZE="-0.7075507651123056" ORDER="795" O_E="-17.916666666666664" SE="0.3015491022641642" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="10.997245499689633" WEIGHT="8.429869073814206"/>
<DICH_DATA CI_END="16.49617446289731" CI_START="0.06062011542428635" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2173832410452208" LOG_CI_START="-1.2173832410452208" LOG_EFFECT_SIZE="0.0" ORDER="792" O_E="0.0" SE="1.4301938838683885" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" VAR="0.48888888888888893" WEIGHT="0.3747546897168156"/>
<DICH_DATA CI_END="1.4987998134327865" CI_START="0.4368736671347858" EFFECT_SIZE="0.8091885879047691" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.17574363036176807" LOG_CI_START="-0.35964413190455674" LOG_EFFECT_SIZE="-0.09195025077139433" ORDER="794" O_E="-2.1407035175879408" SE="0.31448942176740446" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="10.110855786470037" WEIGHT="7.750412638016006"/>
<DICH_DATA CI_END="418.41746282785317" CI_START="0.16295887236075834" EFFECT_SIZE="8.257411090558376" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6216098016993516" LOG_CI_START="-0.7879219892189541" LOG_EFFECT_SIZE="0.9168439062401987" ORDER="797" O_E="0.5263157894736843" SE="2.002775851439974" STUDY_ID="STD-Sorkness-1999a" TOTAL_1="27" TOTAL_2="30" VAR="0.24930747922437668" WEIGHT="0.1911050734516624"/>
<DICH_DATA CI_END="23.05669793406771" CI_START="0.4115449089728986" EFFECT_SIZE="3.0804004045726776" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3627971099101763" LOG_CI_START="-0.3855827663935633" LOG_EFFECT_SIZE="0.4886071717583066" ORDER="798" O_E="1.0666666666666667" SE="1.0270069939607844" STUDY_ID="STD-Sorkness-1999b" TOTAL_1="29" TOTAL_2="31" VAR="0.9480979284369114" WEIGHT="0.726758478393812"/>
<DICH_DATA CI_END="0.6740421637267968" CI_START="0.17470231744568876" EFFECT_SIZE="0.3431570020547122" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="43" LOG_CI_END="-0.17131293595555763" LOG_CI_START="-0.7577013340142107" LOG_EFFECT_SIZE="-0.4645071349848842" ORDER="800" O_E="-9.014925373134325" SE="0.34444744768903685" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" VAR="8.428573103509498" WEIGHT="6.460869473511543"/>
<DICH_DATA CI_END="0.6318385317566108" CI_START="0.16277467463627174" EFFECT_SIZE="0.32069816249760763" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.19939389280407274" LOG_CI_START="-0.7884131640739118" LOG_EFFECT_SIZE="-0.4939035284389923" ORDER="799" O_E="-9.5" SE="0.34599283563631994" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" VAR="8.35344827586207" WEIGHT="6.403283011403504"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.684028746462497" CI_END="1.8617081563283806" CI_START="0.8085470669554854" CI_STUDY="95" CI_TOTAL="95" DF="20.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2268979865198315" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-003.40" LOG_CI_END="0.2699116014411987" LOG_CI_START="-0.09229469397145176" LOG_EFFECT_SIZE="0.08880845373487349" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="40" P_CHI2="0.9540086332940716" P_Q="0.36377502521541705" P_Z="0.3364931971629299" Q="0.8248189993752373" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3062" TOTAL_2="2222" WEIGHT="100.00000000000003" Z="0.9611173137934605">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3146243141881912" CI_END="7.407245076909257" CI_START="0.6064488193624331" DF="1.0" EFFECT_SIZE="2.1194610238501235" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-003.40.01" LOG_CI_END="0.8696567140033624" LOG_CI_START="-0.21720584509647106" LOG_EFFECT_SIZE="0.3262254344534457" MODIFIED="2008-07-04 14:43:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.5748564040938797" P_Z="0.2393634053272028" STUDIES="2" TAU2="0.0" TOTAL_1="399" TOTAL_2="211" WEIGHT="11.10612948263468" Z="1.1765794985140428">
<NAME>Children</NAME>
<DICH_DATA CI_END="85.84982246386414" CI_START="0.239909162504431" EFFECT_SIZE="4.538299131663727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9337394013834366" LOG_CI_START="-0.6199531653330138" LOG_EFFECT_SIZE="0.6568931180252114" ORDER="801" O_E="0.6721991701244814" SE="1.5000516546713194" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="0.4444138358499337" WEIGHT="2.011753493263288"/>
<DICH_DATA CI_END="7.1386421890964815" CI_START="0.44930601624148436" EFFECT_SIZE="1.7909312894012235" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.8536156143167193" LOG_CI_START="-0.34745776613213497" LOG_EFFECT_SIZE="0.25307892409229216" MODIFIED="2008-07-04 14:43:19 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="3013" O_E="1.1707317073170733" SE="0.7055164490847766" STUDY_ID="STD-Qaquandah-2006" TOTAL_1="239" TOTAL_2="130" VAR="2.0090267180508494" WEIGHT="9.094375989371391"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.54458543289907" CI_END="1.783322185555909" CI_START="0.7363135384127532" DF="18.0" EFFECT_SIZE="1.1458988910792416" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="35" I2="0.0" ID="CMP-003.40.02" LOG_CI_END="0.25122981247912507" LOG_CI_START="-0.13293721418593832" LOG_EFFECT_SIZE="0.05914629914659335" NO="2" P_CHI2="0.9457621004971186" P_Z="0.5461684468717831" STUDIES="20" TAU2="0.0" TOTAL_1="2663" TOTAL_2="2011" WEIGHT="88.89387051736534" Z="0.6035115358675707">
<NAME>Adults</NAME>
<DICH_DATA CI_END="4.487454778627292" CI_START="0.32007617709427383" EFFECT_SIZE="1.19846876072197" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6520000850979997" LOG_CI_START="-0.49474664869721896" LOG_EFFECT_SIZE="0.07862671820039036" ORDER="803" O_E="0.39900249376558605" SE="0.673604707919193" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" VAR="2.2038892792955265" WEIGHT="9.976471474856194"/>
<DICH_DATA CI_END="7.154046783342638" CI_START="0.43627272981658677" EFFECT_SIZE="1.7666679142964203" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8545517758578374" LOG_CI_START="-0.3602419326934791" LOG_EFFECT_SIZE="0.24715492158217917" ORDER="802" O_E="1.1176470588235294" SE="0.7135758377288823" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" VAR="1.9639016178808568" WEIGHT="8.890105621129543"/>
<DICH_DATA CI_END="19.19780655198936" CI_START="0.2035684420250432" EFFECT_SIZE="1.9768832970326398" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2832516111626564" LOG_CI_START="-0.6912895471440481" LOG_EFFECT_SIZE="0.2959810320093042" ORDER="804" O_E="0.5066079295154184" SE="1.1598552505257271" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" VAR="0.7433484057521007" WEIGHT="3.364957684369781"/>
<DICH_DATA CI_END="3.663337858038475" CI_START="0.4922332340030947" EFFECT_SIZE="1.3428390227827938" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="0.5638769741150915" LOG_CI_START="-0.3078290674782017" LOG_EFFECT_SIZE="0.1280239533184449" ORDER="819" O_E="1.1243243243243235" SE="0.512044443846398" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="979" TOTAL_2="316" VAR="3.81403508692702" WEIGHT="17.265210465106012"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="806" O_E="-0.5" SE="2.0" STUDY_ID="STD-FLIC15" TOTAL_1="11" TOTAL_2="11" VAR="0.25" WEIGHT="1.131689278651645"/>
<DICH_DATA CI_END="3.9806872554215214" CI_START="0.45371021082310226" EFFECT_SIZE="1.3439041832951242" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5999580583728326" LOG_CI_START="-0.34322144675507876" LOG_EFFECT_SIZE="0.1283683058088769" ORDER="807" O_E="0.9629629629629628" SE="0.5540283101259832" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="3.2578875171467763" WEIGHT="14.747665496832136"/>
<DICH_DATA CI_END="22.41801327855932" CI_START="0.22697864198464107" EFFECT_SIZE="2.2557504759970786" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3505971220684994" LOG_CI_START="-0.6440150067038266" LOG_EFFECT_SIZE="0.35329105768233643" ORDER="808" O_E="0.5925925925925926" SE="1.1716450379301393" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.7284636488340193" WEIGHT="3.297578005091666"/>
<DICH_DATA CI_END="18.4472489222319" CI_START="0.07041523345823139" EFFECT_SIZE="1.139722483555127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2659316080571692" LOG_CI_START="-1.152333376494608" LOG_EFFECT_SIZE="0.05679911578128066" ORDER="809" O_E="0.06481481481481477" SE="1.420500822530447" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="0.4955837081698409" WEIGHT="2.2433870768409383"/>
<DICH_DATA CI_END="14.71969832049462" CI_START="0.05631844109331257" EFFECT_SIZE="0.9104891338034232" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1678989092482817" LOG_CI_START="-1.2493493750652014" LOG_EFFECT_SIZE="-0.04072523290845996" ORDER="810" O_E="-0.04651162790697683" SE="1.4199036077777254" STUDY_ID="STD-Kavuru-2000" TOTAL_1="90" TOTAL_2="82" VAR="0.4960006831573255" WEIGHT="2.2452746213321473"/>
<DICH_DATA CI_END="15.900100558668518" CI_START="0.060605552532706226" EFFECT_SIZE="0.9816488066939705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2013998709831397" LOG_CI_START="-1.2174875850111615" LOG_EFFECT_SIZE="-0.008043857014010915" ORDER="811" O_E="-0.00917431192660545" SE="1.4208664653370688" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.49532867603737063" WEIGHT="2.2422326083208253"/>
<DICH_DATA CI_END="300.04006057291633" CI_START="0.10799664345956317" EFFECT_SIZE="5.692391364380965" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4771792444671092" LOG_CI_START="-0.9665897421949288" LOG_EFFECT_SIZE="0.7552947511360903" ORDER="812" O_E="0.42500000000000004" SE="2.0228869496966944" STUDY_ID="STD-Li-1999" TOTAL_1="23" TOTAL_2="17" VAR="0.24437499999999998" WEIGHT="1.106226269881983"/>
<DICH_DATA CI_END="1.7443813903889738" CI_START="0.0505761537299896" EFFECT_SIZE="0.2970254220837768" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24164144483554964" LOG_CI_START="-1.2960542014320358" LOG_EFFECT_SIZE="-0.527206378298243" ORDER="815" O_E="-1.4879227053140096" SE="0.9032500343337889" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="1.225699549581087" WEIGHT="5.5484441564362665"/>
<DICH_DATA CI_END="16.732544869141034" CI_START="0.06430242287465901" EFFECT_SIZE="1.037276807773466" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2235619982590866" LOG_CI_START="-1.191772662825846" LOG_EFFECT_SIZE="0.015894667716620098" ORDER="813" O_E="0.018181818181818188" SE="1.4187795360206874" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="0.49678693811731506" WEIGHT="2.2488338065661746"/>
<DICH_DATA CI_END="7.057676313757364" CI_START="0.13542687331323924" EFFECT_SIZE="0.9776497512039103" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8486617364307802" LOG_CI_START="-0.8682951482533996" LOG_EFFECT_SIZE="-0.009816705911309719" ORDER="818" O_E="-0.022222222222222143" SE="1.0085489731371378" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="0.983118835781778" WEIGHT="4.450340184378902"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="814" O_E="0.0" SE="0.0" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.75377243885626" CI_START="0.060639939269799034" EFFECT_SIZE="0.9773984878044767" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.197384567852683" LOG_CI_START="-1.2172412423167083" LOG_EFFECT_SIZE="-0.009928337232012497" ORDER="816" O_E="-0.011363636363636465" SE="1.4183631534840297" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" VAR="0.49707865997638734" WEIGHT="2.2501543605672163"/>
<DICH_DATA CI_END="6.752254524225731" CI_START="0.0026582733781472983" EFFECT_SIZE="0.1339751411427654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8294488045274568" LOG_CI_START="-2.5754003580374993" LOG_EFFECT_SIZE="-0.8729757767550212" ORDER="817" O_E="-0.5025125628140703" SE="2.000025252365832" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.24999368702810534" WEIGHT="1.1316607013612066"/>
<DICH_DATA CI_END="2.6111964948745547" CI_START="0.051093690768113584" EFFECT_SIZE="0.36526109325235095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41683955410131734" LOG_CI_START="-1.2916327247921533" LOG_EFFECT_SIZE="-0.4373965853454179" ORDER="805" O_E="-1.0" SE="1.003565073696199" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" VAR="0.9929078014184397" WEIGHT="4.4946524542193"/>
<DICH_DATA CI_END="418.41746282785317" CI_START="0.16295887236075834" EFFECT_SIZE="8.257411090558376" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6216098016993516" LOG_CI_START="-0.7879219892189541" LOG_EFFECT_SIZE="0.9168439062401987" ORDER="820" O_E="0.5263157894736843" SE="2.002775851439974" STUDY_ID="STD-Sorkness-1999a" TOTAL_1="27" TOTAL_2="30" VAR="0.24930747922437668" WEIGHT="1.1285544053035794"/>
<DICH_DATA CI_END="399.84342802650224" CI_START="0.15674390151007733" EFFECT_SIZE="7.916629263899994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6018899621882667" LOG_CI_START="-0.8048093474161904" LOG_EFFECT_SIZE="0.8985403073860381" ORDER="821" O_E="0.5166666666666666" SE="2.0011120378952105" STUDY_ID="STD-Sorkness-1999b" TOTAL_1="29" TOTAL_2="31" VAR="0.2497222222222222" WEIGHT="1.1304318461198097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.754684944269304" CI_END="1.4693912895928474" CI_START="1.0243401823037381" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2268482145143556" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="598" I2="30.17949874014332" I2_Q="0.0" ID="CMP-003.41" LOG_CI_END="0.1671374610609821" LOG_CI_START="0.010444209337668752" LOG_EFFECT_SIZE="0.08879083519932543" METHOD="MH" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="41" P_CHI2="0.1504853639173903" P_Q="0.0" P_Z="0.026334554835676913" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1178" TOTAL_2="1113" WEIGHT="100.0" Z="2.221242296448134">
<NAME>Adverse events (any)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0025687191202994" CI_START="0.66204357555552" DF="0.0" EFFECT_SIZE="1.1514285714285715" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="50" I2="0.0" ID="CMP-003.41.01" LOG_CI_END="0.30158742803851246" LOG_CI_START="-0.17911342445684486" LOG_EFFECT_SIZE="0.06123700179083383" NO="1" P_CHI2="1.0" P_Z="0.6175230720134055" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="81" WEIGHT="10.90395714427416" Z="0.4993638659395067">
<NAME>Children</NAME>
<DICH_DATA CI_END="2.0025687191202994" CI_START="0.66204357555552" EFFECT_SIZE="1.1514285714285715" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="50" LOG_CI_END="0.30158742803851246" LOG_CI_START="-0.17911342445684486" LOG_EFFECT_SIZE="0.06123700179083383" ORDER="822" O_E="0.0" SE="0.28236606026336897" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="0.07973059198865651" WEIGHT="10.90395714427416"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.68019923129379" CI_END="1.4960167692327784" CI_START="1.0213052620843062" DF="10.0" EFFECT_SIZE="1.2360783949992007" ESTIMABLE="YES" EVENTS_1="582" EVENTS_2="548" I2="36.22530012219182" ID="CMP-003.41.02" LOG_CI_END="0.17493646167312432" LOG_CI_START="0.009155569534546975" LOG_EFFECT_SIZE="0.0920460156038357" NO="2" P_CHI2="0.10916042805857629" P_Z="0.029521660839392953" STUDIES="11" TAU2="0.0" TOTAL_1="1018" TOTAL_2="1032" WEIGHT="89.09604285572584" Z="2.1764495675789526">
<NAME>Adults</NAME>
<DICH_DATA CI_END="4.7068062969292" CI_START="1.2484335971998186" EFFECT_SIZE="2.424074074074074" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="60" LOG_CI_END="0.6727263257963445" LOG_CI_START="0.09636544765922994" LOG_EFFECT_SIZE="0.3845458867277873" ORDER="824" O_E="0.0" SE="0.3385572328501011" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="0.11462099991511757" WEIGHT="5.362966677081781"/>
<DICH_DATA CI_END="3.4173853086106942" CI_START="0.5610019328177578" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.5336939480611252" LOG_CI_START="-0.25103564246818666" LOG_EFFECT_SIZE="0.1413291527964693" ORDER="825" O_E="0.0" SE="0.4609540459510389" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.2124786324786325" WEIGHT="3.7656633303583495"/>
<DICH_DATA CI_END="1.747906112128287" CI_START="0.5725427039321282" EFFECT_SIZE="1.0003753753753755" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="74" LOG_CI_END="0.24251810102167567" LOG_CI_START="-0.24219211529302043" LOG_EFFECT_SIZE="1.6299286432764997E-4" ORDER="826" O_E="0.0" SE="0.28472118041751954" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="0.08106615057834571" WEIGHT="11.575069744701512"/>
<DICH_DATA CI_END="9.717844523189973" CI_START="0.2500483301671617" EFFECT_SIZE="1.5588235294117647" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="51" LOG_CI_END="0.9875699464597711" LOG_CI_START="-0.6019760413427034" LOG_EFFECT_SIZE="0.19279695255853393" ORDER="827" O_E="0.0" SE="0.9337071816147128" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.8718091009988902" WEIGHT="0.8782472952835761"/>
<DICH_DATA CI_END="3.4557915431749597" CI_START="1.1162800207537653" EFFECT_SIZE="1.9640852974186307" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="54" LOG_CI_END="0.5385475375165619" LOG_CI_START="0.04777315178227733" LOG_EFFECT_SIZE="0.2931603446494196" ORDER="829" O_E="0.0" SE="0.2882833035527086" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="0.08310726310726312" WEIGHT="8.079425885255812"/>
<DICH_DATA CI_END="1.7716759624813776" CI_START="0.5023471892499612" EFFECT_SIZE="0.9433962264150944" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.2483842928473347" LOG_CI_START="-0.29899602337687525" LOG_EFFECT_SIZE="-0.025305865264770234" ORDER="828" O_E="0.0" SE="0.3215339073263657" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="0.10338405356055995" WEIGHT="9.345375720169327"/>
<DICH_DATA CI_END="2.824840748061117" CI_START="0.8268454279330714" EFFECT_SIZE="1.528301886792453" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="53" LOG_CI_END="0.4509939692571274" LOG_CI_START="-0.0825756707014059" LOG_EFFECT_SIZE="0.18420914927786072" ORDER="831" O_E="0.0" SE="0.3134214477239572" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="0.09823300389338124" WEIGHT="7.737569144656325"/>
<DICH_DATA CI_END="1.6408970314559947" CI_START="0.538160975501282" EFFECT_SIZE="0.9397163120567376" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="54" LOG_CI_END="0.21508132933248336" LOG_CI_START="-0.2690877980975898" LOG_EFFECT_SIZE="-0.02700323438255326" ORDER="830" O_E="0.0" SE="0.2844033421282589" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.08088526101372348" WEIGHT="11.969656530783283"/>
<DICH_DATA CI_END="1.520439781959238" CI_START="0.7093846622239595" EFFECT_SIZE="1.0385454545454544" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="110" LOG_CI_END="0.18196922429554185" LOG_CI_START="-0.1491182057477937" LOG_EFFECT_SIZE="0.016425509273874088" ORDER="823" O_E="0.0" SE="0.19448239531666606" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" VAR="0.03782340208810797" WEIGHT="24.34837465420384"/>
<DICH_DATA CI_END="1.0195880267767854" CI_START="0.01456187688242179" EFFECT_SIZE="0.12184873949579832" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.008424726821450844" LOG_CI_START="-1.8367826451365625" LOG_EFFECT_SIZE="-0.9141789591575559" ORDER="833" O_E="0.0" SE="1.0838839442119386" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="69" TOTAL_2="65" VAR="1.1748044045204287" WEIGHT="3.33384421045457"/>
<DICH_DATA CI_END="5.460056832048458" CI_START="0.7643263494304613" EFFECT_SIZE="2.0428571428571427" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.7371971631656506" LOG_CI_START="-0.11672116826404087" LOG_EFFECT_SIZE="0.31023799745080494" ORDER="832" O_E="0.0" SE="0.501595854845713" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" VAR="0.2515984015984016" WEIGHT="2.699849662777472"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.554575450120808" CI_END="4.722046910391523" CI_START="1.778276955641615" CI_STUDY="95" CI_TOTAL="95" DF="14.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.8977762515777385" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="16" I2="0.0" I2_Q="77.00850411024683" ID="CMP-003.42" LOG_CI_END="0.6741302971906087" LOG_CI_START="0.2499994005824187" LOG_EFFECT_SIZE="0.46206484888651367" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="42" P_CHI2="0.6420254199505386" P_Q="0.03702144957033582" P_Z="1.9501474492692613E-5" Q="4.349434263847439" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1492" TOTAL_2="1349" WEIGHT="100.00000000000003" Z="4.270523414266264">
<NAME>Oral Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7882269946286782" CI_END="3.202998479943453" CI_START="0.5476672993549168" DF="2.0" EFFECT_SIZE="1.3244536712730024" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" ID="CMP-003.42.01" LOG_CI_END="0.5055567325594423" LOG_CI_START="-0.26148318956909783" LOG_EFFECT_SIZE="0.12203677149517224" MODIFIED="2008-07-04 14:45:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.674277730973507" P_Z="0.5328481299296135" STUDIES="4" TAU2="0.0" TOTAL_1="438" TOTAL_2="316" WEIGHT="30.574818292533514" Z="0.6236642188227564">
<NAME>Children</NAME>
<DICH_DATA CI_END="365.61492155256883" CI_START="0.1439027305902849" EFFECT_SIZE="7.253480926835572" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5630239119406277" LOG_CI_START="-0.8419309651388512" LOG_EFFECT_SIZE="0.8605464734008881" ORDER="834" O_E="0.4953271028037384" SE="2.000087349594958" STUDY_ID="STD-Allen-1998" TOTAL_1="108" TOTAL_2="106" VAR="0.24997816403179315" WEIGHT="1.5515904551112691"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="835" O_E="0.0" SE="0.0" STUDY_ID="STD-Hofstra-2000" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.317975357103218" CI_START="0.46876557034883215" EFFECT_SIZE="1.2471377673199782" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5208731561567463" LOG_CI_START="-0.3290442936551072" LOG_EFFECT_SIZE="0.09591443125081961" ORDER="836" O_E="0.886075949367088" SE="0.4992457171787116" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" VAR="4.012095889418343" WEIGHT="24.90269384577496"/>
<DICH_DATA CI_END="11.130791309069146" CI_START="0.09059797455368032" EFFECT_SIZE="1.0042047339966946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0465260402508052" LOG_CI_START="-1.042881511484255" LOG_EFFECT_SIZE="0.0018222643832750982" MODIFIED="2008-07-04 14:45:30 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="3014" O_E="0.0027855153203342198" SE="1.2273283386233609" STUDY_ID="STD-Qaquandah-2006" TOTAL_1="239" TOTAL_2="120" VAR="0.6638630178919976" WEIGHT="4.120533991647288"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.4169141916446915" CI_END="7.350669527772993" CI_START="2.276665463174204" DF="11.0" EFFECT_SIZE="4.090845321579368" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="7" I2="0.0" ID="CMP-003.42.02" LOG_CI_END="0.8663268981283518" LOG_CI_START="0.3572992193848831" LOG_EFFECT_SIZE="0.6118130587566174" NO="2" P_CHI2="0.84415007232055" P_Z="2.459493873135806E-6" STUDIES="13" TAU2="0.0" TOTAL_1="1054" TOTAL_2="1033" WEIGHT="69.4251817074665" Z="4.711459162277015">
<NAME>Adults</NAME>
<DICH_DATA CI_END="8.89037776675396" CI_START="0.2585670259191505" EFFECT_SIZE="1.5161657358109997" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9489202152481676" LOG_CI_START="-0.5874268598672151" LOG_EFFECT_SIZE="0.18074667769047614" ORDER="837" O_E="0.5110132158590308" SE="0.90245787696345" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" VAR="1.2278522773583807" WEIGHT="7.621161157074493"/>
<DICH_DATA CI_END="363.8262285365747" CI_START="0.14316819042322598" EFFECT_SIZE="7.217225420345996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5608940045078463" LOG_CI_START="-0.844153464278521" LOG_EFFECT_SIZE="0.8583702701146627" ORDER="838" O_E="0.49404761904761907" SE="2.0001417384219207" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="85" TOTAL_2="83" VAR="0.24996456916099768" WEIGHT="1.5515060730539545"/>
<DICH_DATA CI_END="27.54738214478455" CI_START="2.4268065796250595" EFFECT_SIZE="8.176317523213553" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.4400803337107038" LOG_CI_START="0.3850351637448072" LOG_EFFECT_SIZE="0.9125577487277555" ORDER="839" O_E="5.470899470899471" SE="0.6197387553957873" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="2.6036505137034234" WEIGHT="16.160608672179812"/>
<DICH_DATA CI_END="110.5328623900775" CI_START="0.4229053044330075" EFFECT_SIZE="6.837026679699844" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0434914167801685" LOG_CI_START="-0.373756867533314" LOG_EFFECT_SIZE="0.8348672746234275" ORDER="840" O_E="0.9534883720930232" SE="1.4199036077777254" STUDY_ID="STD-Kavuru-2000" TOTAL_1="90" TOTAL_2="82" VAR="0.4960006831573255" WEIGHT="3.0786286022074143"/>
<DICH_DATA CI_END="365.73576808846406" CI_START="0.14395208700227247" EFFECT_SIZE="7.255923587505144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.563167435382712" LOG_CI_START="-0.8417820343843684" LOG_EFFECT_SIZE="0.8606927004991718" ORDER="841" O_E="0.4954128440366973" SE="2.0000841733128887" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.24997895800016834" WEIGHT="1.5515953831967175"/>
<DICH_DATA CI_END="7.388440022316605" CI_START="0.13978491495736403" EFFECT_SIZE="1.0162639717057331" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8685527521679596" LOG_CI_START="-0.854539693427687" LOG_EFFECT_SIZE="0.007006529370136253" ORDER="842" O_E="0.015748031496062964" SE="1.0121530319880496" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" VAR="0.9761299522599044" WEIGHT="6.058744861739443"/>
<DICH_DATA CI_END="10.107458120105688" CI_START="0.39576446263067633" EFFECT_SIZE="2.0000431824002436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.004641950525654" LOG_CI_START="-0.40256320552200714" LOG_EFFECT_SIZE="0.30103937250182355" ORDER="844" O_E="1.0144927536231885" SE="0.8265992744402613" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="1.4635580760344467" WEIGHT="9.084164411205318"/>
<DICH_DATA CI_END="42.69843430905763" CI_START="1.2229326190895096" EFFECT_SIZE="7.226154447601934" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6304119503551582" LOG_CI_START="0.08740252902012456" LOG_EFFECT_SIZE="0.8589072396876414" ORDER="843" O_E="2.4074074074074074" SE="0.9063713721120187" STUDY_ID="STD-Pearlman-1997" TOTAL_1="84" TOTAL_2="78" VAR="1.2172720224250015" WEIGHT="7.55549053087857"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="845" O_E="0.0" SE="0.0" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="18.75530026321071" CI_START="0.53538604443025" EFFECT_SIZE="3.1688051407465885" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2731240213852584" LOG_CI_START="-0.2713329534814086" LOG_EFFECT_SIZE="0.5008955339519249" ORDER="846" O_E="1.401315789473684" SE="0.9072216722220057" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" VAR="1.2149912976280017" WEIGHT="7.5413342911147225"/>
<DICH_DATA CI_END="399.84342802650224" CI_START="0.15674390151007733" EFFECT_SIZE="7.916629263899994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6018899621882667" LOG_CI_START="-0.8048093474161904" LOG_EFFECT_SIZE="0.8985403073860381" ORDER="847" O_E="0.5166666666666666" SE="2.0011120378952105" STUDY_ID="STD-Sorkness-1999b" TOTAL_1="29" TOTAL_2="31" VAR="0.2497222222222222" WEIGHT="1.5500018488810718"/>
<DICH_DATA CI_END="127.19222691575949" CI_START="0.48813179311311905" EFFECT_SIZE="7.879503143881623" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1044605711335933" LOG_CI_START="-0.3114629048533716" LOG_EFFECT_SIZE="0.8964988331401107" ORDER="848" O_E="1.025" SE="1.4191254088088217" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" VAR="0.49654481132075473" WEIGHT="3.0820059534572883"/>
<DICH_DATA CI_END="69.56013795121622" CI_START="0.7289101317932769" EFFECT_SIZE="7.120610179021146" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8423604346215399" LOG_CI_START="-0.13732601307045075" LOG_EFFECT_SIZE="0.8525172107755445" ORDER="849" O_E="1.4516129032258065" SE="1.1628776189802374" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" VAR="0.7394894387610308" WEIGHT="4.589939922477694"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.288066916970553" CI_END="2.351696221801245" CI_START="1.3420962140750918" CI_STUDY="95" CI_TOTAL="95" DF="21.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7765704590401552" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-003.43" LOG_CI_END="0.3713812214364175" LOG_CI_START="0.12778365126075159" LOG_EFFECT_SIZE="0.24958243634858449" METHOD="PETO" MODIFIED="2009-05-21 10:28:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="43" P_CHI2="0.80822491153616" P_Q="0.8609449002452155" P_Z="5.913520194281428E-5" Q="0.03068506133306137" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2760" TOTAL_2="2018" WEIGHT="100.00000000000001" Z="4.016235351315109">
<NAME>Sore throat or pharyngitis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5933860442774768" CI_END="3.68786355099272" CI_START="0.7489838203914322" DF="2.0" EFFECT_SIZE="1.661971760140599" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="0.0" ID="CMP-003.43.01" LOG_CI_END="0.5667748440119642" LOG_CI_START="-0.12552756386343825" LOG_EFFECT_SIZE="0.220623640074263" NO="1" P_CHI2="0.74327217642703" P_Z="0.21158952160866407" STUDIES="3" TAU2="0.0" TOTAL_1="348" TOTAL_2="265" WEIGHT="12.380957128474796" Z="1.24920665814442">
<NAME>Children</NAME>
<DICH_DATA CI_END="15.7947433637311" CI_START="0.06097813142155654" EFFECT_SIZE="0.9813938743457454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1985125737916007" LOG_CI_START="-1.2148258880346041" LOG_EFFECT_SIZE="-0.00815665712150175" ORDER="850" O_E="-0.009345794392523255" SE="1.4176069586947648" STUDY_ID="STD-Allen-1998" TOTAL_1="108" TOTAL_2="106" VAR="0.49760911525577606" WEIGHT="1.0188480890952323"/>
<DICH_DATA CI_END="3.928098861206517" CI_START="0.528118469345461" EFFECT_SIZE="1.4403130069599575" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5941824094448953" LOG_CI_START="-0.2772686441105224" LOG_EFFECT_SIZE="0.15845688266718644" ORDER="852" O_E="1.3924050632911396" SE="0.5118946626107388" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" VAR="3.8162673995776855" WEIGHT="7.813757080268885"/>
<DICH_DATA CI_END="11.74359603791131" CI_START="0.5978871723576695" EFFECT_SIZE="2.649782147350518" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.0698011037501807" LOG_CI_START="-0.22338076424842665" LOG_EFFECT_SIZE="0.4232101697508769" ORDER="851" O_E="1.6887966804979255" SE="0.7596214306158682" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="1.7330280126030888" WEIGHT="3.5483519591106796"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.663995811360016" CI_END="2.419882823443153" CI_START="1.329090479276469" DF="18.0" EFFECT_SIZE="1.7933887536178417" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="59" I2="0.0" ID="CMP-003.43.02" LOG_CI_END="0.38379433690435094" LOG_CI_START="0.12355454701718932" LOG_EFFECT_SIZE="0.25367444196077016" NO="2" P_CHI2="0.6848944881119616" P_Z="1.3289238592261457E-4" STUDIES="21" TAU2="0.0" TOTAL_1="2412" TOTAL_2="1753" WEIGHT="87.61904287152522" Z="3.8210357475079855">
<NAME>Adults</NAME>
<DICH_DATA CI_END="6.075346046275174" CI_START="0.30146164119505814" EFFECT_SIZE="1.3533232392662227" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7835710200000012" LOG_CI_START="-0.5207679408277874" LOG_EFFECT_SIZE="0.1314015395861069" ORDER="853" O_E="0.515418502202643" SE="0.7661751621722296" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" VAR="1.7035067631818974" WEIGHT="3.487907590954312"/>
<DICH_DATA CI_END="3.4684298109356297" CI_START="1.0499101616104398" EFFECT_SIZE="1.9082818720864836" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="8" LOG_CI_END="0.5401329103010903" LOG_CI_START="0.02115213908320517" LOG_EFFECT_SIZE="0.2806425246921478" ORDER="868" O_E="6.953307392996109" SE="0.3048518740096356" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="970" TOTAL_2="315" VAR="10.760247525095712" WEIGHT="22.03146464368995"/>
<DICH_DATA CI_END="6.374238925005338" CI_START="1.0433869898163097" EFFECT_SIZE="2.5789141056520806" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.8044283380625175" LOG_CI_START="0.018445417122591387" LOG_EFFECT_SIZE="0.41143687759255443" ORDER="854" O_E="4.444444444444445" SE="0.46169025843831935" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="4.6913580246913575" WEIGHT="9.605493573528125"/>
<DICH_DATA CI_END="18.543562458863875" CI_START="0.0693126928760395" EFFECT_SIZE="1.1337125956515117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2681931714267458" LOG_CI_START="-1.159187227996278" LOG_EFFECT_SIZE="0.054502971715233946" ORDER="855" O_E="0.06172839506172845" SE="1.4258552623478487" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.4918686175887822" WEIGHT="1.007094495965279"/>
<DICH_DATA CI_END="22.277552128034248" CI_START="1.3225726833368034" EFFECT_SIZE="5.428045863489896" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.3478674685621983" LOG_CI_START="0.12141954846126041" LOG_EFFECT_SIZE="0.7346435085117293" ORDER="856" O_E="3.259259259259259" SE="0.7204215792824075" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="1.9267553513892879" WEIGHT="3.945006125757866"/>
<DICH_DATA CI_END="17.47341438614689" CI_START="0.18317751140422484" EFFECT_SIZE="1.7890602457684783" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2423777764297228" LOG_CI_START="-0.7371278454746681" LOG_EFFECT_SIZE="0.2526249654775274" ORDER="857" O_E="0.430232558139535" SE="1.1627714010174992" STUDY_ID="STD-Kavuru-2000" TOTAL_1="90" TOTAL_2="82" VAR="0.7396245481198941" WEIGHT="1.5143714903866636"/>
<DICH_DATA CI_END="20.038060478010383" CI_START="0.376037506426999" EFFECT_SIZE="2.74500679339495" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3018556830404495" LOG_CI_START="-0.42476883586510294" LOG_EFFECT_SIZE="0.4385434235876733" ORDER="858" O_E="0.9816513761467891" SE="1.0142277893343332" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.9721403922228768" WEIGHT="1.990444609197843"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="859" O_E="0.0" SE="0.0" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.01019396263001" CI_START="0.34809540003070083" EFFECT_SIZE="5.958966292456357" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.008643573335502" LOG_CI_START="-0.45830171574036904" LOG_EFFECT_SIZE="0.7751709287975664" ORDER="860" O_E="0.8500000000000001" SE="1.4490958743792932" STUDY_ID="STD-Li-1999" TOTAL_1="23" TOTAL_2="17" VAR="0.47621794871794865" WEIGHT="0.9750499582282347"/>
<DICH_DATA CI_END="8.283581058747657" CI_START="0.6564341298853267" EFFECT_SIZE="2.3318716355394846" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9182181263784704" LOG_CI_START="-0.1828088468213687" LOG_EFFECT_SIZE="0.36770463977855083" ORDER="864" O_E="2.024154589371981" SE="0.646748694229002" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="2.390720903638358" WEIGHT="4.894969464094225"/>
<DICH_DATA CI_END="1.6783603711288178" CI_START="0.21464341012228885" EFFECT_SIZE="0.6002074586950746" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2248852165577391" LOG_CI_START="-0.6682824404780853" LOG_EFFECT_SIZE="-0.22169861196017307" ORDER="861" O_E="-1.8545454545454545" SE="0.5246511029940506" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="3.6329449707720216" WEIGHT="7.438406829337605"/>
<DICH_DATA CI_END="6.530115097800874" CI_START="0.8902249926359492" EFFECT_SIZE="2.4110727207721636" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8149208360835386" LOG_CI_START="-0.05050021727488828" LOG_EFFECT_SIZE="0.38221030940432515" ORDER="867" O_E="3.405555555555555" SE="0.508352610646044" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="3.8696339402717426" WEIGHT="7.923024367263447"/>
<DICH_DATA CI_END="347.6480898152931" CI_START="0.13614321786184416" EFFECT_SIZE="6.879675110859336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5411398474568374" LOG_CI_START="-0.8660039886871516" LOG_EFFECT_SIZE="0.8375679293848429" ORDER="862" O_E="0.4814814814814815" SE="2.0013731549849734" STUDY_ID="STD-Pearlman-1997" TOTAL_1="84" TOTAL_2="78" VAR="0.24965706447187927" WEIGHT="0.5111695410474031"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="863" O_E="0.0" SE="0.0" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.218951454567231" CI_START="0.6033351878174287" EFFECT_SIZE="1.5954440974957205" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6252045281941898" LOG_CI_START="-0.21944134494831502" LOG_EFFECT_SIZE="0.2028815916229374" ORDER="865" O_E="1.8977272727272734" SE="0.4961491669484108" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" VAR="4.0623324970484065" WEIGHT="8.317572116338335"/>
<DICH_DATA CI_END="3.0304263846090325" CI_START="0.4170347682522635" EFFECT_SIZE="1.1241855563077532" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4815037385534549" LOG_CI_START="-0.3798277363196346" LOG_EFFECT_SIZE="0.050838001116910135" ORDER="866" O_E="0.4572864321608048" SE="0.5059503720000168" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="3.906467008408878" WEIGHT="7.998439587637265"/>
<DICH_DATA CI_END="68.71474462687046" CI_START="0.7187726547014461" EFFECT_SIZE="7.027821811385632" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8370499368123065" LOG_CI_START="-0.14340845373636826" LOG_EFFECT_SIZE="0.8468207415379693" ORDER="869" O_E="1.4407894736842106" SE="1.1633310620354325" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" VAR="0.7389130748839684" WEIGHT="1.5129147583360607"/>
<DICH_DATA CI_END="2.9138026740068828" CI_START="0.051535944648466864" EFFECT_SIZE="0.38751202990897393" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46446013751919785" LOG_CI_START="-1.2878897589726592" LOG_EFFECT_SIZE="-0.41171481072673055" ORDER="870" O_E="-0.894736842105263" SE="1.0293390034712013" STUDY_ID="STD-Sorkness-1999a" TOTAL_1="27" TOTAL_2="30" VAR="0.9438068856351404" WEIGHT="1.9324321288005653"/>
<DICH_DATA CI_END="17.549866783837565" CI_START="0.0652673540786159" EFFECT_SIZE="1.0702492090224904" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2442738242056135" LOG_CI_START="-1.1853039931313352" LOG_EFFECT_SIZE="0.02948491553713919" ORDER="871" O_E="0.033333333333333326" SE="1.4271460365078819" STUDY_ID="STD-Sorkness-1999b" TOTAL_1="29" TOTAL_2="31" VAR="0.49097928436911487" WEIGHT="1.0052735979478438"/>
<DICH_DATA CI_END="16.975694979457945" CI_START="0.06514844995325321" EFFECT_SIZE="1.0516369215612902" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2298275631920217" LOG_CI_START="-1.1860959127949429" LOG_EFFECT_SIZE="0.021865825198539263" ORDER="872" O_E="0.025000000000000022" SE="1.4191254088088217" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" VAR="0.49654481132075473" WEIGHT="1.0166689408498155"/>
<DICH_DATA CI_END="350.53798236350906" CI_START="0.13745357340801148" EFFECT_SIZE="6.9413758211970364" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.544735082608432" LOG_CI_START="-0.861843965233331" LOG_EFFECT_SIZE="0.8414455586875504" ORDER="873" O_E="0.4838709677419355" SE="2.001041395540499" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" VAR="0.2497398543184183" WEIGHT="0.5113390521643758"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.352934891413273" CI_END="1.4435694189998571" CI_START="0.952929676232974" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1728683383344254" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="166" I2="13.559290725959977" I2_Q="0.0" ID="CMP-003.44" LOG_CI_END="0.1594376732625817" LOG_CI_START="-0.020939147998473535" LOG_EFFECT_SIZE="0.06924926263205407" METHOD="PETO" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="44" P_CHI2="0.29820745212975" P_Q="0.7696301467399524" P_Z="0.13234545027759653" Q="0.0857662367340275" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2367" TOTAL_2="1642" WEIGHT="99.99999999999999" Z="1.5049168708694363">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.021822556391072723" CI_END="2.6387618054708044" CI_START="0.6384788684332448" DF="1.0" EFFECT_SIZE="1.2979960137157067" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" I2="0.0" ID="CMP-003.44.01" LOG_CI_END="0.42140018929604733" LOG_CI_START="-0.19485347189266272" LOG_EFFECT_SIZE="0.11327335870169229" NO="1" P_CHI2="0.882560131026402" P_Z="0.4712045769854011" STUDIES="2" TAU2="0.0" TOTAL_1="240" TOTAL_2="159" WEIGHT="8.567269594217786" Z="0.7205205175899764">
<NAME>Children</NAME>
<DICH_DATA CI_END="4.5033008954179445" CI_START="0.43073714755486425" EFFECT_SIZE="1.392745124663372" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6535309660288533" LOG_CI_START="-0.3657876722763944" LOG_EFFECT_SIZE="0.14387164687622944" ORDER="875" O_E="0.924050632911392" SE="0.5987528138491383" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" VAR="2.7893619040718" WEIGHT="3.1314214894100383"/>
<DICH_DATA CI_END="3.0372036299290164" CI_START="0.5114690751271274" EFFECT_SIZE="1.246369019019868" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.4824739102553982" LOG_CI_START="-0.2911806198358036" LOG_EFFECT_SIZE="0.09564664520979727" ORDER="874" O_E="1.0663900414937757" SE="0.4544485006272597" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="4.842065391436098" WEIGHT="5.435848104807747"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.245346098288174" CI_END="1.443588275648457" CI_START="0.9349858568867527" DF="13.0" EFFECT_SIZE="1.1617807972672136" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="154" I2="24.617343566735258" ID="CMP-003.44.02" LOG_CI_END="0.15944334620413902" LOG_CI_START="-0.029194958456354655" LOG_EFFECT_SIZE="0.06512419387389219" NO="2" P_CHI2="0.18832972815229365" P_Z="0.17596331121272174" STUDIES="16" TAU2="0.0" TOTAL_1="2127" TOTAL_2="1483" WEIGHT="91.4327304057822" Z="1.3532890336854733">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.4061617605507362" CI_START="0.700570397026955" EFFECT_SIZE="0.9925297491124139" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="50" LOG_CI_END="0.14803528346733866" LOG_CI_START="-0.15454821797388552" LOG_EFFECT_SIZE="-0.003256467253273421" ORDER="889" O_E="-0.23735408560310134" SE="0.17773904655906367" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="970" TOTAL_2="315" VAR="31.65441615634272" WEIGHT="35.53619874208635"/>
<DICH_DATA CI_END="9.997115355139305" CI_START="1.139449804609889" EFFECT_SIZE="3.3750868341534574" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9998747033927953" LOG_CI_START="0.05669519826488407" LOG_EFFECT_SIZE="0.5282849508288397" ORDER="877" O_E="3.962962962962963" SE="0.5540283101259832" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="3.2578875171467763" WEIGHT="3.657402421099219"/>
<DICH_DATA CI_END="7.297048833206453" CI_START="0.33307358059867714" EFFECT_SIZE="1.5589913991678956" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8631472526417496" LOG_CI_START="-0.47745981418738426" LOG_EFFECT_SIZE="0.19284371922718269" ORDER="878" O_E="0.7160493827160495" SE="0.7874792271674399" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="1.6125819234872734" WEIGHT="1.8103329228347558"/>
<DICH_DATA CI_END="2.1351977321121476" CI_START="0.26200187047830564" EFFECT_SIZE="0.7479477252150841" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.32943809949633823" LOG_CI_START="-0.5816956081630524" LOG_EFFECT_SIZE="-0.12612875433335707" ORDER="879" O_E="-1.0138888888888893" SE="0.5352044500637183" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="3.4910861685328745" WEIGHT="3.9191982343946856"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="880" O_E="0.0" SE="0.0" STUDY_ID="STD-Kavuru-2000" TOTAL_1="90" TOTAL_2="82" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9752304530761662" CI_START="0.40741971102469243" EFFECT_SIZE="0.8970773770413921" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.29561777270201617" LOG_CI_START="-0.38995796359757096" LOG_EFFECT_SIZE="-0.047170095447777366" ORDER="881" O_E="-0.6697247706422012" SE="0.4027105811570043" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="6.166147630670819" WEIGHT="6.92230261314287"/>
<DICH_DATA CI_END="65.579298802224" CI_START="0.5963156676107829" EFFECT_SIZE="6.253476101073323" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8167667687232079" LOG_CI_START="-0.22452377984172023" LOG_EFFECT_SIZE="0.7961214944407438" ORDER="882" O_E="1.275" SE="1.1990641727782183" STUDY_ID="STD-Li-1999" TOTAL_1="23" TOTAL_2="17" VAR="0.695528846153846" WEIGHT="0.7808215822304637"/>
<DICH_DATA CI_END="9.214195167767699" CI_START="1.4021436940202299" EFFECT_SIZE="3.5943880772611565" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.9644574068950511" LOG_CI_START="0.14679252313295674" LOG_EFFECT_SIZE="0.5556249650140039" ORDER="885" O_E="5.545893719806763" SE="0.4803004002283062" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="4.334850288221428" WEIGHT="4.866433188929961"/>
<DICH_DATA CI_END="3.832792642228559" CI_START="0.4901710605012927" EFFECT_SIZE="1.3706655442239455" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5835153241403721" LOG_CI_START="-0.30965233289545235" LOG_EFFECT_SIZE="0.13693149562245985" ORDER="883" O_E="1.1454545454545455" SE="0.5246511029940506" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="3.6329449707720216" WEIGHT="4.078453188420257"/>
<DICH_DATA CI_END="3.1922299021559932" CI_START="0.6083453802416458" EFFECT_SIZE="1.3935488199721742" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.504094161388669" LOG_CI_START="-0.21584978561922258" LOG_EFFECT_SIZE="0.14412218788472317" ORDER="888" O_E="1.855555555555556" SE="0.4228986382524491" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="5.591488378508863" WEIGHT="6.277172869067205"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="884" O_E="-0.5" SE="2.0" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" VAR="0.25" WEIGHT="0.280657512103298"/>
<DICH_DATA CI_END="1.643803063981158" CI_START="0.31326064558339367" EFFECT_SIZE="0.7175923696881803" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.21584978561922255" LOG_CI_START="-0.504094161388669" LOG_EFFECT_SIZE="-0.14412218788472328" ORDER="886" O_E="-1.855555555555556" SE="0.4228986382524491" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="91" VAR="5.591488378508863" WEIGHT="6.277172869067205"/>
<DICH_DATA CI_END="2.448892767624857" CI_START="0.2999227931178315" EFFECT_SIZE="0.8570173620832332" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.38896976860841903" LOG_CI_START="-0.5229905280745921" LOG_EFFECT_SIZE="-0.06701037973308654" ORDER="887" O_E="-0.5376884422110555" SE="0.5356899925478746" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="3.484760485846317" WEIGHT="3.912096832934029"/>
<DICH_DATA CI_END="2.126761420045986" CI_START="0.6671606336139277" EFFECT_SIZE="1.1911723202557791" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.3277187735092137" LOG_CI_START="-0.1757695875331379" LOG_EFFECT_SIZE="0.07597459298803781" ORDER="876" O_E="2.0" SE="0.2957515555838599" STUDY_ID="STD-SAS30022" TOTAL_1="212" TOTAL_2="212" VAR="11.432624113475176" WEIGHT="12.834607362000463"/>
<DICH_DATA CI_END="418.41746282785317" CI_START="0.16295887236075834" EFFECT_SIZE="8.257411090558376" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6216098016993516" LOG_CI_START="-0.7879219892189541" LOG_EFFECT_SIZE="0.9168439062401987" ORDER="890" O_E="0.5263157894736843" SE="2.002775851439974" STUDY_ID="STD-Sorkness-1999a" TOTAL_1="27" TOTAL_2="30" VAR="0.24930747922437668" WEIGHT="0.27988006747143285"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="891" O_E="0.0" SE="0.0" STUDY_ID="STD-Sorkness-1999b" TOTAL_1="29" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.4523020298977976" CI_END="7.720724855828437" CI_START="2.206863558718896" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.127782253368384" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.45" LOG_CI_END="0.8876580757383985" LOG_CI_START="0.34377548335321945" LOG_EFFECT_SIZE="0.6157167795458088" METHOD="PETO" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="45" P_CHI2="0.9738250368249949" P_Q="0.5459053853789055" P_Z="9.094258389430454E-6" Q="0.3647042925147801" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1169" TOTAL_2="1152" WEIGHT="100.0" Z="4.437658897279535">
<NAME>Hoarseness or dysphonia (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="79.00656459666001" CI_START="0.8312342556052514" DF="0.0" EFFECT_SIZE="8.103885667408747" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.45.01" LOG_CI_END="1.8976631779949942" LOG_CI_START="-0.08027656757577578" LOG_EFFECT_SIZE="0.9086933052096093" NO="1" P_CHI2="1.0" P_Z="0.07172337623806249" STUDIES="2" TAU2="0.0" TOTAL_1="195" TOTAL_2="199" WEIGHT="7.561086438280154" Z="1.800869976137272">
<NAME>Children</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="892" O_E="0.0" SE="0.0" STUDY_ID="STD-Allen-1998" TOTAL_1="108" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="79.00656459666001" CI_START="0.8312342556052514" EFFECT_SIZE="8.103885667408747" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8976631779949942" LOG_CI_START="-0.08027656757577578" LOG_EFFECT_SIZE="0.9086933052096093" ORDER="893" O_E="1.55" SE="1.1618515975079176" STUDY_ID="STD-Katz-1998" TOTAL_1="87" TOTAL_2="93" VAR="0.7407960893854749" WEIGHT="7.561086438280154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.0875977373830175" CI_END="7.491988915342803" CI_START="2.0366111385805965" DF="11.0" EFFECT_SIZE="3.906183313044783" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" I2="0.0" ID="CMP-003.45.02" LOG_CI_END="0.8745971261499408" LOG_CI_START="0.30890811467013124" LOG_EFFECT_SIZE="0.5917526204100361" NO="2" P_CHI2="0.9672841143101368" P_Z="4.121959063422184E-5" STUDIES="12" TAU2="0.0" TOTAL_1="974" TOTAL_2="953" WEIGHT="92.43891356171984" Z="4.100535100467541">
<NAME>Adults</NAME>
<DICH_DATA CI_END="363.8262285365747" CI_START="0.14316819042322598" EFFECT_SIZE="7.217225420345996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5608940045078463" LOG_CI_START="-0.844153464278521" LOG_EFFECT_SIZE="0.8583702701146627" ORDER="894" O_E="0.49404761904761907" SE="2.0001417384219207" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="85" TOTAL_2="83" VAR="0.24996456916099768" WEIGHT="2.5513143778898835"/>
<DICH_DATA CI_END="6.826612744156557" CI_START="0.4049026399625322" EFFECT_SIZE="1.6625623363082829" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8342052671630741" LOG_CI_START="-0.3926493916252085" LOG_EFFECT_SIZE="0.22077793776893279" ORDER="895" O_E="0.9788359788359786" SE="0.7206604996007427" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="1.9254780101340947" WEIGHT="19.652784184793266"/>
<DICH_DATA CI_END="427.9458049572349" CI_START="0.16598818482764696" EFFECT_SIZE="8.428163938216773" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.63138877345641" LOG_CI_START="-0.7799228242899152" LOG_EFFECT_SIZE="0.9257329745832474" ORDER="896" O_E="0.5308641975308642" SE="2.0038213187809384" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.2490474013107758" WEIGHT="2.541953117087748"/>
<DICH_DATA CI_END="20.37421959330876" CI_START="0.5866231199038879" EFFECT_SIZE="3.4571647723870074" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3090809826728427" LOG_CI_START="-0.23164082466809213" LOG_EFFECT_SIZE="0.5387200790023753" ORDER="897" O_E="1.5144508670520231" SE="0.9050276163280133" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" VAR="1.2208894383373985" WEIGHT="12.461257162561608"/>
<DICH_DATA CI_END="342.162586761007" CI_START="0.13357878815771884" EFFECT_SIZE="6.760596400647332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5342325205424907" LOG_CI_START="-0.8742625008233952" LOG_EFFECT_SIZE="0.8299850098595479" ORDER="898" O_E="0.4767441860465116" SE="2.0021668478727905" STUDY_ID="STD-Kavuru-2000" TOTAL_1="90" TOTAL_2="82" VAR="0.24945916711736074" WEIGHT="2.546155888809315"/>
<DICH_DATA CI_END="119.72374286315481" CI_START="0.4563445093150253" EFFECT_SIZE="7.391567674738876" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0781802855103333" LOG_CI_START="-0.340707170483968" LOG_EFFECT_SIZE="0.8687365575131827" ORDER="899" O_E="0.9908256880733946" SE="1.4208664653370688" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.49532867603737063" WEIGHT="5.055673198793834"/>
<DICH_DATA CI_END="15.940820729320304" CI_START="0.06152562359052828" EFFECT_SIZE="0.9903377887954449" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2025106777275336" LOG_CI_START="-1.2109439758282814" LOG_EFFECT_SIZE="-0.0042166490503739995" ORDER="901" O_E="-0.004830917874396157" SE="1.4176752102918964" STUDY_ID="STD-Lumry-2006" TOTAL_1="104" TOTAL_2="103" VAR="0.4975612032952928" WEIGHT="5.078459943776477"/>
<DICH_DATA CI_END="347.6480898152931" CI_START="0.13614321786184416" EFFECT_SIZE="6.879675110859336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5411398474568374" LOG_CI_START="-0.8660039886871516" LOG_EFFECT_SIZE="0.8375679293848429" ORDER="900" O_E="0.4814814814814815" SE="2.0013731549849734" STUDY_ID="STD-Pearlman-1997" TOTAL_1="84" TOTAL_2="78" VAR="0.24965706447187927" WEIGHT="2.548175768537167"/>
<DICH_DATA CI_END="19.797651634939676" CI_START="0.5731932273912288" EFFECT_SIZE="3.3686614308057603" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2966136780154116" LOG_CI_START="-0.24169894968431277" LOG_EFFECT_SIZE="0.5274573641655493" ORDER="902" O_E="1.487437185929648" SE="0.9036124522811346" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="1.2247165475619302" WEIGHT="12.500319333744812"/>
<DICH_DATA CI_END="42.71403504146211" CI_START="1.219308565662422" EFFECT_SIZE="7.216757499047589" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6305705996044721" LOG_CI_START="0.08611362473780533" LOG_EFFECT_SIZE="0.8583421121711388" ORDER="903" O_E="2.401315789473684" SE="0.9072216722220057" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" VAR="1.2149912976280017" WEIGHT="12.40105658595505"/>
<DICH_DATA CI_END="77.91870607176297" CI_START="0.8180433180852213" EFFECT_SIZE="7.98378837744664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8916417319793994" LOG_CI_START="-0.08722369839802971" LOG_EFFECT_SIZE="0.9022090167906848" ORDER="904" O_E="1.5375" SE="1.1623953493455625" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" VAR="0.7401031839622642" WEIGHT="7.554014157697794"/>
<DICH_DATA CI_END="69.56013795121622" CI_START="0.7289101317932769" EFFECT_SIZE="7.120610179021146" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8423604346215399" LOG_CI_START="-0.13732601307045075" LOG_EFFECT_SIZE="0.8525172107755445" ORDER="905" O_E="1.4516129032258065" SE="1.1628776189802374" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" VAR="0.7394894387610308" WEIGHT="7.54774984207289"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.090421172498754" CI_END="1.3095268191810232" CI_START="0.8810476336187403" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0741301155817746" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="220" I2="0.0" I2_Q="0.0" ID="CMP-003.46" LOG_CI_END="0.117114397227121" LOG_CI_START="-0.05500061093126344" LOG_EFFECT_SIZE="0.031056893147928786" METHOD="MH" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="46" P_CHI2="0.8672634768730988" P_Q="0.0" P_Z="0.4793662132259243" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2113" TOTAL_2="1276" WEIGHT="100.00000000000003" Z="0.7073223037660352">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.001225531519731" CI_END="1.410494285673801" CI_START="0.6070947648947336" DF="2.0" EFFECT_SIZE="0.9253667903844947" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="42" I2="0.06123905079306479" ID="CMP-003.46.01" LOG_CI_END="0.14937133104057823" LOG_CI_START="-0.21674351212315077" LOG_EFFECT_SIZE="-0.033686090541286295" MODIFIED="2008-07-04 14:42:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.36765419834627144" P_Z="0.7183453213562878" STUDIES="3" TAU2="0.0" TOTAL_1="479" TOTAL_2="279" WEIGHT="23.53126014993806" Z="0.3606711143986608">
<NAME>Children</NAME>
<DICH_DATA CI_END="2.3140965492390273" CI_START="0.40708825342708044" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.36438147472247506" LOG_CI_START="-0.39031142905121036" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="907" O_E="0.0" SE="0.44331034746678655" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" VAR="0.196524064171123" WEIGHT="5.4437831056731065"/>
<DICH_DATA CI_END="1.2646068133228148" CI_START="0.3158792699403413" EFFECT_SIZE="0.6320309145556032" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.10195551733211865" LOG_CI_START="-0.50047887439852" LOG_EFFECT_SIZE="-0.19926167853320068" ORDER="906" O_E="0.0" SE="0.3538729438009109" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="0.12522606035432263" WEIGHT="10.18638737079876"/>
<DICH_DATA CI_END="2.5255611346304634" CI_START="0.6410357210770282" EFFECT_SIZE="1.2723894463024898" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.4023578856621938" LOG_CI_START="-0.1931177691794716" LOG_EFFECT_SIZE="0.10462005824136111" MODIFIED="2008-07-04 14:42:32 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="3012" O_E="0.0" SE="0.34978534730602484" STUDY_ID="STD-Qaquandah-2006" TOTAL_1="239" TOTAL_2="120" VAR="0.12234978918999642" WEIGHT="7.901089673466191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4122089423249387" CI_END="1.4018064915578101" CI_START="0.8946985686655705" DF="8.0" EFFECT_SIZE="1.119908148708133" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="178" I2="0.0" ID="CMP-003.46.02" LOG_CI_END="0.14668806680547108" LOG_CI_START="-0.04832325743834878" LOG_EFFECT_SIZE="0.04918240468356116" NO="2" P_CHI2="0.9058953200630635" P_Z="0.32285064533094465" STUDIES="9" TAU2="0.0" TOTAL_1="1634" TOTAL_2="997" WEIGHT="76.46873985006197" Z="0.9886168634220617">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.5519066684756786" CI_START="0.7001663858739677" EFFECT_SIZE="1.0423976608187135" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="36" LOG_CI_END="0.19086559927731625" LOG_CI_START="-0.15479874301381755" LOG_EFFECT_SIZE="0.018033428131749372" ORDER="916" O_E="0.0" SE="0.20304494572790202" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="970" TOTAL_2="315" VAR="0.041227249985646676" WEIGHT="25.248363232274432"/>
<DICH_DATA CI_END="2.312171764786331" CI_START="0.680763426697591" EFFECT_SIZE="1.2546082949308757" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.364020093471691" LOG_CI_START="-0.16700378431312482" LOG_EFFECT_SIZE="0.0985081545792831" ORDER="908" O_E="0.0" SE="0.31192605442138954" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="0.09729786342689568" WEIGHT="9.681789996945126"/>
<DICH_DATA CI_END="1.451391942825742" CI_START="0.1616511251731325" EFFECT_SIZE="0.484375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.1617847078346562" LOG_CI_START="-0.7914212681338852" LOG_EFFECT_SIZE="-0.3148182801496145" ORDER="909" O_E="0.0" SE="0.5599179087296003" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.313508064516129" WEIGHT="4.997052901649097"/>
<DICH_DATA CI_END="2.83050116959965" CI_START="0.563206769703301" EFFECT_SIZE="1.2625994694960212" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.45186333867674017" LOG_CI_START="-0.24933213364733958" LOG_EFFECT_SIZE="0.10126560251470028" ORDER="910" O_E="0.0" SE="0.4118856914167316" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="0.16964982279383903" WEIGHT="5.519205890395633"/>
<DICH_DATA CI_END="2.2168050676372255" CI_START="0.47973390986222486" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" LOG_CI_END="0.34572750557657866" LOG_CI_START="-0.31899958246061566" LOG_EFFECT_SIZE="0.013363961557981502" ORDER="911" O_E="0.0" SE="0.3904639819652015" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="0.15246212121212122" WEIGHT="6.8079115219714765"/>
<DICH_DATA CI_END="3.0420280633554837" CI_START="0.7335631161034034" EFFECT_SIZE="1.4938271604938271" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.4831632161943671" LOG_CI_START="-0.1345625133187665" LOG_EFFECT_SIZE="0.17430035143780032" ORDER="913" O_E="0.0" SE="0.36285515130769125" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="0.1316638608305275" WEIGHT="6.599368777721362"/>
<DICH_DATA CI_END="2.531162659025842" CI_START="0.5763091708792474" EFFECT_SIZE="1.2077798861480076" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.40332005493600637" LOG_CI_START="-0.2393444693817512" LOG_EFFECT_SIZE="0.08198779277712759" ORDER="912" O_E="0.0" SE="0.37750432282495255" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="0.14250951375152598" WEIGHT="6.733244861511837"/>
<DICH_DATA CI_END="3.0168513243273125" CI_START="0.5509656811964586" EFFECT_SIZE="1.2892561983471074" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4795539079160384" LOG_CI_START="-0.2588754518400154" LOG_EFFECT_SIZE="0.1103392280380115" ORDER="915" O_E="0.0" SE="0.4337570612049885" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="0.18814518814518816" WEIGHT="4.959965399644671"/>
<DICH_DATA CI_END="2.4254897462217304" CI_START="0.47815634570959165" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.38479944298239405" LOG_CI_START="-0.3204300762395916" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="914" O_E="0.0" SE="0.41425531053341574" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.1716074623051367" WEIGHT="5.921837267948321"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.985012104400869" CI_END="1.8003026774885822" CI_START="0.9449348406459561" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3042885891040992" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="64" I2="0.0" I2_Q="2.474960145055393" ID="CMP-003.47" LOG_CI_END="0.25534552738791516" LOG_CI_START="-0.024598137864874667" LOG_EFFECT_SIZE="0.11537369476152026" METHOD="PETO" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="47" P_CHI2="0.8743624648444892" P_Q="0.3112470962033441" P_Z="0.106196600150326" Q="1.0253776891425685" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1978" TOTAL_2="1260" WEIGHT="100.00000000000001" Z="1.6155270832201387">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23680838672520155" CI_END="4.562519607111889" CI_START="0.8379365867640662" DF="1.0" EFFECT_SIZE="1.9552754554352347" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" ID="CMP-003.47.01" LOG_CI_END="0.6592047438189864" LOG_CI_START="-0.07678884659705525" LOG_EFFECT_SIZE="0.29120794861096555" NO="1" P_CHI2="0.6265208544531843" P_Z="0.12090555098784088" STUDIES="2" TAU2="0.0" TOTAL_1="240" TOTAL_2="159" WEIGHT="14.467491121152786" Z="1.5509838637769837">
<NAME>Children</NAME>
<DICH_DATA CI_END="4.737148212754666" CI_START="0.6031346820937175" EFFECT_SIZE="1.6903071854933962" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6755169728585324" LOG_CI_START="-0.21958569754653764" LOG_EFFECT_SIZE="0.2279656376559973" ORDER="918" O_E="1.8987341772151893" SE="0.5257877394256162" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" VAR="3.6172547066501886" WEIGHT="9.781277569330697"/>
<DICH_DATA CI_END="11.74359603791131" CI_START="0.5978871723576695" EFFECT_SIZE="2.649782147350518" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.0698011037501807" LOG_CI_START="-0.22338076424842665" LOG_EFFECT_SIZE="0.4232101697508769" ORDER="917" O_E="1.6887966804979255" SE="0.7596214306158682" STUDY_ID="STD-Levy-2006" TOTAL_1="160" TOTAL_2="81" VAR="1.7330280126030888" WEIGHT="4.686213551822089"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.722826028533098" CI_END="1.725756199445838" CI_START="0.8595766061059942" DF="9.0" EFFECT_SIZE="1.2179571654561718" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="57" I2="0.0" ID="CMP-003.47.02" LOG_CI_END="0.23697944218219325" LOG_CI_START="-0.06571541260512752" LOG_EFFECT_SIZE="0.0856320147885329" NO="2" P_CHI2="0.8577701286220056" P_Z="0.2674548049847967" STUDIES="10" TAU2="0.0" TOTAL_1="1738" TOTAL_2="1101" WEIGHT="85.53250887884722" Z="1.108942965198733">
<NAME>Adults</NAME>
<DICH_DATA CI_END="7.216370410955175" CI_START="1.1068727723296228" EFFECT_SIZE="2.826234937674399" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8583188171205254" LOG_CI_START="0.04409770448249475" LOG_EFFECT_SIZE="0.4512082608015101" ORDER="919" O_E="4.541850220264317" SE="0.4782775120230892" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" VAR="4.371596576684973" WEIGHT="11.821064040383797"/>
<DICH_DATA CI_END="1.7694581539829572" CI_START="0.44413054804013263" EFFECT_SIZE="0.8864933274777268" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" LOG_CI_END="0.24784029643994646" LOG_CI_START="-0.35248935429987904" LOG_EFFECT_SIZE="-0.05232452892996631" ORDER="928" O_E="-0.9688715953307394" SE="0.3526366085242713" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="970" TOTAL_2="315" VAR="8.041650754049352" WEIGHT="21.74511460206689"/>
<DICH_DATA CI_END="3.9806872554215214" CI_START="0.45371021082310226" EFFECT_SIZE="1.3439041832951242" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5999580583728326" LOG_CI_START="-0.34322144675507876" LOG_EFFECT_SIZE="0.1283683058088769" ORDER="920" O_E="0.9629629629629628" SE="0.5540283101259832" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" VAR="3.2578875171467763" WEIGHT="8.80952674863764"/>
<DICH_DATA CI_END="18.543562458863875" CI_START="0.0693126928760395" EFFECT_SIZE="1.1337125956515117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2681931714267458" LOG_CI_START="-1.159187227996278" LOG_EFFECT_SIZE="0.054502971715233946" ORDER="921" O_E="0.06172839506172845" SE="1.4258552623478487" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.4918686175887822" WEIGHT="1.330042771783203"/>
<DICH_DATA CI_END="4.695280168847127" CI_START="0.27874917568325214" EFFECT_SIZE="1.1440303652736048" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6716615118639018" LOG_CI_START="-0.554786408237036" LOG_EFFECT_SIZE="0.05843755181343298" ORDER="922" O_E="0.2592592592592591" SE="0.7204215792824075" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" VAR="1.9267553513892879" WEIGHT="5.210064103443979"/>
<DICH_DATA CI_END="2.975580767454011" CI_START="0.4899239080889389" EFFECT_SIZE="1.2073972661992212" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.47357174300059046" LOG_CI_START="-0.3098713666311401" LOG_EFFECT_SIZE="0.08185018818472514" ORDER="923" O_E="0.8899082568807337" SE="0.46019836070361647" STUDY_ID="STD-Kemp-2004" TOTAL_1="55" TOTAL_2="54" VAR="4.721824762225402" WEIGHT="12.76810243640164"/>
<DICH_DATA CI_END="6.942672299517241" CI_START="0.41375434375919073" EFFECT_SIZE="1.694863068575709" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8415266666435463" LOG_CI_START="-0.38325743379448524" LOG_EFFECT_SIZE="0.22913461642453048" ORDER="925" O_E="1.0193236714975846" SE="0.7194442433763761" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="1.9319937454783076" WEIGHT="5.224229040877896"/>
<DICH_DATA CI_END="3.1408533863586703" CI_START="0.21536880271860948" EFFECT_SIZE="0.8224608400007607" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4970476641980898" LOG_CI_START="-0.6668172062767475" LOG_EFFECT_SIZE="-0.08488477103932886" ORDER="924" O_E="-0.418181818181818" SE="0.6836599861409441" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" VAR="2.13953638379359" WEIGHT="5.785437005885404"/>
<DICH_DATA CI_END="3.4856569312286263" CI_START="0.2737719844064145" EFFECT_SIZE="0.9768701116435257" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5422846403166472" LOG_CI_START="-0.5626109960859473" LOG_EFFECT_SIZE="-0.010163177884650028" ORDER="927" O_E="-0.05555555555555536" SE="0.6490211661444923" STUDY_ID="STD-Nathan-2006" TOTAL_1="91" TOTAL_2="89" VAR="2.3740085523139527" WEIGHT="6.41946406468338"/>
<DICH_DATA CI_END="3.4856569312286263" CI_START="0.2737719844064145" EFFECT_SIZE="0.9768701116435257" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5422846403166472" LOG_CI_START="-0.5626109960859473" LOG_EFFECT_SIZE="-0.010163177884650028" ORDER="926" O_E="-0.05555555555555536" SE="0.6490211661444923" STUDY_ID="STD-Pearlman-2004" TOTAL_1="91" TOTAL_2="89" VAR="2.3740085523139527" WEIGHT="6.41946406468338"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.48" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="48" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total urinary free cortisol excretion (mcg/24 hours)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.48.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="5.511915021293881" CI_START="-2.5119150212938806" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="9.8" ORDER="929" SD_1="12.7" SD_2="6.9" SE="2.0469330319022974" STUDY_ID="STD-Peden-1998" TOTAL_1="57" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.48.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.49" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="49" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>AUC serum cortisol (ng*h/mL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="136.74531181246024" CI_START="-266.7453118124603" EFFECT_SIZE="-65.0" ESTIMABLE="YES" MEAN_1="1185.0" MEAN_2="1250.0" ORDER="930" SD_1="300.0" SD_2="250.0" SE="102.93317295817755" STUDY_ID="STD-Casale-2001" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5837409245308512" CI_END="1.3321580514391838" CI_START="-1.3288265717872734" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0016657398259552858" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.50" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="50" P_CHI2="0.4448498610755105" P_Q="0.4448498610755105" P_Z="0.9980421360185934" Q="0.5837409245308512" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="0.0024538210690806654">
<NAME>Morning plasma cortisol (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8349004313897663" CI_START="-1.2349004313897685" DF="0.0" EFFECT_SIZE="0.29999999999999893" ESTIMABLE="YES" I2="0.0" ID="CMP-003.50.01" NO="1" P_CHI2="1.0" P_Z="0.701660672265712" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="73" WEIGHT="75.13881165216301" Z="0.38307969907183004">
<NAME>Children</NAME>
<CONT_DATA CI_END="1.8349004313897663" CI_START="-1.2349004313897685" EFFECT_SIZE="0.29999999999999893" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="10.3" ORDER="931" SD_1="5.4" SD_2="4.3" SE="0.7831268551345157" STUDY_ID="STD-Peden-1998" TOTAL_1="81" TOTAL_2="73" WEIGHT="75.13881165216301"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7684030438960896" CI_START="-3.5684030438960903" DF="0.0" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.50.02" NO="2" P_CHI2="1.0" P_Z="0.5085755057463741" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="17" WEIGHT="24.861188347836986" Z="0.6610574028991176">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.7684030438960896" CI_START="-3.5684030438960903" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="13.4" ORDER="932" SD_1="3.84" SD_2="4.54" SE="1.361455141494493" STUDY_ID="STD-Li-1999" TOTAL_1="23" TOTAL_2="17" WEIGHT="24.861188347836986"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.51" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="51" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="63" TOTAL_2="64" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in morning plasma cortisol compared to baseline (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.51.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.51.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="64" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="2.274230912694491" CI_START="-1.8742309126944905" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.9" ORDER="933" SD_1="6.3" SD_2="5.6" SE="1.058300524425836" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6901181258115276" CI_END="1.3603511667269872" CI_START="-2.5599234050917063" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5997861191823597" ESTIMABLE="YES" I2="40.832537990808206" I2_Q="0.0" ID="CMP-003.52" MODIFIED="2009-05-21 10:28:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="52" P_CHI2="0.193585481546365" P_Q="1.0" P_Z="0.5486841346143244" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="61" UNITS="" WEIGHT="99.99999999999999" Z="0.5997330903682637">
<NAME>Change in peak plasma cortisol expression (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.52.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6901181258115276" CI_END="1.3603511667269872" CI_START="-2.5599234050917063" DF="1.0" EFFECT_SIZE="-0.5997861191823597" ESTIMABLE="YES" I2="40.832537990808206" ID="CMP-003.52.02" NO="2" P_CHI2="0.193585481546365" P_Z="0.5486841346143244" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="61" WEIGHT="99.99999999999999" Z="0.5997330903682637">
<NAME>Adults</NAME>
<CONT_DATA CI_END="6.3822792869968765" CI_START="-2.3822792869968765" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="3.0" ORDER="934" SD_1="10.39" SD_2="5.48" SE="2.235897864227984" STUDY_ID="STD-Sorkness-1999a" TOTAL_1="27" TOTAL_2="30" WEIGHT="20.006580948235083"/>
<CONT_DATA CI_END="0.9415902522540276" CI_START="-3.4415902522540276" EFFECT_SIZE="-1.25" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.75" ORDER="935" SD_1="2.69" SD_2="5.57" SE="1.1181788387649017" STUDY_ID="STD-Sorkness-1999b" TOTAL_1="29" TOTAL_2="31" WEIGHT="79.9934190517649"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-05-21 09:48:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="4">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 200 mcg/d (subgroups)</NAME>
<IV_OUTCOME CHI2="3.7434560580481424" CI_END="0.22261009906889745" CI_START="0.1288729806494764" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.17574153985918692" ESTIMABLE="YES" I2="19.860151862869316" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.6524551370794566" LOG_CI_START="-0.8898381267494384" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.7551255726006394" MODIFIED="2008-07-14 14:00:04 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.29053226342326577" P_Q="0.6339432333348594" P_Z="1.993752167353667E-13" Q="0.2267513139548516" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="334" TOTAL_2="336" WEIGHT="200.0" Z="7.349214367149822">
<NAME>Paediatric studies: change in FEV1 compared to baseline (litres); study duration</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 13:59:02 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.516704744093291" CI_END="0.2418240343836723" CI_START="0.12613306646393188" DF="2.0" EFFECT_SIZE="0.1839785504238021" ESTIMABLE="YES" I2="43.12857787224732" ID="CMP-004.01.02" LOG_CI_END="-0.6165005377122934" LOG_CI_START="-0.8991710458590751" LOG_EFFECT_SIZE="-0.7352328072925924" MODIFIED="2008-07-14 13:59:44 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.17232861194888627" P_Z="4.555481495173072E-10" STUDIES="3" TAU2="0.0" TOTAL_1="237" TOTAL_2="240" WEIGHT="99.99999999999999" Z="6.233698952345103">
<NAME>1-5 months</NAME>
<IV_DATA CI_END="0.3093576229796436" CI_START="0.0506423770203564" EFFECT_SIZE="0.18" ESTIMABLE="YES" ESTIMATE="0.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="944" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="70" TOTAL_2="76" WEIGHT="19.99654039093582"/>
<IV_DATA CI_END="0.37995397953269705" CI_START="0.16004602046730299" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="946" SE="0.0561" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="27.676872513405986"/>
<IV_DATA CI_END="0.21996653056923424" CI_START="0.06003346943076579" EFFECT_SIZE="0.14" ESTIMABLE="YES" ESTIMATE="0.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="953" SE="0.0408" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="52.326587095658184"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.23996653056923423" CI_START="0.08003346943076578" DF="0.0" EFFECT_SIZE="0.16" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="-0.6198493274664171" LOG_CI_START="-1.0967283561414316" LOG_EFFECT_SIZE="-0.7958800173440752" MODIFIED="2008-07-14 13:59:25 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="1.0" P_Z="8.79743843025883E-5" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="96" WEIGHT="100.0" Z="3.9215686274509802">
<NAME>6 months or longer</NAME>
<IV_DATA CI_END="0.23996653056923423" CI_START="0.08003346943076578" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="961" SE="0.0408" STUDY_ID="STD-Allen-1998" TOTAL_1="97" TOTAL_2="96" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="140.98508290460182" CI_END="0.27573623440390976" CI_START="0.2264051863949554" CI_STUDY="95" CI_TOTAL="95" DF="24.0" EFFECT_SIZE="0.2510707103994326" ESTIMABLE="YES" I2="82.9769224477176" I2_Q="86.86674827080763" ID="CMP-004.02" LOG_CI_END="-0.5595061596553064" LOG_CI_START="-0.6451136287341587" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.6002039485927037" MODIFIED="2009-05-21 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="7.771561172376096E-16" P_Q="4.933681372152332E-4" P_Z="0.0" Q="15.228521018556549" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="3022" TOTAL_2="2392" WEIGHT="299.99999999999994" Z="19.950500539394664">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); study duration</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.4899079590653941" CI_START="0.05009204093460595" DF="0.0" EFFECT_SIZE="0.27" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.309885504919861" LOG_CI_START="-1.3002312731901" LOG_EFFECT_SIZE="-0.5686362358410126" MODIFIED="2008-07-14 13:58:00 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.0" P_Z="0.016109859308717434" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="2.4064171122994655">
<NAME>1-4 weeks</NAME>
<IV_DATA CI_END="0.4899079590653941" CI_START="0.05009204093460595" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2698" SE="0.1122" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="104.27831884962049" CI_END="0.30454684676492333" CI_START="0.24856737816101543" DF="20.0" EFFECT_SIZE="0.2765571124629694" ESTIMABLE="YES" I2="80.82055769537102" ID="CMP-004.02.02" LOG_CI_END="-0.5163458927630635" LOG_CI_START="-0.6045558685112933" LOG_EFFECT_SIZE="-0.5582151679172891" MODIFIED="2009-05-21 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="2.1438406605511773E-13" P_Z="0.0" STUDIES="21" TAU2="0.0" TOTAL_1="1917" TOTAL_2="1928" WEIGHT="99.99999999999999" Z="19.365742248506216">
<NAME>1-5 months</NAME>
<IV_DATA CI_END="0.22997071424807997" CI_START="0.09002928575192005" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2720" SE="0.0357" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="16.0016562817465"/>
<IV_DATA CI_END="0.20996653056923423" CI_START="0.05003346943076578" EFFECT_SIZE="0.13" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2708" SE="0.0408" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="12.251268090712161"/>
<IV_DATA CI_END="0.45995816321154276" CI_START="0.2600418367884572" EFFECT_SIZE="0.36" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2701" SE="0.051" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="7.840811578055785"/>
<IV_DATA CI_END="0.5499372448173142" CI_START="0.25006275518268584" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2716" SE="0.0765" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="3.4848051458025706"/>
<IV_DATA CI_END="0.35989540802885694" CI_START="-0.13989540802885692" EFFECT_SIZE="0.11" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2710" SE="0.1275" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="1.2545298524889255"/>
<IV_DATA CI_END="0.2099414284961599" CI_START="-0.06994142849615989" EFFECT_SIZE="0.07" ESTIMABLE="YES" ESTIMATE="0.07" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2709" SE="0.0714" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="4.000414070436625"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2702" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="4.000414070436625"/>
<IV_DATA CI_END="0.4399288774596227" CI_START="0.10007112254037731" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2715" SE="0.0867" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="2.7130835910227624"/>
<IV_DATA CI_END="0.6599163264230855" CI_START="0.26008367357691453" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2717" SE="0.102" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="1.9602028945139462"/>
<IV_DATA CI_END="0.459757983134243" CI_START="0.24024201686575694" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2721" SE="0.056" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="6.503173123253537"/>
<IV_DATA CI_END="0.32992887745962274" CI_START="-0.009928877459622704" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2703" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="2.7130835910227624"/>
<IV_DATA CI_END="0.4399456121750056" CI_START="0.18005438782499442" EFFECT_SIZE="0.31" ESTIMABLE="YES" ESTIMATE="0.31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2719" SE="0.0663" STUDY_ID="STD-Nathan-2006" TOTAL_1="90" TOTAL_2="88" WEIGHT="4.639533478139517"/>
<IV_DATA CI_END="0.7402748497892278" CI_START="0.1797251502107723" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2700" SE="0.143" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.9973079815405691"/>
<IV_DATA CI_END="0.8703166865776849" CI_START="0.509683313422315" EFFECT_SIZE="0.69" ESTIMABLE="YES" ESTIMATE="0.69" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2705" SE="0.092" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="2.4094932554965847"/>
<IV_DATA CI_END="0.3599414284961599" CI_START="0.0800585715038401" EFFECT_SIZE="0.22" ESTIMABLE="YES" ESTIMATE="0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2712" SE="0.0714" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="4.000414070436625"/>
<IV_DATA CI_END="0.319953979532697" CI_START="0.10004602046730296" EFFECT_SIZE="0.21" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2707" SE="0.0561" STUDY_ID="STD-Pinnas-2005" TOTAL_1="95" TOTAL_2="96" WEIGHT="6.480009568641144"/>
<IV_DATA CI_END="0.45992469378077705" CI_START="0.10007530621922303" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2699" SE="0.0918" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="2.420003573474007"/>
<IV_DATA CI_END="0.39995816321154276" CI_START="0.20004183678845722" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2718" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="7.840811578055785"/>
<IV_DATA CI_END="0.8599330611384683" CI_START="0.5400669388615316" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2714" SE="0.0816" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="3.0628170226780402"/>
<IV_DATA CI_END="0.5199288774596227" CI_START="0.18007112254037727" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2706" SE="0.0867" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="2.7130835910227624"/>
<IV_DATA CI_END="0.44992887745962273" CI_START="0.11007112254037732" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2704" SE="0.0867" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="2.7130835910227624"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="21.478243036424782" CI_END="0.2097875237110416" CI_START="0.10235426653686408" DF="2.0" EFFECT_SIZE="0.15607089512395284" ESTIMABLE="YES" I2="90.6882513778794" ID="CMP-004.02.03" LOG_CI_END="-0.67822034333295" LOG_CI_START="-0.9898940494861114" LOG_EFFECT_SIZE="-0.8066780787798863" MODIFIED="2008-07-14 14:00:20 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="2.1680281381275535E-5" P_Z="1.2368010671017274E-8" STUDIES="3" TAU2="0.0" TOTAL_1="1082" TOTAL_2="441" WEIGHT="99.99999999999997" Z="5.6945743156970865">
<NAME>6 months or longer</NAME>
<IV_DATA CI_END="0.15997489792692565" CI_START="0.040025102073074345" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2723" SE="0.0306" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="80.21922455262896"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2724" SE="0.0714" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="14.734143285176744"/>
<IV_DATA CI_END="0.39911560611388663" CI_START="-0.0791156061138866" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2726" SE="0.122" STUDY_ID="STD-Kemp-2004" TOTAL_1="32" TOTAL_2="39" WEIGHT="5.046632162194278"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.743456058048142" CI_END="0.22261009906889748" CI_START="0.12887298064947642" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.17574153985918695" ESTIMABLE="YES" I2="19.860151862869305" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.6524551370794565" LOG_CI_START="-0.8898381267494382" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.7551255726006394" MODIFIED="2008-07-14 14:08:22 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.2905322634232659" P_Q="1.0" P_Z="1.9937521673536526E-13" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="334" TOTAL_2="336" WEIGHT="99.99999999999997" Z="7.3492143671498225">
<NAME>Paediatric studies: change in FEV1 compared to baseline (litres); inhaler device</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 14:01:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.743456058048142" CI_END="0.22261009906889748" CI_START="0.12887298064947642" DF="3.0" EFFECT_SIZE="0.17574153985918695" ESTIMABLE="YES" I2="19.860151862869305" ID="CMP-004.03.02" LOG_CI_END="-0.6524551370794565" LOG_CI_START="-0.8898381267494382" LOG_EFFECT_SIZE="-0.7551255726006394" MODIFIED="2008-07-14 14:01:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.2905322634232659" P_Z="1.9937521673536526E-13" STUDIES="4" TAU2="0.0" TOTAL_1="334" TOTAL_2="336" WEIGHT="99.99999999999997" Z="7.3492143671498225">
<NAME>DPI</NAME>
<IV_DATA CI_END="0.23996653056923423" CI_START="0.08003346943076578" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2630" SE="0.0408" STUDY_ID="STD-Allen-1998" TOTAL_1="97" TOTAL_2="96" WEIGHT="34.35157846922552"/>
<IV_DATA CI_END="0.3093576229796436" CI_START="0.0506423770203564" EFFECT_SIZE="0.18" ESTIMABLE="YES" ESTIMATE="0.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2632" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="70" TOTAL_2="76" WEIGHT="13.127413127413126"/>
<IV_DATA CI_END="0.37995397953269705" CI_START="0.16004602046730299" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2636" SE="0.0561" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="18.169429934135817"/>
<IV_DATA CI_END="0.21996653056923424" CI_START="0.06003346943076579" EFFECT_SIZE="0.14" ESTIMABLE="YES" ESTIMATE="0.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2634" SE="0.0408" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="34.35157846922552"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="140.98508290460182" CI_END="0.3673124320226162" CI_START="0.24022459511964592" CI_STUDY="95" CI_TOTAL="95" DF="24.0" EFFECT_SIZE="0.30376851357113105" ESTIMABLE="YES" I2="82.9769224477176" I2_Q="96.39607365046938" ID="CMP-004.04" LOG_CI_END="-0.4349643723150646" LOG_CI_START="-0.6193825299143056" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.5174572439392677" MODIFIED="2009-05-21 09:48:24 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="7.771561172376096E-16" P_Q="1.382302190489071E-7" P_Z="7.287039181686678E-21" Q="27.747514877218194" RANDOM="YES" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.020033819027199102" TOTALS="SUB" TOTAL_1="3022" TOTAL_2="2392" WEIGHT="200.0" Z="9.369509478570228">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); inhaler device</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="55.10510522062151" CI_END="0.4025606421300282" CI_START="0.24760962571514109" DF="14.0" EFFECT_SIZE="0.32508513392258465" ESTIMABLE="YES" I2="74.59400550284967" ID="CMP-004.04.01" LOG_CI_END="-0.3951686878211781" LOG_CI_START="-0.6062324763170506" LOG_EFFECT_SIZE="-0.4880028902485931" MODIFIED="2009-05-21 09:48:24 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="8.305396662633413E-7" P_Z="1.9689869677975409E-16" STUDIES="15" TAU2="0.016468945035902634" TOTAL_1="1138" TOTAL_2="1154" WEIGHT="100.0" Z="8.223955791185512">
<NAME>MDI</NAME>
<IV_DATA CI_END="0.45995816321154276" CI_START="0.2600418367884572" EFFECT_SIZE="0.36" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2768" SE="0.051" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="7.98399751111171"/>
<IV_DATA CI_END="0.5499372448173142" CI_START="0.25006275518268584" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2772" SE="0.0765" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="6.981219844068974"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2761" SE="0.0714" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="7.190749949776323"/>
<IV_DATA CI_END="0.35989540802885694" CI_START="-0.13989540802885692" EFFECT_SIZE="0.11" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2774" SE="0.1275" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="4.979773905697899"/>
<IV_DATA CI_END="0.2099414284961599" CI_START="-0.06994142849615989" EFFECT_SIZE="0.07" ESTIMABLE="YES" ESTIMATE="0.07" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2762" SE="0.0714" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="7.190749949776323"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2766" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="7.190749949776323"/>
<IV_DATA CI_END="0.39911560611388663" CI_START="-0.0791156061138866" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2773" SE="0.122" STUDY_ID="STD-Kemp-2004" TOTAL_1="32" TOTAL_2="39" WEIGHT="5.175476126869588"/>
<IV_DATA CI_END="0.459757983134243" CI_START="0.24024201686575694" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2770" SE="0.056" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="7.799643949116663"/>
<IV_DATA CI_END="0.4399456121750056" CI_START="0.18005438782499442" EFFECT_SIZE="0.31" ESTIMABLE="YES" ESTIMATE="0.31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2767" SE="0.0663" STUDY_ID="STD-Nathan-2006" TOTAL_1="90" TOTAL_2="88" WEIGHT="7.397460938589363"/>
<IV_DATA CI_END="0.7402748497892278" CI_START="0.1797251502107723" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2764" SE="0.143" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="4.464025557513773"/>
<IV_DATA CI_END="0.4899079590653941" CI_START="0.05009204093460595" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2771" SE="0.1122" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="5.539595611349449"/>
<IV_DATA CI_END="0.3599414284961599" CI_START="0.0800585715038401" EFFECT_SIZE="0.22" ESTIMABLE="YES" ESTIMATE="0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2769" SE="0.0714" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="7.190749949776323"/>
<IV_DATA CI_END="0.319953979532697" CI_START="0.10004602046730296" EFFECT_SIZE="0.21" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:48:24 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2765" SE="0.0561" STUDY_ID="STD-Pinnas-2005" TOTAL_1="95" TOTAL_2="96" WEIGHT="7.795872157598391"/>
<IV_DATA CI_END="0.45992469378077705" CI_START="0.10007530621922303" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2760" SE="0.0918" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="6.349599943028059"/>
<IV_DATA CI_END="0.8599330611384683" CI_START="0.5400669388615316" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2763" SE="0.0816" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="6.770334655950846"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="58.13246280676212" CI_END="0.3638891060844224" CI_START="0.18080910807004802" DF="9.0" EFFECT_SIZE="0.2723491070772352" ESTIMABLE="YES" I2="84.51811678800388" ID="CMP-004.04.02" LOG_CI_END="-0.43903094589285374" LOG_CI_START="-0.7427796961785109" LOG_EFFECT_SIZE="-0.5648740442647806" MODIFIED="2008-07-14 14:03:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="3.065472098384703E-9" P_Z="5.500712577801807E-9" STUDIES="10" TAU2="0.01679135120515811" TOTAL_1="1884" TOTAL_2="1238" WEIGHT="100.0" Z="5.831269902582294">
<NAME>DPI</NAME>
<IV_DATA CI_END="0.22997071424807997" CI_START="0.09002928575192005" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2782" SE="0.0357" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="11.791059321381402"/>
<IV_DATA CI_END="0.20996653056923423" CI_START="0.05003346943076578" EFFECT_SIZE="0.13" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2787" SE="0.0408" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="11.579049713304144"/>
<IV_DATA CI_END="0.15997489792692565" CI_START="0.040025102073074345" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2776" SE="0.0306" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="11.981182204126824"/>
<IV_DATA CI_END="0.4399288774596227" CI_START="0.10007112254037731" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2784" SE="0.0867" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="9.11945807020757"/>
<IV_DATA CI_END="0.6599163264230855" CI_START="0.26008367357691453" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2780" SE="0.102" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="8.254452645030767"/>
<IV_DATA CI_END="0.32992887745962274" CI_START="-0.009928877459622704" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2777" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="9.11945807020757"/>
<IV_DATA CI_END="0.8703166865776849" CI_START="0.509683313422315" EFFECT_SIZE="0.69" ESTIMABLE="YES" ESTIMATE="0.69" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2788" SE="0.092" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="8.816377686244477"/>
<IV_DATA CI_END="0.39995816321154276" CI_START="0.20004183678845722" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2778" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="11.100046149082091"/>
<IV_DATA CI_END="0.5199288774596227" CI_START="0.18007112254037727" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2775" SE="0.0867" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="9.11945807020757"/>
<IV_DATA CI_END="0.44992887745962273" CI_START="0.11007112254037732" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2786" SE="0.0867" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="9.11945807020757"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.743456058048142" CI_END="0.22261009906889745" CI_START="0.1288729806494764" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.17574153985918692" ESTIMABLE="YES" I2="19.860151862869305" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.6524551370794566" LOG_CI_START="-0.8898381267494384" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.7551255726006394" MODIFIED="2008-07-14 14:08:23 +0100" MODIFIED_BY="Toby J Lasserson" NO="5" P_CHI2="0.2905322634232659" P_Q="0.3264127314764699" P_Z="1.993752167353667E-13" Q="0.9630782279106884" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="334" TOTAL_2="336" WEIGHT="99.99999999999999" Z="7.349214367149822">
<NAME>Paediatric studies: change in FEV1 compared to baseline (litres); severity</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-14 14:07:04 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mild</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.514625351995595" CI_END="0.2627258728619278" CI_START="0.13338223524618037" DF="1.0" EFFECT_SIZE="0.19805405405405407" ESTIMABLE="YES" I2="60.23264462809919" ID="CMP-004.05.02" LOG_CI_END="-0.5804971564188253" LOG_CI_START="-0.874902008862577" LOG_EFFECT_SIZE="-0.703216263407201" MODIFIED="2008-07-14 14:07:15 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.11279473382723093" P_Z="1.945574839223236E-9" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="52.521008403361336" Z="6.002286932601853">
<NAME>Mild to moderate</NAME>
<IV_DATA CI_END="0.23996653056923423" CI_START="0.08003346943076578" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2676" SE="0.0408" STUDY_ID="STD-Allen-1998" TOTAL_1="97" TOTAL_2="96" WEIGHT="34.35157846922552"/>
<IV_DATA CI_END="0.37995397953269705" CI_START="0.16004602046730299" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2677" SE="0.0561" STUDY_ID="STD-Laforce-2000" TOTAL_1="80" TOTAL_2="78" WEIGHT="18.169429934135817"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.2657524781418584" CI_END="0.2190786517779795" CI_START="0.0830404584827237" DF="1.0" EFFECT_SIZE="0.1510595551303516" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="-0.6593999404070535" LOG_CI_START="-1.0807102616636415" LOG_EFFECT_SIZE="-0.8208517986320856" MODIFIED="2008-07-14 14:07:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.6061954307438724" P_Z="1.3442992461576466E-5" STUDIES="2" TAU2="0.0" TOTAL_1="157" TOTAL_2="162" WEIGHT="47.47899159663865" Z="4.352767122296928">
<NAME>Moderate</NAME>
<IV_DATA CI_END="0.3093576229796436" CI_START="0.0506423770203564" EFFECT_SIZE="0.18" ESTIMABLE="YES" ESTIMATE="0.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2693" SE="0.066" STUDY_ID="STD-Katz-1998" TOTAL_1="70" TOTAL_2="76" WEIGHT="13.127413127413126"/>
<IV_DATA CI_END="0.21996653056923424" CI_START="0.06003346943076579" EFFECT_SIZE="0.14" ESTIMABLE="YES" ESTIMATE="0.14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2686" SE="0.0408" STUDY_ID="STD-Peden-1998" TOTAL_1="87" TOTAL_2="86" WEIGHT="34.35157846922552"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="140.98508290460182" CI_END="0.2757362344039098" CI_START="0.22640518639495544" CI_STUDY="95" CI_TOTAL="95" DF="24.0" EFFECT_SIZE="0.25107071039943263" ESTIMABLE="YES" I2="82.9769224477176" I2_Q="94.91105332786528" ID="CMP-004.06" LOG_CI_END="-0.5595061596553064" LOG_CI_START="-0.6451136287341587" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.6002039485927035" MODIFIED="2009-05-21 09:48:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="6" P_CHI2="7.771561172376096E-16" P_Q="2.9237190446451677E-9" P_Z="0.0" Q="39.30086379075837" RANDOM="NO" SCALE="1.11" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3022" TOTAL_2="2392" WEIGHT="300.0" Z="19.950500539394667">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); severity</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.2275548723290747" CI_END="0.16172418197936023" CI_START="0.04537826069577486" DF="1.0" EFFECT_SIZE="0.10355122133756754" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="-0.7912250368963837" LOG_CI_START="-1.3431521542136091" LOG_EFFECT_SIZE="-0.9848447744427827" MODIFIED="2008-07-14 14:01:53 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.6333428309303615" P_Z="4.851054481642207E-4" STUDIES="2" TAU2="0.0" TOTAL_1="987" TOTAL_2="347" WEIGHT="100.0" Z="3.4888488077218405">
<NAME>Mild</NAME>
<IV_DATA CI_END="0.15997489792692565" CI_START="0.040025102073074345" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2731" SE="0.0306" STUDY_ID="STD-Chuchalin-2008" TOTAL_1="955" TOTAL_2="308" WEIGHT="94.08129777072077"/>
<IV_DATA CI_END="0.39911560611388663" CI_START="-0.0791156061138866" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2732" SE="0.122" STUDY_ID="STD-Kemp-2004" TOTAL_1="32" TOTAL_2="39" WEIGHT="5.918702229279232"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="45.042578471083154" CI_END="0.2733029368149899" CI_START="0.18390592632863834" DF="9.0" EFFECT_SIZE="0.22860443157181412" ESTIMABLE="YES" I2="80.0189058764078" ID="CMP-004.06.02" LOG_CI_END="-0.5633557015100772" LOG_CI_START="-0.7354042754908213" LOG_EFFECT_SIZE="-0.6409153549182947" MODIFIED="2009-05-21 09:48:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="9.06084639984428E-7" P_Z="1.1960070076770637E-23" STUDIES="10" TAU2="0.0" TOTAL_1="812" TOTAL_2="838" WEIGHT="100.00000000000001" Z="10.023969485096208">
<NAME>Mild to moderate</NAME>
<IV_DATA CI_END="0.20996653056923423" CI_START="0.05003346943076578" EFFECT_SIZE="0.13" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2742" SE="0.0408" STUDY_ID="STD-Berger-2002-SABA" TOTAL_1="198" TOTAL_2="210" WEIGHT="31.244205972461685"/>
<IV_DATA CI_END="0.5499372448173142" CI_START="0.25006275518268584" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2736" SE="0.0765" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="80" TOTAL_2="80" WEIGHT="8.88724080994466"/>
<IV_DATA CI_END="0.35989540802885694" CI_START="-0.13989540802885692" EFFECT_SIZE="0.11" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2739" SE="0.1275" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="3.1994066915800774"/>
<IV_DATA CI_END="0.2099414284961599" CI_START="-0.06994142849615989" EFFECT_SIZE="0.07" ESTIMABLE="YES" ESTIMATE="0.07" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2744" SE="0.0714" STUDY_ID="STD-FLTA4030" TOTAL_1="101" TOTAL_2="115" WEIGHT="10.202189705293613"/>
<IV_DATA CI_END="0.7402748497892278" CI_START="0.1797251502107723" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2740" SE="0.143" STUDY_ID="STD-Noonan-1998" TOTAL_1="34" TOTAL_2="36" WEIGHT="2.5434180170178804"/>
<IV_DATA CI_END="0.8703166865776849" CI_START="0.509683313422315" EFFECT_SIZE="0.69" ESTIMABLE="YES" ESTIMATE="0.69" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2738" SE="0.092" STUDY_ID="STD-Pearlman-1997" TOTAL_1="81" TOTAL_2="75" WEIGHT="6.144890717154848"/>
<IV_DATA CI_END="0.4899079590653941" CI_START="0.05009204093460595" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2737" SE="0.1122" STUDY_ID="STD-Pearlman-1999" TOTAL_1="23" TOTAL_2="23" WEIGHT="4.131465252556918"/>
<IV_DATA CI_END="0.3599414284961599" CI_START="0.0800585715038401" EFFECT_SIZE="0.22" ESTIMABLE="YES" ESTIMATE="0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2735" SE="0.0714" STUDY_ID="STD-Pearlman-2004" TOTAL_1="89" TOTAL_2="87" WEIGHT="10.202189705293613"/>
<IV_DATA CI_END="0.319953979532697" CI_START="0.10004602046730296" EFFECT_SIZE="0.21" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:48:49 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2733" SE="0.0561" STUDY_ID="STD-Pinnas-2005" TOTAL_1="95" TOTAL_2="96" WEIGHT="16.525861010227672"/>
<IV_DATA CI_END="0.44992887745962273" CI_START="0.11007112254037732" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2741" SE="0.0867" STUDY_ID="STD-Wolfe-2000-SABA" TOTAL_1="73" TOTAL_2="73" WEIGHT="6.919132118469025"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="56.41408577043122" CI_END="0.3501079835966455" CI_START="0.2814145836618622" DF="12.0" EFFECT_SIZE="0.3157612836292539" ESTIMABLE="YES" I2="78.72871670945405" ID="CMP-004.06.03" LOG_CI_END="-0.45579798580041575" LOG_CI_START="-0.5506534000080334" LOG_EFFECT_SIZE="-0.500641121119861" MODIFIED="2008-07-14 14:07:58 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="1.0081598778022283E-7" P_Z="1.391273280073092E-72" STUDIES="13" TAU2="0.0" TOTAL_1="1223" TOTAL_2="1207" WEIGHT="100.0" Z="18.018637721033826">
<NAME>Moderate</NAME>
<IV_DATA CI_END="0.22997071424807997" CI_START="0.09002928575192005" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2750" SE="0.0357" STUDY_ID="STD-Berger-2002-ICS" TOTAL_1="205" TOTAL_2="196" WEIGHT="24.095581879992345"/>
<IV_DATA CI_END="0.45995816321154276" CI_START="0.2600418367884572" EFFECT_SIZE="0.36" ESTIMABLE="YES" ESTIMATE="0.36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2745" SE="0.051" STUDY_ID="STD-Busse-2001" TOTAL_1="113" TOTAL_2="114" WEIGHT="11.806835121196253"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2746" SE="0.0714" STUDY_ID="STD-FLTA3014" TOTAL_1="95" TOTAL_2="94" WEIGHT="6.023895469998086"/>
<IV_DATA CI_END="0.59994142849616" CI_START="0.3200585715038401" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2752" SE="0.0714" STUDY_ID="STD-Galant-1996" TOTAL_1="86" TOTAL_2="87" WEIGHT="6.023895469998086"/>
<IV_DATA CI_END="0.4399288774596227" CI_START="0.10007112254037731" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2757" SE="0.0867" STUDY_ID="STD-Kavuru-2000" TOTAL_1="85" TOTAL_2="77" WEIGHT="4.085410076538495"/>
<IV_DATA CI_END="0.6599163264230855" CI_START="0.26008367357691453" EFFECT_SIZE="0.46" ESTIMABLE="YES" ESTIMATE="0.46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2747" SE="0.102" STUDY_ID="STD-Lawrence-1997" TOTAL_1="63" TOTAL_2="64" WEIGHT="2.951708780299063"/>
<IV_DATA CI_END="0.459757983134243" CI_START="0.24024201686575694" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2749" SE="0.056" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" WEIGHT="9.792595073415638"/>
<IV_DATA CI_END="0.32992887745962274" CI_START="-0.009928877459622704" EFFECT_SIZE="0.16" ESTIMABLE="YES" ESTIMATE="0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2751" SE="0.0867" STUDY_ID="STD-Nathan-2000" TOTAL_1="81" TOTAL_2="84" WEIGHT="4.085410076538495"/>
<IV_DATA CI_END="0.4399456121750056" CI_START="0.18005438782499442" EFFECT_SIZE="0.31" ESTIMABLE="YES" ESTIMATE="0.31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2755" SE="0.0663" STUDY_ID="STD-Nathan-2006" TOTAL_1="90" TOTAL_2="88" WEIGHT="6.986292971122042"/>
<IV_DATA CI_END="0.45992469378077705" CI_START="0.10007530621922303" EFFECT_SIZE="0.28" ESTIMABLE="YES" ESTIMATE="0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2759" SE="0.0918" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="73" WEIGHT="3.6440849139494595"/>
<IV_DATA CI_END="0.39995816321154276" CI_START="0.20004183678845722" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2754" SE="0.051" STUDY_ID="STD-Wasserman-1996" TOTAL_1="78" TOTAL_2="82" WEIGHT="11.806835121196253"/>
<IV_DATA CI_END="0.8599330611384683" CI_START="0.5400669388615316" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2756" SE="0.0816" STUDY_ID="STD-Wolfe-1996" TOTAL_1="80" TOTAL_2="75" WEIGHT="4.612044969217284"/>
<IV_DATA CI_END="0.5199288774596227" CI_START="0.18007112254037727" EFFECT_SIZE="0.35" ESTIMABLE="YES" ESTIMATE="0.35" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2748" SE="0.0867" STUDY_ID="STD-Wolfe-2000-ICS" TOTAL_1="65" TOTAL_2="69" WEIGHT="4.085410076538495"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-05-21 10:41:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="5">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (all ages)</NAME>
<CONT_OUTCOME CHI2="40.12306239088412" CI_END="0.42773747516840643" CI_START="0.3445368469358404" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3861371610521234" ESTIMABLE="YES" I2="75.07667808957679" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2009-05-21 10:36:11 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.611975584481229E-5" P_Q="1.0" P_Z="5.914674353178411E-74" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="865" TOTAL_2="865" UNITS="" WEIGHT="100.00000000000003" Z="18.192529187140813">
<NAME>Change in FEV1 compared to baseline (Litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="40.12306239088412" CI_END="0.42773747516840643" CI_START="0.3445368469358404" DF="10.0" EFFECT_SIZE="0.3861371610521234" ESTIMABLE="YES" I2="75.07667808957679" ID="CMP-005.01.02" MODIFIED="2009-05-21 09:50:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.611975584481229E-5" P_Z="5.914674353178411E-74" STUDIES="11" TAU2="0.0" TOTAL_1="865" TOTAL_2="865" WEIGHT="100.00000000000003" Z="18.192529187140813">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.6026813334377111" CI_START="0.2973186665622889" EFFECT_SIZE="0.45" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.18" ORDER="1934" SD_1="0.49" SD_2="0.58" SE="0.07790007094112032" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="7.42371569562372"/>
<CONT_DATA CI_END="0.38449449502638544" CI_START="-0.14449449502638545" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.07" ORDER="1935" SD_1="0.62" SD_2="0.59" SE="0.1349486506449528" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="2.4737735690649485"/>
<CONT_DATA CI_END="0.6533944838306422" CI_START="0.34660551616935775" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-0.18" ORDER="1944" SD_1="0.6" SD_2="0.51" SE="0.07826392986840491" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="7.354848564678506"/>
<CONT_DATA CI_END="0.5003440546802245" CI_START="0.2796559453197756" EFFECT_SIZE="0.39" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="-0.25" ORDER="1937" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="14.213313752884195"/>
<CONT_DATA CI_END="0.3568584704998477" CI_START="0.023141529500152302" EFFECT_SIZE="0.19" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.11" ORDER="1943" SD_1="0.56" SD_2="0.55" SE="0.08513343705088768" STUDY_ID="STD-Nathan-2000" TOTAL_1="86" TOTAL_2="84" WEIGHT="6.215795291945778"/>
<CONT_DATA CI_END="0.8269061526507122" CI_START="0.49309384734928785" EFFECT_SIZE="0.66" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="-0.22" ORDER="1936" SD_1="0.56" SD_2="0.52" SE="0.08515776512591386" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="6.212244312565853"/>
<CONT_DATA CI_END="0.3317147608834454" CI_START="0.1082852391165545" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.13" MODIFIED="2009-05-21 09:50:51 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1938" SD_1="0.4" SD_2="0.4" SE="0.05699837433985382" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="13.866667412473172"/>
<CONT_DATA CI_END="0.4979575815703875" CI_START="0.2220424184296125" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-0.11" ORDER="1939" SD_1="0.45" SD_2="0.47" SE="0.07038781460199232" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="9.092892880571208"/>
<CONT_DATA CI_END="0.6326720312767347" CI_START="0.28732796872326527" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="-0.3" ORDER="1940" SD_1="0.15" SD_2="0.28" SE="0.08809959399190477" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="5.804291615549732"/>
<CONT_DATA CI_END="0.43739881623902277" CI_START="0.24260118376097717" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="0.24" ORDER="1941" SD_1="0.36" SD_2="0.27" SE="0.049694186733680944" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" WEIGHT="18.24256333095361"/>
<CONT_DATA CI_END="0.7179045048774223" CI_START="0.4420954951225776" EFFECT_SIZE="0.58" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.16" ORDER="1942" SD_1="0.45" SD_2="0.44" SE="0.07036073415899244" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="9.099893573689293"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.1246788114898218" CI_START="-0.004678811489821799" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.06" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.9042073463203842" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.2218487496163564" MODIFIED="2009-05-21 10:36:11 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0690363479958339" Q="0.0" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="1.8181818181818181">
<NAME>FEV1 (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.1246788114898218" CI_START="-0.004678811489821799" DF="0.0" EFFECT_SIZE="0.06" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-0.9042073463203842" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.2218487496163564" NO="1" P_CHI2="1.0" P_Z="0.0690363479958339" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="1.8181818181818181">
<NAME>Children</NAME>
<IV_DATA CI_END="0.1246788114898218" CI_START="-0.004678811489821799" EFFECT_SIZE="0.06" ESTIMABLE="YES" ESTIMATE="0.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2079" SE="0.033" STUDY_ID="STD-Arets-2002" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2009-05-21 10:36:07 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="43" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEV1 (%)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="10.094825905525333" CI_START="-3.8348259055253324" EFFECT_SIZE="3.13" ESTIMABLE="YES" MEAN_1="5.05" MEAN_2="1.92" ORDER="1945" SD_1="17.2" SD_2="14.43" SE="3.553547902136463" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="5.346831675258799" CI_END="15.782490244064636" CI_START="4.045349874268694" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="9.913920059166665" ESTIMABLE="YES" I2="81.29733530555556" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="1.1981755295406424" LOG_CI_START="0.6069560888390708" LOG_DATA="NO" LOG_EFFECT_SIZE="0.996245412652371" MODIFIED="2009-05-21 10:36:07 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.020760027292038852" P_Q="1.0" P_Z="9.295809246959788E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="14.633520354999996" TOTALS="YES" TOTAL_1="200" TOTAL_2="202" WEIGHT="100.0" Z="3.311015400578989">
<NAME>Change in FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>Fluticasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fluticasone</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.346831675258799" CI_END="15.782490244064636" CI_START="4.045349874268694" DF="1.0" EFFECT_SIZE="9.913920059166665" ESTIMABLE="YES" I2="81.29733530555556" ID="CMP-005.04.02" LOG_CI_END="1.1981755295406424" LOG_CI_START="0.6069560888390708" LOG_EFFECT_SIZE="0.996245412652371" NO="2" P_CHI2="0.020760027292038852" P_Z="9.295809246959788E-4" STUDIES="2" TAU2="14.633520354999996" TOTAL_1="200" TOTAL_2="202" WEIGHT="100.0" Z="3.311015400578989">
<NAME>Adults</NAME>
<IV_DATA CI_END="17.249831744466658" CI_START="8.950168255533342" EFFECT_SIZE="13.1" ESTIMABLE="YES" ESTIMATE="13.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2078" SE="2.1173" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="46.898667652777775"/>
<IV_DATA CI_END="10.039945976810081" CI_START="4.160054023189918" EFFECT_SIZE="7.1" ESTIMABLE="YES" ESTIMATE="7.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2077" SE="1.5" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="53.10133234722223"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="1.8863018890409373" CI_END="32.95291437214511" CI_START="15.899287691343657" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="24.426101031744384" ESTIMABLE="YES" I2="46.986216479461014" I2_Q="46.986216479461014" ID="CMP-005.05" MODIFIED="2009-05-21 10:36:06 +0100" MODIFIED_BY="Toby J Lasserson" NO="5" P_CHI2="0.16961983854208973" P_Q="0.16961983854208973" P_Z="1.970666250215993E-8" Q="1.8863018890409373" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="5.6145568565601724">
<NAME>FEV1 (% predicted - absolute scores)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.26017686698782" CI_START="-25.660176866987822" DF="0.0" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="1.0" P_Z="0.7784790977752123" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="8.099995288838448" Z="0.28130158146057566">
<NAME>Children</NAME>
<CONT_DATA CI_END="34.26017686698782" CI_START="-25.660176866987822" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="99.7" MEAN_2="95.4" ORDER="1946" SD_1="46.77" SD_2="30.48" SE="15.286085409379902" STUDY_ID="STD-Hofstra-2000" TOTAL_1="14" TOTAL_2="12" WEIGHT="8.099995288838448"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="35.09465257400173" CI_START="17.305347425998278" DF="0.0" EFFECT_SIZE="26.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="1.0" P_Z="7.775676313804965E-9" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="91.90000471116156" Z="5.7732503847361025">
<NAME>Adults</NAME>
<CONT_DATA CI_END="35.09465257400173" CI_START="17.305347425998278" EFFECT_SIZE="26.200000000000003" ESTIMABLE="YES" MEAN_1="94.4" MEAN_2="68.2" ORDER="1947" SD_1="11.7" SD_2="10.5" SE="4.538171437925191" STUDY_ID="STD-Micheletto-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="91.90000471116156"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="30.357912154482953" CI_END="40.7472980767426" CI_START="32.92742516875865" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_SIZE="36.83736162275063" ESTIMABLE="YES" I2="63.76562411794307" I2_Q="93.06166103464088" ID="CMP-005.06" LOG_CI_END="1.6100988162842162" LOG_CI_START="1.5175577714431494" LOG_DATA="NO" LOG_EFFECT_SIZE="1.5662885174609351" MODIFIED="2009-05-21 10:39:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="6" P_CHI2="0.001391880374676635" P_Q="1.468127693430299E-4" P_Z="3.895874706424493E-76" Q="14.412671462041219" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="831" TOTAL_2="832" WEIGHT="200.0" Z="18.465748207328133">
<NAME>Change in morning PEF (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="27.446189669713917" CI_START="4.553810330286083" DF="0.0" EFFECT_SIZE="16.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="1.4384820602513293" LOG_CI_START="0.6583749379555505" LOG_EFFECT_SIZE="1.2041199826559248" NO="1" P_CHI2="1.0" P_Z="0.006149041805486623" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="2.73972602739726">
<NAME>Children</NAME>
<IV_DATA CI_END="27.446189669713917" CI_START="4.553810330286083" EFFECT_SIZE="16.0" ESTIMABLE="YES" ESTIMATE="16.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1948" SE="5.84" STUDY_ID="STD-Arets-2002" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="15.945240692441734" CI_END="43.75015288447567" CI_START="35.42979405075499" DF="10.0" EFFECT_SIZE="39.58997346761533" ESTIMABLE="YES" I2="37.28536186512294" ID="CMP-005.06.02" LOG_CI_END="1.6409795749987466" LOG_CI_START="1.5493686278375347" LOG_EFFECT_SIZE="1.5975852106970867" NO="2" P_CHI2="0.1012108118657099" P_Z="1.220484750131108E-77" STUDIES="11" TAU2="0.0" TOTAL_1="796" TOTAL_2="799" WEIGHT="100.0" Z="18.651821080347233">
<NAME>Adults</NAME>
<IV_DATA CI_END="60.52458822909552" CI_START="37.47541177090448" EFFECT_SIZE="49.0" ESTIMABLE="YES" ESTIMATE="49.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1949" SE="5.88" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="13.030866265078743"/>
<IV_DATA CI_END="57.64068130956091" CI_START="16.85931869043909" EFFECT_SIZE="37.25" ESTIMABLE="YES" ESTIMATE="37.25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1950" SE="10.4036" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="4.162561354052809"/>
<IV_DATA CI_END="53.08947622452763" CI_START="30.91052377547237" EFFECT_SIZE="42.0" ESTIMABLE="YES" ESTIMATE="42.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1959" SE="5.658" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="14.07349793025533"/>
<IV_DATA CI_END="88.9861938598091" CI_START="23.013806140190887" EFFECT_SIZE="56.0" ESTIMABLE="YES" ESTIMATE="56.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1951" SE="16.83" STUDY_ID="STD-Lindqvist-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.5905953477501187"/>
<IV_DATA CI_END="51.93376049719136" CI_START="25.86623950280864" EFFECT_SIZE="38.9" ESTIMABLE="YES" ESTIMATE="38.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1953" SE="6.65" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="10.187899431179567"/>
<IV_DATA CI_END="63.52416986121095" CI_START="38.47583013878905" EFFECT_SIZE="51.0" ESTIMABLE="YES" ESTIMATE="51.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1952" SE="6.39" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="11.033828350619697"/>
<IV_DATA CI_END="44.738266140198846" CI_START="21.461733859801157" EFFECT_SIZE="33.1" ESTIMABLE="YES" ESTIMATE="33.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1954" SE="5.938" STUDY_ID="STD-Pinnas-2005" TOTAL_1="97" TOTAL_2="98" WEIGHT="12.77754894761697"/>
<IV_DATA CI_END="41.11858282677653" CI_START="17.481417173223473" EFFECT_SIZE="29.3" ESTIMABLE="YES" ESTIMATE="29.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1955" SE="6.03" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="12.390627916122495"/>
<IV_DATA CI_END="44.42790334680734" CI_START="-9.627903346807347" EFFECT_SIZE="17.4" ESTIMABLE="YES" ESTIMATE="17.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1956" SE="13.79" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="11" TOTAL_2="12" WEIGHT="2.3691873628899383"/>
<IV_DATA CI_END="44.543769501056346" CI_START="19.456230498943654" EFFECT_SIZE="32.0" ESTIMABLE="YES" ESTIMATE="32.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1957" SE="6.4" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" WEIGHT="10.999374575081504"/>
<IV_DATA CI_END="62.309670676039275" CI_START="31.690329323960725" EFFECT_SIZE="47.0" ESTIMABLE="YES" ESTIMATE="47.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1958" SE="7.8112" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="7.384012519352838"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="13.97901195502174" CI_END="44.342344539128014" CI_START="35.67713691004543" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="40.00974072458672" ESTIMABLE="YES" I2="35.61776734322849" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2009-05-21 10:36:04 +0100" MODIFIED_BY="Toby J Lasserson" NO="7" P_CHI2="0.12307382863994598" P_Q="1.0" P_Z="3.219941678276455E-73" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="777" TOTAL_2="780" UNITS="" WEIGHT="100.00000000000001" Z="18.09942801319298">
<NAME>Change in morning PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.07.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.97901195502174" CI_END="44.342344539128014" CI_START="35.67713691004543" DF="9.0" EFFECT_SIZE="40.00974072458672" ESTIMABLE="YES" I2="35.61776734322849" ID="CMP-005.07.02" MODIFIED="2009-05-21 09:53:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.12307382863994598" P_Z="3.219941678276455E-73" STUDIES="10" TAU2="0.0" TOTAL_1="777" TOTAL_2="780" WEIGHT="100.00000000000001" Z="18.09942801319298">
<NAME>Adults</NAME>
<CONT_DATA CI_END="60.37525857483836" CI_START="37.62474142516164" EFFECT_SIZE="49.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="-28.0" ORDER="1960" SD_1="40.0" SD_2="40.0" SE="5.803810000880093" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="14.506926157048618"/>
<CONT_DATA CI_END="57.64127539003694" CI_START="16.85872460996306" EFFECT_SIZE="37.25" ESTIMABLE="YES" MEAN_1="39.53" MEAN_2="2.28" ORDER="1961" SD_1="51.04" SD_2="41.31" SE="10.403903107853369" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="4.514494991891374"/>
<CONT_DATA CI_END="53.08783607022696" CI_START="30.912163929773037" EFFECT_SIZE="42.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="-24.0" ORDER="1968" SD_1="40.0" SD_2="40.6" SE="5.657163171204369" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="15.26878087971748"/>
<CONT_DATA CI_END="51.931310173598106" CI_START="25.868689826401887" EFFECT_SIZE="38.9" ESTIMABLE="YES" MEAN_1="18.9" MEAN_2="-20.0" ORDER="1963" SD_1="47.14" SD_2="48.48" SE="6.648749811928904" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="11.054059333439271"/>
<CONT_DATA CI_END="63.5403979858725" CI_START="38.4596020141275" EFFECT_SIZE="51.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="-24.0" ORDER="1962" SD_1="46.0" SD_2="35.0" SE="6.398279807582975" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="11.936453657360884"/>
<CONT_DATA CI_END="52.83137513276189" CI_START="19.56862486723811" EFFECT_SIZE="36.2" ESTIMABLE="YES" MEAN_1="47.6" MEAN_2="11.4" MODIFIED="2009-05-21 09:53:16 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1154" SD_1="59.4" SD_2="59.7" SE="8.48555139989717" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="6.786434104448038"/>
<CONT_DATA CI_END="41.118906232660876" CI_START="17.481093767339118" EFFECT_SIZE="29.299999999999997" ESTIMABLE="YES" MEAN_1="15.2" MEAN_2="-14.1" ORDER="1964" SD_1="41.4" SD_2="36.99" SE="6.030165006034246" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="13.438270576506511"/>
<CONT_DATA CI_END="44.44083122796949" CI_START="-9.640831227969493" EFFECT_SIZE="17.4" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="-3.4" ORDER="1965" SD_1="25.9" SD_2="39.4" SE="13.796595978938448" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="11" TOTAL_2="12" WEIGHT="2.567189219508251"/>
<CONT_DATA CI_END="44.55088206420638" CI_START="19.449117935793623" EFFECT_SIZE="32.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="7.0" ORDER="1966" SD_1="45.3" SD_2="36.2" SE="6.403628925432371" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" WEIGHT="11.916520325655659"/>
<CONT_DATA CI_END="62.30767084734544" CI_START="31.69232915265456" EFFECT_SIZE="47.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="-15.0" ORDER="1967" SD_1="54.0" SD_2="44.44" SE="7.8101796604888625" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="8.010870754423921"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2009-05-21 10:36:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="81" TOTAL_2="90" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in am PEF (% predicted)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.08.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.08.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="9.035735813285278" CI_START="3.764264186714722" EFFECT_SIZE="6.4" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="-3.1" ORDER="1969" SD_1="9.0" SD_2="8.53" SE="1.3447878808363958" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="9.657262695440597" CI_END="36.590044071158204" CI_START="23.621961248936422" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="30.106002660047313" ESTIMABLE="YES" I2="48.22549455591999" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="1.5633629325762302" LOG_CI_START="1.3733159527284036" LOG_DATA="NO" LOG_EFFECT_SIZE="1.4786530956678807" MODIFIED="2009-05-21 10:36:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.08554995799571508" P_Q="1.0" P_Z="9.00879146581663E-20" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="399" TOTAL_2="392" WEIGHT="100.00000000000001" Z="9.100293658064462">
<NAME>Change in evening PEF compared with baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres/min</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="9.657262695440597" CI_END="36.590044071158204" CI_START="23.621961248936422" DF="5.0" EFFECT_SIZE="30.106002660047313" ESTIMABLE="YES" I2="48.22549455591999" ID="CMP-005.09.02" LOG_CI_END="1.5633629325762302" LOG_CI_START="1.3733159527284036" LOG_EFFECT_SIZE="1.4786530956678807" MODIFIED="2009-05-21 09:56:13 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.08554995799571508" P_Z="9.00879146581663E-20" STUDIES="6" TAU2="0.0" TOTAL_1="399" TOTAL_2="392" WEIGHT="100.00000000000001" Z="9.100293658064462">
<NAME>Adults</NAME>
<IV_DATA CI_END="52.70003120169016" CI_START="12.559968798309846" EFFECT_SIZE="32.63" ESTIMABLE="YES" ESTIMATE="32.63" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1970" SE="10.24" STUDY_ID="STD-FLTA3020" TOTAL_1="42" TOTAL_2="37" WEIGHT="10.437475387766256"/>
<IV_DATA CI_END="64.9672235885496" CI_START="17.0327764114504" EFFECT_SIZE="41.0" ESTIMABLE="YES" ESTIMATE="41.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1971" SE="12.2284" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="7.319073440052047"/>
<IV_DATA CI_END="43.529704145470035" CI_START="13.070295854529963" EFFECT_SIZE="28.3" ESTIMABLE="YES" ESTIMATE="28.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-21 09:56:13 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1158" SE="7.7704" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="18.12627757451822"/>
<IV_DATA CI_END="36.03973725026573" CI_START="11.360262749734272" EFFECT_SIZE="23.7" ESTIMABLE="YES" ESTIMATE="23.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1972" SE="6.2959" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="27.61084735339308"/>
<IV_DATA CI_END="28.999571633524422" CI_START="-12.39957163352442" EFFECT_SIZE="8.3" ESTIMABLE="YES" ESTIMATE="8.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1973" SE="10.5612" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="11" TOTAL_2="12" WEIGHT="9.812255395663342"/>
<IV_DATA CI_END="54.54984538940842" CI_START="29.45015461059158" EFFECT_SIZE="42.0" ESTIMABLE="YES" ESTIMATE="42.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1974" SE="6.4031" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="26.694070848607062"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="8.803424296517793" CI_END="35.97849022702651" CI_START="22.509247592607256" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="29.243868909816882" ESTIMABLE="YES" I2="54.56313514751066" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2009-05-21 10:36:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="10" P_CHI2="0.06620525325084325" P_Q="1.0" P_Z="1.7275623078297693E-17" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="307" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="8.510787337869203">
<NAME>Change in evening PEF compared with baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.10.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.803424296517793" CI_END="35.97849022702651" CI_START="22.509247592607256" DF="4.0" EFFECT_SIZE="29.243868909816882" ESTIMABLE="YES" I2="54.56313514751066" ID="CMP-005.10.02" MODIFIED="2009-05-21 09:54:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.06620525325084325" P_Z="1.7275623078297693E-17" STUDIES="5" TAU2="0.0" TOTAL_1="307" TOTAL_2="322" WEIGHT="100.0" Z="8.510787337869203">
<NAME>Adults</NAME>
<CONT_DATA CI_END="52.6983926286685" CI_START="12.561607371331505" EFFECT_SIZE="32.63" ESTIMABLE="YES" MEAN_1="34.78" MEAN_2="2.15" ORDER="1975" SD_1="53.51" SD_2="32.6" SE="10.239163977994197" STUDY_ID="STD-FLTA3020" TOTAL_1="36" TOTAL_2="42" WEIGHT="11.261628144247913"/>
<CONT_DATA CI_END="43.53494545781287" CI_START="13.06505454218713" EFFECT_SIZE="28.3" ESTIMABLE="YES" MEAN_1="35.1" MEAN_2="6.8" MODIFIED="2009-05-21 09:54:28 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1157" SD_1="54.4" SD_2="54.7" SE="7.773074188089258" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="19.540899622544128"/>
<CONT_DATA CI_END="36.03502433560263" CI_START="11.364975664397381" EFFECT_SIZE="23.700000000000003" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="-15.8" ORDER="1976" SD_1="40.5" SD_2="41.74" SE="6.293495407517546" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="29.808926767497976"/>
<CONT_DATA CI_END="28.99513491652815" CI_START="-12.39513491652815" EFFECT_SIZE="8.3" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="4.0" ORDER="1977" SD_1="17.8" SD_2="31.5" SE="10.558936327283936" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="11" TOTAL_2="12" WEIGHT="10.589850701265304"/>
<CONT_DATA CI_END="54.549510269385316" CI_START="29.450489730614684" EFFECT_SIZE="42.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="-10.0" ORDER="1978" SD_1="45.0" SD_2="35.55" SE="6.402929017254525" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="28.79869476444467"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.933487830208335" CI_END="-0.576968491223798" CI_START="-0.7957548978605626" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6863616945421803" ESTIMABLE="YES" I2="56.06737159751875" I2_Q="0.0" ID="CMP-005.11" MODIFIED="2009-05-21 10:36:00 +0100" MODIFIED_BY="Toby J Lasserson" NO="11" P_CHI2="0.025731071874674383" P_Q="1.0" P_Z="9.361905876798239E-35" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="683" TOTAL_2="688" UNITS="" WEIGHT="100.0" Z="12.297328909505495">
<NAME>Change in daily asthma symptom score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.11.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="15.933487830208335" CI_END="-0.576968491223798" CI_START="-0.7957548978605626" DF="7.0" EFFECT_SIZE="-0.6863616945421803" ESTIMABLE="YES" I2="56.06737159751875" ID="CMP-005.11.02" MODIFIED="2009-05-21 10:16:47 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.025731071874674383" P_Z="9.361905876798239E-35" STUDIES="8" TAU2="0.0" TOTAL_1="683" TOTAL_2="688" WEIGHT="100.0" Z="12.297328909505495">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.36809252541806786" CI_START="-0.9524670786687526" EFFECT_SIZE="-0.6602798020434102" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.7" ORDER="1979" SD_1="0.97" SD_2="1.9" SE="0.14907788047641604" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="14.017096993236708"/>
<CONT_DATA CI_END="-0.2878429824476172" CI_START="-1.1980019742012418" EFFECT_SIZE="-0.7429224783244295" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="-0.07" ORDER="1980" SD_1="0.73" SD_2="0.66" SE="0.23218768276683718" STUDY_ID="STD-FLTA3020" TOTAL_1="37" TOTAL_2="43" WEIGHT="5.7783805890400854"/>
<CONT_DATA CI_END="-0.26349874794156886" CI_START="-0.8240827079366428" EFFECT_SIZE="-0.5437907279391059" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.8" ORDER="1986" SD_1="2.0" SD_2="2.03" SE="0.14300874006279932" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="15.23208437294474"/>
<CONT_DATA CI_END="-0.3578095911832095" CI_START="-0.918125311712159" EFFECT_SIZE="-0.6379674514476843" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="0.33" ORDER="1982" SD_1="1.02" SD_2="1.01" SE="0.1429403103701518" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="101" WEIGHT="15.246671949331601"/>
<CONT_DATA CI_END="-0.759904043807487" CI_START="-1.417603947187927" EFFECT_SIZE="-1.088753995497707" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="0.21" ORDER="1981" SD_1="0.46" SD_2="0.35" SE="0.1677836706613726" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="78" WEIGHT="11.065858557134083"/>
<CONT_DATA CI_END="-0.037676728296413664" CI_START="-0.5998585733723925" EFFECT_SIZE="-0.31876765083440306" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.33" MODIFIED="2009-05-21 10:16:47 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1983" SD_1="1.0" SD_2="1.0" SE="0.1434163712982477" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="15.145619357621564"/>
<CONT_DATA CI_END="-0.5887225489039625" CI_START="-1.219618972004411" EFFECT_SIZE="-0.9041707604541868" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.4" ORDER="1984" SD_1="0.81" SD_2="0.94" SE="0.16094592249573944" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="12.026092518127625"/>
<CONT_DATA CI_END="-0.4892635922426978" CI_START="-1.1347608826988536" EFFECT_SIZE="-0.8120122374707757" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="0.17" ORDER="1985" SD_1="0.63" SD_2="0.62" SE="0.16467070199956632" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="11.488195662563603"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6195847119779253" CI_END="-0.19509479727938853" CI_START="-0.34449068048146947" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.269792738880429" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2009-05-21 10:35:57 +0100" MODIFIED_BY="Toby J Lasserson" NO="12" P_CHI2="0.4312018525816178" P_Q="1.0" P_Z="1.4523593614462706E-12" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="178" UNITS="" WEIGHT="100.0" Z="7.078964161024413">
<NAME>Change in number night-time awakenings per week</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6195847119779253" CI_END="-0.19509479727938853" CI_START="-0.34449068048146947" DF="1.0" EFFECT_SIZE="-0.269792738880429" ESTIMABLE="YES" I2="0.0" ID="CMP-005.12.02" NO="2" P_CHI2="0.4312018525816178" P_Z="1.4523593614462706E-12" STUDIES="2" TAU2="0.0" TOTAL_1="186" TOTAL_2="178" WEIGHT="100.0" Z="7.078964161024413">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.1939943423988702" CI_START="-0.4060056576011298" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="0.26" ORDER="1996" SD_1="0.2" SD_2="0.51" SE="0.05408551301824364" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="49.654564800714965"/>
<CONT_DATA CI_END="-0.1347241916608584" CI_START="-0.3452758083391416" EFFECT_SIZE="-0.24" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.21" ORDER="1995" SD_1="0.19" SD_2="0.43" SE="0.053713134103250744" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="50.34543519928503"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2028107572508818" CI_END="-0.044115317907270704" CI_START="-0.19657651378186985" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12034591584457029" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2009-05-21 10:35:57 +0100" MODIFIED_BY="Toby J Lasserson" NO="13" P_CHI2="0.6524615965319809" P_Q="1.0" P_Z="0.001973361613279324" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="121" UNITS="" WEIGHT="99.99999999999999" Z="3.0942123914055406">
<NAME>Change in number of night-time awakenings per night</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2028107572508818" CI_END="-0.044115317907270704" CI_START="-0.19657651378186985" DF="1.0" EFFECT_SIZE="-0.12034591584457029" ESTIMABLE="YES" I2="0.0" ID="CMP-005.13.02" NO="2" P_CHI2="0.6524615965319809" P_Z="0.001973361613279324" STUDIES="2" TAU2="0.0" TOTAL_1="119" TOTAL_2="121" WEIGHT="99.99999999999999" Z="3.0942123914055406">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-1.092435902993738E-4" CI_START="-0.29989075640970064" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="-0.13" MEAN_2="0.02" ORDER="1997" SD_1="0.36" SD_2="0.32" SE="0.07647628098884458" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="42" WEIGHT="25.864789611425753"/>
<CONT_DATA CI_END="-0.021464577503369456" CI_START="-0.19853542249663053" EFFECT_SIZE="-0.11" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.08" ORDER="1998" SD_1="0.18" SD_2="0.36" SE="0.04517196397229064" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="74.13521038857424"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2009-05-21 10:35:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="90" TOTAL_2="81" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in % nights with no awakenings</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.14.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.14.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-6.644041362056532" CI_START="-22.955958637943468" EFFECT_SIZE="-14.8" ESTIMABLE="YES" MEAN_1="-12.0" MEAN_2="2.8" ORDER="1999" SD_1="32.25" SD_2="21.6" SE="4.1612798511996285" STUDY_ID="STD-Shapiro-2000" TOTAL_1="90" TOTAL_2="81" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.880871939896164E-4" CI_END="-0.5226628952733234" CI_START="-0.9559335862667384" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7392982407700309" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2009-05-21 10:35:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="15" P_CHI2="0.9776040165392561" P_Q="1.0" P_Z="2.2523925606546228E-11" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="170" UNITS="" WEIGHT="100.0" Z="6.688649640347376">
<NAME>Change in night-time wakening score</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.15.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.880871939896164E-4" CI_END="-0.5226628952733234" CI_START="-0.9559335862667384" DF="1.0" EFFECT_SIZE="-0.7392982407700309" ESTIMABLE="YES" I2="0.0" ID="CMP-005.15.02" NO="2" P_CHI2="0.9776040165392561" P_Z="2.2523925606546228E-11" STUDIES="2" TAU2="0.0" TOTAL_1="181" TOTAL_2="170" WEIGHT="100.0" Z="6.688649640347376">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.44794095837949643" CI_START="-1.036358072248273" EFFECT_SIZE="-0.7421495153138847" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.27" ORDER="2000" SD_1="0.29" SD_2="0.49" SE="0.1501091648903081" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="54.21856669235261"/>
<CONT_DATA CI_END="-0.41574856064581084" CI_START="-1.0560944399372305" EFFECT_SIZE="-0.7359215002915207" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.21" ORDER="2001" SD_1="0.19" SD_2="0.43" SE="0.1633565423503662" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="45.7814333076474"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="29.475348102584267" CI_END="-1.4922854866925601" CI_START="-1.9772349904001143" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7347602385463372" ESTIMABLE="YES" I2="76.2513406944759" I2_Q="0.0" ID="CMP-005.16" MODIFIED="2009-05-21 10:41:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="16" P_CHI2="1.1847537257447804E-4" P_Q="1.0" P_Z="1.1377196253353656E-44" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="692" TOTAL_2="677" UNITS="" WEIGHT="100.0" Z="14.022357228406712">
<NAME>Change in daily use of beta2 agonist compared to baseline (puffs/d)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.16.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="29.475348102584267" CI_END="-1.4922854866925601" CI_START="-1.9772349904001143" DF="7.0" EFFECT_SIZE="-1.7347602385463372" ESTIMABLE="YES" I2="76.2513406944759" ID="CMP-005.16.02" MODIFIED="2009-05-21 10:41:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.1847537257447804E-4" P_Z="1.1377196253353656E-44" STUDIES="8" TAU2="0.0" TOTAL_1="692" TOTAL_2="677" WEIGHT="100.0" Z="14.022357228406712">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-1.6752937533242185" CI_START="-3.3247062466757815" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="1.6" ORDER="2002" SD_1="2.9" SD_2="2.9" SE="0.4207762250638068" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="8.644392520309285"/>
<CONT_DATA CI_END="-0.7183249821583421" CI_START="-2.5216750178416576" EFFECT_SIZE="-1.6199999999999999" ESTIMABLE="YES" MEAN_1="-1.67" MEAN_2="-0.05" ORDER="2003" SD_1="2.07" SD_2="2.03" SE="0.4600467278755912" STUDY_ID="STD-FLTA3020" TOTAL_1="37" TOTAL_2="43" WEIGHT="7.231576301654491"/>
<CONT_DATA CI_END="-1.6690948373186631" CI_START="-3.330905162681337" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="1.9" ORDER="2008" SD_1="3.0" SD_2="3.04" SE="0.4239389954281868" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="8.515891751365587"/>
<CONT_DATA CI_END="-1.025542397017428" CI_START="-2.134457602982572" EFFECT_SIZE="-1.58" ESTIMABLE="YES" MEAN_1="-0.69" MEAN_2="0.89" ORDER="2005" SD_1="2.05" SD_2="2.02" SE="0.28289173033589543" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="19.124776164830813"/>
<CONT_DATA CI_END="-2.0564296767039925" CI_START="-3.7435703232960074" EFFECT_SIZE="-2.9" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="1.7" ORDER="2004" SD_1="2.86" SD_2="2.6" SE="0.4304009308079039" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="8.262100269149357"/>
<CONT_DATA CI_END="-0.24728357602449547" CI_START="-1.2527164239755044" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="-1.51" MEAN_2="-0.76" MODIFIED="2009-05-21 10:41:31 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1166" SD_1="1.8" SD_2="1.8" SE="0.25649268452934215" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="23.264134443931958"/>
<CONT_DATA CI_END="-0.9655114629665221" CI_START="-2.634488537033478" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="0.9" ORDER="2006" SD_1="2.7" SD_2="2.85" SE="0.42576728124384783" STUDY_ID="STD-Shapiro-2000" TOTAL_1="90" TOTAL_2="81" WEIGHT="8.442912655286026"/>
<CONT_DATA CI_END="-1.3433254083048205" CI_START="-2.5366745916951796" EFFECT_SIZE="-1.94" ESTIMABLE="YES" MEAN_1="-1.03" MEAN_2="0.91" ORDER="2007" SD_1="1.8" SD_2="2.04" SE="0.30443140608790387" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="16.514215893472482"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2919970119573654" CI_END="29.09197375663917" CI_START="13.54280868040258" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="21.317391218520875" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.17" MODIFIED="2009-05-21 10:35:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="17" P_CHI2="0.5889437089152423" P_Q="1.0" P_Z="7.696970666922105E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="185" UNITS="" WEIGHT="100.0" Z="5.374091641293937">
<NAME>Change in percentage of symptom free days compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.17.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2919970119573654" CI_END="29.09197375663917" CI_START="13.54280868040258" DF="1.0" EFFECT_SIZE="21.317391218520875" ESTIMABLE="YES" I2="0.0" ID="CMP-005.17.02" NO="2" P_CHI2="0.5889437089152423" P_Z="7.696970666922105E-8" STUDIES="2" TAU2="0.0" TOTAL_1="176" TOTAL_2="185" WEIGHT="100.0" Z="5.374091641293937">
<NAME>Adults</NAME>
<CONT_DATA CI_END="30.449665357872558" CI_START="7.550334642127442" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="-5.0" ORDER="2017" SD_1="49.0" SD_2="29.0" SE="5.841773342870612" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="46.10718096463075"/>
<CONT_DATA CI_END="33.89038205607762" CI_START="12.70961794392238" EFFECT_SIZE="23.3" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="-7.9" ORDER="2018" SD_1="37.8" SD_2="32.25" SE="5.403355438984187" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="53.89281903536924"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.18" MODIFIED="2009-05-21 10:35:53 +0100" MODIFIED_BY="Toby J Lasserson" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="95" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in percentage of rescue beta2 agonist free days compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.18.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.18.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-13.909122889532595" CI_START="-36.0908771104674" EFFECT_SIZE="-25.0" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="11.0" ORDER="2019" SD_1="39.0" SD_2="39.0" SE="5.658714750858091" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.19" MODIFIED="2009-05-21 10:35:49 +0100" MODIFIED_BY="Toby J Lasserson" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: AQLQ</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.19.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.19.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.603327555481014" CI_END="8.389215770112937" CI_START="4.089387645303419" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.857196882817279" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="66" I2="56.553167770590804" I2_Q="0.0" ID="CMP-005.20" LOG_CI_END="0.923721364567539" LOG_CI_START="0.6116582805804189" LOG_EFFECT_SIZE="0.7676898225739789" METHOD="PETO" MODIFIED="2009-05-21 10:35:48 +0100" MODIFIED_BY="Toby J Lasserson" NO="20" P_CHI2="0.10009233249439875" P_Q="1.0" P_Z="5.252115272659789E-22" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="235" WEIGHT="100.0" Z="9.643206651159325">
<NAME>Physician rated global efficacy: effective or very effective (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.603327555481014" CI_END="8.389215770112937" CI_START="4.089387645303419" DF="2.0" EFFECT_SIZE="5.857196882817279" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="66" I2="56.553167770590804" ID="CMP-005.20.02" LOG_CI_END="0.923721364567539" LOG_CI_START="0.6116582805804189" LOG_EFFECT_SIZE="0.7676898225739789" NO="2" P_CHI2="0.10009233249439875" P_Z="5.252115272659789E-22" STUDIES="3" TAU2="0.0" TOTAL_1="245" TOTAL_2="235" WEIGHT="100.0" Z="9.643206651159325">
<NAME>Adults</NAME>
<DICH_DATA CI_END="17.73023079527825" CI_START="5.2985091683265395" EFFECT_SIZE="9.692460493874988" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="13" LOG_CI_END="1.2487143888701462" LOG_CI_START="0.7241536901577715" LOG_EFFECT_SIZE="0.9864340395139589" ORDER="2020" O_E="23.92307692307692" SE="0.3081295510409852" STUDY_ID="STD-Pearlman-1997" TOTAL_1="91" TOTAL_2="78" VAR="10.532544378698224" WEIGHT="35.391037473171345"/>
<DICH_DATA CI_END="7.105931812774034" CI_START="2.0640160467974114" EFFECT_SIZE="3.829720262501404" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="34" LOG_CI_END="0.8516210357626456" LOG_CI_START="0.31471306941276933" LOG_EFFECT_SIZE="0.5831670525877075" ORDER="2021" O_E="13.5" SE="0.3153823971712142" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" VAR="10.053680981595091" WEIGHT="33.78197969738044"/>
<DICH_DATA CI_END="9.995317243660296" CI_START="2.739959101442495" EFFECT_SIZE="5.233236135850564" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="19" LOG_CI_END="0.9997965828447902" LOG_CI_START="0.43774408028374356" LOG_EFFECT_SIZE="0.718770331564267" ORDER="2022" O_E="15.183673469387756" SE="0.33015242220911734" STUDY_ID="STD-Wolfe-1996" TOTAL_1="72" TOTAL_2="75" VAR="9.17425958362098" WEIGHT="30.82698282944821"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3117084515921209" CI_END="0.7244499962780392" CI_START="0.2256217112410452" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4042915382107571" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-005.21" LOG_CI_END="-0.13999158547226637" LOG_CI_START="-0.6466191111670027" LOG_EFFECT_SIZE="-0.3933053483196345" METHOD="PETO" MODIFIED="2009-05-21 10:35:47 +0100" MODIFIED_BY="Toby J Lasserson" NO="21" P_CHI2="0.8556839353415318" P_Q="1.0" P_Z="0.0023413851617158157" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="191" TOTAL_2="203" WEIGHT="100.0" Z="3.0431205512427764">
<NAME>Withdrawal due to clinical asthma exacerbation (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.21.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3117084515921209" CI_END="0.7244499962780392" CI_START="0.2256217112410452" DF="2.0" EFFECT_SIZE="0.4042915382107571" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="37" I2="0.0" ID="CMP-005.21.02" LOG_CI_END="-0.13999158547226637" LOG_CI_START="-0.6466191111670027" LOG_EFFECT_SIZE="-0.3933053483196345" NO="2" P_CHI2="0.8556839353415318" P_Z="0.0023413851617158157" STUDIES="3" TAU2="0.0" TOTAL_1="191" TOTAL_2="203" WEIGHT="100.0" Z="3.0431205512427764">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.8812926371637536" CI_START="0.1876431780762297" EFFECT_SIZE="0.40665532242009117" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" LOG_CI_END="-0.05487985821387331" LOG_CI_START="-0.7266672201009116" LOG_EFFECT_SIZE="-0.39077353915739244" ORDER="2025" O_E="-5.77832512315271" SE="0.394611221773519" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="6.421864492256209" WEIGHT="56.874017201861555"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="2023" O_E="-0.5" SE="2.0" STUDY_ID="STD-Olivieri-1997" TOTAL_1="10" TOTAL_2="10" VAR="0.25" WEIGHT="2.2140772851265766"/>
<DICH_DATA CI_END="1.0590875082068318" CI_START="0.17094688152933107" EFFECT_SIZE="0.42549701149905594" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.024931845623284217" LOG_CI_START="-0.76713881734154" LOG_EFFECT_SIZE="-0.3711034858591279" ORDER="2024" O_E="-3.947368421052632" SE="0.4652662282385535" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" VAR="4.619520938569334" WEIGHT="40.91190551301187"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.914897631670458" CI_END="0.18813790070187053" CI_START="0.12181542639633669" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.15138724713564883" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="421" I2="42.507661847314544" I2_Q="0.0" ID="CMP-005.22" LOG_CI_END="-0.7255237062698385" LOG_CI_START="-0.9142977102698374" LOG_EFFECT_SIZE="-0.819910708269838" METHOD="PETO" MODIFIED="2009-05-21 10:35:42 +0100" MODIFIED_BY="Toby J Lasserson" NO="22" P_CHI2="0.08401081895440254" P_Q="1.0" P_Z="5.304481877670124E-65" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="767" TOTAL_2="771" WEIGHT="100.00000000000001" Z="17.025601244836867">
<NAME>Withdrawal due to lack of treatment efficacy (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.22.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.914897631670458" CI_END="0.18813790070187053" CI_START="0.12181542639633669" DF="8.0" EFFECT_SIZE="0.15138724713564883" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="421" I2="42.507661847314544" ID="CMP-005.22.02" LOG_CI_END="-0.7255237062698385" LOG_CI_START="-0.9142977102698374" LOG_EFFECT_SIZE="-0.819910708269838" NO="2" P_CHI2="0.08401081895440254" P_Z="5.304481877670124E-65" STUDIES="9" TAU2="0.0" TOTAL_1="767" TOTAL_2="771" WEIGHT="100.00000000000001" Z="17.025601244836867">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.37250580169541786" CI_START="0.11951652305806511" EFFECT_SIZE="0.2109990479542347" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="69" LOG_CI_END="-0.42886695882257664" LOG_CI_START="-0.9225720497209497" LOG_EFFECT_SIZE="-0.6757195042717632" ORDER="2026" O_E="-18.5" SE="0.2900048142733187" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" VAR="11.890211640211641" WEIGHT="14.620060306171128"/>
<DICH_DATA CI_END="0.8241074140613708" CI_START="0.08836054504963234" EFFECT_SIZE="0.26984918062856106" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.08401617872295004" LOG_CI_START="-1.0537416138585745" LOG_EFFECT_SIZE="-0.5688788962907623" ORDER="2027" O_E="-4.037037037037037" SE="0.5696215208169867" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="3.0819615912208507" WEIGHT="3.789542666555088"/>
<DICH_DATA CI_END="0.24322502185652248" CI_START="0.07978930784591713" EFFECT_SIZE="0.13930813380682405" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="67" LOG_CI_END="-0.6139917489090483" LOG_CI_START="-1.0980553023163462" LOG_EFFECT_SIZE="-0.8560235256126971" ORDER="2034" O_E="-24.379310344827587" SE="0.2843413274246808" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="12.368585253293462" WEIGHT="15.20826271028012"/>
<DICH_DATA CI_END="0.2755717789579224" CI_START="0.08486374487985186" EFFECT_SIZE="0.15292499189332023" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="52" LOG_CI_END="-0.5597652601693519" LOG_CI_START="-1.071277807535583" LOG_EFFECT_SIZE="-0.8155215338524675" ORDER="2029" O_E="-20.8" SE="0.3004650023508698" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="11.076746411483253" WEIGHT="13.619833307623722"/>
<DICH_DATA CI_END="0.13850129160467947" CI_START="0.03867941701398102" EFFECT_SIZE="0.07319254890323458" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="51" LOG_CI_END="-0.8585461765333264" LOG_CI_START="-1.4125200803366862" LOG_EFFECT_SIZE="-1.1355331284350063" ORDER="2028" O_E="-24.692307692307693" SE="0.3254070133091433" STUDY_ID="STD-Pearlman-1997" TOTAL_1="91" TOTAL_2="78" VAR="9.44378698224852" WEIGHT="11.611966159809217"/>
<DICH_DATA CI_END="0.9602524707344327" CI_START="0.1578723356069865" EFFECT_SIZE="0.3893549798413067" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.017614566719464285" LOG_CI_START="-0.8016939659121328" LOG_EFFECT_SIZE="-0.40965426631579854" ORDER="2030" O_E="-4.446700507614214" SE="0.46057212034139555" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="4.71416424025355" WEIGHT="5.796479286593718"/>
<DICH_DATA CI_END="0.36209172098173636" CI_START="0.10817100038286606" EFFECT_SIZE="0.19790862459465489" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="56" LOG_CI_END="-0.4411814049621986" LOG_CI_START="-0.9658891538483373" LOG_EFFECT_SIZE="-0.7035352794052679" ORDER="2031" O_E="-17.05263157894737" SE="0.30821592904096423" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" VAR="10.526641681603389" WEIGHT="12.94343119057861"/>
<DICH_DATA CI_END="0.20732388077890124" CI_START="0.05673634596415543" EFFECT_SIZE="0.10845644022603293" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="54" LOG_CI_END="-0.6833506704427313" LOG_CI_START="-1.2461386378511456" LOG_EFFECT_SIZE="-0.9647446541469386" ORDER="2032" O_E="-20.326530612244895" SE="0.3305844379010707" STUDY_ID="STD-Wolfe-1996" TOTAL_1="72" TOTAL_2="75" VAR="9.150296965305552" WEIGHT="11.251094387564715"/>
<DICH_DATA CI_END="0.22840805981738707" CI_START="0.06217478054304873" EFFECT_SIZE="0.1191688759425446" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="45" LOG_CI_END="-0.641288575240298" LOG_CI_START="-1.206385738974973" LOG_EFFECT_SIZE="-0.9238371571076356" ORDER="2033" O_E="-19.305882352941175" SE="0.3319408712538225" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="86" TOTAL_2="84" VAR="9.075666755389939" WEIGHT="11.159329984823684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.961597744836489" CI_END="0.2776584249263992" CI_START="0.15462043681819077" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.20719958240394856" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="239" I2="69.88434910900689" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="-0.5564891442928572" LOG_CI_START="-0.8107331041383926" LOG_EFFECT_SIZE="-0.6836111242156249" METHOD="PETO" MODIFIED="2009-05-21 10:35:41 +0100" MODIFIED_BY="Toby J Lasserson" NO="23" P_CHI2="0.01889544139044097" P_Q="1.0" P_Z="5.655793446790397E-26" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="382" TOTAL_2="396" WEIGHT="100.00000000000001" Z="10.539901783370452">
<NAME>Withdrawals (total)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.23.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.961597744836489" CI_END="0.2776584249263992" CI_START="0.15462043681819077" DF="3.0" EFFECT_SIZE="0.20719958240394856" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="239" I2="69.88434910900689" ID="CMP-005.23.02" LOG_CI_END="-0.5564891442928572" LOG_CI_START="-0.8107331041383926" LOG_EFFECT_SIZE="-0.6836111242156249" NO="2" P_CHI2="0.01889544139044097" P_Z="5.655793446790397E-26" STUDIES="4" TAU2="0.0" TOTAL_1="382" TOTAL_2="396" WEIGHT="100.00000000000001" Z="10.539901783370452">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.27487179402046064" CI_START="0.09091973934113112" EFFECT_SIZE="0.158086279811277" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="81" LOG_CI_END="-0.560869823014847" LOG_CI_START="-1.0413418180292344" LOG_EFFECT_SIZE="-0.8011058205220407" ORDER="2038" O_E="-23.1576354679803" SE="0.28223162824618453" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="12.554188273300866" WEIGHT="28.000457641149055"/>
<DICH_DATA CI_END="0.2787674899353282" CI_START="0.09173840687723411" EFFECT_SIZE="0.15991774578148732" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="64" LOG_CI_END="-0.5547578753550247" LOG_CI_START="-1.037448806066188" LOG_EFFECT_SIZE="-0.7961033407106063" ORDER="2035" O_E="-22.80193236714976" SE="0.28353504205837926" STUDY_ID="STD-Lumry-2006" TOTAL_1="103" TOTAL_2="104" VAR="12.43903008238232" WEIGHT="27.743612516904452"/>
<DICH_DATA CI_END="1.0045604940412458" CI_START="0.27436108531319164" EFFECT_SIZE="0.5249879116778902" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="0.0019760948296498894" LOG_CI_START="-0.5616774878349897" LOG_EFFECT_SIZE="-0.27985069650266986" ORDER="2036" O_E="-5.878172588832488" SE="0.3310929045874421" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="9.122213919451674" WEIGHT="20.34589245314447"/>
<DICH_DATA CI_END="0.3168931818991607" CI_START="0.0957115108077233" EFFECT_SIZE="0.17415603694456117" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="64" LOG_CI_END="-0.4990871047523491" LOG_CI_START="-1.019035828370956" LOG_EFFECT_SIZE="-0.7590614665616524" ORDER="2037" O_E="-18.736842105263158" SE="0.305420454041261" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" VAR="10.7202216066482" WEIGHT="23.91003738880204"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45351416303580244" CI_END="1.8804149248779336" CI_START="0.4153666450118594" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8837769167480982" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-005.24" LOG_CI_END="0.2742536895308962" LOG_CI_START="-0.3815683813418549" LOG_EFFECT_SIZE="-0.05365734590547934" METHOD="MH" MODIFIED="2009-05-21 10:35:41 +0100" MODIFIED_BY="Toby J Lasserson" NO="24" P_CHI2="0.9289788236299495" P_Q="0.0" P_Z="0.7484252752467235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="342" TOTAL_2="349" WEIGHT="99.99999999999999" Z="0.32071645695240003">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.24.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.45351416303580244" CI_END="1.8804149248779336" CI_START="0.4153666450118594" DF="3.0" EFFECT_SIZE="0.8837769167480982" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-005.24.02" LOG_CI_END="0.2742536895308962" LOG_CI_START="-0.3815683813418549" LOG_EFFECT_SIZE="-0.05365734590547934" NO="2" P_CHI2="0.9289788236299495" P_Z="0.7484252752467235" STUDIES="4" TAU2="0.0" TOTAL_1="342" TOTAL_2="349" WEIGHT="99.99999999999999" Z="0.32071645695240003">
<NAME>Adults</NAME>
<DICH_DATA CI_END="9.303702390156696" CI_START="0.014553186069788731" EFFECT_SIZE="0.36796536796536794" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9686558095901323" LOG_CI_START="-1.837041917945836" LOG_EFFECT_SIZE="-0.4341930541778516" ORDER="2039" O_E="0.0" SE="1.6480807335823686" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="2.716170104405398" WEIGHT="9.6844271230182"/>
<DICH_DATA CI_END="2.7190634526292965" CI_START="0.392422210730287" EFFECT_SIZE="1.032967032967033" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.434419342491959" LOG_CI_START="-0.40624641993474886" LOG_EFFECT_SIZE="0.014086461278605102" ORDER="2042" O_E="0.0" SE="0.49381123021208584" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="0.24384953108357363" WEIGHT="56.15493165644409"/>
<DICH_DATA CI_END="3.336040130472038" CI_START="0.15893399903816924" EFFECT_SIZE="0.7281553398058253" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5232312662875642" LOG_CI_START="-0.7987831889145085" LOG_EFFECT_SIZE="-0.13777596131347214" ORDER="2040" O_E="0.0" SE="0.7765578350627923" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="0.6030420711974109" WEIGHT="27.307249630899225"/>
<DICH_DATA CI_END="16.382974535849932" CI_START="0.06230399953851756" EFFECT_SIZE="1.0103092783505154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2143927562293586" LOG_CI_START="-1.2054840733768586" LOG_EFFECT_SIZE="0.004454341426249989" ORDER="2041" O_E="0.0" SE="1.4214476282941868" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="2.0205133599831684" WEIGHT="6.853391589638475"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0778235082223997" CI_END="4.133633511156073" CI_START="1.1708573675610203" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.1999761933562407" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.25" LOG_CI_END="0.616331969355094" LOG_CI_START="0.06850399306208367" LOG_EFFECT_SIZE="0.3424179812085888" METHOD="PETO" MODIFIED="2009-05-21 10:35:39 +0100" MODIFIED_BY="Toby J Lasserson" NO="25" P_CHI2="0.6879890052336814" P_Q="1.0" P_Z="0.014280170490765031" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="582" TOTAL_2="576" WEIGHT="100.0" Z="2.450137414920152">
<NAME>Sore throat or pharyngitis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.25.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0778235082223997" CI_END="4.133633511156073" CI_START="1.1708573675610203" DF="5.0" EFFECT_SIZE="2.1999761933562407" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" I2="0.0" ID="CMP-005.25.02" LOG_CI_END="0.616331969355094" LOG_CI_START="0.06850399306208367" LOG_EFFECT_SIZE="0.3424179812085888" NO="2" P_CHI2="0.6879890052336814" P_Z="0.014280170490765031" STUDIES="7" TAU2="0.0" TOTAL_1="582" TOTAL_2="576" WEIGHT="100.0" Z="2.450137414920152">
<NAME>Adults</NAME>
<DICH_DATA CI_END="73.45200325119966" CI_START="0.7758070572671062" EFFECT_SIZE="7.548813316852333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8660036447699517" LOG_CI_START="-0.11024627408086934" LOG_EFFECT_SIZE="0.8778786853445412" ORDER="2043" O_E="1.5" SE="1.1608589849278423" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" VAR="0.742063492063492" WEIGHT="7.684306580391756"/>
<DICH_DATA CI_END="24.543911325538506" CI_START="0.6679234109370076" EFFECT_SIZE="4.048882928696399" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3899437732133588" LOG_CI_START="-0.1752733341029047" LOG_EFFECT_SIZE="0.6073352195552271" ORDER="2044" O_E="1.6543209876543208" SE="0.9194162767872117" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="1.182975156226185" WEIGHT="12.250088940706243"/>
<DICH_DATA CI_END="8.031735859113084" CI_START="0.6369512593735154" EFFECT_SIZE="2.2618187969900467" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9048094173288406" LOG_CI_START="-0.19589379936795273" LOG_EFFECT_SIZE="0.35445780898044393" ORDER="2046" O_E="1.9523809523809526" SE="0.6465585180564926" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="2.3921275049094595" WEIGHT="24.771251144557176"/>
<DICH_DATA CI_END="326.5947054196098" CI_START="0.12562748052241401" EFFECT_SIZE="6.405409432177272" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.514009139905592" LOG_CI_START="-0.900915349979228" LOG_EFFECT_SIZE="0.806546894963182" ORDER="2045" O_E="0.46153846153846156" SE="2.0059435495071947" STUDY_ID="STD-Pearlman-1997" TOTAL_1="91" TOTAL_2="78" VAR="0.2485207100591716" WEIGHT="2.5735120351506615"/>
<DICH_DATA CI_END="3.391517799774331" CI_START="0.49047682470311477" EFFECT_SIZE="1.2897522558062877" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5303941007239027" LOG_CI_START="-0.30938150844985546" LOG_EFFECT_SIZE="0.11050629613702358" ORDER="2047" O_E="1.0456852791878166" SE="0.49328834978497343" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="4.109587982169084" WEIGHT="42.5561078153388"/>
<DICH_DATA CI_END="20.025436967308774" CI_START="0.3830831108226944" EFFECT_SIZE="2.7697304361653012" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3015820014314554" LOG_CI_START="-0.41670699455357985" LOG_EFFECT_SIZE="0.44243750343893784" ORDER="2048" O_E="1.0" SE="1.0093314619093174" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" VAR="0.9815950920245399" WEIGHT="10.164733483855374"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2049" O_E="0.0" SE="0.0" STUDY_ID="STD-Wolfe-1996" TOTAL_1="72" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0786330418728065" CI_END="11.895002415002047" CI_START="2.595103572557469" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.555966456229873" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.26" LOG_CI_END="1.0753645345466316" LOG_CI_START="0.41415469555347884" LOG_EFFECT_SIZE="0.7447596150500552" METHOD="PETO" MODIFIED="2009-05-21 10:35:37 +0100" MODIFIED_BY="Toby J Lasserson" NO="26" P_CHI2="0.955360195611052" P_Q="1.0" P_Z="1.0089522276515096E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="682" TOTAL_2="679" WEIGHT="99.99999999999999" Z="4.415245922113811">
<NAME>Hoarseness or dysphonia (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.26.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0786330418728065" CI_END="11.895002415002047" CI_START="2.595103572557469" DF="7.0" EFFECT_SIZE="5.555966456229873" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" I2="0.0" ID="CMP-005.26.02" LOG_CI_END="1.0753645345466316" LOG_CI_START="0.41415469555347884" LOG_EFFECT_SIZE="0.7447596150500552" NO="2" P_CHI2="0.955360195611052" P_Z="1.0089522276515096E-5" STUDIES="8" TAU2="0.0" TOTAL_1="682" TOTAL_2="679" WEIGHT="99.99999999999999" Z="4.415245922113811">
<NAME>Adults</NAME>
<DICH_DATA CI_END="73.45200325119966" CI_START="0.7758070572671062" EFFECT_SIZE="7.548813316852333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8660036447699517" LOG_CI_START="-0.11024627408086934" LOG_EFFECT_SIZE="0.8778786853445412" ORDER="2050" O_E="1.5" SE="1.1608589849278423" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" VAR="0.742063492063492" WEIGHT="11.194246979171554"/>
<DICH_DATA CI_END="427.9458049572349" CI_START="0.16598818482764696" EFFECT_SIZE="8.428163938216773" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.63138877345641" LOG_CI_START="-0.7799228242899152" LOG_EFFECT_SIZE="0.9257329745832474" ORDER="2051" O_E="0.5308641975308642" SE="2.0038213187809384" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.2490474013107758" WEIGHT="3.7569536159786465"/>
<DICH_DATA CI_END="75.56608616187137" CI_START="0.7989894104613438" EFFECT_SIZE="7.770231826229172" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8783269291342788" LOG_CI_START="-0.09745897664180439" LOG_EFFECT_SIZE="0.8904339762462372" ORDER="2057" O_E="1.522167487684729" SE="1.1605864213508394" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="0.7424120800296196" WEIGHT="11.19950553161152"/>
<DICH_DATA CI_END="19.423641303930346" CI_START="0.7609029458736315" EFFECT_SIZE="3.8444122941944383" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.2883306493600466" LOG_CI_START="-0.11867073450348864" LOG_EFFECT_SIZE="0.5848299574282789" ORDER="2053" O_E="1.9714285714285715" SE="0.826479577650617" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="1.4639820330045894" WEIGHT="22.084601419956204"/>
<DICH_DATA CI_END="39.72603306259381" CI_START="1.1307389209300311" EFFECT_SIZE="6.70222140473053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.599075199713284" LOG_CI_START="0.05336234118689356" LOG_EFFECT_SIZE="0.8262187704500888" ORDER="2052" O_E="2.3076923076923075" SE="0.9079593845004517" STUDY_ID="STD-Pearlman-1997" TOTAL_1="91" TOTAL_2="78" VAR="1.21301775147929" WEIGHT="18.298731099705805"/>
<DICH_DATA CI_END="16.267124552708587" CI_START="0.06274119985762731" EFFECT_SIZE="1.0102568548000086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2113107919500117" LOG_CI_START="-1.20244718014634" LOG_EFFECT_SIZE="0.004431805901835847" ORDER="2054" O_E="0.005076142131979711" SE="1.4178533811040586" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="0.49743616171506605" WEIGHT="7.503971439324128"/>
<DICH_DATA CI_END="55.465062265864916" CI_START="1.061036951626502" EFFECT_SIZE="7.67140668902043" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7440195048703935" LOG_CI_START="0.02573050888535798" LOG_EFFECT_SIZE="0.8848750068778757" ORDER="2055" O_E="2.0" SE="1.0093314619093174" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" VAR="0.9815950920245399" WEIGHT="14.807651920875205"/>
<DICH_DATA CI_END="77.42669339559417" CI_START="0.8111637769889665" EFFECT_SIZE="7.925006564952287" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.888890712567021" LOG_CI_START="-0.09089145126154467" LOG_EFFECT_SIZE="0.8989996306527381" ORDER="2056" O_E="1.530612244897959" SE="1.1629338431126641" STUDY_ID="STD-Wolfe-1996" TOTAL_1="72" TOTAL_2="75" VAR="0.7394179365903476" WEIGHT="11.154337993376922"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5819526456235744" CI_END="10.66949477184724" CI_START="2.504761842430197" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.169578646517669" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.27" LOG_CI_END="1.0281438549452044" LOG_CI_START="0.3987664386122788" LOG_EFFECT_SIZE="0.7134551467787416" METHOD="PETO" MODIFIED="2009-05-21 10:35:36 +0100" MODIFIED_BY="Toby J Lasserson" NO="27" P_CHI2="0.8591854858905286" P_Q="1.0" P_Z="8.847169787077481E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="627" TOTAL_2="627" WEIGHT="100.0" Z="4.443586172565746">
<NAME>Oral Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.27.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5819526456235744" CI_END="10.66949477184724" CI_START="2.504761842430197" DF="6.0" EFFECT_SIZE="5.169578646517669" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-005.27.02" LOG_CI_END="1.0281438549452044" LOG_CI_START="0.3987664386122788" LOG_EFFECT_SIZE="0.7134551467787416" NO="2" P_CHI2="0.8591854858905286" P_Z="8.847169787077481E-6" STUDIES="7" TAU2="0.0" TOTAL_1="627" TOTAL_2="627" WEIGHT="100.0" Z="4.443586172565746">
<NAME>Adults</NAME>
<DICH_DATA CI_END="19.288632236475255" CI_START="1.33522907039244" EFFECT_SIZE="5.074913052481836" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.2853014327651053" LOG_CI_START="0.1255557791636907" LOG_EFFECT_SIZE="0.705428605964398" ORDER="2058" O_E="3.5" SE="0.6812403377590432" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" VAR="2.1547619047619047" WEIGHT="29.450780125917685"/>
<DICH_DATA CI_END="46.61244453583785" CI_START="1.3500648744108348" EFFECT_SIZE="7.932832033911843" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.668501879602533" LOG_CI_START="0.1303546380666336" LOG_EFFECT_SIZE="0.8994282588345832" ORDER="2064" O_E="2.5369458128078817" SE="0.903515303629829" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="1.2249799320488721" WEIGHT="16.7427382847755"/>
<DICH_DATA CI_END="8.658716011846707" CI_START="0.2511450076513688" EFFECT_SIZE="1.474650229392133" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9374534959073296" LOG_CI_START="-0.6000754504768059" LOG_EFFECT_SIZE="0.16868902271526187" ORDER="2060" O_E="0.4761904761904763" SE="0.9031521139970726" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="1.225965346266098" WEIGHT="16.75620669508122"/>
<DICH_DATA CI_END="105.27956904352732" CI_START="0.3984822084571169" EFFECT_SIZE="6.477039074907476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0223440985115113" LOG_CI_START="-0.3995910643340911" LOG_EFFECT_SIZE="0.8113765170887102" ORDER="2059" O_E="0.9230769230769231" SE="1.4226567034279154" STUDY_ID="STD-Pearlman-1997" TOTAL_1="91" TOTAL_2="78" VAR="0.49408284023668636" WEIGHT="6.753008329895931"/>
<DICH_DATA CI_END="135.29498770903518" CI_START="0.5167212577972362" EFFECT_SIZE="8.361207820804017" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1312817075316253" LOG_CI_START="-0.28674367130874057" LOG_EFFECT_SIZE="0.9222690181114422" ORDER="2061" O_E="1.0526315789473686" SE="1.4203600769494964" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" VAR="0.4956819292814078" WEIGHT="6.774864303752615"/>
<DICH_DATA CI_END="55.465062265864916" CI_START="1.061036951626502" EFFECT_SIZE="7.67140668902043" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7440195048703935" LOG_CI_START="0.02573050888535798" LOG_EFFECT_SIZE="0.8848750068778757" ORDER="2062" O_E="2.0" SE="1.0093314619093174" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" VAR="0.9815950920245399" WEIGHT="13.416211398580948"/>
<DICH_DATA CI_END="77.42669339559417" CI_START="0.8111637769889665" EFFECT_SIZE="7.925006564952287" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.888890712567021" LOG_CI_START="-0.09089145126154467" LOG_EFFECT_SIZE="0.8989996306527381" ORDER="2063" O_E="1.530612244897959" SE="1.1629338431126641" STUDY_ID="STD-Wolfe-1996" TOTAL_1="72" TOTAL_2="75" VAR="0.7394179365903476" WEIGHT="10.106190861996101"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9613564300147228" CI_END="1.7308752026470091" CI_START="0.7859040329735506" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1663197684744078" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-005.28" LOG_CI_END="0.23826575605817868" LOG_CI_START="-0.10463048257965428" LOG_EFFECT_SIZE="0.0668176367392622" METHOD="MH" MODIFIED="2009-05-21 10:35:35 +0100" MODIFIED_BY="Toby J Lasserson" NO="28" P_CHI2="0.5804659647751467" P_Q="0.0" P_Z="0.44495832679058145" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="330" WEIGHT="100.0" Z="0.7638471746513055">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.28.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9613564300147228" CI_END="1.7308752026470091" CI_START="0.7859040329735506" DF="3.0" EFFECT_SIZE="1.1663197684744078" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="58" I2="0.0" ID="CMP-005.28.02" LOG_CI_END="0.23826575605817868" LOG_CI_START="-0.10463048257965428" LOG_EFFECT_SIZE="0.0668176367392622" NO="2" P_CHI2="0.5804659647751467" P_Z="0.44495832679058145" STUDIES="4" TAU2="0.0" TOTAL_1="328" TOTAL_2="330" WEIGHT="100.0" Z="0.7638471746513055">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.9215403308550025" CI_START="0.2469726466909001" EFFECT_SIZE="0.6888888888888889" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.28364950422267426" LOG_CI_START="-0.6073511441048163" LOG_EFFECT_SIZE="-0.161850819941071" ORDER="2065" O_E="0.0" SE="0.5233781913519092" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.2739247311827957" WEIGHT="19.453276868516163"/>
<DICH_DATA CI_END="2.075498066503331" CI_START="0.46063612303274337" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.3171223331337985" LOG_CI_START="-0.33664200771211106" LOG_EFFECT_SIZE="-0.009759837289156264" ORDER="2067" O_E="0.0" SE="0.384024409998567" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="0.14747474747474748" WEIGHT="30.013627168567794"/>
<DICH_DATA CI_END="3.105763521530586" CI_START="0.7494151740699854" EFFECT_SIZE="1.5256166982922201" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.4921683846815971" LOG_CI_START="-0.12527751760978784" LOG_EFFECT_SIZE="0.18344543353590465" ORDER="2066" O_E="0.0" SE="0.36269077941246897" STUDY_ID="STD-Nathan-2000" TOTAL_1="86" TOTAL_2="84" VAR="0.13154460147082422" WEIGHT="27.13732123158005"/>
<DICH_DATA CI_END="3.038797584657988" CI_START="0.6343606425377137" EFFECT_SIZE="1.3884140550807218" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.4827017725400252" LOG_CI_START="-0.19766376966731486" LOG_EFFECT_SIZE="0.14251900143635515" ORDER="2068" O_E="0.0" SE="0.39965008735634167" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="0.1597201923239315" WEIGHT="23.395774731335997"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5473632456714856" CI_END="2.967370057813132" CI_START="0.8245562837883187" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5642134213383811" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-005.29" LOG_CI_END="0.47237171013368207" LOG_CI_START="-0.08377969428943219" LOG_EFFECT_SIZE="0.19429600792212487" METHOD="MH" MODIFIED="2009-05-21 10:35:34 +0100" MODIFIED_BY="Toby J Lasserson" NO="29" P_CHI2="0.671382877149413" P_Q="0.0" P_Z="0.17085594942815108" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="342" TOTAL_2="349" WEIGHT="100.0" Z="1.369458657619626">
<NAME>Headache</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.29.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5473632456714856" CI_END="2.967370057813132" CI_START="0.8245562837883187" DF="3.0" EFFECT_SIZE="1.5642134213383811" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" I2="0.0" ID="CMP-005.29.02" LOG_CI_END="0.47237171013368207" LOG_CI_START="-0.08377969428943219" LOG_EFFECT_SIZE="0.19429600792212487" NO="2" P_CHI2="0.671382877149413" P_Z="0.17085594942815108" STUDIES="4" TAU2="0.0" TOTAL_1="342" TOTAL_2="349" WEIGHT="100.0" Z="1.369458657619626">
<NAME>Adults</NAME>
<DICH_DATA CI_END="10.784116875793305" CI_START="0.57955603337619" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.0327845860010596" LOG_CI_START="-0.23690456865698448" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="2069" O_E="0.0" SE="0.7458216945088149" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="0.55625" WEIGHT="15.592848504633409"/>
<DICH_DATA CI_END="5.7159525705493" CI_START="0.045522253254292724" EFFECT_SIZE="0.51010101010101" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7570886164740449" LOG_CI_START="-1.3417762494318222" LOG_EFFECT_SIZE="-0.2923438164788886" ORDER="2072" O_E="0.0" SE="1.232883611781753" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" VAR="1.52000200020002" WEIGHT="12.832415040912903"/>
<DICH_DATA CI_END="6.997033876337298" CI_START="0.5952424058884359" EFFECT_SIZE="2.0408163265306123" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.844913976566241" LOG_CI_START="-0.22530613662326837" LOG_EFFECT_SIZE="0.3098039199714864" ORDER="2070" O_E="0.0" SE="0.6286525921625179" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="0.3952040816326531" WEIGHT="24.558736394797624"/>
<DICH_DATA CI_END="3.426179219782843" CI_START="0.4876715156246626" EFFECT_SIZE="1.2926136363636365" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5348100767050872" LOG_CI_START="-0.3118726103471244" LOG_EFFECT_SIZE="0.1114687331789814" ORDER="2071" O_E="0.0" SE="0.497345601521364" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" VAR="0.24735264735264736" WEIGHT="47.01600005965607"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5017609427389901" CI_END="17.364051132019135" CI_START="0.35695575862611545" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.4896180519614948" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.30" LOG_CI_END="1.2396510560379514" LOG_CI_START="-0.4473856073477126" LOG_EFFECT_SIZE="0.39613272434511937" METHOD="MH" MODIFIED="2009-05-21 10:35:33 +0100" MODIFIED_BY="Toby J Lasserson" NO="30" P_CHI2="0.47872745320110843" P_Q="0.0" P_Z="0.3573442099782562" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.00000000000001" Z="0.9204374625220308">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.30.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5017609427389901" CI_END="17.364051132019135" CI_START="0.35695575862611545" DF="1.0" EFFECT_SIZE="2.4896180519614948" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-005.30.02" LOG_CI_END="1.2396510560379514" LOG_CI_START="-0.4473856073477126" LOG_EFFECT_SIZE="0.39613272434511937" NO="2" P_CHI2="0.47872745320110843" P_Z="0.3573442099782562" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.00000000000001" Z="0.9204374625220308">
<NAME>Adults</NAME>
<DICH_DATA CI_END="18.79452465810365" CI_START="0.06855889140365588" EFFECT_SIZE="1.135135135135135" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2740313462257744" LOG_CI_START="-1.1639362135639635" LOG_EFFECT_SIZE="0.05504756633090544" ORDER="2073" O_E="0.0" SE="1.4320742127545454" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" VAR="2.050836550836551" WEIGHT="64.95393851568161"/>
<DICH_DATA CI_END="105.4127642421847" CI_START="0.2371629297431453" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.022893201999017" LOG_CI_START="-0.6249531933269795" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="2074" O_E="0.0" SE="1.555358079665535" STUDY_ID="STD-Lumry-2006" TOTAL_1="106" TOTAL_2="104" VAR="2.4191387559808613" WEIGHT="35.0460614843184"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.31" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2009-05-21 10:35:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="81" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>No. patients with &lt;/=18 mcg/dL post-stimulation cortisol</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.31.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-005.31.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="8.066232044426716" CI_START="0.15369534149513375" EFFECT_SIZE="1.1134371507396161" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9066707113691624" LOG_CI_START="-0.8133392957638726" LOG_EFFECT_SIZE="0.04666570780264482" ORDER="2075" O_E="0.10526315789473695" SE="1.0103423923767951" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" VAR="0.9796317418934333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.32" MODIFIED="2009-05-21 10:35:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="1" TOTAL_2="75" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Plasma cortisol (AUC)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.32.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.32.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.1" ORDER="2076" SD_1="0.0" SD_2="0.17" SE="0.0" STUDY_ID="STD-Falcoz-2000" TOTAL_1="1" TOTAL_2="75" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-05-21 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="6">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 500 mcg/d (subgroups)</NAME>
<CONT_OUTCOME CHI2="34.46341029849497" CI_END="0.44209345222012436" CI_START="0.35617988423922725" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3991366682296758" ESTIMABLE="YES" I2="73.88534703313144" I2_Q="44.51338123027577" ID="CMP-006.01" MODIFIED="2009-05-21 09:52:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="7.406541012600076E-5" P_Q="0.17944251450485282" P_Z="4.208206885252999E-74" Q="1.8022363268342474" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="779" TOTAL_2="781" UNITS="" WEIGHT="199.99999999999997" Z="18.211174626420366">
<NAME>Adults studies: change in FEV1 compared to baseline (litres); study duration</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="32.66117397166072" CI_END="0.4353007476303217" CI_START="0.34580632579059994" DF="8.0" EFFECT_SIZE="0.39055353671046084" ESTIMABLE="YES" I2="75.50608558363089" ID="CMP-006.01.02" MODIFIED="2009-05-21 09:52:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="7.087405996042406E-5" P_Z="1.3260238869260014E-65" STUDIES="9" TAU2="0.0" TOTAL_1="679" TOTAL_2="678" WEIGHT="99.99999999999999" Z="17.106560392292373">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.6026813334377111" CI_START="0.2973186665622889" EFFECT_SIZE="0.45" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.18" ORDER="2080" SD_1="0.49" SD_2="0.58" SE="0.07790007094112032" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="8.589345133277034"/>
<CONT_DATA CI_END="0.38449449502638544" CI_START="-0.14449449502638545" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.07" ORDER="2081" SD_1="0.62" SD_2="0.59" SE="0.1349486506449528" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="2.8621913658147125"/>
<CONT_DATA CI_END="0.5003440546802245" CI_START="0.2796559453197756" EFFECT_SIZE="0.39" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="-0.25" ORDER="2083" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="16.445007098405366"/>
<CONT_DATA CI_END="0.8269061526507122" CI_START="0.49309384734928785" EFFECT_SIZE="0.66" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="-0.22" ORDER="2082" SD_1="0.56" SD_2="0.52" SE="0.08515776512591386" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="7.187655433022663"/>
<CONT_DATA CI_END="0.3317147608834454" CI_START="0.1082852391165545" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.13" MODIFIED="2009-05-21 09:52:05 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2084" SD_1="0.4" SD_2="0.4" SE="0.05699837433985382" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="16.043932329508582"/>
<CONT_DATA CI_END="0.4979575815703875" CI_START="0.2220424184296125" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-0.11" ORDER="2085" SD_1="0.45" SD_2="0.47" SE="0.07038781460199232" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="10.520606986227238"/>
<CONT_DATA CI_END="0.6326720312767347" CI_START="0.28732796872326527" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="-0.3" ORDER="2086" SD_1="0.15" SD_2="0.28" SE="0.08809959399190477" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.715648333560558"/>
<CONT_DATA CI_END="0.43739881623902277" CI_START="0.24260118376097717" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="0.24" ORDER="2087" SD_1="0.36" SD_2="0.27" SE="0.049694186733680944" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" WEIGHT="21.106906431989874"/>
<CONT_DATA CI_END="0.7179045048774223" CI_START="0.4420954951225776" EFFECT_SIZE="0.58" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.16" ORDER="2088" SD_1="0.45" SD_2="0.44" SE="0.07036073415899244" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="10.528706888193962"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6533944838306422" CI_START="0.34660551616935775" DF="0.0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.03" MODIFIED="2008-07-08 09:23:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="1.0" P_Z="1.6736857381699516E-10" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="103" WEIGHT="99.99999999999999" Z="6.388639068351328">
<NAME>6 months or longer</NAME>
<CONT_DATA CI_END="0.6533944838306422" CI_START="0.34660551616935775" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-0.18" ORDER="2572" SD_1="0.6" SD_2="0.51" SE="0.07826392986840491" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="34.46341029849497" CI_END="0.4420934522201244" CI_START="0.3561798842392273" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.39913666822967586" ESTIMABLE="YES" I2="73.88534703313144" I2_Q="78.4596369319224" ID="CMP-006.02" MODIFIED="2009-05-21 09:52:17 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="7.406541012600076E-5" P_Q="0.03119056246693741" P_Z="4.208206885252999E-74" Q="4.6424472829893055" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="779" TOTAL_2="781" UNITS="" WEIGHT="200.0" Z="18.211174626420366">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); inhaler device</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.84189018956591" CI_END="0.4115157675299973" CI_START="0.28567486593874336" DF="4.0" EFFECT_SIZE="0.34859531673437033" ESTIMABLE="YES" I2="71.10221259365848" ID="CMP-006.02.01" MODIFIED="2009-05-21 09:52:17 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.007817178176618866" P_Z="1.813129280772678E-27" STUDIES="5" TAU2="0.0" TOTAL_1="354" TOTAL_2="360" WEIGHT="100.0" Z="10.858699474323922">
<NAME>MDI</NAME>
<CONT_DATA CI_END="0.38449449502638544" CI_START="-0.14449449502638545" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.07" ORDER="2793" SD_1="0.62" SD_2="0.59" SE="0.1349486506449528" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="5.659139194269774"/>
<CONT_DATA CI_END="0.6533944838306422" CI_START="0.34660551616935775" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-0.18" ORDER="2791" SD_1="0.6" SD_2="0.51" SE="0.07826392986840491" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="16.825352288012155"/>
<CONT_DATA CI_END="0.5003440546802245" CI_START="0.2796559453197756" EFFECT_SIZE="0.39" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="-0.25" ORDER="2789" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="32.51515091973592"/>
<CONT_DATA CI_END="0.3317147608834454" CI_START="0.1082852391165545" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.13" MODIFIED="2009-05-21 09:52:17 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2792" SD_1="0.4" SD_2="0.4" SE="0.05699837433985382" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="31.722143865209215"/>
<CONT_DATA CI_END="0.6326720312767347" CI_START="0.28732796872326527" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="-0.3" ORDER="2790" SD_1="0.15" SD_2="0.28" SE="0.08809959399190477" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="13.278213732772937"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="15.979072825939754" CI_END="0.5020497360314377" CI_START="0.3844700951121715" DF="4.0" EFFECT_SIZE="0.4432599155718046" ESTIMABLE="YES" I2="74.96725846629494" ID="CMP-006.02.02" MODIFIED="2008-07-14 14:13:53 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.0030473814796968535" P_Z="2.042652948253416E-49" STUDIES="5" TAU2="0.0" TOTAL_1="425" TOTAL_2="421" WEIGHT="100.0" Z="14.777617341211798">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.6026813334377111" CI_START="0.2973186665622889" EFFECT_SIZE="0.45" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.18" ORDER="2794" SD_1="0.49" SD_2="0.58" SE="0.07790007094112032" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="14.826286203125662"/>
<CONT_DATA CI_END="0.8269061526507122" CI_START="0.49309384734928785" EFFECT_SIZE="0.66" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="-0.22" ORDER="2798" SD_1="0.56" SD_2="0.52" SE="0.08515776512591386" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="12.406794106640774"/>
<CONT_DATA CI_END="0.4979575815703875" CI_START="0.2220424184296125" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-0.11" ORDER="2796" SD_1="0.45" SD_2="0.47" SE="0.07038781460199232" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="18.15988620647006"/>
<CONT_DATA CI_END="0.43739881623902277" CI_START="0.24260118376097717" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="0.24" ORDER="2795" SD_1="0.36" SD_2="0.27" SE="0.049694186733680944" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" WEIGHT="36.43316583133772"/>
<CONT_DATA CI_END="0.7179045048774223" CI_START="0.4420954951225776" EFFECT_SIZE="0.58" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.16" ORDER="2797" SD_1="0.45" SD_2="0.44" SE="0.07036073415899244" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="18.173867652425777"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="34.46341029849498" CI_END="0.4420934522201244" CI_START="0.3561798842392273" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.39913666822967586" ESTIMABLE="YES" I2="73.88534703313145" I2_Q="87.97611065917022" ID="CMP-006.03" MODIFIED="2009-05-21 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="7.406541012544565E-5" P_Q="2.4438368945489675E-4" P_Z="4.208206885252999E-74" Q="16.633552948699858" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="779" TOTAL_2="781" UNITS="" WEIGHT="300.0" Z="18.211174626420366">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); severity</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6326720312767347" CI_START="0.28732796872326527" DF="0.0" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" MODIFIED="2008-07-14 14:13:59 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.0" P_Z="1.7761056942766734E-7" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="5.221363449668884">
<NAME>Mild</NAME>
<CONT_DATA CI_END="0.6326720312767347" CI_START="0.28732796872326527" EFFECT_SIZE="0.45999999999999996" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="-0.3" ORDER="2799" SD_1="0.15" SD_2="0.28" SE="0.08809959399190477" STUDY_ID="STD-Sovij_x00e4_rvi-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.46598424542036543" CI_END="0.3077727286116394" CI_START="0.10194934226931304" DF="1.0" EFFECT_SIZE="0.20486103544047624" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" MODIFIED="2009-05-21 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.49484046138704507" P_Z="9.555901140656048E-5" STUDIES="2" TAU2="0.0" TOTAL_1="136" TOTAL_2="142" WEIGHT="100.0" Z="3.901599895272414">
<NAME>Mild to moderate</NAME>
<CONT_DATA CI_END="0.38449449502638544" CI_START="-0.14449449502638545" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.07" ORDER="2800" SD_1="0.62" SD_2="0.59" SE="0.1349486506449528" STUDY_ID="STD-FLTA3020" TOTAL_1="38" TOTAL_2="43" WEIGHT="15.138964559523735"/>
<CONT_DATA CI_END="0.3317147608834454" CI_START="0.1082852391165545" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.13" MODIFIED="2009-05-21 09:52:32 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2801" SD_1="0.4" SD_2="0.4" SE="0.05699837433985382" STUDY_ID="STD-Pinnas-2005" TOTAL_1="98" TOTAL_2="99" WEIGHT="84.86103544047627"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.363873104374754" CI_END="0.4876679724571963" CI_START="0.38936867429243616" DF="6.0" EFFECT_SIZE="0.4385183233748162" ESTIMABLE="YES" I2="65.4454973038917" ID="CMP-006.03.03" MODIFIED="2008-07-14 14:13:59 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.008035010652135632" P_Z="1.7997270805213703E-68" STUDIES="7" TAU2="0.0" TOTAL_1="630" TOTAL_2="626" WEIGHT="100.00000000000001" Z="17.48700420902188">
<NAME>Moderate</NAME>
<CONT_DATA CI_END="0.6026813334377111" CI_START="0.2973186665622889" EFFECT_SIZE="0.45" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="-0.18" ORDER="2807" SD_1="0.49" SD_2="0.58" SE="0.07790007094112032" STUDY_ID="STD-Condemi-1997" TOTAL_1="95" TOTAL_2="95" WEIGHT="10.362605246622579"/>
<CONT_DATA CI_END="0.6533944838306422" CI_START="0.34660551616935775" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-0.18" ORDER="2805" SD_1="0.6" SD_2="0.51" SE="0.07826392986840491" STUDY_ID="STD-Gross-1998" TOTAL_1="100" TOTAL_2="103" WEIGHT="10.266475098094206"/>
<CONT_DATA CI_END="0.5003440546802245" CI_START="0.2796559453197756" EFFECT_SIZE="0.39" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="-0.25" ORDER="2802" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="19.84005930539019"/>
<CONT_DATA CI_END="0.8269061526507122" CI_START="0.49309384734928785" EFFECT_SIZE="0.66" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="-0.22" ORDER="2804" SD_1="0.56" SD_2="0.52" SE="0.08515776512591386" STUDY_ID="STD-Pearlman-1997" TOTAL_1="86" TOTAL_2="75" WEIGHT="8.671538370555497"/>
<CONT_DATA CI_END="0.4979575815703875" CI_START="0.2220424184296125" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-0.11" ORDER="2808" SD_1="0.45" SD_2="0.47" SE="0.07038781460199232" STUDY_ID="STD-Shapiro-2000" TOTAL_1="81" TOTAL_2="90" WEIGHT="12.692573818085537"/>
<CONT_DATA CI_END="0.43739881623902277" CI_START="0.24260118376097717" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="0.24" ORDER="2803" SD_1="0.36" SD_2="0.27" SE="0.049694186733680944" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="82" WEIGHT="25.46440222604752"/>
<CONT_DATA CI_END="0.7179045048774223" CI_START="0.4420954951225776" EFFECT_SIZE="0.58" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.16" ORDER="2806" SD_1="0.45" SD_2="0.44" SE="0.07036073415899244" STUDY_ID="STD-ZuWallack-2000" TOTAL_1="81" TOTAL_2="79" WEIGHT="12.702345935204493"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-05-21 10:59:47 +0100" MODIFIED_BY="Toby J Lasserson" NO="7">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 1000-1500 mcg/d (all ages)</NAME>
<CONT_OUTCOME CHI2="4.4722793110522545" CI_END="0.47555935004666783" CI_START="-0.22344933340522233" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12605500832072275" ESTIMABLE="YES" I2="55.28007396457909" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="0.10687037753066764" P_Q="1.0" P_Z="0.4796310167886939" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.706896158026105">
<NAME>FEV1 (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.4722793110522545" CI_END="0.47555935004666783" CI_START="-0.22344933340522233" DF="2.0" EFFECT_SIZE="0.12605500832072275" ESTIMABLE="YES" I2="55.28007396457909" ID="CMP-007.01.02" NO="2" P_CHI2="0.10687037753066764" P_Z="0.4796310167886939" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="38" WEIGHT="100.0" Z="0.706896158026105">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.32756296280872166" CI_START="-0.7875629628087216" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="3.81" ORDER="2314" SD_1="0.82" SD_2="0.76" SE="0.2844761267077901" STUDY_ID="STD-Corsico-2000" TOTAL_1="15" TOTAL_2="16" WEIGHT="39.29319250134668"/>
<CONT_DATA CI_END="1.2830918376490097" CI_START="0.03690816235099059" EFFECT_SIZE="0.6600000000000001" ESTIMABLE="YES" MEAN_1="3.73" MEAN_2="3.07" ORDER="2315" SD_1="0.85" SD_2="0.92" SE="0.3179098404684364" STUDY_ID="STD-Overbeek-1996" TOTAL_1="15" TOTAL_2="16" WEIGHT="31.46306489273399"/>
<CONT_DATA CI_END="0.6763028912975274" CI_START="-0.6163028912975278" EFFECT_SIZE="0.029999999999999805" ESTIMABLE="YES" MEAN_1="3.27" MEAN_2="3.24" ORDER="2316" SD_1="0.54" SD_2="0.55" SE="0.32975243238931035" STUDY_ID="STD-van-Schoor-2002" TOTAL_1="5" TOTAL_2="6" WEIGHT="29.243742605919333"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.838604131681196" CI_END="0.48105135111584757" CI_START="0.3588436913060376" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4199475212109426" ESTIMABLE="YES" I2="71.09535064419784" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2009-05-21 09:59:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.007828408274485166" P_Q="1.0" P_Z="2.3416800940477765E-41" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="412" TOTAL_2="408" UNITS="" WEIGHT="100.0" Z="13.470219759567753">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.838604131681196" CI_END="0.48105135111584757" CI_START="0.3588436913060376" DF="4.0" EFFECT_SIZE="0.4199475212109426" ESTIMABLE="YES" I2="71.09535064419784" ID="CMP-007.02.02" MODIFIED="2009-05-21 09:59:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.007828408274485166" P_Z="2.3416800940477765E-41" STUDIES="5" TAU2="0.0" TOTAL_1="412" TOTAL_2="408" WEIGHT="100.0" Z="13.470219759567753">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.6637483351155297" CI_START="0.37625166488447037" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="-0.26" ORDER="2317" SD_1="0.41" SD_2="0.51" SE="0.07334233498645801" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="18.068879321342944"/>
<CONT_DATA CI_END="0.6513810699305987" CI_START="0.2886189300694013" EFFECT_SIZE="0.47000000000000003" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.05" ORDER="2318" SD_1="0.46" SD_2="0.56" SE="0.09254306270998318" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="63" WEIGHT="11.348878470545147"/>
<CONT_DATA CI_END="0.806223509073017" CI_START="0.413776490926983" EFFECT_SIZE="0.61" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.19" ORDER="2319" SD_1="0.5" SD_2="0.64" SE="0.10011587489403018" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="9.696941782838579"/>
<CONT_DATA CI_END="0.5503440546802244" CI_START="0.3296559453197756" EFFECT_SIZE="0.44" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.25" ORDER="2320" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="30.66471885965061"/>
<CONT_DATA CI_END="0.3711519338976247" CI_START="0.14884806610237536" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.13" MODIFIED="2009-05-21 09:59:55 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1159" SD_1="0.4" SD_2="0.4" SE="0.056711212437767694" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="30.220581565622716"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2009-05-21 10:09:26 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="89" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FVC compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.692212488389272" CI_START="0.347787511610728" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="-0.31" ORDER="2326" SD_1="0.45" SD_2="0.66" SE="0.08786512902668729" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="89" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2009-05-21 10:09:26 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="89" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEF25-75 compared to baseline (L/second)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.7788468125829967" CI_START="0.3411531874170034" EFFECT_SIZE="0.56" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-0.16" ORDER="2327" SD_1="0.73" SD_2="0.72" SE="0.11165858878491255" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="89" TOTAL_2="80" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.947244300180834" CI_END="52.79446377570602" CI_START="39.57737042831364" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="46.18591710200983" ESTIMABLE="YES" I2="59.78785803091935" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2009-05-21 10:09:26 +0100" MODIFIED_BY="Toby J Lasserson" NO="5" P_CHI2="0.04132585767261976" P_Q="1.0" P_Z="1.0460719401953282E-42" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="407" UNITS="" WEIGHT="100.00000000000001" Z="13.697827764945188">
<NAME>Change in morning PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.947244300180834" CI_END="52.79446377570602" CI_START="39.57737042831364" DF="4.0" EFFECT_SIZE="46.18591710200983" ESTIMABLE="YES" I2="59.78785803091935" ID="CMP-007.05.02" MODIFIED="2009-05-21 10:01:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.04132585767261976" P_Z="1.0460719401953282E-42" STUDIES="5" TAU2="0.0" TOTAL_1="416" TOTAL_2="407" WEIGHT="100.00000000000001" Z="13.697827764945188">
<NAME>Adults</NAME>
<CONT_DATA CI_END="72.1807769330623" CI_START="43.8192230669377" EFFECT_SIZE="58.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="-19.0" ORDER="2328" SD_1="56.0" SD_2="37.0" SE="7.235223220895107" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="89" TOTAL_2="80" WEIGHT="21.717602112280307"/>
<CONT_DATA CI_END="77.74172881582469" CI_START="44.258271184175314" EFFECT_SIZE="61.0" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="-15.0" ORDER="2329" SD_1="53.0" SD_2="39.0" SE="8.541855334017004" STUDY_ID="STD-Galant-1999" TOTAL_1="58" TOTAL_2="62" WEIGHT="15.581573670981001"/>
<CONT_DATA CI_END="46.93715180257939" CI_START="19.062848197420607" EFFECT_SIZE="33.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="-15.0" ORDER="2330" SD_1="42.0" SD_2="40.0" SE="7.110922400877705" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="22.48349709059511"/>
<CONT_DATA CI_END="54.044304172817206" CI_START="27.155695827182797" EFFECT_SIZE="40.6" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="-20.0" ORDER="2331" SD_1="49.0" SD_2="48.48" SE="6.859464907959615" STUDY_ID="STD-Lumry-2006" TOTAL_1="100" TOTAL_2="102" WEIGHT="24.16213262718388"/>
<CONT_DATA CI_END="59.19294368294037" CI_START="26.207056317059635" EFFECT_SIZE="42.7" ESTIMABLE="YES" MEAN_1="54.1" MEAN_2="11.4" MODIFIED="2009-05-21 10:01:54 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2332" SD_1="59.0" SD_2="59.7" SE="8.414921811336638" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="16.05519449895972"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.279388117083858" CI_END="45.06789195132349" CI_START="28.676388989528277" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="36.87214047042588" ESTIMABLE="YES" I2="62.11682195654281" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2009-05-21 10:10:15 +0100" MODIFIED_BY="Toby J Lasserson" NO="6" P_CHI2="0.07138324259294138" P_Q="1.0" P_Z="1.1678521604732108E-18" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="239" UNITS="" WEIGHT="100.0" Z="8.817747527286132">
<NAME>Change in evening PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.279388117083858" CI_END="45.06789195132349" CI_START="28.676388989528277" DF="2.0" EFFECT_SIZE="36.87214047042588" ESTIMABLE="YES" I2="62.11682195654281" ID="CMP-007.06.02" MODIFIED="2009-05-21 10:10:15 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.07138324259294138" P_Z="1.1678521604732108E-18" STUDIES="3" TAU2="0.0" TOTAL_1="238" TOTAL_2="239" WEIGHT="100.0" Z="8.817747527286132">
<NAME>Adults</NAME>
<CONT_DATA CI_END="60.64782923055563" CI_START="35.35217076944437" EFFECT_SIZE="48.0" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="-23.0" ORDER="2338" SD_1="49.0" SD_2="30.0" SE="6.453092674314474" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="41.98997106415943"/>
<CONT_DATA CI_END="46.334686918137166" CI_START="15.665313081862834" EFFECT_SIZE="31.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="-7.0" ORDER="2339" SD_1="46.0" SD_2="39.0" SE="7.82396362336003" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="60" WEIGHT="28.564572878137817"/>
<CONT_DATA CI_END="41.80357088847752" CI_START="11.596429111522472" EFFECT_SIZE="26.7" ESTIMABLE="YES" MEAN_1="33.5" MEAN_2="6.8" MODIFIED="2009-05-21 10:10:15 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1160" SD_1="54.0" SD_2="54.7" SE="7.7060451149166855" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="29.445456057702756"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7690987144709281" CI_END="-0.5098118167694943" CI_START="-0.8362337558235207" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6730227862965075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.07" MODIFIED="2009-05-21 10:59:47 +0100" MODIFIED_BY="Toby J Lasserson" NO="7" P_CHI2="0.856843062371267" P_Q="1.0" P_Z="6.36191455198758E-16" Q="0.0" RANDOM="NO" SCALE="2.841750065650712" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="306" UNITS="" WEIGHT="100.0" Z="8.082179927848703">
<NAME>Change in daily asthma symptom score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.07.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7690987144709281" CI_END="-0.5098118167694943" CI_START="-0.8362337558235207" DF="3.0" EFFECT_SIZE="-0.6730227862965075" ESTIMABLE="YES" I2="0.0" ID="CMP-007.07.02" NO="2" P_CHI2="0.856843062371267" P_Z="6.36191455198758E-16" STUDIES="4" TAU2="0.0" TOTAL_1="305" TOTAL_2="306" WEIGHT="100.0" Z="8.082179927848703">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.4355686500890908" CI_START="-1.0797903755769394" EFFECT_SIZE="-0.757679512833015" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="0.1" ORDER="2340" SD_1="0.32" SD_2="0.5" SE="0.1643452967935603" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="25.67366955969025"/>
<CONT_DATA CI_END="-0.2525709246034026" CI_START="-0.9858642343156093" EFFECT_SIZE="-0.619217579459506" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.04" ORDER="2341" SD_1="0.38" SD_2="0.39" SE="0.18706805724399295" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="61" WEIGHT="19.81541787181685"/>
<CONT_DATA CI_END="-0.2204731353567287" CI_START="-0.9147083410887575" EFFECT_SIZE="-0.5675907382227431" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="0.06" ORDER="2342" SD_1="0.5" SD_2="0.48" SE="0.17710407211766835" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="22.107794212240815"/>
<CONT_DATA CI_END="-0.42406574573630124" CI_START="-0.9975030430353902" EFFECT_SIZE="-0.7107843943858457" ESTIMABLE="YES" MEAN_1="-0.38" MEAN_2="0.33" ORDER="2343" SD_1="0.99" SD_2="1.0" SE="0.14628771289224934" STUDY_ID="STD-Lumry-2006" TOTAL_1="98" TOTAL_2="101" WEIGHT="32.40311835625208"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5764712278773194" CI_END="-0.1116234414443048" CI_START="-0.25077470693195647" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18119907418813064" ESTIMABLE="YES" I2="36.567189916527944" I2_Q="0.0" ID="CMP-007.08" MODIFIED="2009-05-21 10:43:09 +0100" MODIFIED_BY="Toby J Lasserson" NO="8" P_CHI2="0.20926976292280786" P_Q="1.0" P_Z="3.318003115202759E-7" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="140" UNITS="" WEIGHT="100.0" Z="5.104425866285104">
<NAME>Change in number of night-time awakenings per week compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.08.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5764712278773194" CI_END="-0.1116234414443048" CI_START="-0.25077470693195647" DF="1.0" EFFECT_SIZE="-0.18119907418813064" ESTIMABLE="YES" I2="36.567189916527944" ID="CMP-007.08.02" NO="2" P_CHI2="0.20926976292280786" P_Z="3.318003115202759E-7" STUDIES="2" TAU2="0.0" TOTAL_1="137" TOTAL_2="140" WEIGHT="100.0" Z="5.104425866285104">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.1277540377661564" CI_START="-0.31224596223384365" EFFECT_SIZE="-0.22000000000000003" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.14" ORDER="2349" SD_1="0.18" SD_2="0.38" SE="0.04706513127867042" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="56.88786020903402"/>
<CONT_DATA CI_END="-0.024036236360280225" CI_START="-0.23596376363971977" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.1" ORDER="2350" SD_1="0.15" SD_2="0.39" SE="0.054064138155368376" STUDY_ID="STD-Galant-1999" TOTAL_1="58" TOTAL_2="60" WEIGHT="43.11213979096598"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.590021796256165" CI_END="-1.0847079229432073" CI_START="-1.6406146730661042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3626612980046557" ESTIMABLE="YES" I2="53.43434399964688" I2_Q="0.0" ID="CMP-007.09" MODIFIED="2009-05-21 10:43:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.07220516001275301" P_Q="1.0" P_Z="7.347975373024895E-22" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="408" TOTAL_2="404" UNITS="" WEIGHT="99.99999999999997" Z="9.608687308169179">
<NAME>Change in daily use of beta2 agonist compared to baseline (puffs/d)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.09.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.590021796256165" CI_END="-1.0847079229432073" CI_START="-1.6406146730661042" DF="4.0" EFFECT_SIZE="-1.3626612980046557" ESTIMABLE="YES" I2="53.43434399964688" ID="CMP-007.09.02" MODIFIED="2009-05-21 10:43:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.07220516001275301" P_Z="7.347975373024895E-22" STUDIES="5" TAU2="0.0" TOTAL_1="408" TOTAL_2="404" WEIGHT="99.99999999999997" Z="9.608687308169179">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.4381105399069345" CI_START="-1.4818894600930654" EFFECT_SIZE="-0.96" ESTIMABLE="YES" MEAN_1="-0.76" MEAN_2="0.2" ORDER="2351" SD_1="1.33" SD_2="1.97" SE="0.26627502556662414" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="28.36526540910094"/>
<CONT_DATA CI_END="-1.3737914972392669" CI_START="-3.226208502760733" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="-1.54" MEAN_2="0.76" ORDER="2352" SD_1="2.7" SD_2="2.4" SE="0.4725640420265613" STUDY_ID="STD-Galant-1999" TOTAL_1="58" TOTAL_2="59" WEIGHT="9.005884576315303"/>
<CONT_DATA CI_END="-0.8202992603132647" CI_START="-2.7797007396867355" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="0.7" ORDER="2353" SD_1="2.49" SD_2="3.2" SE="0.4998565011472097" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="8.049279942535007"/>
<CONT_DATA CI_END="-1.0590387572652762" CI_START="-2.2009612427347234" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-0.74" MEAN_2="0.89" ORDER="2354" SD_1="2.12" SD_2="2.04" SE="0.2913121094256798" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="102" WEIGHT="23.699034088785485"/>
<CONT_DATA CI_END="-0.639816297460689" CI_START="-1.6401837025393107" EFFECT_SIZE="-1.14" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.76" MODIFIED="2009-05-21 10:43:43 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="1167" SD_1="1.8" SD_2="1.8" SE="0.2552004559699546" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="30.880535983263254"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.10" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Methacholine BHR (log base 2 PC20 FEV1 mg/ml)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.10.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.10.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="5.180950241563876" CI_START="1.8390497584361236" EFFECT_SIZE="3.51" ESTIMABLE="YES" MEAN_1="3.77" MEAN_2="0.26" ORDER="2360" SD_1="2.78" SD_2="1.84" SE="0.8525412990973907" STUDY_ID="STD-Overbeek-1996" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.475635898434863" CI_END="14.991464320273149" CI_START="6.177739369379426" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.623583497637375" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="33" I2="71.22828658633901" I2_Q="0.0" ID="CMP-007.11" LOG_CI_END="1.1758440554736775" LOG_CI_START="0.790829582044426" LOG_EFFECT_SIZE="0.9833368187590518" METHOD="PETO" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="11" P_CHI2="0.06227889884847937" P_Q="1.0" P_Z="1.3554743812127026E-23" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="155" WEIGHT="100.0" Z="10.011596355190447">
<NAME>Physician-rated efficacy: effective or very effective (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.475635898434863" CI_END="14.991464320273149" CI_START="6.177739369379426" DF="1.0" EFFECT_SIZE="9.623583497637375" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="33" I2="71.22828658633901" ID="CMP-007.11.02" LOG_CI_END="1.1758440554736775" LOG_CI_START="0.790829582044426" LOG_EFFECT_SIZE="0.9833368187590518" NO="2" P_CHI2="0.06227889884847937" P_Z="1.3554743812127026E-23" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="155" WEIGHT="100.0" Z="10.011596355190447">
<NAME>Adults</NAME>
<DICH_DATA CI_END="27.013314829100636" CI_START="7.818706382032533" EFFECT_SIZE="14.533037433865752" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="14" LOG_CI_END="1.4315778801391421" LOG_CI_START="0.8931349042595036" LOG_EFFECT_SIZE="1.162356392199323" ORDER="2361" O_E="26.754716981132077" SE="0.31628406936741615" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" VAR="9.996440014239944" WEIGHT="51.129868978181655"/>
<DICH_DATA CI_END="11.787316593132052" CI_START="3.3163773166843074" EFFECT_SIZE="6.252294728660805" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="19" LOG_CI_END="1.0714149483150244" LOG_CI_START="0.5206639360011898" LOG_EFFECT_SIZE="0.7960394421581071" ORDER="2362" O_E="17.513157894736842" SE="0.3235138708946259" STUDY_ID="STD-Wolfe-1996" TOTAL_1="77" TOTAL_2="75" VAR="9.554636908146978" WEIGHT="48.870131021818345"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.12" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Morning plasma cortisol (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.12.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="3.9222265269472505" CI_START="-2.722226526947251" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="13.6" MEAN_2="13.0" ORDER="2363" SD_1="5.8" SD_2="4.5" SE="1.6950446810005437" STUDY_ID="STD-Li-1999b" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.13" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="69" TOTAL_2="64" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in morning plasma cortisol compared to baseline (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.13.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="64" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.37059595399755674" CI_START="-5.829404046002443" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="0.9" ORDER="2364" SD_1="10.0" SD_2="5.6" SE="1.3925786736550436" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.14" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>8 hour area under curve (AUC) plasma cortisol during 6 hour 250 mcg co-syntropin infusion (mcg hour/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.14.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.14.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-2.0111367750060936" CI_START="-68.9888632249939" EFFECT_SIZE="-35.5" ESTIMABLE="YES" MEAN_1="311.0" MEAN_2="346.5" ORDER="2365" SD_1="62.6" SD_2="40.4" SE="17.086468674501056" STUDY_ID="STD-Li-1999b" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.15" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Peak plasma cortisol during during 6 hour 250 mcg co-syntropin infusion (mcg/dL)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.15.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.15.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.2668494050680703" CI_START="-11.133150594931935" EFFECT_SIZE="-5.700000000000003" ESTIMABLE="YES" MEAN_1="49.4" MEAN_2="55.1" ORDER="2366" SD_1="9.8" SD_2="7.0" SE="2.7720665470324612" STUDY_ID="STD-Li-1999b" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to clinical asthma exacerbation (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-007.16.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="17.815553657116062" CI_START="0.06361953605883412" EFFECT_SIZE="1.0646207110032142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2507993235432835" LOG_CI_START="-1.1964095022802577" LOG_EFFECT_SIZE="0.02719491063151286" ORDER="2367" O_E="0.030303030303030276" SE="1.437502578167806" STUDY_ID="STD-Overbeek-1996" TOTAL_1="16" TOTAL_2="17" VAR="0.48393021120293844" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.695191246899976" CI_END="0.1522252160687434" CI_START="0.0851133584773337" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.11382618057612462" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="229" I2="0.0" I2_Q="0.0" ID="CMP-007.17" LOG_CI_END="-0.8175134008346395" LOG_CI_START="-1.0700022723749034" LOG_EFFECT_SIZE="-0.9437578366047715" METHOD="PETO" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="17" P_CHI2="0.5834582700531425" P_Q="1.0" P_Z="1.3083992417444066E-48" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="537" TOTAL_2="540" WEIGHT="100.0" Z="14.651983341593072">
<NAME>Withdrawal due to lack of treatment efficacy (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.695191246899976" CI_END="0.1522252160687434" CI_START="0.0851133584773337" DF="6.0" EFFECT_SIZE="0.11382618057612462" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="229" I2="0.0" ID="CMP-007.17.02" LOG_CI_END="-0.8175134008346395" LOG_CI_START="-1.0700022723749034" LOG_EFFECT_SIZE="-0.9437578366047715" MODIFIED="2008-07-04 15:53:25 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.5834582700531425" P_Z="1.3083992417444066E-48" STUDIES="7" TAU2="0.0" TOTAL_1="537" TOTAL_2="540" WEIGHT="100.0" Z="14.651983341593072">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.1397908230763726" CI_START="0.0375383611291457" EFFECT_SIZE="0.0724397570342515" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="50" LOG_CI_END="-0.8545213380188644" LOG_CI_START="-1.4255246919732072" LOG_EFFECT_SIZE="-1.1400230149960358" ORDER="2368" O_E="-23.333333333333332" SE="0.33541019662496846" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" VAR="8.88888888888889" WEIGHT="19.552719240255996"/>
<DICH_DATA CI_END="0.39057032948338255" CI_START="0.06772322216187249" EFFECT_SIZE="0.16263665390507412" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="22" LOG_CI_END="-0.40830075191113513" LOG_CI_START="-1.1692623870393182" LOG_EFFECT_SIZE="-0.7887815694752265" ORDER="2369" O_E="-9.09016393442623" SE="0.44699263129513905" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="63" VAR="5.004944574128078" WEIGHT="11.009281057984003"/>
<DICH_DATA CI_END="1.3547463399616035" CI_START="0.013999189470221038" EFFECT_SIZE="0.13771474393546604" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.13185798637819024" LOG_CI_START="-1.8538971085218034" LOG_EFFECT_SIZE="-0.8610195610718065" ORDER="2370" O_E="-1.457142857142857" SE="1.1664423723905064" STUDY_ID="STD-Kemp-2004" TOTAL_1="51" TOTAL_2="54" VAR="0.7349764521193092" WEIGHT="1.6167136743549346"/>
<DICH_DATA CI_END="0.3241892536590564" CI_START="0.07471630535284521" EFFECT_SIZE="0.15563490376037453" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="33" LOG_CI_END="-0.48920138539720337" LOG_CI_START="-1.1265846116781681" LOG_EFFECT_SIZE="-0.8078929985376857" ORDER="2371" O_E="-13.270676691729324" SE="0.37440206221529365" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" VAR="7.13384280934736" WEIGHT="15.692177874969902"/>
<DICH_DATA CI_END="0.209167950696711" CI_START="0.06227335955413572" EFFECT_SIZE="0.11412971129788255" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="52" LOG_CI_END="-0.6795048585325569" LOG_CI_START="-1.2056977041121364" LOG_EFFECT_SIZE="-0.9426012813223466" ORDER="2372" O_E="-22.718446601941746" SE="0.30908828219003853" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="104" VAR="10.467305945940977" WEIGHT="23.02473311582019"/>
<DICH_DATA CI_END="0.5108303176710399" CI_START="0.07033091287067746" EFFECT_SIZE="0.18954461892605232" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.2917233353582978" LOG_CI_START="-1.1528537455593653" LOG_EFFECT_SIZE="-0.7222885404588316" MODIFIED="2008-07-04 15:53:25 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2373" O_E="-6.5" SE="0.505832265616385" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="100" VAR="3.908291457286432" WEIGHT="8.596994127008914"/>
<DICH_DATA CI_END="0.17152284712813834" CI_START="0.04750810548175577" EFFECT_SIZE="0.09027029142466897" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="54" LOG_CI_END="-0.7656780230217377" LOG_CI_START="-1.3232322879395488" LOG_EFFECT_SIZE="-1.0444551554806434" ORDER="2374" O_E="-22.421052631578945" SE="0.32751013515084537" STUDY_ID="STD-Wolfe-1996" TOTAL_1="77" TOTAL_2="75" VAR="9.322888958191925" WEIGHT="20.507380909606063"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0787305283113326" CI_END="4.769865301632159" CI_START="1.4626132028990386" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.641300430889527" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-007.18" LOG_CI_END="0.678506114976413" LOG_CI_START="0.16512948944944678" LOG_EFFECT_SIZE="0.42181780221292986" METHOD="PETO" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="18" P_CHI2="0.6878492308491442" P_Q="1.0" P_Z="0.0012782292790721687" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="463" TOTAL_2="466" WEIGHT="99.99999999999999" Z="3.220823306969031">
<NAME>Sore throat or pharyngitis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.18.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0787305283113326" CI_END="4.769865301632159" CI_START="1.4626132028990386" DF="5.0" EFFECT_SIZE="2.641300430889527" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="13" I2="0.0" ID="CMP-007.18.02" LOG_CI_END="0.678506114976413" LOG_CI_START="0.16512948944944678" LOG_EFFECT_SIZE="0.42181780221292986" NO="2" P_CHI2="0.6878492308491442" P_Z="0.0012782292790721687" STUDIES="6" TAU2="0.0" TOTAL_1="463" TOTAL_2="466" WEIGHT="99.99999999999999" Z="3.220823306969031">
<NAME>Adults</NAME>
<DICH_DATA CI_END="22.437867073539067" CI_START="1.0782397378399475" EFFECT_SIZE="4.918678675321286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.350981570845334" LOG_CI_START="0.03271533343455136" LOG_EFFECT_SIZE="0.6918484521399427" ORDER="2375" O_E="2.656716417910448" SE="0.7743561133782113" STUDY_ID="STD-Galant-1999" TOTAL_1="64" TOTAL_2="70" VAR="1.6677023367061001" WEIGHT="15.165820913254388"/>
<DICH_DATA CI_END="22.131215839813446" CI_START="0.6187860963302378" EFFECT_SIZE="3.700606525498231" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3450052737563192" LOG_CI_START="-0.20845945314153455" LOG_EFFECT_SIZE="0.5682729103073924" ORDER="2376" O_E="1.5714285714285716" SE="0.9125128703542167" STUDY_ID="STD-Kemp-2004" TOTAL_1="51" TOTAL_2="54" VAR="1.2009419152276295" WEIGHT="10.921175567539361"/>
<DICH_DATA CI_END="112.90936982702148" CI_START="0.4308113610191232" EFFECT_SIZE="6.974427523961422" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0527299835132977" LOG_CI_START="-0.36571285234978657" LOG_EFFECT_SIZE="0.8435085655817556" ORDER="2377" O_E="0.9624060150375939" SE="1.4206052932710869" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" VAR="0.4955108207977223" WEIGHT="4.5060969235316755"/>
<DICH_DATA CI_END="8.918273835429844" CI_START="0.7900413624777263" EFFECT_SIZE="2.6543935676331896" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9502808032221906" LOG_CI_START="-0.10235017070248476" LOG_EFFECT_SIZE="0.42396531625985295" ORDER="2378" O_E="2.5533980582524274" SE="0.6183206446907109" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="104" VAR="2.6156070892408425" WEIGHT="23.78591660020914"/>
<DICH_DATA CI_END="3.869914851673863" CI_START="0.6123026490999868" EFFECT_SIZE="1.5393372325359018" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5877014095008224" LOG_CI_START="-0.21303386160457818" LOG_EFFECT_SIZE="0.18733377394812215" ORDER="2379" O_E="1.949748743718592" SE="0.4703558619508301" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="4.520087876568773" WEIGHT="41.1049632415878"/>
<DICH_DATA CI_END="117.73761871365028" CI_START="0.4519940404567453" EFFECT_SIZE="7.294977861250745" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.070915247800426" LOG_CI_START="-0.34486729132537186" LOG_EFFECT_SIZE="0.8630239782375271" ORDER="2380" O_E="0.986842105263158" SE="1.4190426217989236" STUDY_ID="STD-Wolfe-1996" TOTAL_1="77" TOTAL_2="75" VAR="0.49660274990368913" WEIGHT="4.516026753877641"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9154119183934224" CI_END="12.256070973369138" CI_START="3.365915827453054" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="6.422842304747263" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.19" LOG_CI_END="1.0883512672406608" LOG_CI_START="0.5271032512328703" LOG_EFFECT_SIZE="0.8077272592367656" METHOD="PETO" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="19" P_CHI2="0.9960801466165085" P_Q="1.0" P_Z="1.6865882358644095E-8" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="585" TOTAL_2="590" WEIGHT="100.0" Z="5.641414463060957">
<NAME>Hoarseness or dysphonia (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.19.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9154119183934224" CI_END="12.256070973369138" CI_START="3.365915827453054" DF="7.0" EFFECT_SIZE="6.422842304747263" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="2" I2="0.0" ID="CMP-007.19.02" LOG_CI_END="1.0883512672406608" LOG_CI_START="0.5271032512328703" LOG_EFFECT_SIZE="0.8077272592367656" NO="2" P_CHI2="0.9960801466165085" P_Z="1.6865882358644095E-8" STUDIES="8" TAU2="0.0" TOTAL_1="585" TOTAL_2="590" WEIGHT="100.0" Z="5.641414463060957">
<NAME>Adults</NAME>
<DICH_DATA CI_END="32.11198926958688" CI_START="2.2015323847112582" EFFECT_SIZE="8.408066621673258" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.506667210021338" LOG_CI_START="0.34272507834787347" LOG_EFFECT_SIZE="0.9246961441846058" ORDER="2381" O_E="4.554878048780488" SE="0.6837053697514669" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="81" TOTAL_2="83" VAR="2.1392523530764262" WEIGHT="23.25127967227137"/>
<DICH_DATA CI_END="133.57887914249739" CI_START="0.5089178483935528" EFFECT_SIZE="8.245039464066995" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1257377949883454" LOG_CI_START="-0.2933523176020394" LOG_EFFECT_SIZE="0.9161927386931528" ORDER="2382" O_E="1.044776119402985" SE="1.4209855068247743" STUDY_ID="STD-Galant-1999" TOTAL_1="64" TOTAL_2="70" VAR="0.4952456882906754" WEIGHT="5.38276654849688"/>
<DICH_DATA CI_END="60.92528889149886" CI_START="1.1391758539704346" EFFECT_SIZE="8.330943404043065" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7847975971704486" LOG_CI_START="0.056590771062325226" LOG_EFFECT_SIZE="0.9206941841163869" ORDER="2383" O_E="2.057142857142857" SE="1.0151572444176704" STUDY_ID="STD-Kemp-2004" TOTAL_1="51" TOTAL_2="54" VAR="0.9703610675039246" WEIGHT="10.54673915920732"/>
<DICH_DATA CI_END="69.36052568733892" CI_START="0.7225731339526398" EFFECT_SIZE="7.079410456987435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8411123760230175" LOG_CI_START="-0.14111819000440212" LOG_EFFECT_SIZE="0.8499970930093076" ORDER="2384" O_E="1.443609022556391" SE="1.164372046684057" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" VAR="0.737592443172182" WEIGHT="8.016804635361146"/>
<DICH_DATA CI_END="76.88209882309866" CI_START="0.78583593574242" EFFECT_SIZE="7.772819055560919" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8858252307329186" LOG_CI_START="-0.10466811507907534" LOG_EFFECT_SIZE="0.8905785578269216" ORDER="2385" O_E="1.5" SE="1.1692256444309357" STUDY_ID="STD-Lipworth-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.7314814814814814" WEIGHT="7.950385318756126"/>
<DICH_DATA CI_END="19.53207738369103" CI_START="1.3581365073695042" EFFECT_SIZE="5.150458946497585" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.2907484362368775" LOG_CI_START="0.13294342341860235" LOG_EFFECT_SIZE="0.7118459298277399" ORDER="2386" O_E="3.5436893203883493" SE="0.6801003957567003" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="104" VAR="2.16199131432355" WEIGHT="23.498426740570014"/>
<DICH_DATA CI_END="19.797651634939676" CI_START="0.5731932273912288" EFFECT_SIZE="3.3686614308057603" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2966136780154116" LOG_CI_START="-0.24169894968431277" LOG_EFFECT_SIZE="0.5274573641655493" ORDER="2387" O_E="1.487437185929648" SE="0.9036124522811346" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="1.2247165475619302" WEIGHT="13.311298653321499"/>
<DICH_DATA CI_END="72.17040958207434" CI_START="0.7573087957013828" EFFECT_SIZE="7.392921341788795" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8583591700162163" LOG_CI_START="-0.12072699906817497" LOG_EFFECT_SIZE="0.8688160854740206" ORDER="2388" O_E="1.480263157894737" SE="1.1625250123547064" STUDY_ID="STD-Wolfe-1996" TOTAL_1="77" TOTAL_2="75" VAR="0.7399380973564968" WEIGHT="8.042299272015631"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7945547477914245" CI_END="8.434990246413614" CI_START="2.479416095047738" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.573166362437366" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.20" LOG_CI_END="0.9260845847400586" LOG_CI_START="0.3943494160857569" LOG_EFFECT_SIZE="0.6602170004129079" METHOD="PETO" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="20" P_CHI2="0.8031133616141939" P_Q="1.0" P_Z="1.1325328590403328E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="585" TOTAL_2="590" WEIGHT="99.99999999999997" Z="4.867090307625063">
<NAME>Oral Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7945547477914245" CI_END="8.434990246413614" CI_START="2.479416095047738" DF="7.0" EFFECT_SIZE="4.573166362437366" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" I2="0.0" ID="CMP-007.20.02" LOG_CI_END="0.9260845847400586" LOG_CI_START="0.3943494160857569" LOG_EFFECT_SIZE="0.6602170004129079" NO="2" P_CHI2="0.8031133616141939" P_Z="1.1325328590403328E-6" STUDIES="8" TAU2="0.0" TOTAL_1="585" TOTAL_2="590" WEIGHT="99.99999999999997" Z="4.867090307625063">
<NAME>Adults</NAME>
<DICH_DATA CI_END="41.03037674665206" CI_START="1.5891750578843247" EFFECT_SIZE="8.07492732731239" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6131055047378333" LOG_CI_START="0.20117174018133038" LOG_EFFECT_SIZE="0.9071386224595818" ORDER="2389" O_E="3.0365853658536586" SE="0.8293768824853445" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="81" TOTAL_2="83" VAR="1.4537714915530122" WEIGHT="14.18280470013744"/>
<DICH_DATA CI_END="7.9744537609213175" CI_START="0.1506738995411806" EFFECT_SIZE="1.096148733005174" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9017009441753124" LOG_CI_START="-0.8219619717527875" LOG_EFFECT_SIZE="0.03986948621126246" ORDER="2390" O_E="0.08955223880597019" SE="1.0124881290852064" STUDY_ID="STD-Galant-1999" TOTAL_1="64" TOTAL_2="70" VAR="0.9754839314816334" WEIGHT="9.516693764263266"/>
<DICH_DATA CI_END="40.92626269258223" CI_START="1.9308801255264403" EFFECT_SIZE="8.889527954013152" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.6120020875210264" LOG_CI_START="0.28575531239234353" LOG_EFFECT_SIZE="0.948878699956685" ORDER="2391" O_E="3.6" SE="0.7790439207380045" STUDY_ID="STD-Kemp-2004" TOTAL_1="51" TOTAL_2="54" VAR="1.6476923076923073" WEIGHT="16.074670841807883"/>
<DICH_DATA CI_END="12.108074657269135" CI_START="0.9266077163522283" EFFECT_SIZE="3.349542566917824" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.0830750901124226" LOG_CI_START="-0.03310408751810032" LOG_EFFECT_SIZE="0.5249855012971612" ORDER="2392" O_E="2.8120300751879697" SE="0.6556491741162074" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" VAR="2.326253090004574" WEIGHT="22.694621163179566"/>
<DICH_DATA CI_END="76.88209882309866" CI_START="0.78583593574242" EFFECT_SIZE="7.772819055560919" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8858252307329186" LOG_CI_START="-0.10466811507907534" LOG_EFFECT_SIZE="0.8905785578269216" ORDER="2393" O_E="1.5" SE="1.1692256444309357" STUDY_ID="STD-Lipworth-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.7314814814814814" WEIGHT="7.136237747059125"/>
<DICH_DATA CI_END="13.071350248740284" CI_START="1.1579491222743559" EFFECT_SIZE="3.890495925646176" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.116320451795441" LOG_CI_START="0.06368947787076559" LOG_EFFECT_SIZE="0.5900049648331033" ORDER="2394" O_E="3.5533980582524274" SE="0.6183206446907109" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="104" VAR="2.6156070892408425" WEIGHT="25.517520968421803"/>
<DICH_DATA CI_END="368.6978459014538" CI_START="0.1451514697533527" EFFECT_SIZE="7.315533762309568" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.566670600269949" LOG_CI_START="-0.8381785622950068" LOG_EFFECT_SIZE="0.8642460189874712" ORDER="2395" O_E="0.4974874371859297" SE="2.000025252365832" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.24999368702810534" WEIGHT="2.438905742744515"/>
<DICH_DATA CI_END="362.96024708963716" CI_START="0.1428098336908608" EFFECT_SIZE="7.199603636538945" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5598590619093526" LOG_CI_START="-0.8452418866030075" LOG_EFFECT_SIZE="0.8573085876531725" ORDER="2396" O_E="0.493421052631579" SE="2.000173152677698" STUDY_ID="STD-Wolfe-1996" TOTAL_1="77" TOTAL_2="75" VAR="0.24995671745152354" WEIGHT="2.4385450723863786"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.21" MODIFIED="2009-05-21 10:43:55 +0100" MODIFIED_BY="Toby J Lasserson" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HRQOL: AQLQ</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.21.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.21.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.22" MODIFIED="2009-05-21 10:43:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Log PD20 mg</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.22.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.7546888611670532" CI_START="-0.19468886116705453" EFFECT_SIZE="0.7799999999999994" ESTIMABLE="YES" MEAN_1="6.35" MEAN_2="5.57" ORDER="2397" SD_1="1.64" SD_2="1.09" SE="0.49729937328199664" STUDY_ID="STD-Corsico-2000" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.23" MODIFIED="2009-05-21 10:43:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FVC (absolute values - Litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.23.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.23.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.7771473463382657" CI_START="-0.7371473463382665" EFFECT_SIZE="0.019999999999999574" ESTIMABLE="YES" MEAN_1="4.76" MEAN_2="4.74" ORDER="2398" SD_1="0.95" SD_2="1.18" SE="0.3863067649765749" STUDY_ID="STD-Corsico-2000" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="22.677032445328962" CI_END="0.734680023598517" CI_START="0.3481810790755775" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5057684088511286" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="102" I2="82.3610077304276" I2_Q="0.0" ID="CMP-007.24" LOG_CI_END="-0.13390176872902657" LOG_CI_START="-0.4581948330932911" LOG_EFFECT_SIZE="-0.29604830091115886" METHOD="MH" MODIFIED="2009-05-21 10:43:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="24" P_CHI2="1.4689568079839788E-4" P_Q="0.0" P_Z="3.4555032846453863E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="281" WEIGHT="100.00000000000001" Z="3.578516294251576">
<NAME>Withdrawals (any reason)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.24.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.677032445328962" CI_END="0.734680023598517" CI_START="0.3481810790755775" DF="4.0" EFFECT_SIZE="0.5057684088511286" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="102" I2="82.3610077304276" ID="CMP-007.24.02" LOG_CI_END="-0.13390176872902657" LOG_CI_START="-0.4581948330932911" LOG_EFFECT_SIZE="-0.29604830091115886" NO="2" P_CHI2="1.4689568079839788E-4" P_Z="3.4555032846453863E-4" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="281" WEIGHT="100.00000000000001" Z="3.578516294251576">
<NAME>Adults</NAME>
<DICH_DATA CI_END="4.497978049220528" CI_START="0.07807196410317414" EFFECT_SIZE="0.5925925925925926" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6530173316852826" LOG_CI_START="-1.107504894691408" LOG_EFFECT_SIZE="-0.22724378150306254" ORDER="2399" O_E="0.0" SE="1.034139470499238" STUDY_ID="STD-FLIC15" TOTAL_1="11" TOTAL_2="11" VAR="1.0694444444444444" WEIGHT="3.093459811251202"/>
<DICH_DATA CI_END="6.2354808762057" CI_START="1.2103954461777404" EFFECT_SIZE="2.7472527472527473" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.7948699516124014" LOG_CI_START="0.08292728108948653" LOG_EFFECT_SIZE="0.438898616350944" ORDER="2400" O_E="0.0" SE="0.41819864883821645" STUDY_ID="STD-Kemp-2004" TOTAL_1="51" TOTAL_2="54" VAR="0.1748901098901099" WEIGHT="8.738069195237964"/>
<DICH_DATA CI_END="0.5319894690204054" CI_START="0.1593303294493428" EFFECT_SIZE="0.2911392405063291" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="52" LOG_CI_END="-0.274096964681633" LOG_CI_START="-0.797701545864064" LOG_EFFECT_SIZE="-0.5358992552728485" ORDER="2401" O_E="0.0" SE="0.3075679228710383" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="104" VAR="0.09459802717920494" WEIGHT="50.26510677843197"/>
<DICH_DATA CI_END="0.6072502904306902" CI_START="0.13307402652718917" EFFECT_SIZE="0.2842696629213483" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.21663226881197803" LOG_CI_START="-0.8759067021262117" LOG_EFFECT_SIZE="-0.5462694854690948" ORDER="2402" O_E="0.0" SE="0.3872610655898582" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.14997113292179243" WEIGHT="33.81906370982609"/>
<DICH_DATA CI_END="2.597150437829214" CI_START="0.0055445382717360095" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4144971065129538" LOG_CI_START="-2.2561346144177037" LOG_EFFECT_SIZE="-0.9208187539523752" ORDER="2403" O_E="0.0" SE="1.5687422927148937" STUDY_ID="STD-van-Rensen-1999" TOTAL_1="12" TOTAL_2="13" VAR="2.460952380952381" WEIGHT="4.084300505252787"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6181545530398163" CI_END="3.502917619182013" CI_START="0.5440364467256972" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3804763144337615" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-007.25" LOG_CI_END="0.5444299237991748" LOG_CI_START="-0.26437200456351595" LOG_EFFECT_SIZE="0.14002895961782946" METHOD="MH" MODIFIED="2009-05-21 10:43:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="25" P_CHI2="0.6552804951867414" P_Q="0.0" P_Z="0.4973518174721927" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="256" TOTAL_2="253" WEIGHT="100.00000000000001" Z="0.6786623721314549">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.25.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6181545530398163" CI_END="3.502917619182013" CI_START="0.5440364467256972" DF="3.0" EFFECT_SIZE="1.3804763144337615" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-007.25.02" LOG_CI_END="0.5444299237991748" LOG_CI_START="-0.26437200456351595" LOG_EFFECT_SIZE="0.14002895961782946" NO="2" P_CHI2="0.6552804951867414" P_Z="0.4973518174721927" STUDIES="4" TAU2="0.0" TOTAL_1="256" TOTAL_2="253" WEIGHT="100.00000000000001" Z="0.6786623721314549">
<NAME>Adults</NAME>
<DICH_DATA CI_END="18.303574842997357" CI_START="0.05463413614977969" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2625359194007018" LOG_CI_START="-1.2625359194007018" LOG_EFFECT_SIZE="0.0" ORDER="2404" O_E="0.0" SE="1.4832396974191326" STUDY_ID="STD-FLIC15" TOTAL_1="11" TOTAL_2="11" VAR="2.2" WEIGHT="11.898792085217734"/>
<DICH_DATA CI_END="4.106974994448301" CI_START="0.10273854300140757" EFFECT_SIZE="0.6495726495726496" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6135220586349575" LOG_CI_START="-0.9882665975656979" LOG_EFFECT_SIZE="-0.18737226946537028" ORDER="2407" O_E="0.0" SE="0.9408985856339902" STUDY_ID="STD-Lipworth-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.8852901484480432" WEIGHT="37.35059856993957"/>
<DICH_DATA CI_END="6.0505675354008055" CI_START="0.2879729859728901" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7817961128231893" LOG_CI_START="-0.5406482504114893" LOG_EFFECT_SIZE="0.1205739312058499" ORDER="2405" O_E="0.0" SE="0.7768103651692241" STUDY_ID="STD-Lumry-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.6034343434343433" WEIGHT="38.12234357399856"/>
<DICH_DATA CI_END="37.196721172820446" CI_START="0.448254861863859" EFFECT_SIZE="4.083333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5705046592552874" LOG_CI_START="-0.3484749912935098" LOG_EFFECT_SIZE="0.6110148339808888" ORDER="2406" O_E="0.0" SE="1.1272181458348334" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="1.2706207482993197" WEIGHT="12.628265770844147"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.957018610955391E-4" CI_END="2.1204225832582475" CI_START="0.9606486610978144" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4272284734998124" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-007.26" LOG_CI_END="0.3264224209704481" LOG_CI_START="-0.01743541820610411" LOG_EFFECT_SIZE="0.15449350138217202" METHOD="MH" MODIFIED="2009-05-21 10:43:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="26" P_CHI2="0.977496107823527" P_Q="0.0" P_Z="0.07820408040701513" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="203" WEIGHT="100.0" Z="1.761202823118272">
<NAME>Any adverse event</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.26.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.957018610955391E-4" CI_END="2.1204225832582475" CI_START="0.9606486610978144" DF="1.0" EFFECT_SIZE="1.4272284734998124" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="108" I2="0.0" ID="CMP-007.26.02" LOG_CI_END="0.3264224209704481" LOG_CI_START="-0.01743541820610411" LOG_EFFECT_SIZE="0.15449350138217202" NO="2" P_CHI2="0.977496107823527" P_Z="0.07820408040701513" STUDIES="2" TAU2="0.0" TOTAL_1="202" TOTAL_2="203" WEIGHT="100.0" Z="1.761202823118272">
<NAME>Adults</NAME>
<DICH_DATA CI_END="2.495359781391758" CI_START="0.8254346852645947" EFFECT_SIZE="1.4351851851851851" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="54" LOG_CI_END="0.3971331711251152" LOG_CI_START="-0.08331728575843174" LOG_EFFECT_SIZE="0.15690794268334174" ORDER="2408" O_E="0.0" SE="0.2822189766415133" STUDY_ID="STD-Lumry-2006" TOTAL_1="102" TOTAL_2="104" VAR="0.07964755077658303" WEIGHT="51.08458477730716"/>
<DICH_DATA CI_END="2.501100618099149" CI_START="0.8049779700571089" EFFECT_SIZE="1.4189189189189189" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="54" LOG_CI_END="0.39813116354427924" LOG_CI_START="-0.09421600486635552" LOG_EFFECT_SIZE="0.15195757933896184" ORDER="2409" O_E="0.0" SE="0.28920716388219647" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" VAR="0.08364078364078364" WEIGHT="48.91541522269285"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-05-21 10:00:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="8">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 1000-1500 mcg/d (subgroups)</NAME>
<CONT_OUTCOME CHI2="13.838604131681196" CI_END="0.48105135111584757" CI_START="0.3588436913060376" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4199475212109426" ESTIMABLE="YES" I2="71.09535064419784" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2009-05-21 10:00:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.007828408274485166" P_Q="1.0" P_Z="2.3416800940477765E-41" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="412" TOTAL_2="408" UNITS="" WEIGHT="99.99999999999999" Z="13.470219759567753">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); study duration</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.838604131681196" CI_END="0.48105135111584757" CI_START="0.3588436913060376" DF="4.0" EFFECT_SIZE="0.4199475212109426" ESTIMABLE="YES" I2="71.09535064419784" ID="CMP-008.01.02" MODIFIED="2009-05-21 10:00:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.007828408274485166" P_Z="2.3416800940477765E-41" STUDIES="5" TAU2="0.0" TOTAL_1="412" TOTAL_2="408" WEIGHT="99.99999999999999" Z="13.470219759567753">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.6637483351155297" CI_START="0.37625166488447037" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="-0.26" ORDER="2413" SD_1="0.41" SD_2="0.51" SE="0.07334233498645801" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="18.068879321342944"/>
<CONT_DATA CI_END="0.6513810699305987" CI_START="0.2886189300694013" EFFECT_SIZE="0.47000000000000003" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.05" ORDER="2414" SD_1="0.46" SD_2="0.56" SE="0.09254306270998318" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="63" WEIGHT="11.348878470545147"/>
<CONT_DATA CI_END="0.806223509073017" CI_START="0.413776490926983" EFFECT_SIZE="0.61" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.19" ORDER="2415" SD_1="0.5" SD_2="0.64" SE="0.10011587489403018" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="9.696941782838579"/>
<CONT_DATA CI_END="0.5503440546802244" CI_START="0.3296559453197756" EFFECT_SIZE="0.44" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.25" ORDER="2416" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="30.66471885965061"/>
<CONT_DATA CI_END="0.3711519338976247" CI_START="0.14884806610237536" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.13" MODIFIED="2009-05-21 10:00:31 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2417" SD_1="0.4" SD_2="0.4" SE="0.056711212437767694" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="30.220581565622716"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.838604131681194" CI_END="0.48105135111584757" CI_START="0.3588436913060376" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4199475212109426" ESTIMABLE="YES" I2="71.09535064419784" I2_Q="72.21572830530117" ID="CMP-008.02" MODIFIED="2009-05-21 10:00:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.007828408274485499" P_Q="0.05780899548165963" P_Z="2.3416800940477765E-41" Q="3.5991585850738623" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="412" TOTAL_2="408" UNITS="" WEIGHT="200.0" Z="13.470219759567753">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); inhaler devices</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.184968171360644" CI_END="0.45817836157420067" CI_START="0.3206441111834667" DF="2.0" EFFECT_SIZE="0.3894112363788337" ESTIMABLE="YES" I2="78.22529199136328" ID="CMP-008.02.01" MODIFIED="2009-05-21 10:00:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.010127689082593871" P_Z="1.2715122060415008E-28" STUDIES="3" TAU2="0.0" TOTAL_1="284" TOTAL_2="281" WEIGHT="100.0" Z="11.09879170183995">
<NAME>MDI</NAME>
<CONT_DATA CI_END="0.6637483351155297" CI_START="0.37625166488447037" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="-0.26" ORDER="2810" SD_1="0.41" SD_2="0.51" SE="0.07334233498645801" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="22.885272672492455"/>
<CONT_DATA CI_END="0.5503440546802244" CI_START="0.3296559453197756" EFFECT_SIZE="0.44" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.25" ORDER="2809" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="38.83862635019624"/>
<CONT_DATA CI_END="0.3711519338976247" CI_START="0.14884806610237536" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.13" MODIFIED="2009-05-21 10:00:43 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2811" SD_1="0.4" SD_2="0.4" SE="0.056711212437767694" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="38.27610097731131"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0544773752466867" CI_END="0.6676997910967069" CI_START="0.4013112745926082" DF="1.0" EFFECT_SIZE="0.5345055328446575" ESTIMABLE="YES" I2="5.166291522750042" ID="CMP-008.02.02" MODIFIED="2008-07-14 14:16:33 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.30447852451764723" P_Z="3.682405735658827E-15" STUDIES="2" TAU2="0.0" TOTAL_1="128" TOTAL_2="127" WEIGHT="100.0" Z="7.865290949182497">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.6513810699305987" CI_START="0.2886189300694013" EFFECT_SIZE="0.47000000000000003" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.05" ORDER="2813" SD_1="0.46" SD_2="0.56" SE="0.09254306270998318" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="63" WEIGHT="53.92461939667324"/>
<CONT_DATA CI_END="0.806223509073017" CI_START="0.413776490926983" EFFECT_SIZE="0.61" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.19" ORDER="2812" SD_1="0.5" SD_2="0.64" SE="0.10011587489403018" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="46.07538060332676"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.838604131681194" CI_END="0.48105135111584757" CI_START="0.3588436913060376" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4199475212109426" ESTIMABLE="YES" I2="71.09535064419784" I2_Q="61.271466030260775" ID="CMP-008.03" MODIFIED="2009-05-21 10:00:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.007828408274485499" P_Q="0.10808024171968411" P_Z="2.3416800940477765E-41" Q="2.5820755332008076" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="412" TOTAL_2="408" UNITS="" WEIGHT="200.0" Z="13.470219759567753">
<NAME>Adult studies: change in FEV1 compared to baseline (litres); severity</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.03.01" MODIFIED="2008-07-14 14:17:44 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mild</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.065934518509426" CI_END="0.45785878068158264" CI_START="0.29961171828434313" DF="2.0" EFFECT_SIZE="0.3787352494829629" ESTIMABLE="YES" I2="77.93939504066891" ID="CMP-008.03.02" MODIFIED="2009-05-21 10:00:54 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.010748750495745862" P_Z="6.496249599517474E-21" STUDIES="3" TAU2="0.0" TOTAL_1="238" TOTAL_2="242" WEIGHT="100.00000000000001" Z="9.381626899323074">
<NAME>Mild to moderate</NAME>
<CONT_DATA CI_END="0.6637483351155297" CI_START="0.37625166488447037" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="-0.26" ORDER="2815" SD_1="0.41" SD_2="0.51" SE="0.07334233498645801" STUDY_ID="STD-Chervinsky-1994" TOTAL_1="79" TOTAL_2="80" WEIGHT="30.297421953730787"/>
<CONT_DATA CI_END="0.6513810699305987" CI_START="0.2886189300694013" EFFECT_SIZE="0.47000000000000003" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.05" ORDER="2816" SD_1="0.46" SD_2="0.56" SE="0.09254306270998318" STUDY_ID="STD-Galant-1999" TOTAL_1="59" TOTAL_2="63" WEIGHT="19.029501144410855"/>
<CONT_DATA CI_END="0.3711519338976247" CI_START="0.14884806610237536" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.13" MODIFIED="2009-05-21 10:00:54 +0100" MODIFIED_BY="Toby J Lasserson" ORDER="2814" SD_1="0.4" SD_2="0.4" SE="0.056711212437767694" STUDY_ID="STD-Pinnas-2005" TOTAL_1="100" TOTAL_2="99" WEIGHT="50.67307690185837"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1905940799709613" CI_END="0.5770225333304669" CI_START="0.3846629115616189" DF="1.0" EFFECT_SIZE="0.4808427224460429" ESTIMABLE="YES" I2="54.35028291442949" ID="CMP-008.03.03" MODIFIED="2008-07-14 14:17:44 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.13885583056769424" P_Z="1.1407552784087348E-22" STUDIES="2" TAU2="0.0" TOTAL_1="174" TOTAL_2="166" WEIGHT="100.0" Z="9.798671982781553">
<NAME>Moderate</NAME>
<CONT_DATA CI_END="0.806223509073017" CI_START="0.413776490926983" EFFECT_SIZE="0.61" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.19" ORDER="2818" SD_1="0.5" SD_2="0.64" SE="0.10011587489403018" STUDY_ID="STD-Lawrence-1997" TOTAL_1="69" TOTAL_2="64" WEIGHT="24.025130850613454"/>
<CONT_DATA CI_END="0.5503440546802244" CI_START="0.3296559453197756" EFFECT_SIZE="0.44" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-0.25" ORDER="2817" SD_1="0.41" SD_2="0.4" SE="0.05629902158948034" STUDY_ID="STD-Lumry-2006" TOTAL_1="105" TOTAL_2="102" WEIGHT="75.97486914938655"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2008-07-14 14:18:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="9">
<NAME>FP versus placebo: Parallel group studies, no oral steroids: 2000 mcg/d (all ages)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PD20 - change from baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="368.0" MEAN_2="419.0" ORDER="2581" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Convery-2000" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2008-07-14 14:18:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="10">
<NAME>FP versus placebo: Crossover studies, no oral steroids: 100mcg/d or less (all ages)</NAME>
<IV_OUTCOME CHI2="0.020681240047153226" CI_END="10.52500343613839" CI_START="-1.9308686358157612" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="4.297067400161314" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="1.0222222462935204" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6331721657128938" NO="1" P_CHI2="0.8856507245023214" P_Q="0.8856507245023214" P_Z="0.17627631240687064" Q="0.020681240047153226" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.3523095444149071">
<NAME>FEV1 (% predicted - absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="11.428263501406807" CI_START="-3.428263501406806" DF="0.0" EFFECT_SIZE="4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="1.057980245351557" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.6020599913279624" NO="1" P_CHI2="1.0" P_Z="0.29123833726694026" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="70.29325998386864" Z="1.0554089709762533">
<NAME>Children</NAME>
<IV_DATA CI_END="11.428263501406807" CI_START="-3.428263501406806" EFFECT_SIZE="4.0" ESTIMABLE="YES" ESTIMATE="4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2582" SE="3.79" STUDY_ID="STD-Caffey-2005" TOTAL_1="26" TOTAL_2="26" WEIGHT="70.29325998386864"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="16.426590029868514" CI_START="-6.426590029868516" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="1.2155474182790653" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.6989700043360189" NO="2" P_CHI2="1.0" P_Z="0.39109519270353943" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="29.70674001613137" Z="0.8576329331046312">
<NAME>Adults</NAME>
<IV_DATA CI_END="16.426590029868514" CI_START="-6.426590029868516" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2583" SE="5.83" STUDY_ID="STD-Lanz-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="29.70674001613137"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>PEF (% predicted - absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="22.855690267044466" CI_START="-10.855690267044466" EFFECT_SIZE="6.0" ESTIMABLE="YES" ESTIMATE="6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2584" SE="8.6" STUDY_ID="STD-Lanz-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life (absolute scores - AQLQ)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>QoL</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="41.90821366831209" CI_START="-21.908213668312086" EFFECT_SIZE="10.0" ESTIMABLE="YES" ESTIMATE="10.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2585" SE="16.28" STUDY_ID="STD-Lanz-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.41641114372070626" CI_END="0.005352205465634863" CI_START="-0.5794224669751185" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="-0.2870351307547418" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-2.271467222804014" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="0.5187332843603281" P_Q="0.5187332843603281" P_Z="0.05434374531474148" Q="0.41641114372070626" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.9240864732698801">
<NAME>Symptoms</NAME>
<GROUP_LABEL_1>Fluticasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluticasone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>SD units</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.17915294096985065" CI_START="-0.5891529409698506" DF="0.0" EFFECT_SIZE="-0.205" ESTIMABLE="YES" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="-0.7467760580728419" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.2955987385746477" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="57.930702177055494" Z="1.0459183673469388">
<NAME>Children</NAME>
<IV_DATA CI_END="0.17915294096985065" CI_START="-0.5891529409698506" EFFECT_SIZE="-0.205" ESTIMABLE="YES" ESTIMATE="-0.205" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2586" SE="0.196" STUDY_ID="STD-Caffey-2005" TOTAL_1="26" TOTAL_2="26" WEIGHT="57.930702177055494"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.05079171644421249" CI_START="-0.8507917164442125" DF="0.0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-010.04.02" LOG_CI_END="-1.2942071104701978" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.08201182232733806" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="42.0692978229445" Z="1.7391304347826086">
<NAME>Adults</NAME>
<IV_DATA CI_END="0.05079171644421249" CI_START="-0.8507917164442125" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2587" SE="0.23" STUDY_ID="STD-Lanz-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="42.0692978229445"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Rescue medication usage (unclear time frame - absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Puffs</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="19.1221362350732" CI_START="-53.1221362350732" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2588" SE="18.43" STUDY_ID="STD-Lanz-2001" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2008-07-14 14:18:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="11">
<NAME>FP versus placebo: Crossover studies, no oral steroids: 200mcg/d (all ages)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>FEV1</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="0.13979891953620163" CI_START="0.02220108046379838" EFFECT_SIZE="0.081" ESTIMABLE="YES" ESTIMATE="0.081" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2589" SE="0.03" STUDY_ID="STD-Langley-2002" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Throat irritation</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="6.447590794315745" CI_START="0.2884029386403927" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8093974665436207" LOG_CI_START="-0.5400003187487084" LOG_EFFECT_SIZE="0.13469857389745615" ORDER="2590" O_E="0.0" SE="0.7926429387074789" STUDY_ID="STD-Langley-2002" TOTAL_1="48" TOTAL_2="48" VAR="0.6282828282828282" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Upper respiratory tract infections</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-011.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="2.976145036090028" CI_START="0.42883973958203314" EFFECT_SIZE="1.1297297297297297" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4736540918062164" LOG_CI_START="-0.367704976390136" LOG_EFFECT_SIZE="0.0529745577080402" ORDER="2591" O_E="0.0" SE="0.49421848145309394" STUDY_ID="STD-Langley-2002" TOTAL_1="48" TOTAL_2="48" VAR="0.24425190740980215" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Lower respiratory tract infection</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-011.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="23.31938657460438" CI_START="0.17907003639598734" EFFECT_SIZE="2.0434782608695654" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3677171219545443" LOG_CI_START="-0.746977078118295" LOG_EFFECT_SIZE="0.31037002191812463" ORDER="2592" O_E="0.0" SE="1.2421818410279002" STUDY_ID="STD-Langley-2002" TOTAL_1="48" TOTAL_2="48" VAR="1.5430157261794635" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2008-07-14 14:18:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="12">
<NAME>FP versus placebo: Crossover studies, no oral steroids: 500mcg/d (all ages)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>FEV1 (absolute values)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Litres</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="0.6487899156712152" CI_START="-0.4487899156712153" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2593" SE="0.28" STUDY_ID="STD-Parameswaren-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.8736791331256142" CI_END="3.2671511791037036" CI_START="1.6271668993848873" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="2.4471590392442955" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.5141692308119713" LOG_CI_START="0.21143210104037916" LOG_DATA="NO" LOG_EFFECT_SIZE="0.38866219477955893" NO="2" P_CHI2="0.3499388760536646" P_Q="1.0" P_Z="4.937779464562506E-9" Q="0.0" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="5.849255557721345">
<NAME>PC 20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Doses (n)</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.8736791331256142" CI_END="3.2671511791037036" CI_START="1.6271668993848873" DF="1.0" EFFECT_SIZE="2.4471590392442955" ESTIMABLE="YES" I2="0.0" ID="CMP-012.02.02" LOG_CI_END="0.5141692308119713" LOG_CI_START="0.21143210104037916" LOG_EFFECT_SIZE="0.38866219477955893" NO="2" P_CHI2="0.3499388760536646" P_Z="4.937779464562506E-9" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="5.849255557721345">
<NAME>Adults</NAME>
<IV_DATA CI_END="3.3827845133522234" CI_START="1.6972154866477767" EFFECT_SIZE="2.54" ESTIMABLE="YES" ESTIMATE="2.54" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2594" SE="0.43" STUDY_ID="STD-Derom-2005" TOTAL_1="25" TOTAL_2="25" WEIGHT="94.66431260024686"/>
<IV_DATA CI_END="4.349886768798946" CI_START="-2.7498867687989463" EFFECT_SIZE="0.8" ESTIMABLE="YES" ESTIMATE="0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2595" SE="1.8112" STUDY_ID="STD-Parameswaren-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.335687399753139"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Cortisol suppression</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="45.483297109981855" CI_START="12.516702890018145" EFFECT_SIZE="29.0" ESTIMABLE="YES" ESTIMATE="29.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2596" SE="8.41" STUDY_ID="STD-Derom-2005" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2008-07-14 14:18:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="13">
<NAME>FP versus placebo: Crossover studies, no oral steroids: 1000mcg/d (all ages)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Cortisol suppression</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<IV_DATA CI_END="66.50666206078841" CI_START="51.49333793921159" EFFECT_SIZE="59.0" ESTIMABLE="YES" ESTIMATE="59.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2597" SE="3.83" STUDY_ID="STD-Derom-2005" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.27307001795332153" CI_END="3.508303871307521" CI_START="2.130622520074885" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="2.819463195691203" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.5450972026862018" LOG_CI_START="0.32850651307884154" LOG_DATA="NO" LOG_EFFECT_SIZE="0.4501664298296585" NO="2" P_CHI2="0.6012798278674572" P_Q="1.0" P_Z="1.0383266630166081E-15" Q="0.0" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="8.02224159359741">
<NAME>PC 20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<EFFECT_MEASURE>Doses (n)</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.27307001795332153" CI_END="3.508303871307521" CI_START="2.130622520074885" DF="1.0" EFFECT_SIZE="2.819463195691203" ESTIMABLE="YES" I2="0.0" ID="CMP-013.02.02" LOG_CI_END="0.5450972026862018" LOG_CI_START="0.32850651307884154" LOG_EFFECT_SIZE="0.4501664298296585" NO="2" P_CHI2="0.6012798278674572" P_Z="1.0383266630166081E-15" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="8.02224159359741">
<NAME>Adults</NAME>
<IV_DATA CI_END="3.5327845133522233" CI_START="1.8472154866477766" EFFECT_SIZE="2.69" ESTIMABLE="YES" ESTIMATE="2.69" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2598" SE="0.43" STUDY_ID="STD-Derom-2005" TOTAL_1="25" TOTAL_2="25" WEIGHT="66.80430879712746"/>
<IV_DATA CI_END="4.275578030569433" CI_START="1.884421969430567" EFFECT_SIZE="3.08" ESTIMABLE="YES" ESTIMATE="3.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2599" SE="0.61" STUDY_ID="STD-van-Schoor-2002" TOTAL_1="25" TOTAL_2="25" WEIGHT="33.19569120287253"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2008-07-14 14:18:46 +0100" MODIFIED_BY="Toby J Lasserson" NO="14">
<NAME>FP versus placebo: Parallel group studies, oral steroid dependent: 1000-1500 mcg/d</NAME>
<DICH_OUTCOME CHI2="0.0024239160422209194" CI_END="27.573456624580924" CI_START="7.17485642803015" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="14.065404100340842" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="1.4404912129277672" LOG_CI_START="0.8558132150731925" LOG_EFFECT_SIZE="1.1481522140004798" METHOD="PETO" NO="1" P_CHI2="0.9607334037055716" P_Q="1.0" P_Z="1.3854057749759322E-14" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" WEIGHT="100.0" Z="7.697696839861542">
<NAME>Number of patients able to discontinue OCS completely</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.37862124675518" CI_START="5.765416132105544" EFFECT_SIZE="14.28189321020481" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" LOG_CI_END="1.5487409038537012" LOG_CI_START="0.7608306589602831" LOG_EFFECT_SIZE="1.1547857814069922" ORDER="2600" O_E="12.413333333333334" SE="0.4628223780690079" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" VAR="4.668434834834835" WEIGHT="55.06555328553388"/>
<DICH_DATA CI_END="37.682007377231514" CI_START="5.057221780965293" EFFECT_SIZE="13.804574186067095" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.5761340302576092" LOG_CI_START="0.703911999734463" LOG_EFFECT_SIZE="1.140023014996036" ORDER="2601" O_E="10.0" SE="0.51234753829798" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="3.8095238095238093" WEIGHT="44.93444671446613"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3356265771744671" CI_END="-5.254685990799957" CI_START="-9.922933040174332" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.588809515487144" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" NO="2" P_CHI2="0.5623647531777246" P_Q="1.0" P_Z="1.8618399704236144E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="6.372324848524462">
<NAME>Change in daily dose of oral prednisolone compared to baseline (mg)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.2899977283758712" CI_START="-10.330002271624128" EFFECT_SIZE="-6.81" ESTIMABLE="YES" MEAN_1="-12.0" MEAN_2="-5.19" ORDER="2602" SD_1="6.53" SD_2="8.62" SE="1.795952527387981" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" WEIGHT="43.97053845416232"/>
<CONT_DATA CI_END="-5.081716395213224" CI_START="-11.318283604786775" EFFECT_SIZE="-8.2" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="1.6" ORDER="2603" SD_1="5.4" SD_2="7.2" SE="1.590990257669732" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="56.029461545837684"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8196566322385912" CI_END="0.42657755551069904" CI_START="0.0855097579811645" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.25604365674593177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.03" NO="3" P_CHI2="0.3652806393698934" P_Q="1.0" P_Z="0.0032532508398818295" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="2.942736601502264">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4125397826060328" CI_START="-0.0325397826060328" EFFECT_SIZE="0.19" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="-0.06" ORDER="2604" SD_1="0.45" SD_2="0.52" SE="0.11354279178668496" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" WEIGHT="58.72271453379264"/>
<CONT_DATA CI_END="0.6154331472956858" CI_START="0.08456685270431424" EFFECT_SIZE="0.35" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="-0.17" ORDER="2605" SD_1="0.62" SD_2="0.45" SE="0.13542756366412267" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="41.27728546620736"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20024942200377355" CI_END="70.73467639801808" CI_START="30.964130488569534" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="50.84940344329381" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.04" NO="4" P_CHI2="0.6545196052185772" P_Q="1.0" P_Z="5.389521380394629E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="5.011899993081327">
<NAME>Change in morning PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="75.09559948531361" CI_START="16.90440051468639" EFFECT_SIZE="46.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="-23.0" ORDER="2606" SD_1="64.0" SD_2="64.0" SE="14.844966394697037" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" WEIGHT="46.709852271496665"/>
<CONT_DATA CI_END="82.34006218107447" CI_START="27.859937818925538" EFFECT_SIZE="55.1" ESTIMABLE="YES" MEAN_1="40.1" MEAN_2="-15.0" ORDER="2607" SD_1="61.0" SD_2="49.6" SE="13.89824629224853" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="53.29014772850333"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.3940415669233888" CI_END="46.64561554004452" CI_START="6.39927063481074" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="26.52244308742763" ESTIMABLE="YES" I2="58.22963085452557" I2_Q="0.0" ID="CMP-014.05" NO="5" P_CHI2="0.12179856447536308" P_Q="1.0" P_Z="0.009787651524200941" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="2.583242446277968">
<NAME>Change in evening PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="39.26449329452244" CI_START="-15.264493294522442" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="-9.0" ORDER="2608" SD_1="45.0" SD_2="70.0" SE="13.91071137509734" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" WEIGHT="54.47510003941185"/>
<CONT_DATA CI_END="73.72441604141031" CI_START="14.075583958589704" EFFECT_SIZE="43.900000000000006" ESTIMABLE="YES" MEAN_1="19.8" MEAN_2="-24.1" ORDER="2609" SD_1="59.4" SD_2="62.3" SE="15.216818409247052" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="45.52489996058816"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3251488908802409" CI_END="-0.4120761945560519" CI_START="-1.103777590801588" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.75792689267882" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.06" NO="6" P_CHI2="0.5685297954463069" P_Q="1.0" P_Z="1.7450976995815904E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="4.29523323395902">
<NAME>Change in daily asthma symptom score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.37721773972207073" CI_START="-1.3287303142864286" EFFECT_SIZE="-0.8529740270042497" ESTIMABLE="YES" MEAN_1="-0.26" MEAN_2="0.26" ORDER="2610" SD_1="0.51" SD_2="0.7" SE="0.2427372599878793" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" WEIGHT="52.84552790020015"/>
<CONT_DATA CI_END="-0.14776043963794017" CI_START="-1.155056670080619" EFFECT_SIZE="-0.6514085548592796" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.02" ORDER="2611" SD_1="0.54" SD_2="0.49" SE="0.256968045940666" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="47.154472099799854"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1555459337998094" CI_END="-2.1597611079674905" CI_START="-5.042589015222771" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.601175061595131" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.07" NO="7" P_CHI2="0.6932910047472385" P_Q="1.0" P_Z="9.745886123593412E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="4.896701190512828">
<NAME>Change in daily use of rescue beta2 agonist compared to baseline (puffs/d)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.4853898479097642" CI_START="-5.234610152090236" EFFECT_SIZE="-3.3600000000000003" ESTIMABLE="YES" MEAN_1="-2.06" MEAN_2="1.3" ORDER="2612" SD_1="3.9" SD_2="4.3" SE="0.9564513260840105" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" WEIGHT="59.12287091607956"/>
<CONT_DATA CI_END="-1.6955088817804325" CI_START="-6.204491118219568" EFFECT_SIZE="-3.95" ESTIMABLE="YES" MEAN_1="-3.04" MEAN_2="0.91" ORDER="2613" SD_1="4.7" SD_2="4.5" SE="1.1502717070327342" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="40.87712908392043"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.08" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in overall score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7653961508381606" CI_START="0.6746038491618392" EFFECT_SIZE="1.22" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="-0.38" ORDER="2614" SD_1="1.26" SD_2="1.0" SE="0.278268455512538" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.09" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="24" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.528607067250968" CI_START="0.35139293274903205" EFFECT_SIZE="0.9400000000000001" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="-0.04" ORDER="2615" SD_1="1.34" SD_2="0.88" SE="0.3003152465523986" STUDY_ID="STD-Nelson-1999" TOTAL_1="31" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.10" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="31" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.9394780423696298" CI_START="0.6605219576303702" EFFECT_SIZE="1.3" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="-0.52" ORDER="2616" SD_1="1.34" SD_2="1.34" SE="0.3262703026248191" STUDY_ID="STD-Nelson-1999" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.11" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="31" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1655076574499454" CI_START="0.8344923425500546" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="1.08" MEAN_2="-0.42" ORDER="2617" SD_1="1.52" SD_2="1.28" SE="0.33955096251736505" STUDY_ID="STD-Nelson-1999" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.12" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in enviromental exposure domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6046209395851" CI_START="0.2953790604148999" EFFECT_SIZE="0.95" ESTIMABLE="YES" MEAN_1="0.82" MEAN_2="-0.13" ORDER="2618" SD_1="1.58" SD_2="1.15" SE="0.3339964125609789" STUDY_ID="STD-Nelson-1999" TOTAL_1="37" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.7970785000674074" CI_END="17.63907473395604" CI_START="0.33185230512295283" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.4194147248248585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="64.2484113343297" I2_Q="0.0" ID="CMP-014.13" LOG_CI_END="1.2464758002699337" LOG_CI_START="-0.4790551613014274" LOG_EFFECT_SIZE="0.38371031948425305" METHOD="PETO" MODIFIED="2008-07-04 15:00:11 +0100" MODIFIED_BY="Toby J Lasserson" NO="13" P_CHI2="0.09443633435452992" P_Q="1.0" P_Z="0.3833810904966718" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" WEIGHT="100.0" Z="0.8716834683750085">
<NAME>Sore throat (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.66259994896754" CI_START="0.6541838133707829" EFFECT_SIZE="6.554037689123838" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8173180748772535" LOG_CI_START="-0.1843002059320987" LOG_EFFECT_SIZE="0.8165089344725773" ORDER="2619" O_E="1.36" SE="1.1757604863177005" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" VAR="0.7233729729729729" WEIGHT="74.31611448626676"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="2620" O_E="-0.5" SE="2.0" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="0.25" WEIGHT="25.683885513733244"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.012468900653659465" CI_END="36.63171431614981" CI_START="1.4121328693472632" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.19227695840294" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.14" LOG_CI_END="1.5638572435518667" LOG_CI_START="0.14987556194914517" LOG_EFFECT_SIZE="0.856866402750506" METHOD="PETO" MODIFIED="2008-07-04 15:00:12 +0100" MODIFIED_BY="Toby J Lasserson" NO="14" P_CHI2="0.9110896424699656" P_Q="1.0" P_Z="0.017527170830800704" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" WEIGHT="100.0" Z="2.3754583398135476">
<NAME>Hoarseness or dysphonia (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.66259994896754" CI_START="0.6541838133707829" EFFECT_SIZE="6.554037689123838" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8173180748772535" LOG_CI_START="-0.1843002059320987" LOG_EFFECT_SIZE="0.8165089344725773" ORDER="2621" O_E="1.36" SE="1.1757604863177005" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" VAR="0.7233729729729729" WEIGHT="49.90281545733202"/>
<DICH_DATA CI_END="78.69244771002059" CI_START="0.791045613858192" EFFECT_SIZE="7.889823547125557" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8959330541475108" LOG_CI_START="-0.10179847317014251" LOG_EFFECT_SIZE="0.897067290488684" ORDER="2622" O_E="1.5" SE="1.1734773880769365" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="0.7261904761904762" WEIGHT="50.097184542667975"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.002057018636468108" CI_END="16.470858609211717" CI_START="1.9767619138737353" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.706046441056104" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.15" LOG_CI_END="1.216716239092245" LOG_CI_START="0.2959543649548202" LOG_EFFECT_SIZE="0.7563353020235326" METHOD="PETO" MODIFIED="2008-07-04 15:00:12 +0100" MODIFIED_BY="Toby J Lasserson" NO="15" P_CHI2="0.9638248633215583" P_Q="1.0" P_Z="0.0012822621416113582" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="66" WEIGHT="99.99999999999999" Z="3.2199203590853718">
<NAME>Oral Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="319.38015074481785" CI_START="0.1214994548504957" EFFECT_SIZE="6.22932694643366" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5043079215398887" LOG_CI_START="-0.915425670674333" LOG_EFFECT_SIZE="0.7944411254327779" ORDER="2623" O_E="0.45333333333333337" SE="2.008768440020926" STUDY_ID="STD-Nelson-1999" TOTAL_1="41" TOTAL_2="34" VAR="0.2478222222222222" WEIGHT="7.249534274257206"/>
<DICH_DATA CI_END="17.03693365926406" CI_START="1.8850476803660152" EFFECT_SIZE="5.667047933002279" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.2313914322913273" LOG_CI_START="0.27532233971845255" LOG_EFFECT_SIZE="0.7533568860048899" ORDER="2624" O_E="5.5" SE="0.5615997175956416" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="3.1706349206349205" WEIGHT="92.75046572574279"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2009-05-21 09:13:46 +0100" MODIFIED_BY="Toby J Lasserson" NO="15">
<NAME>FP versus placebo: Parallel group studies, oral steroid dependent: 2000 mcg/d</NAME>
<DICH_OUTCOME CHI2="0.006378651045501282" CI_END="0.08125997714941213" CI_START="0.021152019726014767" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.04145856533455873" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-1.090123304134707" LOG_CI_START="-1.6746481571785985" LOG_EFFECT_SIZE="-1.3823857306566527" METHOD="PETO" NO="1" P_CHI2="0.9363434677160408" P_Q="1.0" P_Z="1.8523124163276984E-20" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" WEIGHT="100.0" Z="9.270525387312073">
<NAME>Number of patients able to discontinue OCS completely</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.10794234784269235" CI_START="0.016780001651268087" EFFECT_SIZE="0.04255905044807899" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="31" LOG_CI_END="-0.9668081398743219" LOG_CI_START="-1.775208000769739" LOG_EFFECT_SIZE="-1.3710080703220304" ORDER="2625" O_E="-14.0" SE="0.47485807993381707" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" VAR="4.434782608695651" WEIGHT="52.28215767634854"/>
<DICH_DATA CI_END="0.1067181140682121" CI_START="0.015207522944337545" EFFECT_SIZE="0.040285458521267525" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="30" LOG_CI_END="-0.9717618582495451" LOG_CI_START="-1.817941519623108" LOG_EFFECT_SIZE="-1.3948516889363265" ORDER="2626" O_E="-13.0" SE="0.4970501217477084" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="4.0476190476190474" WEIGHT="47.71784232365145"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.5351047768542232" CI_END="-7.348520650885421" CI_START="-12.096347930740942" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.722434290813181" ESTIMABLE="YES" I2="34.85786670215266" I2_Q="0.0" ID="CMP-015.02" NO="2" P_CHI2="0.21534836902255294" P_Q="1.0" P_Z="9.981096879887293E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="8.02709110034472">
<NAME>Change in daily dose of oral prednisolone compared to baseline (mg)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.9645109390965096" CI_START="-11.65548906090349" EFFECT_SIZE="-7.81" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-5.19" ORDER="2627" SD_1="7.74" SD_2="8.62" SE="1.9620202673295106" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" WEIGHT="38.108922627405185"/>
<CONT_DATA CI_END="-7.882474878161485" CI_START="-13.917525121838516" EFFECT_SIZE="-10.9" ESTIMABLE="YES" MEAN_1="-9.3" MEAN_2="1.6" ORDER="2628" SD_1="4.9" SD_2="7.2" SE="1.5395819237702164" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="61.89107737259482"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4876656910716113" CI_END="0.7552982171940099" CI_START="0.4018055085244085" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5785518628592092" ESTIMABLE="YES" I2="32.78059674282942" I2_Q="0.0" ID="CMP-015.03" NO="3" P_CHI2="0.22257934368126253" P_Q="1.0" P_Z="1.4023334113959027E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="6.415639058923083">
<NAME>Change in FEV1 compared to baseline (litres)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7183278326737397" CI_START="0.22167216732626022" EFFECT_SIZE="0.47" ESTIMABLE="YES" MEAN_1="0.41" MEAN_2="-0.06" ORDER="2629" SD_1="0.54" SD_2="0.52" SE="0.12670020195907578" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" WEIGHT="50.6582441549049"/>
<CONT_DATA CI_END="0.9416188450584835" CI_START="0.4383811549415167" EFFECT_SIZE="0.6900000000000001" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="-0.17" ORDER="2630" SD_1="0.57" SD_2="0.45" SE="0.12837932076467767" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="49.34175584509509"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1349013236155318" CI_END="116.18871683804309" CI_START="72.51309594496166" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="94.35090639150238" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.04" NO="4" P_CHI2="0.7134034396775798" P_Q="1.0" P_Z="2.4946580321670573E-17" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="8.468082406372762">
<NAME>Change in morning PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="121.87401565524235" CI_START="58.12598434475765" EFFECT_SIZE="90.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="-23.0" ORDER="2631" SD_1="72.0" SD_2="64.0" SE="16.26255171353174" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" WEIGHT="46.94016595728815"/>
<CONT_DATA CI_END="128.1796216968566" CI_START="68.2203783031434" EFFECT_SIZE="98.2" ESTIMABLE="YES" MEAN_1="83.2" MEAN_2="-15.0" ORDER="2632" SD_1="70.9" SD_2="49.6" SE="15.29600642324656" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="53.059834042711856"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.793489922859957" CI_END="89.23675803255566" CI_START="43.03728847060097" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="66.13702325157831" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.05" NO="5" P_CHI2="0.3730469802641483" P_Q="1.0" P_Z="2.0047883898223527E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="5.611587528897905">
<NAME>Change in evening PEFR compared to baseline (L/min)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="87.6229960745387" CI_START="26.377003925461292" EFFECT_SIZE="57.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="-9.0" ORDER="2633" SD_1="60.0" SD_2="70.0" SE="15.624264688580501" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" WEIGHT="56.90083371897026"/>
<CONT_DATA CI_END="113.38621556236075" CI_START="43.01378443763926" EFFECT_SIZE="78.2" ESTIMABLE="YES" MEAN_1="54.1" MEAN_2="-24.1" ORDER="2634" SD_1="80.2" SD_2="62.3" SE="17.95248067816813" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="43.09916628102974"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.09851197080987578" CI_END="-0.6655008456337769" CI_START="-1.3889527291882011" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.027226787410989" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.06" NO="6" P_CHI2="0.7536227115794404" P_Q="1.0" P_Z="2.608148262377572E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="5.565891949547634">
<NAME>Change in daily asthma symptom score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4754157503397792" CI_START="-1.4697908875718935" EFFECT_SIZE="-0.9726033189558363" ESTIMABLE="YES" MEAN_1="-0.47" MEAN_2="0.26" ORDER="2635" SD_1="0.78" SD_2="0.7" SE="0.25367178812356206" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" WEIGHT="52.93205919815003"/>
<CONT_DATA CI_END="-0.5614051366184984" CI_START="-1.615906273775619" EFFECT_SIZE="-1.0886557051970587" ESTIMABLE="YES" MEAN_1="-0.56" MEAN_2="-0.02" ORDER="2636" SD_1="0.49" SD_2="0.49" SE="0.2690103352599565" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="47.06794080184998"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.08785895635143945" CI_END="-3.150849557990653" CI_START="-6.103839416660304" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.6273444873254785" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.07" NO="7" P_CHI2="0.7669169158628075" P_Q="1.0" P_Z="8.121243354319122E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="6.142539577364996">
<NAME>Change in daily use of rescue beta2 agonist compared to baseline (puffs/d)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.4595118501130067" CI_START="-6.400488149886993" EFFECT_SIZE="-4.43" ESTIMABLE="YES" MEAN_1="-3.13" MEAN_2="1.3" ORDER="2637" SD_1="4.1" SD_2="4.3" SE="1.0053695707829082" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" WEIGHT="56.145669483226925"/>
<CONT_DATA CI_END="-2.650406358738325" CI_START="-7.109593641261675" EFFECT_SIZE="-4.88" ESTIMABLE="YES" MEAN_1="-3.97" MEAN_2="0.91" ORDER="2638" SD_1="4.6" SD_2="4.5" SE="1.1375686792453457" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" WEIGHT="43.854330516773075"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.08" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="34" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in overall score compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FP</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.211443724236307" CI_START="1.1285562757636929" EFFECT_SIZE="1.67" ESTIMABLE="YES" MEAN_1="1.29" MEAN_2="-0.38" ORDER="2639" SD_1="1.17" SD_2="1.04" SE="0.2762518742727652" STUDY_ID="STD-Nelson-1999" TOTAL_1="34" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.09" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="24" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in activity limitation domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.635284696956779" CI_START="0.5247153030432211" EFFECT_SIZE="1.08" ESTIMABLE="YES" MEAN_1="1.04" MEAN_2="-0.04" ORDER="2640" SD_1="1.2" SD_2="0.88" SE="0.28331372481167705" STUDY_ID="STD-Nelson-1999" TOTAL_1="30" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.10" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="35" TOTAL_2="31" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in asthma symptoms domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.678744699698632" CI_START="1.4012553003013681" EFFECT_SIZE="2.04" ESTIMABLE="YES" MEAN_1="1.52" MEAN_2="-0.52" ORDER="2641" SD_1="1.3" SD_2="1.34" SE="0.32589614132553885" STUDY_ID="STD-Nelson-1999" TOTAL_1="35" TOTAL_2="31" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.11" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="35" TOTAL_2="31" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in emotional function domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.571413252116897" CI_START="1.2685867478831028" EFFECT_SIZE="1.92" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="-0.42" ORDER="2642" SD_1="1.42" SD_2="1.28" SE="0.3323598072490932" STUDY_ID="STD-Nelson-1999" TOTAL_1="35" TOTAL_2="31" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.12" MODIFIED="2009-05-21 09:13:46 +0100" MODIFIED_BY="Toby J Lasserson" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="34" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Asthma Quality of Life Questionnaire: change in environmental exposure domain compared to baseline</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7751344753600242" CI_START="0.5248655246399756" EFFECT_SIZE="1.15" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="-0.13" ORDER="2643" SD_1="1.4" SD_2="1.15" SE="0.3189520217162179" STUDY_ID="STD-Nelson-1999" TOTAL_1="34" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-04 15:00:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="68" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>Sore throat (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2644" O_E="0.0" SE="0.0" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.039842184716285" CI_START="0.5885225946157062" EFFECT_SIZE="3.601519832996887" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3432084804450715" LOG_CI_START="-0.23023685902521238" LOG_EFFECT_SIZE="0.5564858107099295" ORDER="2645" O_E="1.5" SE="0.9242495810848893" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="1.1706349206349205" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0561698082181981E-7" CI_END="38.92083418265628" CI_START="1.4974134851998895" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.634171989177237" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-015.14" LOG_CI_END="1.5901821398450848" LOG_CI_START="0.1753417399189924" LOG_EFFECT_SIZE="0.8827619398820385" METHOD="PETO" MODIFIED="2008-07-04 15:00:16 +0100" MODIFIED_BY="Toby J Lasserson" NO="14" P_CHI2="0.9997406973752785" P_Q="1.0" P_Z="0.014454628915863816" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" WEIGHT="100.0" Z="2.445762234640583">
<NAME>Hoarseness or dysphonia (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="56.69354546965135" CI_START="1.0283917743829174" EFFECT_SIZE="7.635651630449975" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7535336175088294" LOG_CI_START="0.012158594269543422" LOG_EFFECT_SIZE="0.8828461058891863" ORDER="2646" O_E="1.942857142857143" SE="1.0228923085961423" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" VAR="0.9557409050576752" WEIGHT="66.01312352401213"/>
<DICH_DATA CI_END="124.75222699359861" CI_START="0.4668191025365988" EFFECT_SIZE="7.6312988831911" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0960483071002245" LOG_CI_START="-0.33085138065474906" LOG_EFFECT_SIZE="0.8825984632227376" ORDER="2647" O_E="1.0" SE="1.4255728899344744" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="0.49206349206349204" WEIGHT="33.98687647598788"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6970356349795161" CI_END="12.50905800877424" CI_START="1.703872592642829" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.616691575244085" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-015.15" LOG_CI_END="1.0972246064964093" LOG_CI_START="0.23143711720247526" LOG_EFFECT_SIZE="0.6643308618494422" METHOD="PETO" MODIFIED="2008-07-04 15:00:17 +0100" MODIFIED_BY="Toby J Lasserson" NO="15" P_CHI2="0.4037819784763951" P_Q="1.0" P_Z="0.0026313273817733396" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="66" WEIGHT="100.0" Z="3.0078156109768215">
<NAME>Oral Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>FP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours FP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="42.891476147679896" CI_START="1.5434732257200374" EFFECT_SIZE="8.136451624974706" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.632370993120864" LOG_CI_START="0.18849910027558256" LOG_EFFECT_SIZE="0.9104350466982234" ORDER="2648" O_E="2.914285714285714" SE="0.8481374971384579" STUDY_ID="STD-Nelson-1999" TOTAL_1="36" TOTAL_2="34" VAR="1.3901685891748001" WEIGHT="35.95549626075568"/>
<DICH_DATA CI_END="11.670611407864584" CI_START="0.9665744881887491" EFFECT_SIZE="3.3586478303636547" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0670936087537035" LOG_CI_START="-0.014764671834285611" LOG_EFFECT_SIZE="0.5261644684597089" ORDER="2649" O_E="3.0" SE="0.6354889093022426" STUDY_ID="STD-Noonan-1995" TOTAL_1="32" TOTAL_2="32" VAR="2.4761904761904763" WEIGHT="64.04450373924432"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-07-23 17:11:27 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAOkAAArgCAIAAADNKokyAABrTklEQVR42u3dv44UWba28ZRwMDAw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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-07-09 11:31:44 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-07-04 10:10:20 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE MODIFIED="2008-07-04 10:10:17 +0100" MODIFIED_BY="Toby J Lasserson">Archive of methodological approach to assessing study quality</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-04 10:10:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All trials were scored using the Cochrane approach:</P>
<P>Grade A: adequate allocation concealment<BR/>Grade B: unclear allocation concealment<BR/>Grade C: clearly inadequate concealment</P>
<P>Studies were also assessed using a five point scoring instrument (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>):</P>
<P>1. Was the study described as randomised? (Yes = 1 no = 0)<BR/>2. Was the study described as double blind? (Yes = 1 no = 0)<BR/>3. Was of a description of withdrawals and dropouts? (Yes = 1 no = 0)<BR/>4. Was the method of randomisation well described and appropriate? (Yes = 1 no = 0)<BR/>5. Was the method of double blinding well described and appropriate? (Yes = 1 no = 0)<BR/>6. Deduct one point if method of randomisation or blinding inappropriate</P>
<P>Inter rater agreement was measured using the kappa statistic. Disagreement was resolved by consensus.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-07-09 11:31:44 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-07-07 12:28:58 +0100" MODIFIED_BY="Toby J Lasserson">GSK randomisation procedures</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-09 11:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>The procedures for randomising GSK sponsored studies has been detailed in correspondence between Richard Follows and TL, the details of which are given below:</P>
<P>The randomisation software is a computer-generated, centralised programme (RandAll). After verification that the randomisation sequence is suitable for the study design (crossover, block or stratification), Clinical Supplies then package the treatments according to the randomisation list generated. Concealment of allocation is maintained by a third party, since the sites phone in and are allocated treatments on that basis. Alternatively a third party may dispense the drug at the sites. Unblinding of data for interim analyses can only be done through RandAll, and are restricted so that only those reviewing the data are unblinded to treatment group allocation.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>